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Abstract  
Background: The antiepileptic drug vigabatrin (VGB) is associated with the development of 
visual field loss in around 50% of exposed individuals. The mechanisms of VGB retinotoxicity 
are unknown, and there is continued debate as to the best methods of assessing visual function 
in VGB-exposed individuals, particularly in those unable to perform perimetry.    
Methods: 204 VGB-exposed individuals, 90 non-exposed individuals with epilepsy and 90 
healthy controls participated.  Individuals underwent visual field testing using Goldmann kinetic 
perimetry and peripapillary retinal nerve fibre layer (ppRNFL) imaging using optical coherence 
tomography (OCT). 
Results: A retrospective analysis of the evolution of vigabatrin associated visual field loss 
(VAVFL) in individuals continuing VGB showed progression of VAVFL in all individuals over 
a ten-year period.   
More VGB-exposed individuals were able to perform OCT compared to perimetry.  Measures 
of ppRNFL thickness were found to be highly repeatable in this population.  There was a strong 
correlation between ppRNFL thickness and visual field size suggesting that irreversible VAVFL 
may be related to loss of retinal ganglion cells (RGCs).  Duration of VGB exposure, maximum 
daily VGB dose, male gender and the presence of a homonymous visual field defect were 
associated with ppRNFL thinning. 
The pattern of ppRNFL thinning suggested that ppRNFL loss progresses with increasing VGB 
exposure.  Subtle ppRNFL thinning may occur in discrete areas after exposure to small amounts 
of VGB, whilst other ppRNFL areas appear to be resistant to large cumulative VGB exposure.   
The ppRNFL was significantly thinner in non-exposed individuals with epilepsy compared to 
healthy controls.  Factors that may be associated with ppRNFL thinning included the presence 
of learning disability, MTLE with HS and longer duration of epilepsy. 
Conclusions: ppRNFL imaging using OCT provides a useful tool to assess VGB-exposed 
individuals, and can provide an accurate estimate of the extent of VAVFL in the absence of a 
reliable direct measure of the visual field. Understanding patterns of ppRNFL thinning 
associated with cumulative VGB-exposure may aid in the early detection of VGB toxicity.  
Pathophysiological mechanisms of VAVFL are unknown; however, pathology of RGC 
apparatus is evidently implicated.  
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MRD Mean radial degrees  
Na
+ 
Sodium 
Nas Nasal  
NI Nasal-inferior 
NS Nasal-superior 
OCT Optical coherence tomography 
ONH Optic nerve head 
ONL Outer nuclear layer 
OP Oscillatory potential 
OPL Outer plexiform layer 
OXC Oxcarbazepine 
PERG Pattern electroretinogram 
PB Phenobarbital 
PHT Phenytoin 
PGB Pregabalin 
PMD Primidone 
ppRNFL Peripapillary retinal nerve fibre layer  
RGC Retinal ganglion cell 
RNFL Retinal nerve fibre layer  
RPE Retinal pigment epithelium 
Sup Superior  
SD-OCT Spectral-domain optical coherence tomography  
SN Superior-nasal 
ST Superior-temporal  
TD-OCT Time-domain optical coherence tomography   
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Temp Temporal 
TGB Tiagabine 
TI Temporal-inferior 
TLE Temporal lobe epilepsy 
TPM Topiramate 
TS Temporal-superior 
TSC Tuberous sclerosis complex 
TSNIT Temporal-superior-nasal-inferior-temporal  
UK United Kingdom 
VAVFL Vigabatrin associated visual field loss 
VEP Visual evoked potential  
VGB Vigabatrin  
VPA Valproate 
ZNS Zonisamide 
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Glossary of commonly used terms  
VGB-exposed Includes all individuals who have any history of exposure to 
VGB.  Includes both individuals currently receiving VGB and 
individuals previously exposed to VGB. 
Non-exposed   Includes individuals with epilepsy who have nerve been 
exposed to vigabatrin  
Healthy controls  Includes individuals who have never been diagnosed with 
epilepsy and have never been exposed to any antiepileptic 
drug.  
ppRNFL and RNFL Please note that ppRNFL refers specifically to the retinal 
nerve fibre layer immediately surrounding the ONH. 
RNFL refers in general to the whole retinal nerve fibre layer 
throughout the retina, or in focal retinal areas as specified in 
the text.    
TD-OCT and SD-
OCT 
Unless otherwise stated, discussion of TD-OCT refers to 
(Stratus OCT software version 4.0, Carl Zeiss Meditec, Inc., 
Dublin, CA, USA) discussion of SD-OCT refers to (Cirrus 
HD-OCT software version 5.0, Carl Zeiss Meditec, Inc., 
Dublin, CA, USA).   
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Chapter 1  Introduction 
 
1.1 γ-aminobutyric acid 
 
In the late 1950’s it was discovered that γ-aminobutyric acid (GABA) was the major 
inhibitory neurotransmitter in the central nervous system (CNS) (1-3).  GABA is 
synthesized in presynaptic GABAergic axon terminals from intracellular glutamate in a 
reaction that is dependent on the enzyme glutamic acid decarboxylase (GAD).  After 
synthesis, GABA is loaded into vesicles and released from nerve terminals during 
membrane depolarization via calcium-dependent exocytosis.  The effects of GABA are 
mediated both pre- and post-synaptically through ionotropic GABAA and GABAC 
receptors and metabotropic GABAB receptors.  Termination of GABA signaling is 
achieved by active transport of GABA from the synaptic cleft into the pre-synaptic 
nerve terminal or surrounding glial cells through high affinity Na
+
-
 
 and Cl
- 
-dependent 
GABA-transporters (GAT) in the plasma membrane.  Within the neuron or glial cell, 
GABA is metabolized in a reaction catalyzed by the mitochondrial enzyme GABA-
transaminase (GABA-T) (1) (Figure 1.1).  The end product of this metabolic process is 
glutamate.  In GABAergic neurons that contain GAD, glutamate is metabolized again to 
form GABA.  In glial cells GAD is not present, and glutamate is converted to glutamine 
(via glutamine synthetase) which diffuses from glial cells into neighboring neurons 
where it is again converted to glutamate (Figure 1.1). 
 
  
26 
 
Figure 1.1 Normal GABA metabolism  
 
Figure 1.1 legend: yellow cell = GABAergic neurone; Grey cell = Glial cell; Green cell = 
post-synaptic neurone; GAD = glutamic acid decarboxylase; GABA = γ-aminobutyric acid; 
TCA = tricarboxylic acid cycle; GABA-T = GABA transaminase; GAT-1 = GABA-transporter 
1; GAT-3 = GABA-transporter 3 
 
1.1.1 The search for GABAergic antiepileptic drugs 
The identification of GABA as the major inhibitory neurotransmitter in the CNS led to 
much attention directed toward this molecule and its role in neurological disease.  Soon 
compounds aimed at targeting processes within CNS GABAergic systems were sought 
as potential therapies for diseases in which impairment of GABA-mediated inhibition 
was suggested as a pathological mechanism (2;3), including epilepsy (3) in which an 
imbalance of excitatory and inhibitory neurotransmission is implicated (4).  Several 
inhibitors of GABA-T, the metabolising enzyme of GABA were synthesised and some 
were found to have anticonvulsant properties (5).  However, many of these compounds 
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were hampered by toxicity, lack of specificity for GABA-T, low potency and inability 
to penetrate the blood brain barrier (2;5;6). 
 
1.2 Vigabatrin: a designer antiepileptic drug 
 
The first of the GABA-T inhibitors found to have a suitably potent (7;8) and specific 
(8;9) biological action for potential clinical use (10) was 4-amino-5-hexenoic acid 
(vigabatrin, (also γ-vinyl-GABA)).  A structural analogue of GABA (Figure 1.2), 
vigabatrin (VGB) was designed specifically to increase CNS GABA through 
irreversible inhibition of GABA-T, and represented the first attempt at mechanism-
based antiepileptic drug development (11) and became the first ―designer‖ antiepileptic 
drug (AED) available for clinical use (12).   
 
Figure 1.2 Chemical structure of GABA and VGB 
 
Figure 1.2 legend: VGB was designed as a structural analogue to GABA with a vinyl 
appendage.  VGB = vigabatrin; GABA = γ-aminobutyric acid.  Figure taken from (13) 
 
γ-aminobutyric acid 
(GABA)
γ-vinyl γ-aminobutyric acid 
(vigabatrin)
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1.2.1 Vigabatrin: mechanism of action  
Studies in mice and rats showed that when administered peripherally (per oral, intra-
peritoneal, intra-venous), VGB concentration increases in a dose-dependent manner in 
the CNS
1
 (10;14;15) and produces a rapid dose-dependent inhibition of brain GABA-T 
activity (10;15-18) .  In the mitochondria, GABA-T metabolises GABA, thus inhibition 
of this enzyme by VGB results in increased total brain concentrations of GABA 
(9;10;15-19).  The distribution of increased GABA was found to include both increased 
intracellular GABA levels (nerve terminal and glial cell) (20) and increased 
extracellular GABA as detected in the CSF (21).  
In rats exposed to a single dose of VGB, whole brain GABA-T activity decreases 
rapidly, reaching 20% of control activity within 4 hours of dosing which was 
maintained for at least 48 hours (10). Concurrently, whole brain GABA concentrations 
rapidly increase also peaking at around four hours post-dosing, at concentrations around 
five-times the baseline GABA levels.  The pharmacological effects of VGB are 
determined by the half life of GABA-T which is longer than that of VGB (10;22).  As 
new GABA-T is synthesised GABA-T activity slowly begins to increase, and GABA 
levels subsequently decrease.  By five days post-dosing GABA-T activity is still 
reduced, and GABA concentrations were just returning to baseline levels (10).   
In pre-treated rats VGB has also been shown to increase both resting and potassium-
evoked GABA release from cortical slices (14;23;24).  The GABA release recorded 
after pre-treatment with VGB was highly calcium–dependent and thus is likely to 
represent neuronal (as opposed to glial) GABA release (24).  In addition, a reduction in 
GABA uptake after VGB exposure has also been reported (16;23;25).  The mechanisms 
                                                          
1
 cerebellum, pons, hippocampus, frontal cortex, dorsal cortex and retina (Sills 2001);  
cortex, spinal cord and retina (Neal 1990); whole brain (Jeung 1990) 
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of GABA uptake inhibition by VGB are unknown, but have been suggested to represent 
competitive inhibition between GABA and VGB for uptake via one of the GATs 
(16;25).  Alternatively, once GABA has accumulated in the Müller cell, such an 
intracellular GABA accumulation will impair the efficiency of the GABA uptake into 
Müller cells due to a decrease in the transmembrane driving force (26). 
Decreased GAD activity after VGB exposure has also been reported in some studies 
(10;14;16;18), although to a lesser extent than that of GABA-T (10).  VGB may have a 
direct inhibitory effect on GAD activity (10;18).  Alternatively, inhibition of GAD 
activity may be due to a negative feedback loop resulting from high GABA levels 
(9;14;18;27;28).   Decreases in brain glutamine after VGB exposure have also been 
reported (18) which could result from direct inhibition of glutamine synthetase by VGB 
(18).  Alternatively, the decreased GABA metabolism resulting from inhibition of 
GABA-T by VGB may result in decreased production of glutamate and thus less 
glutamate availability for metabolism by glutamine synthetase to glutamine.   
In humans, oral VGB intake was associated with a dose-dependent increase in 
cerebrospinal fluid GABA (22;29-32) and brain GABA concentrations (33). 
1.2.2 Antiepileptic properties in animals 
VGB has shown to protect against seizures in several animal seizure models including 
audiogenic seizures (9), chemically-induced seizures (20;34), photic-induced seizures 
(35) and amygdala-kindled seizures (36). 
1.2.3 VGB for drug-resistant partial seizures 
The anticonvulsant properties of VGB observed in rodents (9;20;34), and non-human 
primates (35), alongside the finding that exposure to VGB results in a dose-dependent 
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increase in CSF GABA in humans (22;29-32) suggested a potential for antiepileptic 
drug use in individuals with epilepsy (37).   
Early single-blind, placebo-controlled studies in individuals with drug-resistant epilepsy 
showed that VGB decreased seizure frequency (32;38;39) and severity (32) when used 
as add-on therapy.  Subsequent double-blind, placebo-control trials confirmed this, 
reporting that around 50% of individuals with drug-resistant epilepsy had a more than 
50% reduction in seizure frequency after VGB add-on therapy (37;40-43), around 20% 
of individuals had a more than 75% reduction in seizure frequency (37;40;42).  More 
recent, larger studies have further confirmed these findings in individuals with drug-
resistant complex partial seizures (44-46).  A recent systematic review of randomised, 
double-blind, placebo-controlled trials of VGB for drug-resistant partial epilepsy 
concluded that VGB is effective in reducing seizure frequency in this group of 
individuals (47).    
1.2.4 VGB for infantile spasms  
Infantile spasms is a devastating childhood epilepsy syndrome characterised by spasms, 
characteristic EEG abnormalities (hypsarrhythmia), psychomotor delay and poor long-
term prognosis.  Seizures associated with infantile spasms are usually refractory to 
treatment with conventional AEDs (48;49), and currently adrenocorticotropic hormone 
and VGB are first-line therapies (50).  In 1991 Chiron et al. (51) reported that cessation 
of spasms was achieved in 43% of children with drug-resistant infantile spasms after 
receiving VGB add-on therapy.  Subsequent studies have reported the effectiveness of 
VGB as first-line monotherapy in infantile spasms (52-59), particularly in infantile 
spasms secondary to tuberous sclerosis complex (TSC)  (55;60;61) where cessation of 
spasms is achieved in up to 100% of children (60).  A recent meta-analysis of treatment 
of infantile spasms found that there is no clear evidence as to which treatment is optimal 
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for infantile spasms; however, VGB may be the superior treatment in infantile spasms 
secondary to TSC (48).  
 
1.3 Vigabatrin tolerability and adverse effects 
 
Double-blind, placebo-controlled trials found VGB to be an effective and well tolerated  
drug (37;46) with few significant drug interactions (46).  Adverse effects in adults were 
generally mild and included drowsiness (37;41-43;45;47), dizziness (47) and mood 
changes (37;41;47;62) (particularly depression (47)).  These tended to improve with 
careful titration and continued VGB use (37).  In children adverse effects were also mild 
and included sedation, irritability and insomnia (55;60;61).  However, the trials were 
typically of short duration, the longest follow-up being 36 weeks (46).    
1.3.1 Intramyelinic oedema 
In VGB-exposed animals microscopic vacuolation resulting from separation of the outer 
layers of the myelin sheaths were reported (63). The lesions, referred to as 
―intramyelinic oedema‖ (IMO), were limited to discrete myelinated tracts, with no 
evidence of structural change to the cell bodies or axons (64) and reverse on cessation 
of treatment (65). IMO was seen in VGB-exposed mice (64;65), rats (63;65) and dogs 
(63;65).  In monkeys, there was no conclusive evidence to suggest that IMO occurred 
after VGB exposure (63;65).  Similarly, in studies of post mortem and surgical brain 
tissue from VGB-exposed adults, no evidence of intamyelinic oedema was detected (65-
69).  However, IMO has recently been described in a post mortem specimen from a 
VGB-exposed infant with quadriplegic cerebral palsy and infantile spasms (70).   
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In VGB-exposed dogs, IMO was found to be prominent in the optic tracts and was 
associated with increased latencies of the visual evoked potentials (71).  In preclinical 
(72;73) and early clinical (74) studies of VGB-exposed individuals with epilepsy, visual 
evoked potentials were assessed to monitor individuals for early damage involving the 
visual pathways.  Studies demonstrated normal VEP after up to 3.5 years of VGB 
exposure (72-74) suggesting that in humans VGB is not associated with visual pathway 
IMO (75).    
1.3.2 Psychosis 
Early clinical trials with VGB found behavioural disturbances to be the most common 
adverse effect (62).  Behavioural adverse effects of VGB included agitation, irritability, 
confusion, hyperactivity and depression (62). In a small number of individuals VGB 
exposure was associated with the development of psychotic episodes (76;77).  However, 
these episodes tended to respond well to careful titration, reduced VGB dose or 
treatment with antipsychotic drugs (76) and resolved after discontinuation of therapy 
(77). 
1.3.3 Vigabatrin associated visual field loss 
In 1997 Eke et al. reported three cases of symptomatic visual-field constriction in 
individuals with two to three years of VGB exposure that could not be explained by any 
opthalmological or neurological insult (78).  Several authors suggested that the visual 
field defect could result as a consequence of the epilepsy, rather than a toxic effect of 
VGB (79-81).  In addition, the individuals reported by Eke et al. (78) had all been 
exposed to several AEDs that could also have contributed to the visual impairment.  
However, in the ensuing year numerous authors reported individual cases and case 
series of vigabatrin-associated visual field loss (VAVFL) (79;82-85).   
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1.4 Prevalence of VAVFL 
 
After the initial case report from Eke et al. (78), several authors reported individual 
cases and case series of visual field constriction associated with VGB exposure (79;82-
85).  At this time, the manufacturers of VGB, Hoechst Marion Roussel, reported that 
since the introduction of VGB in 1989 they had received ―rare‖ reports of visual field 
defects associated with VGB use, with a frequency of less than 0.1% (86), and an 
overall incidence estimated to be 14.5/10,000 patients with epilepsy per year (84).  
Many of the initial statistics were based upon sporadic reports from symptomatic 
individuals and questionnaires of visual symptoms (82;87).  However, it was suggested 
early on that VAVFL may be asymptomatic and may be more common than initially 
suggested by these studies (85;88-90).  Subsequent studies have estimated the 
prevalence of VAVFL to be between 17 and 92% in adults, and between 6 and 65% in 
children (Table 1.1).  Recently, a systematic review of observational studies 
investigating the prevalence of VAVFL was published (91).  The review identified 32 
studies which met the inclusion criteria, and found that the proportion of VGB-exposed 
individuals described as having ―visual field loss‖ was 45%.  The proportion of 
individuals specifically described as showing VAVFL was 31%.  When separated into 
studies of adults and studies of children, the combined random effects estimate for the 
estimated mean proportion of vigabatrin-exposed individuals with field loss was  52% 
and 34% for adults and children, respectively (91).    
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Table 1.1 Summary of studies reporting the prevalence of VAVFL in VGB-exposed 
adults and children 
Reference  Prevalence 
(%) 
Number of 
individuals 
Perimetric 
method  
Mean 
cumulative 
VGB exposure 
(kg) [range] 
Mean duration 
VGB exposure 
(months) 
[range] 
Wild 2009 (92) 34% 301 BOTH 2.5 44 
Sergott 2010 (93) 72% 258 GKP - - 
Hardus 2000 (94) 17% 118 Peritest Static - - 
Newman 2002 (95) 20%∞ 100 GKP 4.0 [0.17-17.5] 61  
Malmgren 2001 (96) 19% 99 GKP [0.3- >7] [1-152] 
Wild 1999 (97) 29% 99 BOTH 4.1 49 
Nicolson 2002 (98) 43% 98  HVFA  - - 
Kinirons 2006 (99) 53 % 93 GKP 5.4 86 
Nousiainen 
2001(100) 
40 % 60  GKP [0.42-18.7] [7-168] 
Daneshvar 1999 
(101) 
29% 41 HVFA 
a, b 
- 39  
Tseng 2006 (102) 79% 34 HVFA 
a 
3.7 46 
McDonagh 2003 
(103) 
59% 32 HVFA 
c 
 5.9  84  
Kalviainen 1999 
(104) 
41% 32 GKP - 69  
Krauss 2003 (105) 53% 32 GKP - 47 
Miller 1999 (106) 50 % 32 BOTH - 52 
Conway 2008 (107) 18% 31 HVFA
a 
>1 >24 
Schmitz  2002 (108) 45% 29 GKP - [4-71] 
van der Torren 2002 
(109) 
69 % 29  BOTH 3.0  55  
Fledelius 2003 (110) 92% 26 GKP - 102  
Lawden 1999 (81) 39 % 25  HVFA 
a,b,c,d,e 
[0.6-10.3] 50 
Paul 2001 (111) 41% 22 BOTH - >24  
Besch 2002(112) 90% 20 GKP [0.06-65] 2-96 
Manuchehri 2000 
(113) 
67% 20 HVFA 
c 
2.9 59 
Arndt 1999 (114) 58%
 
19  HVFA  - 12  
Hui 2008 (115) 56% 18 HVFA 
a 
- 24 
Midelfart 2000 (116) 83%  18 HVFA 
c
 -  - 
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VAVFL = vigabatrin associated visual field loss; VGB = vigabatrin; GKP = Goldmann kinetic 
perimetry; HVFA = Humphrey visual field analyzer; Studies are listed in order of the number of 
VGB-exposed individuals who were examined using perimetry.   
Italic – cases were recruited as ―suspected VAVFL‖ or ―those in whom analysis of the visual 
field should be considered‖ 
a
 HVFA 30-2 program  
b
 HVFA 60-4 program  
c  
HVFA full field 120-point program 
d 
HVFA 24-2 program 
e 
HVFA 30/60-2 program
 
Moreno 2005 (117) 89% 18 HVFA
c 
- 44 
Toggweiler 2001 
(118) 
60 % 15  GKP 3.1 47  
Ardagil 2010 (119) 29 % 12 HVFA 
a 
3.3  78 
Ponjavic 2001(120) 58% 12 GKP - [24-120] 
Jensen 2002 (121) 30% 10 GKP - 79  
Paediatric studies 
 
Vanhatalo 2002 
(122) 
19% 91 GKP 2.1 40 
Wild 2009 (92) 20% 85 BOTH 1.3 37 
You 2006 (123) 22% 67 HVFA
a 
22.8mg/kg 50 
Werth 2006 (124) 27% 30 Non-
commercial 
arc perimetry  
- 46  
Agrawal 2009 (125) 29% 28 White sphere 
kinetic 
perimetry  
- - 
Gross-Tsur 2000 
(126) 
65% 17 BOTH 
 
43mg/kg 36 
Gaily 2009 (127) 6% 16 GKP 0.66 24 
Ascaso 2003 (128) 20% 15 HVFA 
a 
- 42 
Wohlrab 1999 (129) 42% 12 GKP - 26 
Iannetti 2000 (130) 33% 12 BOTH - - 
Spencer 2003 (131) 36% 11 HVFA
a
  - [3-108] 
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The large range in reported prevalence of VAVFL could be due to a number of factors 
including non-blinded assessments, ascertainment bias and small sample sizes (12).  
Different studies have used different perimetric techniques to assess the visual field, 
including both manual kinetic and automated static techniques which could influence 
the reported prevalence of VAVFL (12;93;132;133).  This was investigated in a recent 
systematic review which found no effect of perimetric assessment method on the 
reported prevalence of VAVFL (91).  However, the review only examined the 
difference between using ―static‖ or ―kinetic‖ techniques and did not account for 
different programmes or testing strategies used.   For example, in studies using 
automated static perimetry (mainly the Humphrey Visual Field Analyzer (HVFA)), 
different visual field assessment programmes have been employed between studies 
which examine the visual field out to varying eccentricities.  For example, the 120-point 
programme examines the visual field out to 60
o
 eccentricity in all meridians, compared 
to the 30-2 programme which only examines out to 28
o
 eccentricity.  Individuals with 
mild peripheral VAVFL may not be identified using a programme which assesses only 
the central visual field (97;101;106;122).  Similarly, in studies using manual-kinetic 
perimetry (mainly Goldmann Kinetic Perimetry (GKP)), the use of various testing 
stimuli (i.e. plotting various isopters) between studies may also lead to differences in the 
reported prevalence (91).  
Differences in demographic, clinical and therapeutic factors between the populations 
included in the studies may also contribute to the differences in reported prevalence of 
VAVFL.  For example, studies in which the individuals have a high cumulative VGB 
exposure or long duration of VGB exposure may be expected to report a higher 
prevalence of VAVFL (91).  Other yet unidentified risk factors for VAVFL may differ 
between study cohorts and could influence the prevalence of VAVFL.     
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The criteria used to define VAVFL differ between studies, even those using the same 
perimetric technique.  Differences in the criteria used to define ―normal‖ and 
―abnormal‖ visual fields could result in differences in the prevalence recorded between 
studies (93).  In a large study by Sergott using GKP, 72% of VGB-exposed individuals 
had visual field defects (93), compared to a similar-sized study by Wild et al. who found 
that only 34% of VGB-exposed individuals had VAVFL (92).  In the study by Wild et 
al. each visual-field test result was evaluated by a single investigator who semi-
qualitatively classified each visual field as ―normal‖ or ―VAVFL‖ based on available 
criteria (97).   In the study by Sergott et al. the extent of the visual field in the temporal 
meridian was determined based on the largest available isopter (V4e or IV4e).  Visual 
fields that extended to less than 80
o 
in the temporal meridian were considered abnormal 
(93).  In the study by Sergott et al. 55% of individuals with epilepsy with no history of 
exposure to VGB (non-exposed) showed abnormal visual fields, whereas in the study by 
Wild et al. only 1% of non-exposed individuals showed a visual field that was classified 
as showing VAVFL according to the criteria used (92). 
The effect of using different criteria for defining an abnormal visual field on the 
reported prevalence of VAVFL was highlighted by Vanhatalo et al.  In their study 
different ―limits for normality‖ were applied to visual field data from 91 VGB-exposed 
children illustrating that changing the criteria for normality may result in substantial 
differences in the reported prevalence of VAVFL (Table 1.2) (122). 
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Table 1.2 The effect of changing the criteria for normality of the visual field on the 
prevalence of VAVFL (taken from (122)) 
Limit for normality in the 
temporal meridian (degrees) 
Number of individuals 
(normal:abnormal) 
Prevalence of VAVFL 
≥80o 41:50 54.9% 
≥70o 74:17 23% 
≥60o 84:7 8.3% 
≥50o 90:1 1.1% 
The proportion of individuals included in a study by Vanhatalo et al. with visual fields classified 
as ―abnormal‖ when the limits for normality are set at different degrees in temporal meridian 
(taken from (122)) 
VAVFL = vigabatrin associated visual field loss 
 
1.5 Characteristics of VAVFL 
 
The characteristics of vigabatrin-associated visual field loss (VAVFL) were first 
explored systematically by Wild et al. who observed the severity, type and location of 
visual field defects in VGB-exposed individuals (97). Using static threshold perimetry 
of the central 30
o
 of the visual field (HVFA 30-2 program) a unique pattern of visual 
field loss was described as showing ―localised bilateral nasal loss, extending in an 
annulus over the horizontal midline, with a relative sparing of the temporal field‖.  The 
visual field defect was found to be steeply bordered and absolute, that is, at the edge of 
the remaining, intact visual field the sensitivity to light fell from normal to absolute loss 
of light sensitivity suddenly and rapidly (81;94;134).  In individuals examined using 
Goldmann kinetic perimetry, the visual field (examined beyond 30
o 
eccentricity) was 
found to be concentrically constricted, with a more profound nasal than temporal 
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constriction.  In the most severe cases the visual field loss manifested as a bilateral, 
symmetric, concentric constriction within 30
o 
eccentricity.  In the same study, a 
population of individuals with epilepsy not exposed to VGB (non-exposed) were also 
examined using perimetry.  Visual field defects were found in seven individuals, all of 
which could be attributed to known retinal or cortical pathology.  None of the non-
exposed individuals manifested a pattern of visual field loss with characteristics of that 
seen in the VGB-exposed individuals (97).       
Ensuing studies and clinical experience confirm that the characteristics of VAVFL are 
of a peripheral (101;104;106;116), concentric (94;101;104) contraction of the visual 
field affecting both eyes (94;97;101;104;106;134;135) symmetrically 
(81;97;101;104;107;109;134;136).   
Several groups have described VAVFL as showing more extensive involvement of the 
nasal visual field than the temporal visual field (81;97;126).  However, this 
characteristic of VAVFL is contentious (106;137;138).  An overestimation of the degree 
of involvement of the nasal visual field in individuals with VAVFL may be due to the 
perimetric technique used (137).  The normal monocular visual field extends to around 
60
o 
nasally and 100
o 
temporally.  Many of the automated perimetric techniques used do 
not examine the full extent of the visual field.  For example, the commonly used 30-2 
program of the HVFA examines the monocular visual field out to 28
o 
eccentricity in all 
meridians.  A concentric contraction of the visual field (i.e. by an equal amount in all 
meridians) of around 30
o 
may show as a mild nasal visual field defect in an individual 
assessed using this technique, but would not be detected in the temporal field (137).  
Where studies have compared the percentage constriction in each hemifield in 
individuals with VAVFL, either the temporal hemifield shows more constriction than 
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the nasal hemifield (106) or there was no difference found in the degree of constriction 
between hemifields (94;110). 
1.5.1 The severity of VAVFL 
The severity of VAVFL varies widely (12;96;97;106), with some individuals showing 
very mild loss of the far periphery of the visual field (94;96;116) whist others develop a 
very severe constriction extending to involve the central 30
o 
of the visual field 
(96;101;109;139) (Figure 1.3).  In most individuals with VAVFL the defect is mild to 
moderate with few individuals showing severe defects.  In a large study of 119 adults 
and children with VAVFL, 52% were classified as showing mild VAVFL, 35% as 
moderate and 13% as severe (92).    
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Figure 1.3 The characteristics and severity of VAVFL 
 
Figure 1.3 legend: VAVFL is well characterised as a concentric peripheral constriction of 
the visual field.  A normal visual field plotted with the I4e isopter using Goldmann Kinetic 
perimetry is shown (A).  The severity of VAVFL ranges from mild (B) to severe (C). 
 
1.6 The evolution of VAVFL 
 
1.6.1 Time to onset of VAVFL 
The time to onset of VAVFL after starting VGB has been difficult to establish as most 
studies have been cross sectional and individuals included have been receiving VGB for 
variable periods before entry into the study.  Very few prospective studies of VAVFL 
have been carried out, and even in these studies the time of VAVFL detection may not 
A
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be the time of VAVFL onset due to the asymptomatic and possibly insidious nature of 
the visual field loss (140). 
In an unpublished clinical trial of VGB reported by the FDA, 25 VGB-exposed 
individuals were prospectively assessed for VAVFL at three monthly intervals (141).  
7/25 individuals developed VAVFL within the follow-up period (median duration of 
follow-up was 500 days).  One individual developed VAVFL after two months of VGB 
exposure and five individuals developed VAVFL after around one year of exposure 
(141).   
In a prospective study of the use of VGB for treatment of cocaine and metamphetamine 
abuse, visual field testing was performed at baseline and at one, four and eight weeks 
during VGB exposure.  In the 18 individuals who completed the study, no changes were 
seen in the visual field compared to baseline.  However, the duration of VGB exposure 
and the cumulative VGB exposure were relatively short (eight weeks and 137 grams, 
respectively) compared to the treatment strategies used in individuals with epilepsy 
(142). 
Schmitz et al. performed visual field testing in 29 individuals before exposure to VGB, 
and again 34-120 months after initiation of VGB (108).  At the follow-up examination 
13/29 (45%) had developed VAVFL.  Of the individuals who had developed VAVFL, 
the duration of VGB exposure ranged from 9 - 71 months.  However, because 
individuals had not undergone repeated visual field assessments during the VGB 
exposure period, the time of onset of VAVFL after VGB exposure could not be 
determined.   
 In cross-sectional studies, VAVFL has frequently been detected in individuals within 
around one year of VGB exposure (96;99;112;138;143).  Abnormalities of the ERG 
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have also been reported to occur within six months after VGB exposure (105;144).  It is 
not known whether these abnormalities relate to the development of VAVFL, or are 
associated with the direct effects of VGB on retinal physiology as healthy individuals 
exposed to a one-off dose of VGB develop ERG abnormalities despite maintaining 
normal visual fields (145).  
The onset of symptoms of visual field constriction (e.g. ―bumping into things‖) has been 
reported to occur from 6 – 75 months after starting VGB therapy 
(78;79;82;101;143;146).  The onset of symptoms suggests that the visual field 
constriction is likely to be severe, and encroaching on central vision (97).  In these 
individuals it is possible that a degree of mild VAVFL may have been present before 
the onset of symptoms, and thus the development of symptomatic VAVFL may not 
provide an accurate estimate of the time of onset of VAVFL.   
1.6.2 The development of VAVFL  
The nature of the onset of VAVFL is unknown.  The asymptomatic characteristics of 
VAVFL suggest that the development of visual field constriction is slowly progressive, 
allowing adaptive processes to take place to compensate for impaired peripheral vision 
(81;92;97;112).  In addition, the range in severity of VAVFL from mild and 
asymptomatic to severe constriction suggest that VGB toxicity may be slowly 
progressive, with individuals with varying degrees of VAVFL at varying stages of 
progression (147).  Conversely, in some VGB-exposed individuals, significant changes 
in the visual field occur within short time periods, suggesting that VAVFL onset may 
occur rapidly in some cases (139;143).  Analysis of serial visual field assessments over 
a ten-year period in an individual on VGB therapy showed a significant deterioration in 
visual field size between assessments carried out one year apart (139).  Similarly, in an 
unpublished prospective study of VGB-exposed individuals assessed using perimetry at 
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three-monthly intervals, VAVFL was first detected as a moderate degree of constriction 
within 20-30
o 
of fixation in three individuals (141).  As the individuals included in the 
study were assessed at three-monthly intervals, this demonstrated that in these cases 
moderate VAVFL developed rapidly within the three month period between visual field 
examinations (141).   
The nature of onset of VAVFL will be difficult to determine (140).  VAVFL is largely 
asymptomatic and few individuals who are able to perform reliable perimetry are newly 
started on VGB, meaning that good prospective data are unlikely to become available 
(99).  In addition, inferences about the nature of VAVFL onset may be influenced by 
the frequency of perimetric examinations undertaken.  From the available studies it is 
difficult to determine the nature of VAVFL onset and it is possible that the onset of 
VAVFL may differ between individuals, showing either a slowly progressive or rapidly 
progressive onset (Figure 1.4) (141).   
 
Figure 1.4 The nature of the onset of VAVFL (adapted from (141)) 
 
Figure 1.4 legend: Visual field assessments taken at Time 1 (red arrow) reveal normal 
visual fields.  Repeat assessment at Time 2 (red arrow) show that VAVFL has developed.  
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However, the nature of onset of VAVFL between this period is unknown (black dashed line).  
VAVFL may develop in a slowly progressive pattern occurring over a protracted time period 
(A) (black dashed line).  Alternatively VAVFL may have a sudden and rapid onset, occurring 
over a short time period (B) (black dashed line).    
 
1.6.3 The progression of VAVFL 
It is generally accepted that once established, VAVFL is stable and does not progress 
with continued VGB exposure (111).  Follow-up studies of individuals who continue 
VGB therapy have shown no progression of VAVFL over time (81;100;111;148-150) 
(See Table 3.1).  In addition, several studies have shown that the risk and severity of 
VAVFL does not increase with increasing VGB exposure (see 1.7.1) 
However, other studies have shown an association between increasing VGB exposure 
and increased risk of VAVFL (see 1.7.1).  In addition, progression of VAVFL with 
continued VGB use has been reported in some studies (81;139;151;152) (Table 3.1).   
Overall, studies of the evolution of VAVFL in individuals continuing VGB therapy 
have typically followed patients for less than four years (Table 3.1).  Only one case 
report has assessed the evolution of the visual field with continued VGB therapy over a 
longer period (139).  In this report, rapid, severe VAVFL developed after ten years of 
VGB exposure, suggesting that VAVFL can progress in some individuals after many 
years of VGB use (139).  
1.6.4 The irreversibility of VAVFL 
The irreversible nature of VAVFL has been suggested since the initial case series 
reported by Eke et al. (78).  Subsequent follow-up studies have confirmed that in most 
individuals VAVFL is irreversible after VGB withdrawal (Table 1.3).   
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Table 1.3 Summary of follow-up studies investigating the effect of VGB withdrawal 
on visual field size.  
Reference  Number of 
individuals   
Follow-up after 
VGB withdrawal 
(months) 
Overall finding   
Nousiaien 2001 (100) 29 4 - 38 No change# 
Newman 2002 (95) 21 6- 18 No change# 
Hardus 2000 (152) 16 24
b 
No change 
Johnson 2000 (153) 13 3 - 11  No change 
Schmidt 2002 (149) 11 12 - 24 No change 
Lawden 1999 (81) 10 Not stated No change# 
Kjellstrom 2008 (154) 8 48 - 72 No change 
Fledelius 2003 (110) 8 Not stated Improvement  
Vanhatalo 2001 (155)* 7 Not stated  Improvement  
Hardus 2003 (151) 6 37 – 47  No change 
Eke 1997 (78) 2 12, 48 No change 
Krakow 2000 (156) 2 6, 1 Improvement 
Wong 1997 (82) 1 48 No change 
Giordano 2000 (157)* 1 9 Improvement 
Versino 1999 (158)* 1 10 Improvement  
*Paediatric studies  
#Some individuals included in the study did show an improvement in the visual field, although 
overall the authors concluded that there was no change in the visual field size after VGB 
withdrawal. 
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Some cases of reversibility of VAVFL have been reported, particularly in children 
(155;157;158) and rarely in adults (81;95;100;110;156).  Young age has been suggested 
as a favourable factor for reversal of VAVFL (157) due to more efficient retinal repair 
mechanisms (158) and neural plasticity (155) in childhood.  However, it is still 
unknown whether rare cases of reversibility of VAVFL reflect true improvement in 
visual function after VGB withdrawal or whether they are a product of the limitations of 
perimetry in the assessment of some individuals.  A learning effect in repeat perimetry 
is well recognised (159;160) and the apparent reversal of VAVFL after VGB 
withdrawal may be related to improved performance and familiarly with the task (81).  
In particular, children often show a progressive improvement of the visual field over 
subsequent test sessions related to the learning effect (122), which could explain the 
more frequent reports of VAVFL reversibility in paediatric studies.  For example, in one 
child, progressive improvement of the visual field was seen alongside progressive 
improvement in the reliability of the visual-field assessment (157).  Similarly, in an 
individual with a reported improvement in VAVFL after VGB withdrawal (158), the 
illustrated visual field  taken whilst on VGB showed a ―clover-leaf‖ pattern which is 
typical of functional visual impairment, or concentration and fatigue-related artefact 
(152;161).  Vanhatalo et al.  reported a case series of seven children who showed 
improvement of the visual field after VGB withdrawal (155).  In the analysis to 
determine the change in visual field size the ―worse visual field‖ whilst on VGB was 
chosen to compare against the latest visual field after VGB withdrawal (155).  Several 
factors may have contributed to the integrity of the ―worse visual field‖ that were not 
related to VGB exposure, including poor task performance, impaired attention and 
concentration and fatigue.  Use of the ―worse visual field‖ in the analysis may have led 
to an overestimation of the improvement in visual field size after VGB withdrawal.   
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It is possible that there are both reversible and irreversible effects of VGB on visual 
function.  In most individuals VAVFL does not improve even many years after VGB 
withdrawal.  In agreement with this a post mortem examination of an individual with 
VAVFL concluded that the degree of cell loss from the retina and optic nerve would 
suggest that the damage to the visual pathway was irreversible (162).  On the other 
hand, some features of VAVFL might be transient and related to the physiological 
effects of VGB.  Various retinal electrophysiological abnormalities that are seen during 
VGB exposure return to normal after VGB withdrawal, further suggesting that aspects 
of visual dysfunction related to VGB exposure may be reversible.   
 
1.7 Risk factors for VAVFL 
 
1.7.1 Cumulative VGB exposure and duration of VGB exposure  
The relationship between increasing VGB exposure and the development of VAVFL is 
controversial and studies have shown conflicting findings.  Increasing cumulative VGB 
exposure (81;96;113;122;137;163), duration of VGB exposure 
(81;92;94;96;108;118;126;137;164), maximum daily VGB dose (107) and mean daily 
VGB dose (92;109;137) have been associated with increased risk of VAVFL in some 
studies (Table 5.7).  However, other studies have reported no effect of cumulative VGB 
exposure (95;97-100;104;109;124;164), duration of VGB exposure 
(95;97;99;100;109;122;124;128;135), maximum daily VGB dose (99;102;108) or mean 
daily VGB dose (124;126;128;165) on risk of VAVFL (Table 5.7).   
Recently, a large, multicentre study of VAVFL in 386 VGB-exposed adults and 
children identified increasing duration of VGB therapy, and increasing mean daily dose 
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of VGB, to be risk factors for VAVFL (92).  It appears that there is likely to be an 
association between increasing VGB exposure and increasing risk of VAVFL.  But it is 
clear that there is not a simple dose-related toxic effect (12).  Some individuals develop 
significant VAVFL after relatively small cumulative VGB exposure and short periods 
of VGB exposure; conversely, other individuals maintain normal vision despite 
receiving high doses of VGB for many years (96;98;122).  Multiple clinical, therapeutic 
and demographic factors may contribute to an individual’s risk of developing VAVFL.  
It has been suggested that VAVFL may represent an idiosyncratic adverse drug reaction 
(12;95;99) where susceptible individuals will develop VAVFL irrespective of the dose 
or duration of VGB exposure, possibly dependent on genetic variability (166). 
1.7.2 Male sex  
In a large multicentre study of 386 VGB-exposed individuals male sex was found to be 
a risk factor for VAVFL (92).  This is in agreement with previous findings 
(92;94;95;97;98;103;137) (Table 1.4). In some studies males were found to be more 
than two times as likely to develop VAVFL compared to females (92;97;140).  In 
addition, certain abnormalities of the electroretinogram were found to be more prevalent 
in VGB-exposed males compared to females (167).  Conversely, other studies have 
found no increased risk of VAVFL associated with male sex (100;104;122;135) (Table 
1.4).  Differences in findings between studies may relate to the approach to analysis of 
the data.  Studies that have reported no association between sex and risk of VAVFL 
have not controlled for the amount of VGB exposure (e.g. cumulative VGB exposure, 
duration of VGB exposure) between groups (Table 1.4).  As this variable is likely to be 
associated with risk of VAVFL (see above) it is important to control for it in any 
statistical exploration of other risk factors. 
50 
 
No theories for the mechanisms of increased susceptibility to VAVFL in males have 
been suggested, although Newman et al. proposed that this finding may indicate a 
genetic susceptibility to VGB toxicity (95).       
 
Table 1.4 Summary of studies exploring an association between male sex and 
VAVFL 
Reference  Number of 
participants 
Male gender a 
risk factor  
Control for VGB 
exposure 
Wild 2009 (92) 386 Yes  Yes 
Hardus 2000 (94) 118 Yes  No 
Newman 2002 (95) 100 Yes Yes* 
Wild 1999 (97) 99 Yes  Yes  
Nicolson 2002 (98) 98 Yes No 
Hardus 2001 (137) 92 Yes# Yes 
Vanhatalo 2002 (122) 91 No No 
Nousiainen 2001 (100) 60 No No 
Durbin 2009 (167)** 42 Yes No 
Kalviainen 1999 (104) 32 No No 
McDonagh 2003 (103) 32 Yes No 
*No significant difference was found between males and females in terms of cumulative VGB 
exposure (independent samples T-test). 
#only found when quantifying visual fields using the surface method but no difference was 
found between males and females when visual fields were quantified using the Esterman 
method. 
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**Visual fields were not assessed.  VGB retinotoxicity was defined as a reduction in the 30Hz 
flicker amplitude of the electroretinogram compared to amplitudes measured before VGB 
therapy. 
 
1.7.3 Other risk factors  
Increased risk of VAVFL has also been associated with increasing age (108) and co-
medication with valproate (108;114;164).  However, most demographic, clinical and 
therapeutic factors have shown no association with increased risk of VAVFL, including; 
exposure to other AEDs  (94;97;137), number of other AEDs exposed to (108;112), age 
(97;112;122;135), epilepsy syndrome (104;113), duration of epilepsy (94;112), 
temporal lobe lesions (94), history of status (94) or poor cognitive performance (122).   
1.7.4 Genetic predisposition  
Genetic variation may play a role in the development of VAVFL (95;98;99;104;168).  
In a study by Kinirons et al. three candidate genes were found to be associated with 
increased risk of VAVFL including a gene encoding GABAb receptor (GABRR1/2) and 
two genes encoding GABA-transporters (GAT1/3 and GAT2).  However, no significant 
association was found on replication of the study by the same authors in a second 
independent cohort (168).  Whilst the initial genetic association found in the study 
probably represents a false positive result, a real association between the gene variants 
detected in the study, or indeed other variants, cannot be ruled out.  The study may have 
been underpowered to detect variants of small effect; in addition findings may have 
been confounded by variability in the visual field measurement (168).   
Genetic variation in the mitochondrial enzyme ornithine δ-aminotransferase has also 
been suggested as a possible source of inter-individual susceptibility to VAVFL 
(169;170).  Individuals with a deficiency of ornithine δ-aminotransferase in the rare 
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inherited metabolic disease gyrate atrophy of the choroid and retina (gyrate atrophy), 
develop peripheral visual field loss that was suggested to be similar to that seen in 
individuals with VAVFL (170).  VGB is a weak inhibitor of ornithine δ-
aminotransferase (171) and may lead to accumulation of ornithine resulting in a mild 
form of gyrate atrophy (172).  Allelic variability in the gene encoding ornithine δ-
aminotransferase may modulate its vulnerability to inhibition by VGB, and thus the 
vulnerability of the retina to VGB-induced toxicity (170).  A recent study showed that 
individuals with VAVFL and a history of VGB exposure had reduced ornithine δ-
aminotransferase activity compared to individuals with a history of VGB exposure with 
normal visual fields.   The authors concluded that individuals with congenitally 
decreased ornithine δ-aminotransferase activity may have increased risk of VAVFL 
during VGB exposure (172).  However, the same study found no difference in ornithine 
δ-aminotransferase activity between individuals currently exposed to VGB with 
VAVFL and those with normal visual fields.  In addition, sequencing of the ornithine δ-
aminotransferase gene in 17 VGB-exposed individuals did not reveal any clinically 
significant mutations (169).  A common intronic polymorphism was identified, but it 
was not associated with VAVFL (169). 
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1.8 Symptoms and quality of life in individuals with VAVFL 
 
1.8.1 Symptoms of VAVFL 
The delay in recognition of VAVFL (first reported in 1997) after VGB was licensed (in 
1989 in the UK) was probably largely due to the asymptomatic nature of VAVFL (12).  
The initial reports of VAVFL by Eke et al. (78) and others (79;82) were in symptomatic 
individuals.  Soon thereafter, it was reported that asymptomatic visual field defects may 
also occur with VGB exposure (85;88-90).  In the first study to screen VGB-exposed 
individuals with no visual complaints, 11/15 showed VAVFL (173) demonstrating that 
VAVFL was likely to be largely asymptomatic (173).  Later studies confirmed that in 
most individuals (approximately 90% (12)) VAVFL is asymptomatic 
(81;93;94;96;98;101;104;106;112;121;137).  The peripheral characteristics of VAVFL 
with preserved central vision and normal visual acuity and colour vision account for 
individuals being largely asymptomatic.  In addition, the development of and 
progression of VAVFL may be slow enough to establish adaptation processes such as 
using compensatory gaze movements to explore the visual field (81;92;97;112). 
The first reports of VAVFL from Eke et al. (78) described symptomatic individuals 
with complaints of  ―tunnel vision‖ and ―bumping into objects‖ associated with the 
development of visual field loss.  Subsequent studies have also reported some VGB-
exposed individuals with these symptoms (81;101;103;104;114).  Occasionally 
symptoms were reported spontaneously, but more often individuals only reported 
symptoms of visual field constriction on direct questioning (104;108).  Symptoms of 
VAVFL appear not to occur until the defect encroaches on the central visual field (97).  
In reports of symptomatic VAVFL, the visual field constriction typically encroaches on 
the central 30
o
 (78;104;146).  Using a questionnaire of visual symptoms and disability, 
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the number of complaints experienced by an individual correlated with decreasing 
visual field size (93;174).  In a larger study no correlation was found between the 
presence of visual symptoms and disability and the presence of VAVFL (92). The 
questionnaires used in each study were not specifically developed for the assessment of 
individuals with VAVFL.  In the study which reported no association between visual 
field size and visual disability measures, the questionnaire used was one which was 
developed for individuals with retinitis pigmentosa and Usher syndrome (92).  It is 
possible that the questionnaire was not specific or sensitive enough to detect the impact 
of VAVFL on visual disability (92)  
In some individuals with VAVFL, symptoms of blurred vision (81;103;104;114), 
photopsia (81;104) and phosphenes (81) were also reported.  However, VGB-exposed 
individuals with normal visual fields also reported these symptoms (104), suggesting 
that they may not be directly related to the mechanisms leading to VAVFL.  In addition, 
several AEDs are associated with visual side effects including blurred vision, 
phosphenes and photopsia (175;176); thus these symptoms may have been related to 
concomitant treatment with other AEDs and not directly related to VGB exposure.   
1.8.2 Quality of life in individuals with VAVFL 
Moderate to severe impairment in performing ―daily tasks‖ which involve reading, 
writing and orientation and mobility  occurred in individuals with a visual field area of 
smaller than 2000 degrees
2
 (equivalent to a 50
o 
diameter of the Goldmann II4e isopter 
(177).   
In most individuals with VAVFL, visual field loss is mild and asymptomatic and does 
not affect quality of life or impair ability to perform everyday tasks (93;97).  However, 
using a questionnaire of visual complaints, individuals with VAVFL were found to have 
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more subjective impairments in tasks associated with visual field defects (e.g. 
difficulties in seeing a car in time when crossing the road) compared to individuals 
without VAVFL (174).  Furthermore, VAVFL may be severe in some individuals, 
limiting their ability to perform a number of activities of daily living (97;106;178).  
Individuals with severe VAVFL may not meet the visual field standards required by the 
DVLA for driving eligibility (179) despite having good seizure control (180).    
 
1.9 Clinical features of VAVFL 
 
1.9.1 Visual acuity 
Visual acuity is normal in the majority of studies of VGB-exposed individuals with 
VAVFL and with normal visual fields (78;94;96;101;104;111;112;114-116;120-
122;128;164;181).  Occasional reports of reduced visual acuity with VGB exposure 
have arisen (81;106;113;114;138); this may due to co-existing ocular pathology in some 
cases and not related to VGB exposure (138;182).  In a prospective study of individuals 
receiving eight weeks of VGB therapy for cocaine and metamphetamine abuse, no 
change in visual acuity over the eight week assessment period was observed (142).   
1.9.2 Colour vision 
Most studies have found that VGB-exposed individuals with VAVFL exhibit normal 
colour vision (81;101;112;138;183).  Even in individuals with severe symptomatic 
visual field loss, colour vision can remain intact (101;139;146).  However, in some 
VGB-exposed individuals colour vision impairment has been reported (113;184-186).  
One study of individuals receiving VGB monotherapy showed impaired colour 
discrimination in 32% of VGB-exposed individuals (184).  In addition, healthy 
individuals showed an impairment of colour vision after a one-off dose of 2000mg of 
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VGB (187;188).  The colour vision defects that have been reported with VGB exposure 
have been mainly in the tritanoptic axis (detected using the Farnsworth-Munsell 100 
hue test) (176;184;186;188) and are suggested to be consistent with enhanced retinal 
GABAergic inhibition and relate to the physiological effects of VGB rather than 
retinotoxic mechanisms (187;188).  In individuals currently taking VGB the number of 
misread plates on the Ishihara charts ranged from 0-13 (out of a possible 15) and ranged 
from 0-1 in individuals previously exposed to VGB (113), further suggesting that 
abnormalities with colour perception may be related to physiological effects of current 
VGB exposure as opposed to retinotoxic effects related to the mechanisms of VAVFL.  
Conversely, other studies have shown diffuse, generalised colour vision impairment, 
suggesting that VGB induces toxic damage in all chromatic pathways (176;185). 
Exposure to other AEDs including carbamazepine (184;187;189;190), valproate 
(189;191), topiramate (186), tiagabine (192) and phenytoin (193) is also associated with 
impairments of colour vision (for a review see (176)), making it difficult to distinguish 
physiological effects of AEDs on visual perception from those mechanisms that might 
be related to neurotoxic effects (176). 
1.9.3 Contrast sensitivity  
Measures of contrast sensitivity examine the minimal contrast required to detect a 
difference between the luminance of an object from the luminance of its surroundings.  
Abnormal contrast sensitivity has been described in some VGB-exposed individuals 
(167;181;185), which was found to be related to the presence of VAVFL  (181), but not 
to abnormal electrophysiological measures (167).  Conversely, other studies have found 
normal contrast sensitivity in VGB-exposed individuals (150).  A single dose of VGB 
had no effect on contrast sensitivity in healthy individuals (194).  Furthermore, 
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abnormal contrast sensitivity detected in individuals treated with carbamazepine 
improved after six months add-on therapy with VGB (195). 
1.9.4 Ophthalmoscopic features 
Assessment of the fundus through direct examination, slit-lamp biomicroscopy and 
using fundus photography, reveals that in most individuals with VAVFL, the fundus is 
normal (78;94;95;97;101;104;106;112;116;120;121;128;130;147;148;164;196).  Even 
in individuals with severe VAVFL (i.e. visual field less than 20
o
 eccentricity), the 
fundus can be normal (139;146).  Rare abnormalities that have been described in some 
VGB-exposed individuals include narrowing of the retinal arteries 
(97;105;106;121;138), epiretinal membrane formation (105;106), abnormal retinal 
pigmentation (105;106;197), ―maculopathy‖ (79) and peripheral retinal pigment 
epithelium disturbance (97).  These findings may be incidental and not related to VGB 
toxicity and VAVFL (182).  More commonly described abnormalities include changes 
in the retinal nerve fibre layer (RNFL) and optic disc.  Atrophy of the peripheral RNFL 
(147;183;198), optic disc pallor or optic atrophy 
(78;81;82;97;101;105;112;120;147;183) have been described in several studies, and 
may be associated with the severity of VAVFL (147). 
 
1.10 Electrophysiological features of VAVFL  
 
1.10.1 Retinal electrodiagnostic techniques  
Many studies have been carried out using electrodiagnostic techniques in VGB-exposed 
individuals to explore abnormalities in the visual pathways that may be associated with 
VGB toxicity and the development of VAVFL.  The most commonly used techniques 
include the recording of visual evoked potentials (VEP), the electro-oculogram (EOG), 
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the full-field electroretinogram (ERG), the pattern electroretinogram (PERG) and the 
multifocal electroretinogram (mf-ERG).  Using these techniques can aid in the 
localisation of visual system abnormalities to particular pathways and cell types (Table 
1.5).    
 
Table 1.5 Electrodiagnostic techniques used to explore various visual pathway 
structures and cell types (adapted from (199)). 
Visual pathway structure Electrodiagnostic technique  
Retinal pigment epithelium EOG 
Photoreceptors  
Rod photoreceptors  
Cone photoreceptors 
 
ERG a-wave (scotopic) 
ERG a-wave (photopic) 
30Hz flicker ERG 
Middle/inner retina 
Bipolar cells 
Müller cells 
Amacrine cells 
ERG and PERG (P50 component) 
ERG b-wave 
ERG b-wave 
ERG oscillatory potentials  
Retinal ganglion cells  PERG (N95 component) 
Optic tract, radiation and 
cortex  
VEP 
 EOG = electrooculogram; ERG = electroretinogram; PERG = pattern electroretinogram; VEP = 
visual evoked potentials  
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1.10.1.1 Visual evoked potentials  
The visual evoked potential (VEP) is the electrophysiological response of the visual 
cortex evoked by a visual stimulus (either a flash or pattern-reversal stimulus).  
Recording of the VEP allows assessment of the integrity and function of the intracranial 
visual pathways including the optic nerve, chiasm and retrochiasmal function, and will 
be abnormal in disease involving any of these pathways (200).  Due to cortical 
magnification of central vision in the visual cortex the VEP is dominated by responses 
elicited from activity of the central retina (201).   
1.10.1.2 The electro-oculogram  
The electro-oculogram provides information about the integrity and function of the 
retinal pigment epithelium (RPE) and outer retina (202;203).  The EOG is based on 
recording changes in the standing potential (the potential between the front and the back 
of the eye), under successive periods of light and dark adaption (202).  Changes in the 
standing potential are mainly derived from differences in ion permeability across the 
basal RPE membrane during light and dark adaptation (202).   Under dark adaptation 
the amplitude of the standing potential decreases.   A subsequent light stimulus leads to 
an initial fall in the standing potential, followed by an increase in amplitude (202).  By 
comparing the maximum amplitude achieved during light adaptation, to the minimum 
amplitude during dark adaptation, the EOG ratio, or Arden ratio, is determined (202).  
In diseases affecting the RPE or RPE-photoreceptor complex the ratio between the light 
and dark peak (the Arden ratio) decreases (199). 
1.10.1.3 The full-field electroretinogram 
The ERG is a technique that provides information about the mass retinal electrical 
response elicited by a visual stimulus.  After a visual stimulus a chain of biochemical 
and electrical activity occurs through the retina; the resulting electrical potentials that 
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reflect these events are conducted thorough the ocular media and can be recorded using 
electrode at the cornea.  The resulting ERG waveform reflects a summation of the 
activity of all of these electrical processes (199) (Figure 1.5).  By using various visual 
stimuli and by adapting the eye to different light conditions, the contribution of 
particular retinal sub-structures to the ERG waveform can be elicited and can provide 
information as to the retinal localization of any visual impairment.  Under light-adapted 
(photopic) conditions, cone pathway contributions to the ERG waveform can be 
determined.  Under dark-adapted (scotopic) conditions rod pathways are explored (199).  
Abnormalities of the ERG include changes in the normal amplitude or temporal aspects 
of each component of the ERG waveform (i.e. the a-wave, b-wave and oscillatory 
potentials), and reflect pathology in various retinal sub-structures.  
 
Figure 1.5 The normal ERG wave form 
 
 
  
Figure 1.5 legend: Example of a 
normal ERG waveform elicited by a 
single flash light stimulus.  The black 
arrow indicates the stimulus onset.  The 
waveform consists of the early negative 
a-wave followed by a positive b-wave.  
Under certain conditions oscillatory 
potentials can be recorded on the 
ascending arm of the b-wave 
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The a-wave 
The a-wave (Figure 1.5) is the early cornea-negative component of the ERG and is 
generated by the rod and cone photoreceptors (204).   
The b-wave 
The b-wave (Figure 1.5) reflects the depolarization of Müller cells in response to a 
light-induced increase in the potassium levels in the inner retina probably following the 
depolarization of ON-bipolar cells, and thus reflects both bipolar and Müller cell 
function (205;206).   
Oscillatory potentials  
Low amplitude rapid oscillations are present on the ascending arm of the b-wave 
(Figure 1.5). These oscillatory potentials (OPs) can be isolated from the ERG using 
certain recording procedures (207) and reflect synaptic activity of amacrine cells (206). 
30Hz flicker response  
Presentation of a flickering stimulus (of 30Hz) to elicit a retinal response allows cone 
pathway function to be assessed independently of rod pathway function.  Cone 
photoreceptors and post-receptoral cone pathway cells including ON- and OFF-bipolar 
cells contribute to the formation of the  30Hz flicker response (208).     
Pattern ERG 
The PERG is the retinal potential that is evoked in response to presentation of a high-
contrast patterned stimulus (typically stripes or a checkerboard) (209;210).  The PERG 
waveform consists of a positive peak at around 50ms after stimulation (P50 component) 
and a negative trough at around 95ms (N95).  The PERG allows assessment of macular 
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function and in particular macular RGC function (reflected predominantly in the N95 
component) (200;209;211). 
Multifocal ERG 
Whilst the ERG reflects a summation of the activity of electrical processes throughout 
the whole retina, the multifocal ERG (mf-ERG) provides a topographic measure of 
retinal electrophysiological activity within the central 60
o
 (200;212).  Using an array of 
hexagonal elements which flicker in a pseudo-random sequence, localized ERG 
responses are recorded from the macular and paramacular retinal areas (212).  In 
addition, a newer technique, the wide-field mf-ERG, enables the assessment of localized 
ERG responses from the central (up to 60
o
) and peripheral (60 – 90o) retina.   
 
1.10.2 Electrophysiology in VGB-exposed: Introduction 
Electrophysiological abnormalities associated with VAVFL were reported in the first 
descriptions of VAVFL by Eke et al.  In the individuals tested, the ERG showed 
reduced OP amplitudes, and the Arden ratio of the EOG was reduced in one individual 
(78).  Ensuing case reports confirmed that ERG and EOG changes were present in some 
individuals with VAVFL, including reduced OP amplitudes reduces a- and b-wave 
amplitudes of the photopic and scotopic ERG (79;82;138).  Others found normal 
electrodiagnostics in individuals with VAVFL (83) and when the individuals with 
VAVFL reported by Eke et al. were re-examined after VGB withdrawal, the EOG and 
ERG abnormalities had returned to normal, despite the persistence of the VAVFL (80).  
Furthermore, the same ERG abnormalities were reported in VGB-exposed individuals 
with normal visual fields (138;213), suggesting that the ERG and EOG changes may be 
related to the physiological effect of VGB-induced increased GABA concentrations in 
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the retina, rather than related to the pathological processes associated with VAVFL 
(97;127;145;214). 
Ensuing studies of the electrophysiological correlates of VAVFL have provided little 
clarity.  Often studies have shown conflicting results.  Even within studies, individuals 
who have comparable visual fields can show markedly different ERG findings 
(101;104;120;150).  Some of the variability in findings between studies and between 
individuals may be explained by the following factors, and should be taken into 
consideration in the interpretation of findings.    
1.10.2.1 Electrodiagnostic techniques and standards  
The International Society of Clinical Electrophysiology have published standards for 
electrodiagnostic assessment including ffERG (207), EOG (202), VEP (201), PERG 
(215) and mf-ERG (212)  to reduce the variability in results between centres .  Whilst 
most studies acknowledged that these standards were met for all electrodiagnostic 
testing , others have not stated if these standards were met (144;196), or have used non-
standard recording conditions (101;135) which could account for some of the variation 
in findings between studies (153). 
1.10.2.2 Control groups  
For all electrophysiological procedures, normative data are established by each 
individual facility; thus the normal ranges used usually vary between laboratories 
(200;207).  Whilst some studies of VGB-exposed individuals have compared ERG 
findings to normative data based on healthy controls (120;154), other studies have used 
non-exposed individuals with epilepsy, often matched for exposure to other AEDs, as a 
control population (103;106).  
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For example in VGB-exposed children assessed using ERG, abnormalities of the 30Hz 
flicker were defined arbitrarily as a response less than 56 µV.  When this definition of 
abnormality was used one out of four children with VAVFL showed a reduced 30Hz 
flicker amplitude, yielding a sensitivity of 25%.  However, when the normal cut-off for 
healthy adults was used (below 70 µV) three out of four children with VAVFL showed 
abnormal responses, yielding a sensitivity of 75% (131).    
1.10.2.3 Other AEDs 
Most VGB-exposed individuals included in the ERG studies are receiving polytherapy 
with a range of other AEDs.  Only three studies have examined individuals on VGB 
monotherapy (128;216;217).  The possible effect of other AEDs on the ERG must be 
considered when interpreting ERG studies.  Several AEDs have been associated with 
abnormalities of retinal electrophysiology  in humans (175) including the ERG 
(carbamazepine (218)), VEP (sodium valproate (219), carbamazepine (187;219) and 
phenytoin (220)) and the EOG (lamotrigine (221)).  In addition, several studies have 
described abnormal ERG findings involving both the rod and cone pathways in 
individuals with epilepsy, with no history of VGB exposure, receiving a variety of 
AEDs, (103;121;165;196).  The effect that multiple AEDs in various combinations may 
have in the ERG is unknown.   
1.10.2.4 Cohorts studied 
Separating the physiological effects of VGB exposure (and concurrent AED exposure), 
from the pathological changes in retinal electrophysiology has proved difficult.  Studies 
have often been small; the largest have included less than 40 VGB-exposed subjects, 
and have typically integrated heterogeneous cohorts including individuals both on and 
off-VGB; with VAVFL and normal visual fields; and receiving a variety of other AEDs.  
Recognizing electrodiagnostic features that are present in discrete sub-groups within 
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each study cohort (e.g. ―current VGB exposure with VAVFL‖ or ―current VGB 
exposure with normal visual fields‖), may help to distinguish the physiological changes 
related to VGB from those associated with pathology.  This review of the literature on 
the electrodiagnostic features of VGB exposure and VAVFL has attempted to do this.  
However, it is important to note that the sub-group populations discussed are often 
small.   
 
1.10.3 VEPs in VGB-exposed individuals 
In agreement with preclinical studies of VGB-exposed individuals (74),  most studies 
have found normal VEPs in individuals with VAVFL 
(78;81;97;101;106;126;134;138;146;183).  Some studies have reported reduced 
amplitude (106) or prolonged latency of the P100 component (101;106;126;138;197) of 
the VEP, which has typically been associated with the presence of moderate to severe 
VAVFL extending to involve the central visual field (101).  However, increased 
latencies of the P100 component of the VEP have also been found in individuals with 
epilepsy with no exposure to VGB (72) and are suggested to be due underlying 
neurological insult, seizure activity or exposure to other AEDs and may not be related to 
VGB exposure or VAVFL (72;197).  In addition, abnormal VEPs were not found to be 
associated with the presence of VAVFL or ERG abnormalities in one study of VGB-
exposed individuals (106).     
The normal VEP in most VGB-exposed individuals suggests that the lesion associated 
with the development of VAVFL is unlikely to be in the anterior visual pathway or 
visual cortex (74;97).  However, the VEP is dominated by responses elicited from 
activity of the central visual field (201), which is typically normal in individuals with 
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VAVFL.  Pathological involvement of projections in the visual pathway and visual 
cortex subserving the retinal periphery may not result in an abnormal VEP if the central 
projections remain intact.   
1.10.4 The EOG in VGB-exposed individuals 
 
1.10.4.1 The EOG in individuals currently exposed to VGB 
In individuals currently exposed to VGB the Arden ratio has been show to be reduced in 
those with VAVFL (78;81;101;112;114;134;135;165) and in individuals with normal 
visual fields (81;114;135), with no relationship seen between the severity of the 
VAVFL and the Arden ratio (114).  The reduction in the Arden ratio was found to be 
present in individuals on VGB monotherapy and in individuals receiving other AEDs 
alongside their VGB therapy (216).  In addition, compared to individuals previously 
exposed to VGB, the Arden index was significantly lower in those currently exposed to 
VGB (165).  Conversely, in some individuals currently exposed to VGB, with normal 
visual fields and with VAVFL, the Arden ratio is normal (101;112;134;216).  
Increasing cumulative VGB exposure (109) and maximum daily VGB dose (164) have 
been shown to correlated with abnormalities of the Arden ratio, suggesting that there 
may be a dose-related effect of VGB on the RPE electrophysiology.   
1.10.4.2 The EOG in individuals after VGB withdrawal 
The Arden ratio was found to be normal in the majority of individuals after VGB 
withdrawal, (with VAVFL and with normal visual fields) (81;134;216).  However, in 
some individuals previously exposed to VGB with VAVFL the Arden ratio was reduced 
(134;151). 
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In a number of studies of VGB-exposed individuals, EOGs were recorded before and 
several months after discontinuing vigabatrin. In all patients, the EOG Arden ratio 
increased substantially on discontinuation, becoming normal in some individuals 
(81;135;150). 
1.10.4.3 Summary of EOG in VGB-exposed individuals 
Abnormalities of the Arden ratio appear to be related to current VGB exposure 
regardless of the presence of VAVFL (134;165).  After VGB withdrawal there is 
recovery of the Arden ratio, even though the VAVFL persists.  This suggests that 
abnormalities of the EOG are not directly related to pathological process leading to 
VAVFL but more likely represent a physiological effect of increased retinal GABA 
levels on normal RPE function (81;135;216). 
 
1.10.5 The ERG oscillatory potentials in VGB-exposed individuals 
 
1.10.5.1 Finding in individuals on-VGB with VAVFL  
One of the most consistently reported ERG abnormalities in individuals with VAVFL 
has been reduced OP amplitudes.  In four studies, reduced OP amplitudes were found in 
all individuals examined (78;112;138;146).  However, it is important to note these 
reports include case reports, case series and observations of subgroups of individuals 
from larger VGB-exposed cohorts, and together these studies only constitute 24 
individuals.  Kalviainen found reduced OP amplitudes in 3/3 individuals with severe 
VAVFL currently receiving VGB, but only 6/10 individuals with mild VAVFL (104), 
suggesting that abnormalities of OP amplitude might reflect the severity of the VAVFL.  
In agreement with this Besch found that although all individuals with VAVFL and 
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current VGB therapy had subnormal OP amplitudes, the degree of abnormality was 
associated with the severity of the VAVFL (112). 
In contradiction to these reports, Daneshvar found normal OPs in 10/10 individuals with 
VAVFL currently receiving VGB (101).  This discrepancy in findings could have been 
related to differences in VGB exposure between the cohorts studied.  The duration of 
VGB exposure was lowest in the individuals studied by Daneshvar et al. (9 – 75 
months) (101), compared to those included in two of the larger studies by Kalviainen et 
al. (29 – 119 months) (104), and Besch et al. (12 – 96 months) (112).  Furthermore, it 
may have related to differences in the recording techniques used between studies, as the 
ERG recordings by Daneshvar et al. did not comply with ISCEV standards (153), or 
differences in the methods used to measure the OP amplitudes (101).  However, in 
agreement with the findings by Daneshvar, others have found normal OP amplitudes in 
some individuals with VAVFL and current VGB therapy (83;104;114).    
1.10.5.2 Findings in individuals on-VGB with normal visual fields  
Several studies of individuals currently taking VGB have found reduced OP in 
individuals with normal visual fields (105;114;121;153).  In healthy individuals with 
normal visual fields exposure to a one-off dose of VGB did not alter the OPs (145), 
suggesting that the abnormal OPs reported in some VGB-exposed individuals is 
unlikely to reflect an acute effect of VGB-associated increases in retinal GABA on 
amacrine cell physiology.  
1.10.5.3 Findings in individuals after VGB withdrawal  
Individuals with VAVFL and decreased OP amplitudes during VGB exposure showed 
no improvement in either measure after VGB withdrawal (153;154).   However, in 
another study, three VGB-exposed individuals with normal visual fields showed a 
substantial improvement in the OP amplitude after VGB withdrawal, two individuals 
69 
 
returning to normal levels (153).  Similarly, the OP amplitudes were found to be 
subnormal in 17/17 children whilst receiving VGB.  After VGB withdrawal, the OP 
amplitudes showed some improvement in 12/17 although the amplitudes remained at 
subnormal levels in most children (222).  
In a study by Harding et al. ERGs were compared between individuals with severe 
VAVFL currently exposed to VGB and those with severe VAVFL previously exposed 
to VGB.  The implicit time of the OP was delayed in individuals currently taking VGB 
compared to those previously taking VGB, suggesting that this abnormality of the ERG 
is related to current VGB exposure rather than irreversible VAVFL (165). 
1.10.5.4 Summary of oscillatory potentials 
OP amplitudes appear to be one of the more sensitive electophysiologcial techniques to 
identify individuals with VAVFL.  However, some individuals with VAVFL may have 
normal OPs and some individuals with normal visual fields have reduced OP 
amplitudes.  Furthermore, OP may improve after VGB withdrawal, particularly if the 
visual fields are normal.     
It is possible that in VGB-exposed individuals, abnormal OP amplitudes reflect both 
physiological effects of increased retinal GABA on amacrine cell physiology (153), and 
pathological changes to amacrine cell function, which manifest as reversible and 
irreversible changes in the ERG OPs, respectively.   
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1.10.6 The ERG a-wave in VGB-exposed individuals 
 
1.10.6.1 Finding in individuals with VAVFL currently taking VGB  
In individuals with VAVFL currently receiving VGB the photopic and scotopic a-wave 
implicit times (78;81;101;106;138) and amplitudes (78;81;101;106) were normal.  
Normal a-waves were also found in individuals on current VGB monotherapy, but the 
visual field was not examined in these individuals (216).  Conversely, in other studies of 
individuals with severe VAVFL the photopic and scotopic a-wave amplitudes were 
decreased (104) and the photopic a-wave implicit time was delayed (112;138).  
1.10.6.2 Findings in individuals after VGB withdrawal  
In individuals with VAVFL previously exposed to VGB the photopic a-wave amplitude 
was reduced compared to individuals with VAVFL currently receiving VGB (136;151).  
The reduction in the a-wave in the previously exposed individuals  was suggested to be 
related to current exposure to other AEDs including carbamazapine (136;151)  which 
decreases the photopic a-b wave amplitude (218). 
In individuals with severe VAVFL and previous VGB exposure the scotopic a-wave 
latency was normal.  In individuals with severe VAVFL and current VGB exposure it 
was delayed, suggesting that this measure reflects current VGB exposure and is not 
related to irreversible VAVFL (223). 
1.10.6.3 Summary of a-wave 
In most individuals with VAVFL, ERG a-waves are normal.  Any abnormalities in the 
a-wave in VGB-exposed individuals may be related to current VGB exposure and not to 
pathological mechanisms associated with VAVFL (223).  Photoreceptor pathology is 
therefore unlikely to be a prominent feature of VGB toxicity and is probably not 
implicated in the mechanisms associated with VAVFL.   
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1.10.7 The ERG b-wave in VGB-exposed individuals 
 
1.10.7.1 Findings in healthy individuals  
In healthy individuals receiving a one-off dose of VGB (1000mg or 2000mg) the group 
mean latency of the photopic ERG b-wave was significantly increased compared to pre-
dose recordings although visual fields were unchanged compared to baseline (145). 
1.10.7.2 Findings in individuals on VGB monotherapy  
In a study of nine adults on VGB monotherapy, the amplitude of the ERG b-wave was 
decreased in 2/9 individuals under photopic conditions and in 3/9 individuals under 
scotopic conditions, (216).  The visual fields were not examined and so the relationship 
between these changes and VAVFL could not be determined.         
In a study of children receiving VGB monotherapy, the ERG was performed prior to 
starting VGB and then repeated at frequent intervals over 18 months of VGB exposure.  
At the earliest follow-up (around six months after initiation of VGB therapy), the 
photopic ERG b-wave amplitude was increased compared to baseline, which was 
subsequently followed by a progressive decrease over time to subnormal amplitudes.  
Again, the visual fields were not assessed in this study owing to the age and cognitive 
impairment of the children included in the cohort (217).   
1.10.7.3 Finding in individuals with VAVFL currently taking VGB 
The amplitude of the ERG b-wave was found to be reduced in individuals with VAVFL 
on current VGB therapy, under both photopic (104;120;138) and scotopic conditions 
(101;104;150;154;196).  Equally, however, the b-wave was normal in some individuals 
with VAVFL and current VGB exposure under both photopic (78;101;104;120;146) and 
scotopic (78;101;104;112;138;146;150) conditions.  Even within the same study where 
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techniques are standardised across subjects, some individuals with VAVFL can show b-
wave abnormalities where others have normal findings (101;104;120;150). 
This difference in findings between studies may be related to differences in co-
medication with other AEDs.  The amplitude of the photopic b-wave was found to be 
reduced in individuals with epilepsy not-exposed to VGB which may have been  related 
to treatment with carbamazepine (165) or other AEDs (223) which reduce the photopic 
b-wave amplitude (218).  Different combinations of AEDs could have a unique effect 
on the retinal electrophysiology and account for some of the differences seen between 
individuals and between studies.  In opposition to this, some, but not all, individuals 
receiving VGB monotherapy were found to have decreased photopic and scotopic b-
wave amplitudes, however, the visual field status of these subjects was not known 
(216). 
In individuals with VAVFL currently receiving VGB the implicit times of photopic b-
wave has been reported as normal (101;112;150;216) and delayed (112;150). The 
scotopic b-wave implicit time was normal (101;216).    
1.10.7.4 Finding in individuals currently taking VGB with normal visual 
fields  
Reduced amplitude of the photopic (109;121;138) and scotopic (109;121) b-wave have 
been reported in individuals with normal visual fields.  Normal scotopic (136;138;196) 
and photopic (136) b-waves have also be reported.  
1.10.7.5 Findings in individuals after VGB withdrawal  
Reductions of the photopic (150;151;153;154;222) and scotopic (151;153;154) b-wave 
amplitudes recorded whilst on VGB did not improve after VGB withdrawal.  In addition 
the photopic b-wave implicit time was delayed and did not improve after VGB 
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withdrawal (150).  However others have found that the scotopic b-wave amplitude 
increased after VGB withdrawal (to normal levels in some individuals) (150).   
In some studies the scotopic and photopic b-wave amplitudes were decreased in 
individuals previously exposed to VGB compared to individuals currently exposed to 
VGB (136).  The authors suggested that this may be related to the current therapy with 
carbamazepine in the group previously exposed to VGB, which decreases the amplitude 
of the ERG (218).  This finding is in agreement with other studies which have found the 
b-wave amplitude to increase when currently exposed to VGB (218;224).  In children 
the b-wave was found to increase after VGB therapy was initiated compared to that 
recorded before VGB was started (217;222).  
The conflicting findings regarding the effect of VGB on the b-wave of the ERG may be 
related to the opposing effects of GABA on GABAA and GABAC receptors (106) which 
are found on the axon terminals of bipolar cells (225).  In isolated rat retina, suppression 
of GABAA receptors using the GABAA receptor antagonist bicuculline led to an 
increase in the b-wave amplitude, whilst suppression of GABAC receptors, with 
GABAC receptor antagonist 3-aminopropylphosponic acid, led to a decrease in b-wave 
amplitude (226).  GABAA receptors located on bipolar cells appear to act to decrease 
the light evoked response of these cells, whereas GABAC receptors appear to enhance 
the response from bipolar cells (226).  Differences in the effect of VGB on the b-wave 
of the ERG seen between studies and between individuals may be related to variation in 
the relative activity of GABA at each of the receptor subtypes.  GABAC receptors have 
a higher affinity for GABA than GABAA receptors (227).  Therefore, the increased 
ERG b-wave seen early after exposure to VGB may result from activity at GABAC 
receptors.  After chronic VGB exposure, and persistently elevated GABA, pathological 
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or long term physiological changes in bipolar cells may occur, resulting in a decrease in 
the ERG b-wave. 
1.10.7.6 Summary b-wave  
An abnormal reduction of the photopic and scotopic ERG b-wave is associated with 
VGB exposure and VAVFL and does not improve in most individuals after VGB 
withdrawal.  However, the effect of VGB on the b-wave is complex, and probably 
includes an early physiological component associated with increased activity at bipolar 
cell GABAC receptors (and a resulting increase in the ERG b-wave amplitude), 
followed by a later irreversible pathological component which could involve both 
bipolar and Müller cell function. 
 
1.10.8 The 30Hz flicker in VGB-exposed individuals 
 
1.10.8.1 Finding in individuals with VAVFL currently taking VGB 
A reduction of the 30Hz flicker amplitude has been suggested as a sensitive and specific 
marker for VAVFL reflecting VGB-associated dysfunction in the cone pathway (165).  
In individuals with VAVFL currently exposed to VGB a decrease in the amplitude of 
the 30Hz flicker response has been reported (101;120;134;153;154;165;196).  However, 
it is also normal in some individuals (101;114;146).  A delayed implicit time of the 
30Hz flicker response has been reported in some individuals with VAVFL (165;196).  
In a study by Harding et al. the amplitude of the 30Hz flicker correlated with the 
severity of VAVFL, and was associated with the presence of VAVFL regardless of 
current or previous VGB exposure (165).   
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Although ERG abnormalities have been reported in both cone and rod pathways, many 
studies have reported that the cone system is affected to a greater extent 
(103;106;138;165). 
The apparent preferential susceptibility of the cone system to VGB toxicity might be 
explained by differences in GABA receptor expression between rod bipolar and cone 
bipolar cells (106).  Both GABAC and GABAA receptors are found on bipolar cell axon 
terminals (225).  The distribution of GABAA and GABAC receptors differs for each 
bipolar-cell type with rod bipolar cells having the highest ratio of GABAC to GABAA 
receptors compared to cone ON-bipolar and OFF-bipolar cells (228).  In addition the 
effect of activity differs between the receptor subtypes; GABAA receptors appear to act 
to decrease the light evoked response of bipolar cells (thus decreasing the ERG b-wave), 
whereas GABAC receptors appear to enhance the response from bipolar cells (and 
increase the ERG b-wave) (226).  After VGB exposure high retinal GABA levels would 
inhibit the response of cone bipolar-cells through activity at GABAA receptors, 
impairing cone pathway output.  Conversely, activity at GABAB receptors on rod 
bipolar cells would lead to enhanced activity through the rod pathway.  Overall this 
manifests as the cone ERG (photopic and 30Hz flicker responses) showing preferential 
susceptibility to VGB toxicity (106).    
1.10.8.2 Findings in individuals currently taking VGB with normal visual 
fields  
A reduced 30Hz flicker amplitude was found in individuals with normal visual fields 
(153;196) which persisted after VGB withdrawal suggesting that it is not a drug-related 
effect (153).  Conversely Ardnt et al. found the amplitude to be normal in 2/2 
individuals with normal visual fields (114).  A delayed implicit time of the 30Hz flicker 
response was also found in individuals with normal visual fields (153).  
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1.10.8.3 Findings in individuals after VGB withdrawal  
A decreased amplitude of the 30Hz flicker response did not improve up to six years 
after VGB withdrawal (154;222).  Similarly Johnson et al. examined the ERG in 
thirteen individuals whilst receiving VGB, and again after VGB withdrawal.  Whilst on 
VGB, individuals showed decreased amplitudes and delayed implicit times of the 30Hz 
flicker response, which did not improve after VGB withdrawal (153) 
1.10.8.4 Summary 30Hz flicker   
A reduction of the 30Hz flicker amplitude has been suggested as a sensitive and specific 
marker for the presence and severity of VAVFL (165), and does not improve after VGB 
withdrawal.  However, it may be normal in some individuals with VAVFL, and reduced 
in some individuals with normal visual fields.  Cone pathway function is evidently 
impaired in individuals with VAVFL.  The reported predominant cone pathway 
dysfunction associated with VGB exposure may reflect physiological differences in 
GABA receptor expression between rod and cone bipolar cells.   
 
1.10.9 The Pattern ERG in VGB-exposed individuals 
In eight individuals with severe VAVFL (within 15
o 
eccentricity), PERG latencies and 
amplitudes of the P50 and N95 components were within normal limits (134).  In  
agreement, a report of one individual with VAVFL currently receiving VGB the PERG 
was normal when the central visual field was stimulated (i.e. according to the ISCEV 
guidelines for PERG recording (215)).  Conversely, when part of the pattern stimulus 
was presented in an area of VAVFL the N95 component was reduced (146).  These 
findings suggest that whilst macular RGC function is normal in individuals with 
VAVFL, peripheral RGC function may be impaired. 
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1.10.10 Multifocal ERG in VGB-exposed individuals 
Several studies have used mf-ERG to assess the distribution of electrophysiological 
abnormalities across the retina.  Harding et al. found that in eight individuals with 
severe VAVFL there was a ―reasonable correlation‖ between the pattern of mf-ERG 
abnormalities and the pattern of VAVFL (134).  However, in some individuals the focal 
ERG abnormalities were more diffuse, and did not appear to be related to areas of 
VAVFL (134).  In agreement, other studies found diffuse mf-ERG abnormalities across 
the retina which were not related to areas of VAVFL (81;153) or even the presence of 
VAVFL, as some individuals with normal visual fields also showed mf-ERG 
abnormalities (120;153).   
Using wide-field mf-ERG, McDonagh et al. found that individuals with VAVFL had 
significantly reduced ERG amplitudes in the central (<60
o
) and peripheral (60
o – 90o) 
retina, and delayed implicit times in the periphery, compared to VGB-exposed 
individuals with normal visual fields (103).  The difference between the central and 
peripheral implicit times was thought to represent a marker for VAVFL, identifying all 
individuals with VAVFL and only 2/13 VGB-exposed individuals with normal visual 
fields.  The authors suggested that although diffuse physiological abnormalities related 
to VGB exposure (and exposure to other AEDs) may be present, certain features of the 
wide-field mf-ERG may be specific to VAVFL and indicative of peripheral retinal 
dysfunction (103).   
1.10.11 Relationship between ERG abnormalities and VAVFL 
Although all ERG measures have been associated with VAVFL in various studies, 
including decreased OP amplitudes (103;112;135) and increased implicit time of the OP 
(109;150); decreased 30Hz flicker amplitude (103;106;134) and increased implicit time 
of the 30Hz flicker (134); decreased amplitude of the photopic 
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(105;106;109;135;150;151) and scotopic (109;135;150;151) b-wave; and an increased 
implicit time of the photopic a-wave (151), non have consistently shown to be 
associated with the presence of or severity of VAVFL (229).   
 
1.11 VGB, GABA and the retina  
 
The mechanisms of VGB toxicity and VAVFL are unknown.  However, the normal 
VEPs reported in most VGB-exposed individuals alongside the abnormal ERG findings 
suggest that the pathological insult associated with the development of VAVFL is 
unlikely to be in the optic tract or visual cortex and suggest a retinal origin of VGB 
toxicity (74;81;97;104;134;154;180).  In addition, concentric visual field loss is most 
commonly associated with retinal disease (81) and pathology involving the optic nerve 
typically involves loss of visual acuity and colour vision, which are rarely seen in 
individuals with VAVFL (81). 
1.11.1 Normal retinal anatomy 
The retina is a thin, multilayered sheet of neural tissue lining the inner, posterior aspect 
of the globe.  The basic organisation of the retinal layers include three layers of cell 
bodies (inner nuclear layer (INL), outer nuclear layer (ONL) and ganglion cell layer 
(GCL)) separated by two synaptic layers (inner plexiform layer (IPL) and the outer 
plexiform layer (OPL)).  The outer most surface of the retina is the retinal pigment 
epithelium (RPE) which abuts Bruch’s membrane, the choroid and the sclera.  The rod 
and cone photoreceptor cell bodies comprise the INL.  In the IPL rod and cone 
photoreceptors make synapses with horizontal cells and their respective bipolar cells, 
the cell bodies of which lie in the INL along with the cell bodies of amacrine cells.  
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Bipolar cells make synapses with amacrine cells and retinal ganglion cells (RGC) 
dendrites in the IPL.  The RGC bodies lie in the innermost nuclear layer, the GCL, and 
project their axons in the retinal nerve fibre layer (RNFL) towards the optic nerve head 
(ONH) where they will exit the globe as the optic nerve.  The RNFL also contains 
displaced amacrine cells, astrocytes and capillaries.  The cell bodies of the Müller cell, 
the principal glial cell of the retina lies in the IPL, but their processes span the entire 
depth of the retina.  Their apical processes form the external limiting membrane (ELM) 
and end-feet form the internal limiting membrane (ILM) (Figure 1.6) (230). 
 
Figure 1.6 Normal anatomy of the retina 
 
Figure 1.6 legend: The normal architecture of the human retina.  RPE = retinal pigment 
epithelium; ELM = external limiting membrane; RGC = retinal ganglion cell; RNFL = retinal 
nerve fibre layer; ILM = internal limiting membrane; ONL = outer nuclear layer; OPL = outer 
plexiform; INL = inner nuclear layer; IPL = inner plexiform layer.  (Image adapted from (231)) 
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1.11.2 Normal GABA activity in the retina  
GABA is the major inhibitory neurotransmitter in the retina. GABAergic pathways in 
the retina modulate neural transmission from photoreceptors to bipolar cells (in the 
OPL), and from bipolar cells to RGC (in the IPL) (225).  In the OPL, inhibitory synaptic 
interactions are mediated by horizontal cells.  In the IPL, inhibitory circuits are driven 
by amacrine cells of which around 50% are GABAergic (Figure 1.7). 
Three types of GABA receptors are found in the IPL (Figure 1.7), the ionotropic 
GABAA and GABAC receptors, and the metabotropic GABAB receptors.  Both GABAC 
and GABAA receptors are found on bipolar cell axon terminals, whereas only GABAA 
receptors are found on amacrine and ganglion cell dendrites (225).  Activity at the pre-
synaptic, GABAA and GABAC receptors modulate neurotransmitter release from the 
bipolar cells (225).  GABAC receptors have a higher affinity for GABA than GABAA 
receptors (227) and give rise to a more sustained inhibitory response than that generated 
by GABAA receptors (225;228).  The combination of both receptor sub-types on the 
bipolar-cell axon terminal allows a dynamic response to a range of GABA 
concentrations (225;228).  The distribution of GABAA and GABAC receptors differs for 
each bipolar-cell type with rod bipolar cells having the highest ratio of GABAC to 
GABAA receptors compared to cone ON-bipolar and OFF-bipolar cells (228).   
Termination of GABA signaling is achieved by active transport of GABA from the 
synaptic cleft via GAT-1 into the pre-synaptic GABAergic amacrine cell and by GAT-
3, and to a lesser extent GAT-1, into surrounding Müller cells (232;233).  Within the 
amacrine cell or Müller cell, GABA is metabolized by the mitochondrial enzyme 
GABA-transaminase (GABA-T) (1) (Figure 1.7). 
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Figure 1.7 Normal GABA in the retina at the level of the inner plexiform layer  
 
Figure 1.7 legend:  In the IPL, pre-synaptic bipolar cell activity is modulated via GABAergic 
amacrine cells, through activity at GABAA (light green) and GABAC (dark green) receptors.  
GABA activity is terminated by uptake via high affinity GABA-transporters (GAT) into the pre-
synaptic GABAergic amacrine cell and surrounding Müller cells, where it is metabolised by 
GABA-transaminase (GABA-T)      
 
1.11.3 VGB in the retina  
In mice and rats, exposure to VGB leads to a dose-dependent decrease in GABA-T 
activity and an increase in GABA concentration in several CNS regions, including 
cerebellum, pons, midbrain, striatum, hippocampus, hypothalamus, frontal cortex, 
dorsal cortex, spinal cord and retina (9;10;14-19).  However, studies have consistently 
shown that the effects of VGB are particularly pronounced in the retina where after a 
single dose, VGB levels are substantially higher than they are in brain and spinal cord 
(15;17).  Sills et al. reported concentrations of VGB in the retina were up to five times 
higher than any other CNS region (15). In another study VGB concentration was up to 
18 times higher in retina than brain (17).  In addition, inhibition of GABA-T activity 
(14;15;17;234;235) and associated increase in GABA concentration (14;15;17;234) are 
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significantly more pronounced in the retina than elsewhere in the CNS.  In rats 
receiving a one-off dose of 1000 mg/kg VGB, retinal concentrations of GABA-T were 
reduced to less than 22% of control animals, with GABA concentration elevated to 
260% of control animals (15) (Table 1.6).  Comparatively, the dorsal cortex showed the 
greatest effect of VGB on the brain with GABA-T activity reduced to 54% of control 
activity, and GABA levels 195% of control levels (Table 1.6) (15).    
 
Table 1.6 Percentage difference in GABA-T activity and GABA concentration in 
different CNS regions in VGB-exposed* rats compared to control rats  
 Cerebellum  Pons Hippocampus Frontal 
cortex 
Dorsal 
cortex 
retina 
GABA 
concentration 
150.6% 178.8% 140.0% 171.7% 195.0% 261.3% 
GABA-T 
activity 
59.2% 68.3% 60.3% 68.3% 53.5% 21.4% 
Results are expressed as the mean percentage concentration, or activity, compared to the control 
group (rats injected with saline).  Table adapted from (15). 
* Rats were exposed to a one-off dose of 1000 mg/kg of VGB 
GABA = γ-aminobutyric acid; GABA-T = GABA transaminase; CNS = central nervous system; 
VGB = vigabatrin 
 
The distribution of retinal GABA was also changed after VGB exposure.  In non-
exposed control animals GABA-immunoreactivity was localised in the IPL, in 
GABAergic amacrine cell bodies in the INL, and in occasional cell bodies in the GCL 
(presumed to be displaced amacrine cells) (234;236).  In VGB-exposed animals 
significant GABA-immunoreactivity was detected in Müller cells as vertical streaks of 
staining extending through the depth of the retina to the ELM (234).  In addition, there 
was increased staining in the amacrine cell bodies and in the IPL (234).  In healthy 
control animals Müller cells fail to show staining for GABA, as any GABA transported 
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into Müller cells via GAT is rapidly metabolised by GABA-T (237).  The prominent 
Müller cell staining seen in VGB-exposed animals suggests that the inhibition of 
GABA-T leads to abnormal accumulation of GABA in these cells (234).  The retinal 
distribution of GABA-T was unchanged in VGB-exposed animals, although there 
appeared to be a decrease in the density of GABA-T immunoreactivity particularly in 
the IPL (234). 
 
1.12 Retinal pathology in VGB-exposed animals 
 
The toxic effects of VGB on the retina were first described in animals more than a 
decade before it was found to be associated with visual field loss in humans.  In 1987 
Butler et al. examined retinal sections from albino and pigmented rats exposed to VGB 
for 90 days.  In the albino rats, diffuse changes were seen in the ONL including 
structural disorganisation, migration of photoreceptor nuclei toward the RPE and loss of 
photoreceptor nuclei (64).  In addition, the frequency of retinal lesions and the severity 
of the lesions showed dose dependence.  Only 1/30 rats exposed to 30mg/kg/day of 
VGB developed retinal lesions, compared to 24/30 rats exposed to 300mg/kg/day.  
Conversely, in the pigmented rats no retinal lesions were detected even after exposure to 
300mg/kg/day of VGB. 
1.12.1 Outer retinal pathology in VGB-exposed animals 
Subsequent studies of the effects of VGB exposure on retinal morphology in albino 
animals have found similar changes to the outer retina as those described by Butler et al.  
Disorganisation of the ONL has been consistently reported (238-242) (Figure 1.8), 
which is associated with migration of photoreceptor nuclei toward the RPE (238;240-
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242) and the OPL (238) (Figure 1.8), and irregularities in the structure of the ELM 
(239).   
 
Figure 1.8 Disorganisation of the ONL in VGB-exposed rats  
 
 
Figure 1.8 legend: Figure (A) shows a normal retinal section from a non-exposed control 
rat.  Note the highly organised retinal structure with distinct demarcation of individual retinal 
layers.  Figure (B) is taken from a VGB-exposed rat.  Note the disorganisation of the retinal 
layers, particularly the ONL (white horizontal arrows), and the migration of photoreceptor 
nuclei toward the RPE (white vertical arrows).  Figure taken from (238) 
OS = outer segment; IS  inner segment; ONL = outer nuclear layer; OPL = outer plexiform 
layer; INL = inner nuclear layer; IPL = inner plexiform layer 
 
Immunohistochemical studies have revealed further pathological changes involving 
photoreceptors, including abnormal morphological changes in cone inner/outer 
segments (238;240;242) which were not restricted to areas of ONL disorganisation, but 
were also seen in areas with apparently normal retinal structure (238).  In addition, a 
decrease in the density of cone inner/outer segments was found (238;241;242), with 
signs of photoreceptor degeneration in some areas (detected using TUNNEL staining 
for evidence of DNA fragmentation) (238).  Under electron microscopy, abnormal 
photoreceptors showed vacuolization of the inner segment, disruption and dilatation of 
discs, and formation of membranous bodies in the outer segments (238).  Changes in the 
A B
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OPL have also been noted, with withdrawal of rod photoreceptor synapses towards the 
retinal pigment epithelium (240).  Cone photoreceptor synapses were found to stay 
localised within the OPL, although they were found not to be as uniformly organised as 
cone photoreceptor synapses in the retinas of non-exposed control animals (240).  In 
conjunction with the withdrawal of rod photoreceptor synapses (240), neuronal 
plasticity was seen to occur, with rod bipolar cells extending their dendrites past the 
OPL, deep into the ONL (240-242), to form ectopic synapses with the withdrawing rod 
photoreceptor cells (240).   
 
All of the pathological changes described in the outer retina after VGB exposure have 
been noted in albino strains of rats and mice (64;238-242).  In the study by Butler et al. 
exposure to 300mg/kg/day of VGB led to pathological changes in the retina in 80% of 
albino rats.  Conversely, pigmented rats exposed to the same amount of VGB, and 
maintained in the same environment (12 hour dark/light cycles with light intensity of 
260 lux), developed no retinal lesions (64).  In addition, pigmented rabbits exposed to 
VGB showed no difference in the intensity and distribution of staining of cone 
inner/outer segments, or in the number of cone/inner outer segments, compared to non-
exposed rabbits (243).   
 
Albino rats are known to develop retinal pathology after excessive light exposure which 
is similar to that seen in the VGB-exposed albino rats (64).  In the study by Butler et al. 
albino rats not exposed to VGB and maintained in the same light conditions as the 
VGB-exposed albino rats, did not develop retinal pathology (64).  Thus the 
morphological changes in the albino VGB-exposed rats could not solely be explained 
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by phototoxicity (64).  The influence of light on VGB retinotoxicity was explored by 
Izumi et al.  Albino rats injected with a single dose of VGB were maintained under two 
different light conditions; either a 12 hour light/dark cycle (light intensity 300-500 lux), 
or 24 hours of light (light intensity 6000-8000 lux) (239).  In rats exposed to 24 hours of 
light, the retina showed changes similar to those described previously in VGB-exposed 
albino animals.  Conversely, VGB-exposed rats maintained in a 12 hour light/dark cycle 
showed no retinal abnormalities (239).  In the same study, the effect of VGB and light 
exposure were assessed ex vivo in retinal sections from normal, healthy rats.  Retinal 
sections were suspended in artificial CSF with added VGB and exposed to either 20 
hours of darkness or light (light intensity 20000 lux).  In addition, control retinal 
sections were suspended in artificial CSF alone or with added GABA, and subject to the 
same light conditions.  The retinal sections exposed to VGB and 20 hours of light 
showed changes comparable with those seen in albino rats.  In addition, the effect of 
VGB and light exposure was dose- and time-dependent, with pathology observed more 
frequently after suspension in higher concentrations of VGB and after exposure to 
longer durations of light.  In contrast, retina exposed to VGB and maintained in 20 
hours of darkness showed no pathological changes.  Retina exposed to GABA showed 
no pathological changes under light or dark conditions (239).    
 
These findings suggest that VGB sensitises the already sensitive albino retina to light, 
enhancing its phototoxic effect and promoting retinal degeneration (63-65).  
Furthermore, whilst VGB and light exposure resulted in pathological changes in retinal 
slices, application of GABA under the same light conditions was not retinotoxic (239), 
suggesting that high levels of GABA alone may be insufficient to lead to retinotoxicity 
and VAVFL in humans. 
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1.12.2 Other retinal pathology in VGB-exposed animals  
In VGB-exposed albino rats and mice, abnormalities involving Müller cells have been 
reported.  Increased GFAP immunoreactivity in Müller cells was found in areas of 
disorganisation and in some areas of normal retinal structure (238;241;242).  In highly 
disorganised retinal areas, GFAP-immunoreactive Müller cell processes extended 
beyond the ELM into the layers of the photoreceptor inner/outer segments (238).  This 
also occurred in some normal-appearing areas suggesting that VGB-induced gliotic 
changes were occurring throughout the retina (238). 
 
In VGB-exposed rabbits (of unknown strain), GFAP immunoreactive Müller cells were 
detected in the peripheral and central retina with some cells showing abnormal 
morphology (236).  No immunoreactive Müller cells were seen in non-exposed rabbits 
(236).  Studies of VGB-exposed pigmented rabbits have found no indication of altered 
Müller cell morphology or function (243;244).  However, in one of these studies, VGB-
exposed  pigmented rabbits were maintained for a 4-5 month treatment-free period 
before sacrifice and enucleation of the eye (244).  The authors suggested that the 
pathological changes in Müller cells that had been previously found in VGB-exposed 
rabbits may only present during VGB exposure and might be reversible on cessation of 
therapy (244).  Alternatively, differences in the findings between studies may be related 
to different rabbit strains used in each study (i.e. pigmented or albino strains), or 
differences in the duration or amount of VGB exposure between studies (243). 
 
1.12.3 Reversibility of VGB-associated retinal pathology in animals 
Two studies have examined whether VGB-associated retinal pathology may be 
reversible on VGB withdrawal.   In a study by Kjellstrom et al. rabbits exposed to VGB 
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for 12 months were maintained for a 4-5 month treatment-free period before sacrifice 
and enucleation of the eye (244).  No difference in retinal morphology was detected 
using immunohistochemical techniques between the VGB-exposed and non-exposed 
animals.  Similarly, Duboc et al. assessed the effect of a ―recovery period‖ on VGB-
exposed albino rats.  After VGB exposure, animals were given either a two-day or a 43-
day recovery period before sacrifice and enucleation of the eye (238).  Animals in both 
the two-day and 43-day recovery period groups showed the same outer retinal 
pathology as described in other VGB-exposed albino animals.  Fewer animals in the 43-
day recovery group showed the retinal changes, and the areas of pathology were 
reduced in size compared to the two-day recovery group (238). 
 
1.13 Retinal pathology in VGB-exposed humans 
 
Only one pathological study of the retina and optic nerve from a single individual with 
VAVFL has been reported (162).  The individual had been exposed to VGB for 28 
months prior to death at a maximum daily dose of 6g/day.  Prior to death the individual 
reported ―visual difficulties‖ and one month prior to death perimetry using HVFA 30-2 
showed VAVFL.  At post mortem examination the retina showed almost complete loss 
of RGC in the periphery, with less severe involvement of RGC in the macula, and 
severe atrophy of the RNFL.  There was some loss of nuclei from the INL and ONL and 
atrophy of the IPL, OPL and RNFL.  The optic nerve was severely atrophic (around a 
third of its normal size) with relative preservation of fibres projecting form the macula 
compared to those projecting form the peripheral retina.  The optic tracts also showed 
some atrophic changes (162). 
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1.14 The retinal nerve fibre layer in VGB-exposed individuals  
 
Although the precise mechanisms of VGB retinotoxicity are unknown, there is evidence 
to suggest that in humans RGC loss is implicated (80;101;146;147;162;165).  RNFL 
atrophy (97;106;147;183;198) and optic atrophy (101;147;183) are the most common 
abnormalities detected using fundoscopy or fundus photography.  These clinical 
observations are supported by finding that RGC loss was the most prominent retinal 
pathological change seen in a post mortem study of an individual with VAVFL (162).  
However, assessment of the fundus through direct examination, slit-lamp 
biomicroscopy and using fundus photography, reveals that in most individuals with 
VAVFL, the fundus appears normal with no evidence of RNFL loss or optic atrophy 
(78;94;95;97;101;104;106;112;116;120;121;128;130;147;148;164;196).  Even in 
individuals with severe VAVFL (i.e. visual field less than 20
o
 eccentricity), the fundus 
can be normal (139;146). 
1.14.1 The normal retinal nerve fibre layer  
The RNFL is an inner-retinal layer composed of the axons of RGC.  Projecting RGC 
axons are organised into bundles which extend in radial wedge-shaped sectors from the 
retinal periphery to the ONH where the RGC axons exit the globe of the eye forming 
the optic nerve (245;246).  The nerve fibre bundles maintain horizontal topographic 
organisation of RGC axons, allowing little, if any, lateral dispersion of axons between 
bundles (247).  Consequently, the projecting RGC axons follow a specific trajectory, 
such that axons from RGC in neighbouring retinal locations project to discrete areas of 
the ONH (Figure 1.9) (246-249). 
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Figure 1.9 Topographic projections of RGC axons in the RNFL  
  
Figure 1.9 legend: RGC axons project from the retinal periphery to the ONH where they 
exit the globe of the eye forming the optic nerve.  The RGC axons follow a specific topographic 
trajectory, such that axons from RGC in neighbouring retinal locations project to discrete areas 
of the ONH.   
Grey vertical line = vertical meridian; grey horizontal line = horizontal meridian; ONH = optic 
nerve head 
 
RGC axons in the nasal hemifovea, and caecocentral area, project directly towards the 
ONH in a rectilinear course, to enter at its most temporal aspect (246-249)  (Pollock).  
Axons from RGC in the temporal hemifovea and extrafoveal area project in an arcuate 
course to avoid the rectilinear central projections, entering the ONH supero- and infero-
temporally (246-249).  At increasing distances from the horizontal raphe, axons in the 
temporal peripheral retina take an increasingly arcuate course to enter the ONH at the 
superior and inferior poles (246-249).  Fibres from RGC in the nasal periphery, take a 
radial trajectory and enter the ONH on the nasal side (247-249) (Figure 1.9).  RGC 
axons respect the horizontal meridian (grey horizontal line on Figure 1.9), such that 
Fovea ONH
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axons from the superior retina do not cross the horizontal meridian, and enter the ONH 
at its superior pole, and RGC axons in the inferior retina enter at the inferior pole (246). 
In the RNFL in the area immediately surrounding the ONH (the peripapillary RNFL 
(ppRNFL)), the organisation of the converging RGC axons creates a ―double hump‖ 
configuration.  The ppRNFL is thickest at the superior and inferior poles of the ONH 
and thinnest in the nasal and temporal aspects of the ONH (250;251).   
1.14.2 Imaging the ppRNFL 
Assessment of the ppRNFL around the ONH not only allows the acquisition of 
information about the structural integrity of the RGC axons (i.e. by measuring ppRNFL 
thickness), but can also provide information about the retinal location of any focal 
pathology, owing to the topographic organisation of the RGC axons at the ONH (250).  
Several instruments are available that allow quantitative imaging of the ppRNFL 
including optical coherence tomography (OCT), scanning laser polarimetry and 
scanning laser opthalmoscopy (252).  The diagnostic abilities of each of these 
instruments in diseases affecting the ppRNFL (e.g. glaucoma) have been extensively 
evaluated, and there is little difference in the capabilities between the three technologies 
(253-255). 
In the output from each of these instruments, quantitative summary measures of 
ppRNFL thickness are provided including average thickness around the circumference 
of the ONH, and thickness in defined areas (e.g. temporal, superior, nasal and inferior 
ONH areas). 
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1.15 Imaging the ppRNFL in VGB-exposed individuals  
 
In 2004 Choi et al. suggested the potential for using RNFL imaging in VGB-exposed 
individuals (198).  They showed that in an individual with VAVFL and atrophy of the 
peripheral RNFL, evident using red-free fundus photography, thinning of the ppRNFL 
could be detected using OCT.  The pattern of ppRNFL thinning detected using OCT 
was consistent with the clinical and photographic features, showing ppRNFL thinning 
restricted to the ONH areas receiving RGC axons from the peripheral retina (198). 
After the initial report of ppRNFL thinning in VGB-exposed individuals (198), 
subsequent studies using OCT (119;198;229;256), scanning laser ophthalmoscopy (229) 
and scanning laser polarimetry (257), confirmed that the ppRNFL was significantly 
thinner in VGB-exposed individuals compared to healthy controls and non-exposed 
individuals with epilepsy (Table 1.7). 
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Table 1.7 Summary of studies using ppRNFL imaging in VGB-exposed individuals  
Reference  Number 
of VGB-
exposed 
Method  Main finding  
Choi 2004 
(198) 
1 TD-OCT (Stratus 
model) 
3.4mm fixed 
diameter scan  
ppRNFL thinning was consistent with 
photographic and clinical abnormalities   
Wild 2006 
(229) 
21 TD-OCT (Stratus 
model)  
Proportional circle 
scan 
100% of individuals with VAVFL were below 
the 95% confidence limit for normality  
ppRNFL was significantly thinner in VGB-
exposed with VAVFL compared to VGB-
exposed with normal visaul fields, non-
exposed individuals and healthy controls 
Durnian 
2008 (257) 
8 SLP (GDx VCC) 100% of individuals with VAVFL showed 
abnormal ppRNFL thinning  
Lawthom 
2009 (256) 
27 TD-OCT (Stratus 
model)  
3.4mm fixed 
diameter scan 
100% of individuals with VAVFL showed 
ppRNFL thinning in the nasal quadrant* 
Ardagil 
2010 (119) 
14 TD-OCT (Stratus 
model)  
3.4mm fixed 
diameter scan 
ppRNFL was significantly thinner in VGB-
exposed compared to non-exposed and healthy 
controls  
Moseng 
2011 (258) 
9 TD-OCT (Stratus 
model)  
3.4mm fixed 
diameter scan 
ppRNFL was significantly thinner in VGB-
exposed individuals with VAVFL compared to 
non-exposed, there was an increased frequency 
of ppRNFL thinning compared to non-
exposed* 
TD-OCT = time-domain optical coherence tomography; SLP = scanning laser ophthalmoscopy; 
VCC = variable corneal compensation   
*compared to the manufacturers’ normative database  
 
1.15.1 ppRNFL thickness in individuals with VAVFL 
In individuals with VAVFL, the ppRNFL was significantly thinner compared to non-
exposed individuals with epilepsy (119;229;258) and compared to healthy controls 
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(119;229).  Furthermore, using OCT, Wild et al. showed that individuals with VAVFL 
had significantly thinner ppRNFL compared to VGB-exposed individuals with normal 
visual fields (229), suggesting that the development of VAVFL may be related to loss of 
RGC axons.  Average ppRNFL thickness was plotted as a function of mean sensitivity 
to illustrate a possible relationship between ppRNFL thinning and the degree of visual 
field loss.  However, no statistical analysis or discussion of the trend was made by the 
authors (229).  Reinspection of the data does not appear to show an association between 
the two measures. 
1.15.2 The pattern of ppRNFL thinning in individuals with VAVFL 
A pattern of ppRNFL thinning associated with VGB exposure, that is in agreement with 
the pattern of RNFL and ONH atrophy observed using fundus photography (147;183), 
has been suggested.  In individuals with VAVFL, ppRNFL thickness was compared to 
ppRNFL thickness data from healthy controls provided in the manufacturers’ normative 
database
2
.  Individuals with ppRNFL thickness falling below the 5
th
 percentile of the 
manufacturers’ normative database were considered to have abnormal thinning.  All 
individuals (n=11) with VAVFL showed abnormal ppRNFL thinning in the nasal 
quadrant leading to the suggestion that ppRNFL attenuation in the nasal quadrant 
should be used as a biomarker for VGB toxicity (256).  Conversely, the ppRNFL in the 
temporal quadrant is relatively preserved with few individuals showing abnormal 
thinning in this area (119;256;259). 
1.15.3 ppRNFL thickness in VGB-exposed individuals with normal visual 
fields 
Thinning of the ppRNFL was also found in some VGB-exposed individuals with 
normal visual fields (229;256).  The pattern of ppRNFL thinning was similar to that 
                                                          
2
 See 1.19.3 
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seen in individuals with VAVFL, with thinning detected in the superior, nasal and 
inferior quadrants, but preservation of the ppRNFL thickness in the temporal quadrant 
(256).  These findings may represent individuals with subtle pathological changes in the 
retina that do not result in functional changes that are detectable using standard white-
on-white perimetry, and thus provide promising evidence that ppRNFL imaging may be 
a more sensitive measure of VGB retinotoxicity than does perimetry (256).  
1.15.4 The relationship between ppRNFL thickness and VGB exposure  
Using OCT, ppRNFL thickness in the nasal quadrant was found to correlate with 
cumulative VGB exposure, with increasing VGB exposure related to decrease ppRNFL 
thickness (256).  However, in a study using scanning laser polarimety no correlation 
was found between any ppRNFL thickness measure and cumulative VGB exposure or 
duration of VGB exposure (257).  In an OCT study by Wild et al., average ppRNFL 
thickness was plotted as a function of cumulative VGB exposure and of duration of 
VGB exposure (229).  However, no statistical analysis or discussion of the trend was 
made by the authors.  On reinspection of the data there does not appear to be an 
association between either measure of VGB exposure and average ppRNFL thickness.  
The disagreement between studies is probably due to the small number of subjects 
included, and larger studies are needed to fully appreciate the relationship between the 
amount and duration of VGB exposure and the degree of ppRNFL thinning. 
 
1.16 ppRNFL thickness in non-exposed individuals with epilepsy 
 
In some non-exposed individuals with epilepsy, ppRNFL thinning was detected as 
compared to the normative database of ppRNFL thickness provided by the 
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manufacturer
3
 (229;256).  In a study by Lawthom et al. 3/13 non-exposed individuals 
showed abnormal thinning in at least one of the ppRNFL quadrants, although all 
showed normal average ppRNFL thickness (256). The individuals all had normal visual 
fields and no clinical reason was found for the attenuation.  The authors suggested that 
the abnormal finding in these individuals was most likely due to misalignment of the 
subject during scanning or misplacement of the scan circle (256).  In an OCT study of 
45 individuals with epilepsy exposed to carbamazepine or valproate monotherapy, no 
difference in ppRNFL thickness was found compared to healthy controls (260).  
 
1.17 ppRNFL imaging for clinical use in VGB-exposed individuals 
 
Based on these OCT studies (Table 1.7), ppRNFL imaging has been proposed as a 
useful tool in the assessment of VGB-exposed individuals, providing a sensitive and 
specific indicator of VAVFL (119;229;256).  In particular Lawthom et al. suggested 
that ppRNFL attenuation in the nasal quadrant should be used as a biomarker for VGB 
toxicity (256). 
In the US, where VGB was recently licensed, the manufacturers of VGB (Lundbeck) 
require an assessment form to be completed at each opthalmological examination of 
individuals undergoing VGB therapy which is to be returned to the manufacturers after 
completion.  The form includes a section for OCT assessment, requiring the 
interpretation of the OCT as ―normal, abnormal or uninterpretable‖ (261).  In addition, a 
recent report on the recommendations for visual testing in VGB-exposed individuals 
compiled by an ―expert panel‖ of neurologists, ophthalmologists and visual 
                                                          
3
 For details See 1.19.3 
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electrophysiologists, included OCT in the suggested visual evaluation protocol, 
particularly when perimetry is unreliable or inconclusive (262).  In a briefing document 
compiled for the FDA during the application for approval of the licensing of VGB in the 
US, it was stated that ―It is highly likely that OCT will be the primary modality of 
assessing VGB retinal effects within 5 years‖ (263).   
At the present time however, the exact role of OCT in the management of VAVFL is 
uncertain (262).  The available OCT studies have been on a small number of 
individuals, and the precise relationship between the degree of ppRNFL thinning and 
the severity of VAVFL is unknown.  In the expert panel’s report on the 
recommendations for visual testing in VGB-exposed individuals, it was stressed that 
currently OCT should be considered as an ―exploratory test‖ (262).  Furthermore, 
although it has been suggested that ppRNFL imaging may provide an alternative tool to 
assess individuals who are unable to perform perimetry (229;256;262), this has not been 
formally assessed, and the repeatability of measurements has not been validated in a 
population of individuals with epilepsy. 
 
1.18 Optical coherence tomography  
 
1.18.1 Introduction to OCT 
OCT (264) is an optical imaging tool that allows non-invasive, high resolution, cross 
sectional imaging of biological tissue microstructure in vivo (264;265).  OCT imaging 
is analogous to ultrasound; however, instead of sound waves, low-coherence light is 
used to obtain images based on the optical properties of the tissue (264;265). Images are 
generated by measuring the time delay and the magnitude of backscattered and back-
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reflected light from the various tissue microstructures (266;267). Detailed imaging of 
discrete tissue architecture relies on the ability to detect difference in the optical 
properties of adjacent structures (268).    
The axial image resolution of OCT is determined by the bandwidth of the light-source 
(267).  Axial resolutions achievable with commercially available OCT instruments 
ranges from 4 - 10µm (265), compared to standard clinical ultrasound which has a 
resolution of 0.1 – 1mm (269).  Transverse resolutions are dependent on the spot size of 
the light beam on the tissue, and in retina transverse resolutions of around 20µm are 
typically achieved (270;271).  The cross-sectional image (tomograph) generated from 
OCT imaging has been referred to as an ―optical biopsy‖ (265), as it provides images of 
tissue microstructure similar to those seen under a microscope, that are not obtainable 
with any other non-invasive techniques (266;267).     
The main disadvantage of OCT is that light (unlike sound waves in clinical ultrasound) 
is substantially scattered by most biological tissues.  Attenuation of the light from this 
scattering limits the imaging depth to around 2mm (265;269), compared to standard 
clinical ultrasound which can reach depths of up to 10cm (269).  The limited penetration 
depths make OCT imaging impractical for many clinical applications.  The retina, 
however, is particularly accessible to OCT imaging as the transparent tissues of the lens, 
cornea and ocular media, allow transmission of light from the OCT instrument to the 
retina with minimal scattering and attenuation (267).   Because of this, the clinical use 
of OCT has developed most rapidly in ophthalmology for imaging the microstructure of 
the retina and optic nerve head (267), and will be further discussed here with reference 
to retinal imaging. 
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1.18.2 The basic principles of OCT 
The basic principles of OCT are illustrated in Figure 1.10.  Low-coherence light (800-
1400 nm wavelength) from a superluminescent diode is directed into a fibre-optic 
Michaelson interferometer.  At the interferometer the incident light beam is split into a 
reference arm and a sample arm via a partially reflective mirror.  Light in the reference 
arm is reflected back to the interferometer from a reference mirror.  At the same time, 
the light beam in the sample arm is incident upon a scanning mechanism, which under 
computerised control, focuses the beam onto the retina in a discrete location.  The light 
beam is then backscattered or reflected from the retina, via the scanning mechanism, 
back to the interferometer.  At the interferometer light from the reference mirror, and 
that from the retina, are combined producing an optical interference pattern on the 
surface of a photodetector (264;266;270). 
The raw signals received at the photodetector are processed into an individual A-scan, 
which represents the depth-resolved reflectivity profiles of the retina at the discrete 
location on which the beam was focused by the scanning mechanism.  Movement of the 
scanning mechanism allows the light beam in the sample arm to ―sweep‖ across the 
retina in a predetermined scan pattern (e.g. a single-line (Figure 1.11)) enabling the 
acquisition of multiple sequential A-scans in a desired pattern and location  (272).  After 
processing, multiple individual A-scans acquired during a scan session are assembled 
into a two-dimensional cross-sectional image (B-scan) (Figure 1.10 and 1.11). Using 
some OCT technologies, a series of B-scans in a raster pattern can be taken to generate 
three-dimensional OCT images (Figure 1.11).   
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Figure 1.10 Basic principles of OCT  
 
Figure 1.10 legend: The basic mechanisms of optical coherence tomography (OCT) of the 
retina.  Figure adapted from (273) 
 
Figure 1.11 Assembly of processed A-scan data into a tomograph 
 
Figure 1.11 legend: (A) The individual A-scan (red arrow) represents the depth-resolved 
reflectivity profiles of the tissue being scanned.  (B) Multiple A-scans (red arrows) are 
Low-coherence 
light source 
Michaelson
interferometer
Reference 
mirror
Sample 
(retina)
Movable scanning 
mechanism 
Photodetector
Computer
Signal 
processing
Raw, unprocessed 
A-scan data
Processed A-scan 
data
B-scan
Two-dimensional B-scan
(multiple A-scans)
Three-dimensional 
(multiple B-scans)
Intensity
D
ep
th
One-dimensional 
A-scan
A B C
Tomograph
Multiple tomographs 
generate a 3D image
101 
 
assembled into a B-scan (black arrow) to produce the two-dimensional tomograph.  (C) Using 
some OCT technologies, a series of B-scans (black arrows) in a raster pattern can be taken to 
generate three-dimensional OCT images. 
 
1.18.3 OCT technology 
Several OCT instruments are commercially available, the first of which was released in 
1995 and utilised time-domain technology.  The most recent instrument to be released 
based on this technology was the Status OCT (Carl Zeiss Meditec, Inc., Dublin, CA, 
USA) (271).  More recently, OCT instruments utilising spectral-domain (also called 
Fourier-domain) technology (e.g. Cirrus HD-OCT (Carl Zeiss Meditec, Inc., Dublin, 
CA, USA)) have been developed, and comprise the latest generation of commercially 
available OCT instruments.   
Although the basic principles of time-domain OCT (TD-OCT) and spectral-domain 
OCT (SD-OCT) are the same (Figure 1.10), they utilise different mechanisms to resolve 
the axial depth of structures within the tissue being scanned, resulting in significant 
differences in scanning speed, and axial resolution (271;274;275). 
1.18.3.1 TD-OCT (Stratus OCT) 
In TD-OCT the depth and relative positions of the retinal structures are determined 
sequentially by moving the reference mirror and analysing the interference patterns 
between the reflected reference light at known distances, and the reflected light from 
different scattering sites in the sample (276;277).   
The dependence on movement of the reference mirror to enable depth resolution, and 
the requirement of sequential resolution of light reflected from various depths, limits 
image acquisition speed to around 400 A-scans per second.  Using this technology, the 
latest commercially available OCT model (Stratus OCT, Carl Zeiss Meditec, Dublin, 
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CA, USA) allows acquisition of a single-line B-scan, comprised of 512 adjacent A-
scans, within 1.28 seconds, with axial resolution of around 10µm (277).   
1.18.3.2 SD-OCT (Cirrus OCT) 
In SD-OCT, depth resolution is not obtained by mechanical manipulation of the 
reference mirror, but by including a spectrometer in the detector arm.  The spectrometer 
allows the interference pattern obtained from the light reflected from the stationary 
reference arm, and that reflected from all scattering sights (i.e. at all depths) in the 
sample, to be collected simultaneously on the photodetector (278).  The interference 
pattern then undergoes Fourier transformation to produce the A-scan image (275;277).  
Because the light reflected from different scattering sights in the sample are measured 
simultaneously, as opposed to sequentially with TD-OCT, the process is up to 100 times 
faster (279) with data acquisition speeds of around 27,000 A-scans per second.  Cirrus 
OCT (Carl Zeiss Meditec, Dublin, CA, USA), acquires a 6x6mm cube of data 
consisting of 40,000 A-scans, in less than 1.49 seconds. 
1.18.4 The OCT image (retinal tomograph) 
After processing, multiple individual A-scans acquired during a scan session are 
assembled into a two-dimensional cross-sectional image (B-scan) (Figure 1.11).  Using 
SD-OCT, a series of B-scans in a raster pattern can be taken to generate three-
dimensional OCT images (Figure 1.11).  The final processed images are displayed in 
the OCT output using a colour-scale (or grey-scale) to represent the logarithm of the 
intensity of the reflected signal (265;266;268;270;272).  Typically, the red end of the 
colour spectrum represents areas of high reflectivity with the blue end corresponding to 
areas of low reflectivity (264;268) (Figure 1.12). 
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The laminated appearance of the retinal tomograph suggested that individual retinal 
layers might be distinguished by differences in their optical properties (280).  To 
determine the retinal structural components represented in OCT images, studies 
compared cross-sectional retinal tissue, seen under light microscopy, with 
corresponding retinal OCT scans, in humans (264;281) and in animals (268;280;282) 
(Figure 1.12).  In the OCT image, a distinct layer of high reflectivity at the vitreoretinal 
interface corresponded to the RNFL (264;268;280). Other highly reflective layers were 
compatible with the IPL, OPL and RPE (268;280-282).  Retinal areas of low reflectivity 
corresponded with the location of the photoreceptor inner and outer-segments and the 
INL and ONL (Figure 1.12 (268;270;280-282).   
 
Figure 1.12 The relationship between the OCT tomograph and retinal histology 
 
Figure 1.12 legend: The retinal substructures observable on light microscopy (A) have 
unique optical properties which produce distinct layers in the OCT tomograph (B).  Light 
microscopy image (A) taken from (231) 
 
For the commercially available OCT instruments, various scanning protocols have been 
developed which allow targeted imaging of particular retinal locations depending on the 
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structure of interest.  The tomograph obtained from each scanning protocol is provided 
in the manufacturers’ summary report and can be used to detect retinal pathology 
through direct observation.  In addition to the tomograph, the summary report provides 
quantitative data (e.g. retinal thickness), summary quantitative data (e.g. average retinal 
thickness in defined retinal areas), and normative data on various retinal structural 
measurements.  
 
1.19 Using OCT to image the ppRNFL 
 
In the OCT tomograph the RNFL appears as a distinct layer of high reflectivity at the 
vitreoretinal interface (264;268;280) (Figure 1.12).  Interest in developing methods to 
image and measure RNFL thickness was stimulated by the need for more objective, 
repeatable tools for use in glaucoma management, where retinal ganglion cell loss and 
associated RNFL attenuation are pathological features (283).   Algorithms developed 
for OCT to measure RNFL thickness employ a circular scan centred on the ONH (in the 
peripapillary area) (Figure 1.13) (283).  As all RGC axons project through the retina in 
the RNFL to leave the orbit in the optic nerve (Figure 1.9), measuring peripapillary 
RNFL (ppRNFL) thickness dictates that the measurement sample contains projections 
from all RGC axons throughout the retina. 
1.19.1 Measuring ppRNFL thickness  
The thickness of the ppRNFL is calculated firstly by determining the borders of the 
ppRNFL. This is achieved using segmentation software which uses ―edge-detection‖ 
algorithms to recognise changes in reflectivity patterns in the OCT signal 
(276;283;284).  The anterior border of the ppRNFL is detected by an early sharp rise in 
the signal intensity as the light passes through the minimally reflective vitreous into the 
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highly reflective RNFL.  Similarly the posterior border of the ppRNFL is defined by a 
sharp decrease in signal intensity as the light leaves the RNFL and passes into the less 
reflective structures of the adjacent inner retina.  Once the inner and outer borders of the 
ppRNFL have been established, the thickness in micrometers can be determined 
between these borders (276;283;284).  This process is carried out for each individual A-
scan.  Measures of ppRNFL thickness that are provided in the manufacturers’ summary 
report are based on the ppRNFL thickness measurements from each of the individual A-
scans.  
1.19.2 ppRNFL thickness scanning methods  
The impact of the dramatic difference in scanning speed between TD and SD-OCT is 
highlighted in the scanning protocols used by each instrument from which ppRNFL 
thickness is determined.  In TD-OCT the instrument acquires three sets of 256 A-scans 
in a 3.46mm diameter circle around the ONH within 1.3 seconds of scanning time.  The 
ppRNFL measurements provided in the manufacturers’ summary report are calculated 
from an average of the three sets of scans.  In SD-OCT instrument acquires a 6x6mm 
cube of data centred on the ONH, consisting of 40,000 A-scans, in 1.48 seconds.  A 
3.46mm diameter circle of data comprised of 256 A-scans, centred around the ONH is 
extracted from the cube of data.  The ppRNFL measurements provided in the 
manufacturers’ summary report are calculated from the 3.46mm diameter circle of data. 
1.19.3 The manufacturers’ summary reports  
After scan acquisition, each OCT instrument provides ppRNFL thickness data in the 
manufacturers’ summary reports.  The reports included summary measures of ppRNFL 
thickness include the average ppRNFL thickness (around the whole ONH), and the 
ppRNFL thickness in 90
o 
quadrants and 30
o 
sectors (Figure 1.13).  Regions of the 
ppRNFL are referred to according to their location around the ONH.  The four 90
o
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quadrants are referred to as temporal, superior, nasal, and inferior quadrants.  The 
twelve 30
o 
sectors are referred to as temporal (Temp), temporal-superior (TS), superior-
temporal (ST), superior (Sup), superior-nasal (SN), nasal-superior (NS), nasal (Nas), 
nasal inferior (NI), inferior-nasal (IN), inferior (Inf), inferior-temporal (IT) and 
temporal-inferior (TI) sectors (Figure 1.13).  A temporal-superior-nasal-inferior-
temporal (TSNIT) plot is also provide in the manufacturers’ summary report, which 
graphically represents the ppRNFL thickness around the whole ONH across each of the 
256 individual A-scans (Figure 1.13). 
In addition to providing quantitative ppRNFL thickness data, the ppRNFL thickness is 
classified according to which percentile it falls into, based on the manufacturers’ 
database of age-corrected normal values.  ppRNFL thickness values for all summary 
measures (average, 90
o 
quadrants, 30
o 
sectors and TSNIT plots), are colour-coded 
according to which percentile they fall into.  Values falling into the ≤95th–>5th percentile 
are colour coded as green, ≤ 5th–>1st percentile are coloured yellow and those falling 
into ≤1st percentile are coloured red (Figure 1.13). 
Details of the normative database in the TD-OCT (Stratus OCT, software version 4.0, 
Carl Zeiss Meditec, Dublin, CA) have been made available.  The normative data base is 
comprised of 328 subjects aged 18 – 85 of whom 155 (48%) were men.  The ethnic 
groups included in the database were ―Caucasian‖ (63%), ―Hispanic‖ (24%), ―African 
American‖ (8%), ―Asian‖ (3%), ―Asian Indian‖ (1%) (285).   
Details of normative data for the SD-OCT model are not currently available.  
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Figure 1.13 The manufacturers’ summary report of ppRNFL thickness data  
 
Figure 1.13 legends: Data provided in the manufacturers’ summary report of ppRNFL 
thickness.  Data illustrated on the left-hand side of the report is taken from the right eye.  Data 
illustrated on the right-hand side of the report is taken from the left eye 
(A) The 3.46mm diameter scan circle composed of 256 A-scans (red circle), centred on the 
ONH. 
(B) The ppRNFL tomograph.  The most superficial red/yellow layer (white arrow) is the 
ppRNFL from which the summary measures of ppRNFL thickness and the TSNIT profile are 
taken.   
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(C) The TSNIT profile is plotted from measures of ppRNFL thickness taken from the ppRNFL 
tomoraph (B).  Both the TSNIT profies and the ppRNFL tomograph (B) show the ―unfolded‖ 
3.46mm circle of ppRNFL thickness data composed of 256 ppRNFL scans.  The scan number is 
shown on the horizontal axis.  The ppRNFL thickness is shown in the vertical axis.  The black 
line represents the individual’s ppRNFL thickness profile. The individuals ppRNFL thickness is 
compared to the manufacturers’ normal distribution percentiles (G). 
(D) The average ppRNFL thickness around the whole ONH.  The colour represents which 
normal distribution percentile the individual’s average ppRNFL thickness falls into (G).  The 
average ppRNFL thickness in the right eye (left-hand side of the report) is 91µm and is 
classified as normal (green).  The average ppRNFL thickness in the left eye (right-hand side of 
the report) is 55µm and is classified as abnormal (red).   
(E) The average ppRNFL thickness in 90
o 
quadrants around the ONH.  The colour of each 
quadrant represents which normal distribution percentile the individual’s mean ppRNFL 
thickness by quadrant falls into (G).   
(F) The average ppRNFL thickness in 30
o 
sectors around the ONH.  The colour of each sector 
represents which normal distribution percentile the individual’s mean sectorial ppRNFL 
thickness by sector falls into (G).   
(G) The normal distribution percentiles for ppRNFL thickness.  ppRNFL thickness is classed as 
normal  (i.e. green area, ≤95th–>5th percentile); showing borderline attenuation (i.e. yellow area, 
≤ 5th–>1st percentile); or showing abnormal thinning (i.e. red area, ≤1st percentile).1.10 
 
1.20 Current problems regarding the clinical management of VAVFL  
 
Guidelines as to the management of VAVFL are available, recommending suitable 
assessment techniques based on developmental age.  However, these may not account 
for individuals unable to perform perimetry (286), and often recommend investigative 
techniques which have not shown consistent sensitivity or specificity for detecting 
VAVFL  (229;261;262;286).   
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1.20.1 The ophthalmological examination  
The ophthalmological history and examination will largely be normal in the majority of 
individuals with VAVFL.  Up to 90% of individuals with VAVFL are asymptomatic 
and symptoms of ―bumping into things‖ or ―tunnel vision‖ may only occur when 
VAVFL is severe.   The asymptomatic nature of VAVFL adds difficulty to monitoring 
VGB-exposed individuals, as pathological changes to visual function may go unnoticed 
until follow-up appointments.  In addition, individuals may be reluctant to attend for 
ophthalmological follow-up when they perceive that their vision is normal.  Colour 
vision, visual acuity and contrast sensitivity are also typically normal, even in 
individuals with severe VAVFL.  In most individuals with VAVFL examination of the 
fundus will reveal a normal retina 
(78;94;95;97;101;104;106;112;116;120;121;128;130;147;148;164;196).  The presence 
of RNFL loss and optic atrophy detected using fundoscopy or photography probably 
indicates already advanced pathology (147).      
1.20.2 Perimetry 
The gold standard for assessing VAVFL is using perimetry.  However, between 5 and 
40%  of adults with epilepsy are unable to perform perimetry (106), and in many others 
perimetric results may be unreliable and inconclusive (229).  Repeated visual field 
testing is often needed, after which results can still prove difficult to interpret (182).  
These issues are further exaggerated in children where perimetry is often unachievable.  
It is estimated that up to 80% of VGB-exposed children are unable to perform 
formalized perimetric testing (122;131;287).  In infants perimetry is not possible, 
creating a great source of contention when considering prescribing VGB for infantile 
spasms (263). 
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1.20.3 Electrodiagnostics  
ERG abnormalities including increased latency and reduced amplitude of the photopic 
b-wave, reduced OP amplitudes and reduced 30Hz flicker response have been suggested 
as markers for VAVFL.  However, non-exposed individuals with epilepsy and VGB-
exposed individuals with normal visual fields may also show these abnormalities.  In 
addition, some individuals with VAVFL have normal ERG.  The VEP and PERG are 
normal in most individuals with VAVFL.  In addition these techniques reflect central 
retinal function and therefore may be insensitive to peripheral retinal disease. 
No electrodiagnostic measure has consistently shown sufficient sensitivity or specificity 
in identifying individuals with VAVFL (229).   
1.20.4 ppRNFL imaging 
Based on the OCT studies discussed previously (Table 1.7) ppRNFL imaging has been 
suggested as a useful tool in the assessment of VGB-exposed individuals, providing a 
sensitive and specific indicator of VAVFL (119;229;256).  In particular Lawthom et al. 
suggested that ppRNFL attenuation in the nasal quadrant should be used as a biomarker 
for VGB toxicity (256). 
At the present time however, the exact role of OCT in the management of VAVFL is 
uncertain (262).  The available OCT studies have been on a small number of 
individuals, and the precise relationship between the degree of ppRNFL thinning and 
the severity of VAVFL is unknown.  In an ―expert panel’s‖ report on the 
recommendations for visual testing in VGB-exposed individuals it was stressed that 
currently OCT should be considered as an ―exploratory test‖ (262).  Furthermore, 
although it has been suggested that ppRNFL imaging may provide an alternative tool to 
assess individuals who are unable to perform perimetry (229;256;262), this has not been 
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formally assessed, and the repeatability of measurements has not been validated in a 
population of individuals with epilepsy. 
1.21 Summary of problems regarding the use of VGB  
 
The use of VGB has been limited by the risk of irreversible VAVFL.  However, 
trepidation regarding its use is augmented because of problems in the clinical 
management of VAVFL (as described above), particularly in those unable to perform 
perimetry, as well as several uncertainties regarding the natural history of VAVFL.  Of 
note, many studies have reported conflicting findings regarding the prevalence, 
progression and risk of VAVFL.  In addition, the pathological mechanisms of VAVFL 
are still unknown.  From a detailed review of the literature, the main issues regarding 
the use of VGB and the management of VAVFL include:   
 Problems in the clinical management of VAVFL, particularly in those unable to 
perform perimetry. 
 Uncertain and conflicting evidence as to the risk factors for VAVFL, particularly 
with regard to cumulative VGB exposure and duration of VGB exposure. 
 The pathological mechanisms of VAVFL are unknown. 
 The natural evolution of VAVFL with continued VGB exposure is unclear, 
particularly over long exposure periods.  
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1.22 Hypotheses and aims of the study  
 
The aims of this study were to address some of the current problems regarding the use 
of VGB and the management of VAVFL by exploring the potential of OCT ppRNFL 
imaging in a large population of VGB-exposed individuals.   
Hypothesis:   
Measurement of ppRNFL thickness using OCT is a suitable tool to use in VGB-exposed 
individuals, providing an indirect assessment of the presence of VAVFL, particularly in 
those unable to perform perimetry. 
Aims to test this hypothesis:  
 Establish whether more VGB-exposed individuals are able to complete OCT 
ppRNFL imaging compared to formal perimetric testing.   
 Determine if ppRNFL thickness measurements show adequate repeatability in 
VGB-exposed individuals. 
 Identify the relationship between ppRNFL thickness and visual field size in VGB-
exposed individuals. 
Hypothesis:   
Particular clinical, demographic and therapeutic risk factors increase the risk of VAVFL 
and thus may also be associated with the risk of ppRNFL thinning in VGB-exposed 
individuals.  
Aims to test this hypothesis:  
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 Explore the effect of clinical, demographic and therapeutic characteristic on 
ppRNFL thinning in VGB-exposed individuals. 
 Identify whether ppRNFL thinning occurs in non-exposed individuals with epilepsy, 
and determine what factors may be associated with ppRNFL thinning in this 
population.   
Hypothesis: 
VAVFL progresses with continued VGB-exposure over long follow-up periods.  
Furthermore, the ppRNFL may also show a progressive pattern of thinning with 
increasing VGB-exposure. 
Aims to test this hypothesis:  
 Explore the evolution of visual field size over a substantial follow-up period in 
individuals continuing VGB therapy.  
 Determine whether a pattern of ppRNFL thinning can be identified in VGB-exposed 
individuals, and to explore the relationship between the amount of VGB exposure 
and patterns of ppRNFL thinning. 
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Chapter 2  Methods 
 
2.1 Subjects and recruitment 
2.1.1  Ethics  
This project was approved by the Joint Research Ethics Committee of the National 
Hospital for Neurology and Neurosurgery and UCL Institute of Neurology and by other 
relevant institutional ethics committees.  All participants provided written, informed 
consent. 
2.1.2 Subjects and recruitment  
301 individuals with epilepsy and 90 healthy individuals participated in the study 
between September 2008 and June 2010.  Individuals with epilepsy were recruited from 
two epilepsy centres: the National Hospital for Neurology and Neurosurgery, Queen 
Square, London, (which includes the National Society for Epilepsy at Chalfont), and 
Stichting Epilepsie Instellingen Nederland.  All individuals, with a diagnosis of 
epilepsy, who were able to provide informed consent, were eligible for invitation to 
participate in the study.  Healthy individuals were recruited from research groups and 
employees at the National Society for Epilepsy.    
2.1.3 Exclusion criteria 
Individuals were excluded if they had diabetes, glaucoma or other known ocular 
disease, a family history of glaucoma or past history of trauma or surgery to the eye or 
orbit.  Individuals with a refractive error of more than 4.50 diopters mean sphere and 
more than 2.5 diopters cylinder were also excluded (288).  Seven of the 391 participants 
were excluded from the study according to these criteria and did not undergo any further 
testing. 
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Healthy individuals were excluded if they had a history of epilepsy or current or 
previous exposure to an antiepileptic drug.   
2.1.4 Subject Groups 
After exclusion of seven individuals based on the exclusion criteria, 384 individuals 
remained in the study, including 294 individuals with epilepsy and 90 healthy controls.  
Individuals were grouped according to a diagnosis of epilepsy, exposure to VGB and 
the OCT model on which they were assessed
4
 (Figure 2.1). 
 
Figure 2.1: Organisation of participants into Groups   
 
 
Figure 2.1 legend: Individuals were grouped according to a diagnosis of epilepsy, 
exposure to VGB and the OCT model on which they were assessed.  VGB-exposed individuals 
were assessed using with SD-OCT or TD-OCT.  All non-exposed individuals and healthy 
controls were assessed using SD-OCT.   
                                                          
4
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VGB = vigabatrin; SD-OCT = spectral-domain optical coherence tomography; TD-OCT = time-
domain optical coherence tomography.   
 
2.1.4.1 Group 1A and Group 1B: VGB-exposed 
VGB-exposed individuals included individuals currently being treated with VGB (on-
VGB), and individuals previously exposed to VGB (off-VGB).  VGB-exposed 
individuals were assessed using one of two OCT models; spectral-domain OCT (SD-
OCT) or time-domain OCT (TD-OCT).  Group 1A included 146 VGB-exposed 
individuals with epilepsy assessed using SD-OCT.  Group 1B included 58 VGB-
exposed individuals with epilepsy assessed using TD-OCT. 
2.1.4.2 Group 2: Non-exposed 
Group 2 included 90 individuals with epilepsy with no history of VGB exposure (non-
exposed).  All individuals in Group 2 were assessed using SD-OCT.  
2.1.4.3 Group 3: Healthy controls 
Group 3 included 90 healthy individuals with no history of epilepsy or antiepileptic 
drug exposure.  All individuals in Group 3 were assessed using SD-OCT.  
 
2.2 Demographic, clinical and therapeutic data 
 
Demographic data for each Group are displayed in Table 2.1. 
  
  
117 
 
Table 2.1 Demographic and clinical data according to Group  
 Group 1A Group 1B Group 2 Group 3 
 VGB-exposed 
individuals 
with epilepsy 
VGB-exposed 
individuals 
with epilepsy 
Non-exposed* 
individuals 
with epilepsy 
Healthy 
controls 
Number of 
participants 
146 58 90 90 
Mean age (years) 
[SD] 
45.9 [±11.4]
 
46.1± 10.6 39.5 ± 11.4 41.9 ± 13.1 
Sex (% males) 51.4 59.3 40.0 40.0 
Mean duration of 
epilepsy (years)  
[SD] 
32.2 [±10.4] 35.3 ± 8.6 22.5 ± 12.8 NA 
Mean age of onset 
(years) [SD] 
8.9 [±7.1] 13.9 ± 8.7 14.0 ± 8.7 NA 
Mean cumulative 
VGB exposure 
(grams) [SD] 
2281.0 ± 
3255.7 
7041.4 ± 
5921.9 
0 NA 
Median cumulative 
VGB exposure 
(grams) [range] 
1061.0  
[10-20085] 
7581.0 
[259-21105] 
0 NA 
Mean duration of 
VGB exposure 
(months) [SD] 
41.3 ± 46.6 104.8 ± 82.3 0 NA 
Median duration of 
VGB exposure 
(months) [range] 
21.0 
[1-230] 
126.0 
[3-231] 
0 NA 
Mean maximum 
daily VGB dose 
2798.6 
[1070.4] 
2746.6  
[965.6] 
0 NA 
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(milligrams) [SD] 
Median maximum 
daily VGB dose 
(milligrams) 
[range] 
2000 
[500-5000] 
3000 
[500-5000] 
0 NA 
VGB = vigabatrin; *non-exposed = not exposed to VGB 
 
For individuals with epilepsy, all clinical and demographic data were obtained from the 
medical records.  Sources of information included out-patient clinic letters and in-
patient admission and discharge summaries and drug charts.  For the healthy controls, 
demographic data were obtained from direct questioning.  The relevant clinical 
variables and the criteria used to classify them are shown in Table 2.2.  Clinical, 
demographic and therapeutic data for each individual were only included in any 
analyses if evidence of that variable could be obtained from the medical records.  For 
example, the presence or absence of a history of febrile seizures was only recorded for 
an individual if it was explicitly discussed in the clinical records.  If an explicit record 
of any clinical variable was not found these data were regarded as missing.          
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Table 2.2 Criteria used to define clinical features  
Clinical feature Definition/method of determination 
VGB-exposed  Individuals with any current or previous exposure to VGB, as 
determined from the information available in the medical notes.  
There were no minimum criteria in terms of the duration of 
exposure or dose received. 
Duration of VGB 
exposure  
The time in months that the individual was exposed to VGB, as 
determined from the information available in the medical notes.  
(See 2.1.x for further details of determination).  
Cumulative VGB 
exposure  
The total amount of VGB in grams that an individual was 
exposed to, as determined from the information available in the 
medical notes.  (See 2.1.x for further details of determination). 
Maximum daily VGB 
dose 
The maximum daily dose of VGB, in milligrams, that an 
individual received, as determined from the information 
available in the medical notes. 
Non-exposed Individuals with no history of VGB exposure, as determined 
from the information available in the medical notes. 
Epilepsy phenotype  Phenotypes were classified according to the criteria described 
by Kasperaviciute et al. (289) adapted from the International 
League Against Epilepsy revised organisation of phenotypes in 
epilepsies (290). 
Duration of epilepsy The length of time in years between the year of diagnosis* of 
epilepsy as recorded in the medical notes, and the year of 
inclusion in the study. (e.g. epilepsy diagnosed in 1973, 
inclusion in the study in 2009, duration of epilepsy = 36 years). 
Drug-resistant epilepsy Adapted from the International League Against Epilepsy 
Commission on Therapeutic Strategies (291). 
Individuals who: 
a) have had one or more seizures (of any type) in the year 
preceding the most recent follow-up 
b) have had three drug trials which are adequate and 
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appropriate. 
        i) Appropriate means the drug is recommended by NICE or 
licensed for the type of seizures in question 
        ii) The drug was tried for a sufficient length of time at an 
adequate dosage - maximum tolerated daily dose usually, or if 
clinician has documented that the drug has shown lack of 
efficacy. Length of time should be for at least the maximum 
duration between seizures. Seizures should have occurred 
during treatment with each drug. 
c) No documented non-epileptic attacks during any of the drug 
trials above 
d) No documented regular (>2 times) non-compliance causing 
seizures 
Learning disability  Individuals described by their epilepsy consultant, in the 
medical notes, as having learning disability or cognitive 
impairment. 
History of febrile seizures Individuals who have a record of febrile seizures in their 
medical notes.  
History of status  Individuals who have a  record of status in their medical notes 
History of head injury Individuals who have a record of a head injury in their medical 
notes. 
History of neurosurgery  Individuals who have a history of neurosurgery involving the 
brain parenchyma.  
History of smoking  Individuals who were current, or ex-smokers. 
Exposure to other AEDs 
(e.g. carbamazepine) 
Any current or previous exposure to any AED, as determined 
from the information available in the medical notes, was 
documented.  There were no minimum criteria in terms of the 
duration of exposure or dose received.  For each AED 
individuals were classed as ―exposed‖ or ―non-exposed‖. 
VGB = vigabatrin; NICE = National Institute for Health and Clinical Excellence; AED = 
antiepileptic drug 
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*Often the age of the individual at the time of the diagnosis was given instead of the year of 
diagnosis.    
 
2.2.1 Choosing relevant clinical and demographic variables  
The demographic and clinical data to be obtained from the medical records were chosen 
based on previous studies of risk factors for VAVFL, and on studies of ppRNFL 
thickness in other neurological disease.  Other clinical variables that are thought to be 
associated with neuronal injury in epilepsy were also chosen. 
2.2.1.1 VAVFL risk factors 
Male gender (92;94;95;97;98;103;137;167) and co-medication with other AEDs 
(particularly valproate) (108;114;164), have been shown to be associated with risk of 
VAVFL and were chosen as variables.  Smoking was also suggested as a possible risk 
factor for VAVFL in a preliminary analysis in one study (92) and was also included.  In 
addition, excessive tobacco and alcohol use is associated with the development of a 
toxic-nutritional optic neuropathy (tobacco-alcohol amblyopia) which can manifest with 
changes in ppRNFL thickness (292). 
2.2.1.2 ppRNFL in neurological disease 
The presence of learning disability was chosen as a clinical variable as an association 
between cognitive function and ppRNFL thickness has been found in studies of 
individuals with multiple sclerosis where ppRNFL thinning is associated with cognitive 
disability (293).  In healthy, young individuals ppRNFL thickness was found to be 
associated with level of cognitive functioning (294).  
A history of neurosurgery involving the brain parenchyma was also chosen.  Individuals 
who have had surgical resections involving the visual pathways (e.g. anterior temporal 
lobe resections for hippocampal sclerosis) may show ppRNFL thinning as a result of 
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retrograde trans-synaptic degeneration.  In a recent study, ppRNFL thinning was 
detected in individuals with acquired occipital lobe lesions, providing evidence for 
trans-synaptic degeneration of the visual pathway that is detectable using OCT (295).     
2.2.1.3 Neuronal injury 
Clinical factors that have been associated with neuronal injury and cell death were also 
chosen.  Local and global neuronal losses related to certain clinical factors may involve 
the visual pathways, leading to ppRNFL thinning through trans-synaptic degeneration.  
Duration of epilepsy was selected as widespread neuronal abnormalities and atrophy 
have been associated with longer duration of epilepsy (296-300), indicating that in some 
individuals progressive brain atrophy can occur with continuing seizure activity (299).  
Status epilepticus (301), febrile seizures (302) and head injury (303) are also associated 
with neuronal injury and cell death, and thus were included as clinical variables. 
 
2.2.2 Calculating cumulative VGB exposure and duration of VGB exposure 
The duration of VGB exposure and the cumulative VGB exposure were calculated from 
information available in the medical notes. 
The duration of VGB exposure was calculated using Excel by inputting the first date of 
VGB exposure; the ―start date‖ and the last date of VGB exposure; the ―end date‖, and 
determining the time in months between these two dates.   
For individuals who were prescribed VGB on an out-patient basis, the exact ―start date‖ 
was not known.  In these cases the date of the out-patient clinic (as determined from the 
clinic letter) where VGB was first prescribed, was used as the ―start date‖.  Where the 
date of the out-patient clinic was not know (i.e. it was not included in the clinic letter 
and could not be found elsewhere in the out-patient notes) the date of the clinic letter 
123 
 
was used.  For individuals prescribed VGB on an in-patient basis the date of the first 
VGB dose, as given in the drug chart, was used as the ―start date‖.     
For individuals prescribed VGB on an out-patient basis the ―end date‖ was determined 
from information provided in the last available clinic letter in which the individual was 
still receiving VGB.  The ―end date‖ was calculated using available withdrawal 
schedules or advice regarding withdrawal provided in the clinic letter.  Withdrawal 
information was calculated from the date of the out-patient clinic, or clinic letter (as 
described above). Clinic letters succeeding the letter which outlined withdrawal 
information were carefully checked to ensure that VGB therapy had been discontinued.  
For individuals withdrawn from VGB on an in-patient basis the date of the last VGB 
dose, as outlined in the drug chart, was used as the ―end date‖.  For individuals who 
were still receiving VGB at the time of the study, the date of participation in the study 
was used as the ―end date‖. 
The cumulative VGB exposure was calculated using Excel, and was determined by 
multiplying the total daily dose of VGB (in grams) by the duration of therapy (in days).  
For example, a total daily dose of 2.5 grams for 1095 days would equate to a cumulative 
VGB exposure of 2.5 x 1095 = 2,737.5 grams.  The ―start date‖ and ―end date‖ of a 
specified daily dose were determined from information available in the medical notes as 
described above for the calculation of duration of VGB exposure.   
Most individuals included in the study underwent several changes in VGB daily dose 
over the duration of VGB exposure.  For these individuals a ―start date‖ and an ―end 
date‖ were determined for each daily dose, as described above for the calculation of 
duration of VGB exposure and the cumulative VGB exposure was determined for each 
of these periods.  See Table 2.3 for an example.  
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Table 2.3 Example of how cumulative VGB exposure was calculated 
Daily dose 
(KG)  
Start date  End date  Days  Cumulative dose 
(KG) 
0.5 8.8.1995 21.8.1995 14 7 
1.0 22.8.1995 18.9.1995 28 28 
2.0 19.9.1995 12.2.1996 147 294 
1.5 13.2.1996 26.2.1996 14 21 
1.0 27.2.1996 12.3.1996 14 14 
0.5 13.3.1996 26.3.1996 14 7 
Cumulative VGB exposure (KG)  371 
 
VGB exposure data were only included for individuals who had a complete historical 
reference of VGB exposure.  This included reference to starting VGB, reference to any 
dose changes and reference to VGB withdrawal.  If cumulative VGB exposure, duration 
of VGB exposure, or maximum daily VGB dose could not reliably be deduced from the 
available clinical records, VGB dose data were regarded as missing.  The most common 
reasons for missing VGB exposure data included exposure to VGB before referral to the 
National Hospital for Neurology and Neurosurgery (in these cases it was known that the 
individual had been exposed to VGB but the details of exposure were often not 
available or were incomplete); and missing clinic letters or outpatient notes which 
provided data on VGB start dates, VGB dose changes and VGB withdrawal schedules.     
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2.3 Examination and test procedures 
 
All examinations and test procedures were undertaken at the same visit and by the same 
operator (LMC)
5
. 
2.3.1 Examinations undertake 
Information sheets were provided to all individuals participating in the study and 
informed consent was obtained
6
.  All individuals underwent a screening questionnaire 
and visual assessment to determine suitability for the study (see exclusion criteria).  
Subsequently, depending on the group that the individual belonged to, individuals were 
assessed using GKP and OCT (Table 2.4).  For individuals recruited from Stichting 
Epilepsie Instellingen Nederland, instructions for GKP and OCT were provided in 
Dutch
7
. 
 
  
                                                          
5
 For fourteen individuals a retrospective analysis of the evolution of VAVFL was carried out (see Chapter 
3).  Some of the visual field examinations included in this analysis were not performed by LMC, and were 
taken at multiple test sessions over a ten-year period by several experienced operators.  
6
 Information sheets and consent forms are provided in the Appendix 1 
7
 For the Dutch translation of OCT and GKP instruction, please see Appendix 3 
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Table 2.4 The order of examination and assessment for all individuals included in the 
study 
Order of 
assessment 
Examination/assessment  Participants included  
1st Information sheets are provided, the study is 
explained to the participant and informed consent 
is obtained 
All participants  
2nd A screening questionnaire
8
 is used to exclude 
subjects according to the criteria.  Visual acuity, 
colour vision and refractive status are assessed. 
All participants  
3rd The visual field is assessed using GKP Individuals in Group 1A 
and Group 1B* 
4th ppRNFL imaging is undertaken using OCT All participants* 
GKP = Goldmann kinetic perimetry; OCT = optical coherence tomography 
*not including those participants who were excluded after the initial screening questionnaire and 
assessment  
 
2.3.2 Screening  
All individuals underwent a screening questionnaire
10
 and examination based upon the 
exclusion criteria.  Refractive status was determined using a focimeter.  Best corrected 
visual acuity was assessed using a six-meter Snellen chart and a near chart.  Colour 
vision was examined using the Ishihara pseudoisochromatic test.  Individuals who met 
the exclusion criteria did not undergo any further examination or test procedures.  
Individuals who were found to have an unexplained impairment of colour vision or 
visual acuity, that could not be corrected with a pinhole or appropriate lens were also 
excluded at this stage and were referred for further ophthalmological examination. 
                                                          
8
 See Appendix 2 for the exclusion criteria questionnaire. 
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2.4 Perimetry  
 
The visual field was examined using GKP for all VGB-exposed individuals (Group 1A 
and Group 1B).  Individuals in Group 2 and Group 3 did not undergo perimetric testing.   
2.4.1 Choosing a perimetric technique 
There is controversy over whether VAVFL should be assessed using automated static or 
manual kinetic perimetry (122).  Screening strategies recommended by the Royal 
College of Ophthalmologists include using either an automated static suprathreshold 
two- or three-zone age-corrected strategy, to at least 45
o
 eccentricity (e.g. HVFA 120-
point or Octopus 07), or kinetic perimetry using GKP (III4e and I4e or I2e stimuli) 
(286).   
Automated perimetry has been recommended by some groups who have suggested that 
VAVFL is more frequently detected using automated perimetry (92;140).  However, 
these studies have not compared the use of each technique in the same group of 
individuals to determine if either method is superior.  The range of prevalence of 
VAVFL reported in the literature using each method is similarly wide, (19 – 92% for 
manual kinetic perimetry (96;110); 17 – 89% for automated static perimetry (94;116)). 
An advantage of using automated perimetry is that it is largely operator-independent 
(108), allowing standardisation of the assessment technique and avoiding the variability 
introduced by an examiner (304).  Manual kinetic perimeters are not always accessible 
(108), and depend on a skilled, trained operator (122;304-307), who may not be 
available (108).   
The use of some of the standard automated visual field assessment programmes (e.g. 
HVFA 30-2 and 24-2 programmes) may miss mild to moderate peripheral visual field 
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defects that do not extend into the central visual field (97;101;108;116;122).  Even 
those recommended automated programmes may not survey the far periphery of the 
visual field.  For example the Humphrey 120-point programme surveys within an 
eccentricity of 50
o
 nasally, 60
o
 temporally, 40
o
 superiorly, and 55
o
 inferiorly.  The 
normal extent of the visual field is 60
o
 nasally, 100
o
 temporally, 60
o
 superiorly, and 75
o
 
inferiorly.  Therefore mild peripheral visual field defects may be missed.  GKP allows 
the visual field to be assessed out to 90
o
 in all planes, thus most of the peripheral visual 
field can be assessed using this technique.
 
   
Many individuals with epilepsy are unable to meet the demanding requirements of 
automated perimetry (81;93;95;110).  Manual kinetic perimetric techniques, including 
GKP, allow a constant interaction between the operator and patient, enabling the testing 
to be guided by the individual being examined (304;305).  In individuals with poor 
fixation, poor attention or cognitive impairment a more reliable visual field can often be 
obtained by a skilled operator using GKP (308).  The operator dependence of GKP also 
introduces disadvantages, in particular, operator bias my influence the recorded visual 
field (309) (see 8.1.1 for further discussion of this).  
GKP has been suggested as a preferential technique for detecting VAVFL because of 
the ability to survey the majority of peripheral visual field in a short period of time, and 
its possible superior sensitivity for detecting peripheral visual field defects (310).    
Importantly, more individuals are able meet the requirements of this technique 
(94;96;97;104;110;122;137).  For these reasons GKP was chosen to examine the visual 
field of VGB-exposed individuals in the present study.   
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2.4.2 Perimetric method 
Visual fields were assessed using a Goldmann kinetic perimeter (Haag Streit, UK).  
Where perimetry was performed it was always carried out first to ensure that the results 
of the OCT scan could not produce any operator bias in the visual field acquisition.   
Both eyes were examined, where possible, using V4e, I4e and I2e stimuli.  Appropriate 
full-aperture spectacle correction was used for examination of the central 30
o 
of the 
visual field.  Monocular vision was examined, with the non-tested eye fully occluded 
using an eye patch.  The right eye was always examined first.  Individuals were 
positioned in the headrest and allowed to adapt to the luminance of the background 
sphere for 1-2 minutes.  During this time the procedure was explained to the subject and 
the subject’s eye was moved into the correct position by adjustment of the headrest.  
Fixation was carefully monitored by direct visualisation of the fixating eye.  The V4e 
target was presented first and the full isopter plotted, followed by the I4e and I2e 
targets.  Before examination of the peripheral visual field, the target was always 
presented into a central area of the visual field to ensure that the individual understood 
the instructions and was responding appropriately to the stimulus (i.e. by pressing the 
response buzzer).  By doing this the reaction time of the subject could also be assessed, 
helping to guide the examination. 
The target was presented in the far peripheral visual field and moved along each of 
twelve meridians, spaced 30
o 
apart, toward the point of fixation.  The target was moved 
at a velocity of approximately 4
o 
per second (311), which was adjusted according to the 
needs of the subject being examined.  A velocity of 4
o 
per second  was chosen as it has 
been shown to be the optimal rate of movement to improve the time efficiency of the 
procedure without significantly influencing the effect of reaction time on the response 
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(311).  Other stimulus velocities have also been suggested, including 2
o 
(312)
 
and 5
o 
(313)
 
per second.  The blind spot was assessed using the I4e isopter.     
2.4.3 Calibration of perimeter  
The Goldmann kinetic perimeter was regularly calibrated according to the 
manufacturers’ instructions (312) to ensure that the target luminance and background 
sphere luminance were correct and did not change between examination periods.  The 
target luminance was maintained at 1000 apostilbs.  The background sphere luminance 
was maintained at 31.5 apostilbs.      
2.4.4 Exclusion of visual field data 
Visual fields were excluded if they were determined to be unreliable by the operator.  A 
disadvantage of using GKP is that there are no objective methods to determine visual 
field reliability, and thus unreliable visual fields must be determined subjectively by the 
examiner.  Factors known to contribute to the reliability of a recorded visual field were 
considered, including fixation accuracy, false positive and false negative responses 
(199).   Fixation was carefully monitored by the operator, and assessments in which 
repeated loss of fixation occurred were deemed unreliable.  Assessments from 
individuals showing a high number of false positive responses (i.e. frequently pressing 
the buzzer when no light stimulus was presented to them) were also determined as 
unreliable.  Where individuals showed highly variable responses to the same stimulus 
examinations were also recorded as unreliable.  In addition the shape of the recorded 
visual field was assessed, particularly in individuals in whom visual field tests were 
subjectively determined to be unreliable.  Visual fields showing a spiral or star-shaped 
pattern are typically associated with functional visual field loss rather than true visual 
pathway pathology (314;315) and are regarded as indications of poor reliability of a 
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visual field result (315).  All of these factors were taken into account when excluding 
visual field test results from the analysis. 
Visual fields with homonymous defects were excluded from the visual field analysis.  
Previous studies have included these visual field data, excluding the quadrant or 
hemifield displaying the defect (99;106;113).  In this study, these visual fields were 
excluded as the radial extent of the visual field is not uniform throughout, (i.e. the 
normal monocular visual field extends to around 100
o 
temporally, 60
o 
nasally, 60
o 
superiorly and 75
o 
inferiorly). Exclusion of a hemifield or quadrant from the analysis 
may result in an over- or under-estimation of the visual field size (Figure 2.2).   
 
Figure 2.2:  Quantifying the visual field using MRD 
 
Figure 2.2 legend: An example of a normal visual field assessed using the I4e isopter.  The 
visual field is quantified using MRD, by measuring the radial distance in degrees, from fixation, 
at 12 points, 30
o 
apart (starting at 90
o
) (black arrow), and calculating the average radial distance.   
A
B C
47o
51o
60o
71o
46o
47o
48o
43o
41o
52o 60
o
66o
A B
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The size of the visual field (using mean radial degrees (MRD)) was calculated using the whole 
visual field, and then after excluding quadrants or hemifields.  Whole visual field= 53 MRD; 
exclude A = 54 MRD; exclude B = 52 MRD; exclude C = 51 MRD; exclude D = 55 MRD; 
exclude A+D = 58 MRD; exclude B+C = 46 MRD.   
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2.5 Quantifying and classifying visual field data 
 
Studies of VAVFL have used various methods and criteria to quantify and classify 
visual field results from GKP.  These methods are outlined in Table 2.5.  Those criteria 
that have been utilised to classify the presence and severity of VAVFL are shown in 
Table 2.6.  
 
Table 2.5 Methods and criteria used to quantify VAVFL as assessed by manual 
kinetic perimetry in different studies 
Reference Method used to quantify visual field loss 
Newman 2002 (95) 
Best 2005 (148) 
Kinirons 2006 (99) 
Kinirons 2006 (168) 
This study 
The MRD was determined from the I4e isopter by measuring the 
radial distance in degrees, from fixation, at 12 points, 30
o 
apart, 
and calculate the average radial distance. 
Miller 1999 (106) 
Paul 2001 (111) 
Krauss 2003 (105) 
Toggweiler 2001 (118) 
The MRD was determined from the V4e isopter by measuring the 
radial distance in degrees, from fixation, at 12 points, 30
o 
apart, 
and calculate the average radial distance. 
Toggweiler 2001 
The radius of the V4e isopter is measured in degrees in the 
temporal, superior, nasal and inferior meridians 
Wild 1999 (97) 
Wild 2009 (92) 
The radius of the I4e isopter is measured in degrees in the 
temporal, superior, nasal and inferior meridians 
Kalviainen 1999 (104) 
The radius of the IV4e isopter was measured in degrees in the 
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Nousiainen 2001 (100) temporal, superior, nasal and inferior meridians 
Hardus 2000 (94) 
Hardus 2000 (152) 
Hardus 2001 (137) 
The Esterman Grid – The Esterman grid comprises 100 dots, each 
dot represents1% of an intact visual field.  The Grid was placed 
over the recorded visual field.  The percentage visual field loss 
was calculated from the number of dots that fall outside the area 
of the V4e isopter (i.e. within the area of the visual field defect). 
Hardus 2001 (137) 
Hardus 2001 (136) 
Hardus 2003 (151) 
The surface method – A line was drawn through 24 bisection 
points of the 15-degree spaced meridians for the V4e isopter.  The 
surface inside this line was calculated using Excel (Microsoft, 
Redmond, WA, USA). 
van der Torren 2002 
(109) 
The extent in degrees of the nasal visual field (to the nearest 5 
degrees) 
Schmitz 2002 (108) 
The radius of the III4e isopter was measured in the temporal and 
nasal meridian. The findings of both eyes were summed and 
divided by two. 
Comaish 2002 (135) 
Visual field plots were scanned into a computer and the areas 
contained within the I4e isopter were measured using ImageJ 
software. The results were summed for the two eyes 
Vanhatalo 2002 (122) Temporal visual field in degrees using the largest isopter tested 
Arndt 2002 (164) 
The area of perception (in square degrees) was determined for 
each test without blind-spot subtraction. 
Schmidt 2002 (149) 
Schmidt 2004 (174) 
The radius of the III4e isopter was measured in the nasal, the nasal 
inferior (225° or 315°) and the temporal axis. The findings of both 
eyes were summed and divided by two. 
 
Sergott 2010 (93) 
The radius of the V4e and IV4e isopter measured in degrees in the 
temporal and nasal meridians 
MRD = mean radial degrees 
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Table 2.6 Methods and criteria used to classify VAVFL as assessed by manual 
kinetic perimetry in different studies 
Reference  Criteria used to classify visual fields  
Wild 1999 (97) 
Wild 2009 (92) 
This study   
See Table 2.7 for details 
 
Kalviainen 1999 (104) 
Nousiainen 2001 (100) 
Sorri 2000 (316) 
Vanhatalo 2002 (122) 
Normal = >70
o 
in the temporal meridian  
Mildly abnormal = 50–70o in the temporal meridian 
Severely abnormal = <50
o
 in the temporal meridian 
(with the largest isopter tested) 
Miller 1999 (106)  Minor constriction = 10-15 degrees less than the MRD in non-
exposed individuals 
Significant constriction = 20-25 degrees less than the MRD in 
non-exposed individuals 
Hardus 2001 (137) 
Hardus 2001 (136) 
Hardus 2003 (151) 
Loss of more than 14% (equivalent to two standard deviations) 
of the visual field surface area in one eye compared to the visual 
field surface area of 24 healthy controls. Using the V4e isopter.  
The surface area of a visual field was determined using Excel. 
van der Toren 2002 
(109) 
VAVFL =  <50
o
 in the nasal meridian (stimulus size unknown) 
Malmgren 2001 (96) Visual field ―contraction‖ =  <80o in the temporal meridian or 
<40
o 
 in the nasal meridian.  Using the V4e isopter 
Schmitz 2002 (108) 
Schmidt 2002 (149) 
 
(compared to baseline visual field size) 
Normal 
– constriction of <10° (III/4e) and <5° (I/2e) 
– any change, if the amount of fluctuation was similar 
Mild changes 
– constriction of between 10° - 25° (III/4e) and/or 5–10° (I/2e) 
Severe changes 
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– constriction of >25° (III/4e) and/or >10° (I/2e) 
Jensen 2002 (121) Normal = >40◦ in the nasal meridian and  > 60◦ in the temporal 
meridian  
Mildly abnormal = 40-20◦ in the nasal meridian and 60-30◦ in the 
temporal meridian 
Severely abnormal =  <20
o 
in the nasal meridian and <30
o 
in the 
temporal meridian  
(Using the IV4e isopter) 
Arndt 2002 (164) moderate VAVFL = visual field area of <2SD of the mean value 
obtained in healthy controls 
severe defect = visual field area of <3SD of the mean value 
obtained in healthy controls 
Sergott 2010 (93)  Normal  =  >80◦ in the temporal meridian  
Mildly impaired  = 60—80◦ in the temporal meridian 
Moderately impaired  = 30—<60◦ in the temporal meridian 
Severely impaired =  <30◦ in the temporal meridian 
Using the V4e or IV4e isopter (averaged for the 2 eyes) 
Newman 2002 (95)  Severe  VAVFL = ≤30 MRD  
Kinirons 2006 (99) 
 
Constricted visual field =  MRD more than two standard 
deviations below the average MRD from non-exposed 
individuals 
Severely constricted visual field = MRD <30 degrees 
Toggweiler 2001 (118) VAVFL  = <60 MRD.  Using the V4e isopter  
 
2.5.1 Quantifying visual field size  
In this study the mean radial degrees (MRD) method was used to quantify the size of 
the visual field.  The MRD was determined using the I4e isopter, and was calculated by 
measuring the radial distance in degrees, from fixation, at 12 points, 30
o 
apart (from 0
o
 – 
120
o
), and calculating the average radial distance (Figure 2.2).   
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This method has been used previously in several studies of VAVFL 
(95;99;105;106;111;118;153;168), including four studies which have been carried out 
fully, or in part, in the department that this study was conducted (National Hospital for 
Neurology and Neurosurgery) (95;99;148;168).    
This method of quantification of visual field size was chosen because the quantitative 
value obtained reflected the visual field size in all meridians, i.e. the size of the whole 
visual field contributed to the obtained MRD value for the visual field.  Other 
classification methods have assessed the extent of only part of the visual field (e.g. the 
temporal meridian) (108;108;109;122).  Assessment of the whole visual field was felt to 
be important as VAVFL is known to affect the entire periphery of the visual field, and is 
not confined to particular hemifields, quadrants or regions (e.g. the arcuate regions).   
Other methods used to quantify the size of the visual field that have utilised the whole 
visual field include the Esterman grid (94;137;152) and the surface method 
(136;137;151).  The Esterman method comprises a grid of 100 points, each one 
representing 1% of the visual field.  Any points that lie outside of the outer boundaries 
of the visual field are counted to determine the percentage visual field loss.  The 
disadvantage of this method is that there is an unequal distribution of points over the 
visual field (e.g. the inferior-temporal quadrant contains 40 points, whilst the superior-
nasal contains only 19) (137), with few points in the far periphery, meaning that small 
changes in the peripheral visual field may be missed.   
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2.5.2 Classifying visual field size  
Several criteria have been used classify the visual field (Table 2.6).  This allows the 
visual field to be classified as normal or abnormal, as well as describing the severity of 
the abnormality (e.g. mild VAVFL or severe VAVFL).   
Some studies have used visual field results from control populations (either non-
exposed individuals with epilepsy or healthy controls) to define the criteria used to 
classify VAVFL.  Typically, an abnormal visual field is one where the quantitative 
measure of visual field size (e.g. radial degrees in the temporal meridian) is more than 
two standard deviations below the control group mean for that measure 
(99;136;137;151;164).  
There are several issues with using a control group to classify the presence and severity 
of VAVFL.  Firstly, whilst it may be easy to classify an ―abnormal‖ visual field (e.g. by 
using a cut off of more than two standard deviations below the control group mean 
visual field size), it becomes more difficult in using criteria to describe the severity of 
VAVFL (e.g. mild, moderate and severe VAVFL).  Most studies that have used a 
control group to define VAVFL have only defined visual fields as ―normal‖ or 
―abnormal‖ (99;136;137;151).  The severity of VAVFL varies widely (12;96;97;106) 
(Figure 1.3), and this classification method may not be sufficient to describe and 
classify VAVFL.  Secondly, the recorded visual field size may be influenced by factors 
not related to visual impairment (for further discussion see Chapter 3), including 
psychomotor slowing, cognitive impairment, delayed reaction time, poor attention and 
concentration.  In individuals with epilepsy this may lead to an underestimation of the 
visual field size.  Using a healthy control group to set the criteria for normality may lead 
to an overestimation of the prevalence of VAVFL in VGB-exposed individuals because 
of differences in the ability to perform the test, rather than because of true visual 
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pathology.  Lastly, differences in the control populations used between studies might 
influence the reported prevalence of VAVFL making results difficult to compare 
between studies.  
For these reasons, a control group was not used to define the presence or severity of 
VAVFL, and an absolute classification criterion was selected for use in this study.  The 
visual field was classified as being normal or showing either mild, moderate or severe 
VAVFL, using the criteria described by Wild et al. (97) (Table 2.7).   
Table 2.7 Guidelines for the classification of severity of visual field loss for kinetic 
perimetry according to the I4e isopter (97) 
 Meridian 
VAVFL 
classification 
Temporal 
(extent in degrees) 
Superior 
(extent in degrees) 
Nasal 
(extent in degrees) 
Inferior 
(extent in degrees) 
Normal  >70
o 
>40
o 
>45
o 
>50° 
Mild 50-70
o 
35-40
o 
35-45
o 
45-50
o 
Moderate 30-50
o
 20-35
o 
20-35
o 
25-45
o 
Severe <30
o
 <20
o 
<20
o 
<25
o 
 
These criteria were used as they were the only criteria to take into account all four of the 
major meridians (temporal, superior, nasal, inferior), whereas most other classification 
systems used only took into account the extent of the nasal and/or temporal meridian 
(Table 2.6).   
2.5.3 Reliability of visual field quantification and classification method 
The methods chosen to quantify and classify the visual field require the examiner to 
make a subjective assessment of the extent of the visual field in each meridian.  To 
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determine whether the chosen methods had adequate intra- and inter-rater reliability, a 
subset of 25 visual fields were analysed. 
To determine intra-rater reliability, visual fields were quantified and classified 
immediately after acquisition by L.M.C.  Several months later the visual fields were re-
examined, quantified and classified by the same examiner who was blinded to the initial 
classification.  To determine the inter-rater reliability, visual fields were quantified and 
classified immediately after acquisition by L.M.C.  At a later date they were assessed by 
a second examiner, who was blinded to the initial quantification and classification, and 
to the individuals medical and drug history.  MRD data were analysed using intraclass 
correlation coefficient (ICC) (317).  Visual field classification data were analysed by 
determining Cohen’s kappa (κ) (318).   
Visual field quantification using MRD showed high intra- and inter-rater agreement 
(Table 2.8).  Visual field classification showed ―substantial‖ intra-rater agreement, and 
―moderate‖ inter-rater agreement (Table 2.8).  The good reliability of the visual field 
quantification and classification methods confirmed that these methods were suitable 
for use in the present study.             
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 Table 2.8 Intra- and inter-rater reliability of visual field quantification and 
classification method 
 MRD 
ICC (95% CI) 
Classification  
κ (p value) 
Intra-rater  0.995 (0.989 – 0.998) 0.709 (p<0.001) 
Inter-rater  0.995 (0.990 – 0.998) 0.523 (p<0.001) 
ICC = intraclass correlation coefficient; CI = confidence interval; κ = Cohen’s kappa.  
Interpreting ICC: an ICC of zero indicates no agreement between the measures, an ICC  of one 
indicates perfect agreement between measures (319). 
Interpreting Cohen’s kappa: a κ of zero indicates that the agreement between the measures is no 
better than that which would be obtained by chance.  A κ of one indicates perfect agreement 
between measures.  The value of κ can be judged as providing agreement that is poor (κ ≤0.20); 
fair (0.21≤ κ ≤0.40); Moderate (0.41≤ κ ≤0.60); substantial (0.61≤ κ ≤0.80) or good (κ ≥0.81) 
(318;319). 
 
2.6 Optical Coherence Tomography 
 
All individuals participating in the study underwent ppRNFL imaging using OCT.  In 
individuals undergoing perimetry (Group 1A and Group 1B), OCT was performed after 
perimetric testing was completed.   
2.6.1 OCT scan method 
For all ppRNFL scans, the contralateral eye was occluded and individuals were 
positioned in the head rest and asked to look into the OCT lenses and fixate on an 
internal target.  The optic disc was clearly visualised, and the scan-circle was centred on 
the optic disc.  Polarisation was machine-optimised, either with the automatic tool or 
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manually.  Individuals were asked to maintain fixation and to avoid blinking whilst the 
scan was taken.  Where possible each participant underwent two ppRNFL thickness 
scans on each eye.  ppRNFL imaging was carried out using two commercially available 
OCT models.  One instrument utilised time-domain technology; the Stratus OCT (Carl 
Zeiss Meditec) and one utilised spectral-domain technology; the Cirrus OCT (Carl Zeiss 
Meditec, Dublin, CA)
9
. 
2.6.2 Pupil dilation  
In individuals in whom clear visualisation of the optic disc was not possible, and in 
whom adequate OCT signal strength (see 2.6.5) was not achieved, pupils were dilated 
using 1% tropicamide drops.  OCT scans were performed 15-20 minutes after 
application of drops.  Pupil dilation was avoided where possible because of the 
increased assessment time, risk of angle closure in predisposed individuals (320) and 
side effects of pain and blurred vision after application of the drops (321).  Recent 
studies have shown that providing that a clear image of the fundus can be visualised, 
and an adequate signal strength obtained (see 2.6.5), pupil dilation does not have a 
significant effect on measurements of ppRNFL thickness (321-323).   
2.6.3 Time-domain OCT 
A commercially available TD-OCT (Stratus OCT, software version 4.0, Carl Zeiss 
Meditec, Dublin, CA) was used to assess VGB-exposed individuals recruited from 
specialist epilepsy clinics at the Queen Square Site of the National Hospital for 
Neurology and Neurosurgery.  These individuals comprised Group 1A.   
2.6.3.1 Why TD-OCT was chosen 
The use of a TD-OCT instrument for the assessment of a subset of VGB-exposed 
individuals was chosen to enable comparison of results with those currently presented in 
                                                          
9
 See 1.18.3 for a description of difference between two OCT technologies  
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the literature.  Four studies (119;229;256;258) and one case report (198) have described 
the use of ppRNFL imaging using OCT in VGB-exposed individuals, all of which have 
used TD-OCT.  
2.6.3.2 The TD-OCT ppRNFL scanning protocol  
For the TD-OCT instrument, two ppRNFL scanning protocols are available; the 
―Proportional Circle Scan‖ and the ―Fast Retinal Nerve Fibre Layer Thickness Scan‖.  
The ―Proportional Circle Scan‖ was used by Wild et al. in the first study to describe 
ppRNFL thinning in individuals with VAVFL (229).  In this scan protocol the radius of 
the scan circle is based on an increment of the vertical diameter of the ONH (229).  This 
technique can be used to allow for differences in ONH size between individuals, as 
ppRNFL thickness decreases with increasing distance from the ONH (324-326).  The 
disadvantage of this technique is that the choice of the increment is arbitrary, and may 
be difficult to standardise between studies (229).  In addition, the reproducibility of 
ppRNFL thickness measures was found to differ with various scan circle diameters 
(283;325).  The current clinical standard for obtaining ppRNFL thickness measures 
using OCT is by using a fixed diameter scan circle of 3.46mm (327).  Using this scan 
diameter was found to provide the most reproducible ppRNFL thickness measures 
compared to other scan circle diameters (283;325).   
The ―Fast Retinal Nerve Fibre Layer Thickness Scan‖ protocol, which has been used in 
the most recent studies of OCT ppRNFL imaging in VGB-exposed individuals 
(119;256;258), adheres to this clinical standard by utilising a fixed-diameter circular 
scan of 3.46mm.  The normative database within the Stratus OCT was created using this 
scan protocol, and comparison of ppRNFL thickness measures with the normative data 
can only be made with scans acquired using this scan method.  Although this scan 
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protocol uses a fixed diameter scan circle, the 3.46mm diameter is considered large 
enough to encompass the whole ONH, without any overlap, in most eyes (229).   
In this study individuals were scanned using the ―Fast Retinal Nerve Fibre Layer 
Thickness‖ protocol.  This protocol was selected to allow for comparison of data with 
the manufacturers’ normative database.  In addition, the ppRNFL thickness measure 
available from the SD-OCT instrument, which was used for imaging Group 1A, Group 
2 and Group 3 in this study, utilises a 3.46mm fixed-diameter circle of data.   
The ―Fast Retinal Nerve Fibre Layer Thickness Scan‖ utilises a circular scan comprised 
of 256 A-scans, centred on the optic nerve head.  Three circular-scans are acquired in 
succession, over 1.3 seconds.  The ppRNFL thickness is determined by the instrument’s 
internal software from an average of the three scans and displayed in the manufacturers’ 
summary report, the ―RNFL Thickness Average Analysis Report‖ (Figure 1.13). 
 
2.6.4 Spectral domain-OCT 
SD-OCT was used in the assessment of all healthy individuals (Group 3), non-exposed 
individuals with epilepsy (Group 2) and in VGB-exposed individuals recruited from the 
Chalfont Epilepsy Centre and from SEIN (Group 1A).   
2.6.4.1 Why SD-OCT was chosen 
Although all previous studies of OCT ppRNFL imaging in VGB-exposed individuals 
have been conducted using TD-OCT, the latest generation of OCT instruments that 
became available at the start of this study utilised spectral domain technology.  The 
differences between SD-OCT and TD-OCT are discussed in Chapter 1 (1.18.3).   
VGB has recently received a license for use in the US and studies using OCT in VGB-
exposed individuals are currently underway (263).  These studies are likely to utilise the 
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latest SD-OCT technology, thus the use of SD-OCT in the assessment of the majority of 
the individuals included in this study will make the results more comparable to any 
future research in this area.     
2.6.4.2 The SD-OCT ppRNFL scanning-protocol  
To measure ppRNFL thickness the ―Optic Disc Cube 200x200‖ protocol was used.  
This protocol generates a 6x6mm grid of data by acquiring 200 horizontal scans each 
composed of 200 A-scans, centred on the optic nerve head.  Using the ―Glaucoma 
Analysis‖ algorithm, a 3.46mm diameter circle of data, made up from 256 A-scans, is 
extracted from the grid.  From this circle of data ppRNFL thickness is calculated and 
displayed in the ―Glaucoma Analysis Report‖ and the ―ONH and RNFL Thickness OU 
Analysis Report‖. 
 
2.6.5 Exclusion of OCT data 
Only data from the right eye were used in the analysis
10
.  All scans were assessed for 
their quality and were excluded if they were off-centred, had significant movement 
artefacts, missing data (Figure 2.3), or a signal strength of less than six (arbitrary units).  
The signal strength is determined by the OCT software from the signal to noise ratio 
and the signal-uniformity within the scan (328).  A signal strength, on a scale of one to 
ten (arbitrary units), is given for each scan, where ten denotes excellent scan quality and 
one denotes poor scan quality (329).  For clinical purposes a cut-off signal strength of 
five out of ten (arbitrary units) is recommended by the manufacturer.  However, for 
research purposes, studies have used a higher cut-off (329) as low signal strength can 
lead to an underestimation of the ppRNFL thickness (330).   
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 See Chapter 2  
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Figure 2.3 An example of ppRNFL scans that did not fulfil the quality control 
criteria 
 
Figure 2.3 legend: (A) Blinking during ppRNFL scan.  The black arrow indicates on the 
fundus image the areas affected by the blink.  The blink results in missing sections of data from 
the tomograph (white arrow).  The inbuilt software cannot detect the borders of the ppRNFL in 
these areas (grey arrow).  (B) Significant eye movement during the ppRNFL scan.  The retinal 
image is blurred and the scan-circle (shown in red) is off-centred (black arrow).  The tomograph 
is jagged (white arrow) and irregular resulting in poorly defined ppRNFL boundaries.  The 
individual retinal layers cannot clearly be identified in some areas (grey arrow). 
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2.7 Quantifying and classifying ppRNFL thickness data 
 
2.7.1 Quantifying  ppRNFL thickness – manufacturers’ summary report 
Quantitative ppRNFL thickness data were obtained from the manufacturers’ summary 
reports (Figure 1.13).  Summary measures that were analysed include the average 
ppRNFL thickness (around the whole ONH), and the ppRNFL thickness in 90
o 
quadrants and 30
o 
sectors (Figure 2.4 A-C).   
2.7.2 Quantifying  ppRNFL thickness – A new summary measure 
For individuals assessed using SD-OCT, the ppRNFL thickness data from each of the 
256 A-scans was exported to a personal computer using Research Browser Software 
(Version 5) (Carl Zeiss Meditec, Dublin, CA).  From this the 256 A-scans were 
combined to form an additional summary measure of 64 segments around the ONH 
each comprised of four A-scans. (Figure 2.4D). 
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Figure 2.4: The distribution of summary measures of ppRNFL thickness around 
the optic nerve head 
 
Figure 2.4 legend: Summary measure of ppRNFL thickness provided by in the 
manufacturers’ summary report include the average ppRNFL thickness around the whole of the 
ONH (A), in 90
o 
quadrants (B), in 30
o 
sectors (C).  In addition a new summary measure was 
created comprised of 64 segments (D). 
 
2.7.3 Classifying ppRNFL thickness  
In addition to quantifying thickness, the ppRNFL thickness was classified according to 
which percentile it fell into, based on the manufacturers’ normative database.  In the 
manufacturers’ summary report the ppRNFL thickness values are colour-coded 
according to which percentile they fall into.  Values falling into the ≤95th–>5th percentile 
are colour coded as green, ≤5th–>1st percentile are coloured yellow and ≤1st percentile 
are coloured red (Figure 1.13).  In this study, ppRNFL thickness was classed as being 
normal if it fell into the ≤95th–>5th percentile (green area); showing borderline 
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attenuation if it fell within the ≤ 5th–>1st percentile (yellow area); or showing thinning if 
it was within the ≤1st percentile (red area) (Figure 1.13).  
In a ―guide to interpreting OCT output‖ available from the manufacturers’ website   the 
normal distribution percentiles have not been defined as ―normal‖, ―borderline‖ or 
―abnormal‖, as used in this study, although the ≤1st percentile is described to be 
―considered outside normal limits‖ (331).  However, the classification system that was 
adopted for this study has frequently been used to classify ppRNFL thickness in other 
areas of research, particularly in glaucoma (332) where OCT ppRNFL imaging is 
widely used.  Although theses definitions are somewhat arbitrary, these percentiles (and 
associated colour coding) are commonly used in the clinical setting to aid the clinician 
in the assessment of the integrity of the ppRNFL and to monitor any changes over time.   
It is important to stress that 5% of normal healthy individuals with no eye-disease will 
fall within the ―borderline‖ area, and 1% of normal healthy individuals with no eye-
disease individuals with fall within the ―abnormal‖ area (285).   
 
 2.8 Data analysis  
 
Many individuals had ppRNFL thickness scans from both the right and left eyes that 
fulfilled the quality control criteria
11
.  Only data from one right eye scan from each 
individual was included in the analysis.   
A ―one-eye design‖ (333) was chosen for this study so that standard statistical 
techniques could be applied to the data without increasing the risk of Type 1 errors.  
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 As described in 2.4.5 
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Analyses in which both eyes of an individual are used (―two-eye designs‖) (333) require 
particular statistical approaches. This is because within an individual data from one eye 
are more likely to be similar to data from the other eye of the same individual, than it is 
from another eye from a different individual, i.e. within a subject the data from each eye 
will be highly correlated (unless there is unilateral eye disease) (333;334).  This is due 
to multiple factors including genetic and environmental effects that will act within an 
individual to influence any structural or functional parameters (334).  In standard 
statistical analysis, data should be independent, and failure to take account of between-
eye correlation in a ―two-eye design‖ can lead to an overestimation of the precision of 
the statistical values (333;334).    A ―two-eye design‖ can be used in the analysis, 
however, data from both eyes should be averaged and the average value can be treated 
with the same standard statistical techniques as a ―single-eye design‖ (333).  
Alternatively, more complex statistical approaches are needed to determine the 
contribution to the outcome measure of variance arising from between-subject factors 
and those arising from within-subject factors (333).  A further complicating factor is 
added to both of these ―two-eye design‖ approaches when some individuals only have 
data from one eye.  In this study, whilst many individuals had data from both eyes, 
some individuals only had data from only one eye.    
For a ―one-eye‖ design, the eye to be entered into the analysis can either be chosen at 
random, or can be chosen to be always the right eye, or always the left eye (334).  
Initially a random-eye approach was going to be used in this study; however analysis of 
a subset of the data from individuals in Group 1A and Group 3 suggested that the right-
eye measures were significantly thicker than the left eye measures
12
.  Recently, this 
observation has also been made in a group of 248 healthy volunteers, where the average 
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ppRNFL thickness in the right eye was 0.52µm thicker than the average ppRNFL 
thickness in the left eye, which reached statistical significance (335).  Thus only the 
right eye was chosen from each individual to use in the analysis 
In individuals who had two right-eye ppRNFL scans that met the quality control 
criteria, the scan with the highest signal strength was used in the analysis.  If both scans 
had equal signal strength, the most recently
13
 obtained scan was selected.  
2.8.1 Quantitative and categorical outcome measures 
For ppRNFL thickness and visual field size, data were available as both quantitative and 
categorical measures (Table 2.9).  Analysis of data included exploration of both 
quantitative and categorical measures of ppRNFL thickness and visual field size. 
 
Table 2.9 Categorical and quantitative data obtained from OCT and perimetry for 
analysis   
Method Quantitative measure  Categorical measure 
OCT Absolute ppRNFL 
thickness in a given 
area (µm) 
Normal (≤95th–>5th percentile*) 
Borderline thinning (≤ 5th–>1st percentile*) 
Abnormal thinning (≤1st percentile*) 
Perimetry Mean radial extent of 
the I4e isopter  
(degrees)  
Normal# 
Mild VAVFL# 
Moderate VAVFL# 
Severe VAVFL# 
*According to the manufacturers’ normative database 
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 In terms of the time-of-day as all scans from an individual were acquired on the same 
day. 
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#According to criteria defined by Wild et al. (97) 
 
For the analysis of absolute measures of ppRNFL thickness, data obtained from Group 
1B could not be analysed alongside data from Group 1A, Group 2 or Group 3 as 
differences in the acquisition methods between the two OCT instruments used do not 
currently allow these data to be pooled for these analyses (336). 
All data analysis was performed using SPSS (version 17.0, SPSS, Chicago).  Data from 
the right eye were used in all analysis.  Continuous variables were checked for 
normality and appropriate parametric or non-parametric analyses were applied.  
Statistical significance was determined at the 5% level, unless otherwise stated.      
153 
 
Chapter 3  The natural evolution of VAVFL in 
individuals who continue VGB therapy  
 
3.1 Introduction 
 
 It is widely accepted that once established, VAVFL is stable and does not progress with 
continued VGB exposure.  Several follow-up studies of individuals who continue VGB 
therapy have shown no progression of VAVFL over time (81;100;111;148-150) (Table 
3.1), although others have suggested that progression can occur (81;139;151;152) 
(Table 3.1). 
Studies of the evolution of VAVFL in individuals continuing VGB therapy have 
followed participants for short periods of time (typically less than four years) (Table 
3.1).  In one case report which has shown the evolution of visual field size with 
continued VGB exposure over a longer period, the visual field size showed a significant 
decrease after ten years of VGB use, suggesting that VAVFL may progress in some 
individuals after many years of VGB exposure (139). 
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Table 3.1: Summary of follow-up studies reporting changes in the visual field with 
continued VGB exposure     
Reference  Number of 
participants  
Follow-up 
(months) 
Conclusion  How the data 
were analysed  
Clayton 2010 (139)  1 120 Progression Observation  
Kinirons 2006 (99)  41 6 - 67 No progression Criteria 
a 
Hardus 2000 (152)  
Hardus 2003 
b
 (151) 
 
11 
5 
13 - 61
 
37 - 47  
Progression 
Progression 
Statistical test 
b 
Statistical test 
b 
Best 2005 (148)  16 18 - 43 No progression Observation 
Statistical test 
b 
Lawden 1999 (81)  1 39 No progression Observation 
Nousiaien 2001 
(100)  
26 4 - 38 No progression
 
Observation 
Statistical test 
b
 
Schmidt 2002 (149)  4 12 - 24 No progression Observation 
Statistical test 
b 
Graniewski-
Wijnands 2002 (150)  
9 18 No progression Observation 
Paul 2001 (111)  15 12 No progression Observation 
Statistical test 
b 
Lawden 1999 (81)  1 11 Progression Observation 
The table is organised in order of the length of the follow-up period.  Observation = 
 
progression 
of VAVFL was determined from either direct observation and qualitative evaluation of serial 
visual field data, or from observation of serial quantitative measure of VAVFL, typically plotted 
in a graphical format (e.g. serial MRD measurements shown graphically in (139))  
a 
when analyzing progression or recovery of visual fields, the authors considered a change in 
MRD of ≤5% as stable, of 6–10% as indeterminate, and of >10% as pathologic change. 
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b 
Either a paired-samples T-test or a Wilcoxon Signed Rank Test was used to determine a 
statistically significant difference in visual field size between tow predefined test points.  
Italics = Hardus 2003 (151) reports five individuals who were included in the earlier report 
(152) of 11 individuals. 
 
The severity of VAVFL varies widely (12;96;97;106), with some individuals showing 
very mild loss of the far periphery of the visual field (94;96;116) whilst others develop a 
very severe constriction extending to involve the central 30
o 
of the visual field 
(96;101;109;139). In addition, a continuum of severity of associated retinal pathology, 
including retinal nerve fibre layer thinning (183), and optic atrophy (147) have also 
been described.  Frisen et al. suggested that RNFL attenuation associated with VAVFL 
may be progressive with continued VGB exposure.  A ―staging system‖  based on the 
photographic appearance of the RNFL was developed, with atrophy  initially only 
detectable in the nasal peripapillary area and later progressing to involve the superior 
and inferior poles of the ONH (147). 
The range of severity of VAVFL and associated retinal pathology may be suggestive of 
a progressive evolution of VGB retinotoxicity with continued VGB exposure 
(96;147;183).  The lack of evidence to suggest VAVFL is progressive with continued 
VGB exposure may be due to short follow up periods or inappropriate statistical or 
observational approaches to the data.      
Understanding the evolution of VAVFL with continued VGB exposure over a long 
period of time is essential for optimal patient management, and for enabling decisions to 
be made about the risks and benefits of continued VGB therapy.  For example, from 
clinical experience, some individuals maintain seizure freedom on VGB, greatly 
improving their quality of life and enabling them to drive (180).  If VAVFL is 
156 
 
progressive, or can develop after many years of VGB therapy, eligibility to drive may 
be jeopardised due to the development of visual field loss (179).  In addition, although 
in most individuals VAVFL is asymptomatic, in severe cases it can be disabling, greatly 
affecting quality of life (106).       
3.1.1 Aims 
The aim of this study was to assess the natural evolution of VAVFL over a ten year 
period in individuals continuing VGB therapy. 
 
3.2 Methods  
3.2.1 Subjects  
Fourteen individuals who were currently taking VGB were included in the study.  
Individuals were participants from Group 1A and Group 1B.  All individuals had 
originally participated in a study of VAVFL at the National Hospital for Neurology and 
Neurosurgery commencing in 1999 (95) and had been taking VGB since before the 
original study.  All individuals were being followed up routinely in the National 
Hospital for Neurology and Neurosurgery Neuro-Ophthalmology Department because 
of continued VGB exposure.   
 
3.2.2 Perimetry  
All individuals were examined on at least one occasion by the author (LMC), according 
to the methods described
14
.  Other examinations of the visual field were performed as 
part of the individual’s on-going neuro-opthalmological assessment related to their 
VGB exposure, and as part of other studies of VAVFL (95).  These examinations were 
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undertaken by several skilled operators according to clinical protocol, which is in 
keeping with those methods described. 
3.2.3 Data analysis 
All visual fields were quantified using the MRD method
15
 for the right eye, using the 
I4e isopter.  This method was also used in the original study of these individuals 
commencing in 1999 (95).  All visual field assessments were quantified and analysed by 
the author (LMC).  Reliability of the visual field was determined based on the 
operator’s comments on the visual field chart and in the medical notes.  
The first recorded visual-field assessment whilst on VGB (Test 1), and the latest 
recorded visual-field assessment whilst still taking VGB (Test 2) were selected from 
each individual to use in part of the analysis.  Follow-up time was defined as the time in 
months between Test 1 and Test 2 and was determined from the medical notes 
according to the method described
16
.  The visual fields taken during Test 1 and Test 2 
were classified according to criteria set out by Wild et al. (97). 
 
3.3 Results  
 
3.3.1 Subject data 
Data from fourteen individuals and 176 visual field tests were available.  Two visual 
field tests were excluded, (one each from participant 5 and 7), as the operator had 
indicated that the results were unreliable, leaving 174 visual field tests available for 
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 See 2.2.2 
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analysis.  One individual included in this study (Subject 12), has recently been reported 
by our group (139).  
 
Details of VGB exposure, follow-up time and visual field size for each participant are 
shown in Table 3.2.  The average follow-up time was 128 months (range 104-148).  At 
the time of Test 1, the mean cumulative VGB exposure was 4737 grams; the mean 
duration of VGB exposure was 65 months.  At Test 2, the mean cumulative VGB 
exposure was 11,677 grams; the mean duration of VGB exposure was 192 months 
(Table 3.2).   
 
3.3.2 Visual-field classification 
Visual fields were classified according to criteria set out by Wild et al. (97).  At Test 1 
9/14 (64.3%) individuals had VAVFL.  At Test 2 13/14 (92.9%) individuals were 
classified as showing VAVFL.  Six individuals had progressed by at least one class (e.g. 
from normal to mild VAVFL).  Seven individuals remained within the same class.  One 
individual (Subject 2) showed an improvement from ―moderate VAVFL‖ to ―mild 
VAVFL‖, but only when considering data at Test 1 and Test 2 (Table 3.2).   
3.3.3  Visual-field size 
A Wilcoxon Signed Rank Test showed that the latest visual field (Test 2) was 
significantly smaller than the first visual field (Test 1) (z=-2.48; p<0.05; Table 3.2).  
The average difference between the visual field size at Test 1 and Test 2 was 7.5 MRD.   
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Table 3.2 VGB exposure and visual field data for each Subject 
Subject  
(number of visual 
field tests) 
Cumulative VGB 
exposure (grams) 
Duration of 
therapy (months) 
Follow-up 
(months) 
Test 1 
 
Test 2 
 
Rate of change of 
MRD/ KG of 
VGB exposure* 
 Test 1 Test 2 Test 1 Test 2  MRD Classification MRD Classification  
1 (8) 7606 13806 122 230 108 52 Normal 38 Mild -1.3 
2 (10) 6570 14427 84 213 129 32 Moderate 39 Mild -0.4 
3 (17) 3134 11654 45 185 140 34 Moderate 28 Moderate -1.1 
4 (13) 2086 8640 35 144 109 50 Normal 33 Moderate -2.2 
5 (16) 1220 3141 58 190 132 50 Normal 51 Normal -1.8 
6 (16) 4286 8961 43 170 127 38 Mild 37 Mild -1.4 
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VGB = vigabatrin; MRD = mean radial degrees; Test 1 = first visual field examination taken whilst on VGB; Test 2 = latest visual field examination taken whilst on 
VGB 
7 (9) 7398 20085 91 230 139 35 Moderate 29 Moderate -0.9 
8 (6) 221 4432 5 139 134 25 Moderate 28 Moderate -0.9 
9 (4) 6299 12627 112 216 104 52 Normal 43 Mild -0.6 
10 (13) 11629 16247 121 235 114 46 Normal 30 Moderate -3.7 
11 (17) 1367 7154 20 164 144 34 Moderate 26 Moderate -1.6 
12 (21) 6297 18950 49 197 148 32 Moderate 1 Severe -2.7 
13 (10) 2516 10250 36 162 126 41 Mild 38 Mild -2.4 
14 (14) 5632 13106 83 216 133 36 Mild 31 Moderate -1.1 
Average (SD) 4737 11677  64.6 192 
(32.4) 
127.6 (14.0) 39.8 (8.8)  32.3 
(11.3) 
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3.3.4 Individuals with normal visual fields at Test 1 
Five individuals (Subjects 1, 4, 5, 9 and 10) had normal visual fields at Test 1 (Table 
3.2).  At Test 2 one individual still showed a normal visual field, two individuals 
showed mild VAVFL and two showed moderate VAVFL.  The average visual field size 
at Test 1 for these five individuals was 50 MRD, at Test 2 it was 39 MRD.  The average 
difference between the visual field size at Test 1 and Test 2 was 11.0 MRD.  
3.3.5 Evolution of VAVFL 
The cumulative VGB exposure at the time of each visual field examination was 
determined, and a graph of cumulative VGB exposure and MRD, at successive 
examinations over the follow-up period, was plotted for each individual (Figure 3.1).  A 
linear trendline was added to each  graph, taking into account all available visual field 
data for that individual (Figure 3.1).  The trendlines for all individuals showed a 
negative trend, suggesting an overall decrease in the visual field size with increasing 
cumulative VGB exposure. Fluctuations in visual field size above and below the 
trendline were seen for all individuals (Figure 3.1).   
3.3.6 Rate of change of visual field size  
The rate of change of the visual field size was determined for each individual from the 
slope of the trendline and ranged from 0.4 to 3.7 MRD per kilogram of cumulative VGB 
dose (Table 3.2).  
 
 Figure 3.1: Visual field size in relation to cumulative VGB exposure for each 
Subject  
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Figure 3.1 legend: Graphs for each individual showing the visual field size in MRD at 
each successive examination (represented by ♦), in relation to the cumulative VGB exposure at 
that time.  Graphs are numbered according to the subject number, and are shown in order of 
increasing cumulative VGB exposure.  A linear trendline was added to each scatter-plot.   
VGB = vigabatrin; MRD = mean radial degrees 
 
3.3.7 Fluctuations in visual field size 
Fluctuations in visual field size above and below the trendline were seen for all 
individuals (Figure 3.1).  The scatterplot for Subject 5 is highlighted (Figure 3.2).  Over 
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relatively small increases in cumulative VGB exposure, the MRD shows variable 
fluctuation above and below the trendline (red arrows; Figure 3.2).  However, overall a 
trend for decreasing visual field size with increasing cumulative VGB exposure is still 
apparent. 
 
Figure 3.2: Fluctuations in visual field size between test sessions  
 
Figure 3.2 legend: A scatterplot of MRD and cumulative VGB exposure is shown for 
Subject 5.  Over a small increase in cumulative VGB exposure there is a high degree of 
fluctuation in the visual field size above and below the trendline over successive test sessions 
(red arrows).  Overall the trendline shows a negative trend   
 
3.4 Discussion  
 
This is the longest follow-up study of VAVFL in individuals continuing VGB therapy, 
and shows the evolution of VAVFL over successive test sessions with increasing VGB 
exposure.  The results suggest VAVFL progresses with continued VGB use over a ten-
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year follow-up period.  The prevalence of VAVFL increased from 64% at Test 1 to 93% 
at Test 2.  All individuals included in the study showed a trend for decreasing visual 
field size with increasing cumulative VGB exposure when all fields for an individual 
were taken into account (Figure 3.1).  Our results concur with Hardus et al. who 
reported an increase in the percentage visual field loss with continued VGB use over a 
13 – 61 month follow-up period in 11 individuals (152).  In addition, individual cases 
have been described of VAVFL progression with continued VGB exposure 
(81;99;111;139;148).  The majority of studies, however, have reported that once 
established, VAVFL is stable and does not progress further with continued VGB use 
(81;100;111;148-150).  The ambiguity regarding the evolution of VAVFL with 
continued VGB exposure may be due to a number of factors.  Good, prospective data on 
the course of VAVFL with continued VGB use are lacking (99), and most studies, 
including the present study, rely on retrospective analysis of visual field data acquired 
by different examiners over many years.  Furthermore, perimetry has inherent 
limitations which may make it impractical to detect changes in the visual field over time 
in VGB-exposed individuals, particularly if these changes are small and follow-up 
periods are short. 
3.4.1 Problems with measuring the visual field 
In many individuals with epilepsy, perimetric results may be unreliable and 
inconclusive and repeated visual field testing is often needed, after which results can 
still prove difficult to interpret (229).  In the present study, evaluation of serial visual 
field tests showed a variable degree of fluctuation in visual field size above and below 
the trendline (Figure 3.1 and 3.2).  These fluctuations are likely to represent variability 
in visual field size that is not related to VGB-associated pathological change in visual 
function, but are the result of both subject-related and examiner-related factors (337).   
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Subject-related factors that may influence the recorded visual field include fatigue 
(338), reaction time (339), an inadequate understanding of the task (337;340) and a 
―learning effect‖ (159) whereby individuals show an improvement of the visual field 
over subsequent test sessions related to improved performance and familiarity with the 
task, rather than true improvement in visual function (159;160).  In healthy individuals 
assessed using Goldmann kinetic perimetry, the visual field size was found to fluctuate 
by up to 16% between test sessions (341).  In individuals with visual impairment due to 
retinitis pigmentosa, the fluctuation in visual field size not related to disease progression 
was as high as 50% between sessions in some individuals (341).  In individuals with 
epilepsy, fluctuations in visual field size may be exaggerated. Certain antiepileptic 
drugs (342;343), seizures, the underlying cause of the epilepsy and psychosocial factors 
(344) can impair cognition, attention and psychomotor speed, all of which are integral 
to performing perimetry reliably.  As these factors may fluctuate over time, their 
influence on the recorded visual field may also fluctuate, exaggerating the normal 
variability in visual field size between test sessions, and making it difficult to detect true 
pathological change (337). 
Examiner-related factors may also contribute to the variability in the recorded visual 
field particularly when using a manual perimetric technique (e.g. Goldmann kinetic 
perimetry) as was utilised in the present study (306).  The speed and direction of 
movement of the light-stimulus which is used to assess the visual field is operator-
dependant.  Although optimal rates of stimulus movement have been suggested 
(311;313), the speed and technique used by an operator during an assessment may be 
influenced by the subject’s performance and ability, the time constraints of the clinical 
setting and the examiner’s skill and experience (304;311).  In addition, the instructions 
given by the examiner to the individual on how to perform the assessment can affect the 
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obtained visual field (340).  As a result, the visual field assessment is difficult to 
accurately standardise between examiners, and inter-examiner factors will add to the 
variability in the recorded visual field between test sessions (304;345). 
3.4.2 Problems with detecting and defining progression of VAVFL  
Several studies of VAVFL have attempted to overcome the effects of ―normal‖ 
fluctuation on detecting progression of VAVFL by using criteria to define pathological 
change in visual field, including a change in the visual field of ≥10% (99) or of more 
than 10 MRD (95;148).  The disadvantage of using these arbitrary criteria to define 
progression of VAVFL is that they may result in missing small pathological changes in 
the visual field size (99).  For example, whilst all individuals in the present study show 
a trend for progression of VAVFL when all visual field tests were considered, only four 
individuals (Subjects 1, 4, 10 and 12) show a decrease in visual field size of ≥ 10 MRD 
when comparing the visual field size at Test 1 and Test 2.  Similarly, whilst Hardus et 
al. reported VAVFL progression with continued VGB use, the average percentage loss 
in the visual field size had only increased by 4.2% and 3.5% for the right and left eyes 
respectively (152).   
In the present study, the rate of decrease in the visual field size over the ten-year 
observation period was between 0.4 and 3.7 MRD per kilogram of cumulative VGB 
exposure suggesting that although progression of VAVFL occurs, for most individuals 
the degree of change with increasing VGB exposure is small.  This degree of change 
may be difficult to detect clinically if serial results are assessed subjectively for 
evidence of progression (337), a method that has been utilised in some studies of 
VAVFL (Table 1).  In addition, when follow-up periods are short, as in previous studies 
of progression of VAVFL (Table 1), any change in the visual field may be too small to 
detect.   
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Failure to detect progression of VAVFL in some studies may also relate to the analysis 
used.  In the present study Subject 2 showed an apparent improvement in the visual 
field from moderate VAVFL at Test 1to mild VAVFL at Test 2 (Table 3), when 
considering only these two time points.  However, when all time points were 
considered, the trendline indicated a progressive decrease in visual field size over the 
follow-up period (Figure 3.1).  Similarly, Subject 5 was classified as having normal 
visual fields at Test 1(50 MRD) and at Test 2 (51 MRD), however, the trendline applied 
to all available visual field results shows  a progressive decrease in the visual field size 
of 1.8 MRD per KG of cumulative VGB exposure (Figure 3.1; Table 3.2).  Many 
studies of VAVFL progression have utilised analysis techniques where only two visual 
field test points are used to determine whether a change in the visual field size has 
occurred (Table 2).  If any of the test points used were significantly influence by non-
pathological subject-related or examiner-related variability then the analysis may fail to 
detect a change in the visual field size.  Although the present study is also subject to all 
the subject- and examiner-related factors discussed, the advantage of the present study 
is that for each individual all available reliable visual field test results were used in the 
evaluation of progression of VAVFL (Figure 3.1).  By plotting the visual field results 
from multiple examinations over a protracted period, no presumptions need to be made 
about the influence of subject-related and examiner-related variability on the visual 
field, enabling trends to be detected despite the inter-test fluctuations in visual field size.  
3.4.3 The progression of VAVFL 
Although the progression of VAVFL with continued VGB use may be small and 
difficult to detect clinically it is important to note that the rate of progression of VAVFL 
appears to differ between individuals.  For example, in the present study, Subject 2 and 
Subject 12 were followed up over similar VGB exposure durations (cumulative VGB-
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exposure from around 6000 to 15,000 grams).  Both individuals had similar visual field 
results at the beginning of the assessment period.  However, in the ensuing follow-up 
period, the average rate of loss for Subject 12 deteriorated was higher (2.7 MRD/kg 
cumulative VGB-exposure), developing severe VAVFL to less than 10
o 
eccentricity, 
whilst Subject 2 showed a more slowly progressive course (0.4 MRD/kg cumulative 
VGB-exposure), with the visual field size showing little change with increasing VGB 
use (Table 3.2; Figure 3.1).  The inter-individual differences in the rate of progression 
of VAVFL with continued VGB use described in this study may account for some of 
the variation in inter-individual susceptibility to VAVFL seen in individuals exposed to 
similar amounts of VGB, and may help to explain the conflicting findings regarding the 
relationship between the amount and duration of VGB exposure and the risk and 
severity of VAVFL. 
At the time of Test 1 the average duration of VGB exposure was more than five years, 
and 9/14 individuals had already developed VAVFL.  It cannot be assumed that the true 
pattern of visual field loss is actually linear, or that the progression of visual field loss 
observed in the present study represents the pattern and rate of progression of VAVFL 
prior to, or subsequent to, the observation period.  Patterns and rates of VAVFL 
progression my change throughout an exposure period, occurring in a slowly 
progressive and/or rapid pattern of onset and change.  Prospective longitudinal studies 
including baseline visual field examinations prior to VGB exposure are needed to fully 
elucidate the pattern of VAVFL onset and progression.    
The finding of intra-individual variation in the rate of progression of VAVFL with 
continued VGB use may have implications for phenotyping in drug response studies of 
VAVFL.  Current understanding of the relationship between VGB-exposure and visual 
field loss come from cross sectional studies typically looking at visual field size after a 
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given VGB exposure.  However, the rate of change in the visual field size with 
increasing cumulative VGB-exposure may provide a stronger indicator of an 
individual’s risk of developing significant VAVFL, and may provide a more useful 
measure to consider in the management of individuals continuing VGB therapy. 
3.4.4 New tools are needed 
The multifactorial contributions to the variability in the recorded visual field, 
particularly in a population of individuals with epilepsy, suggest that perimetry may not 
be the most appropriate tool for monitoring visual dysfunction in VGB-exposed 
individuals.  Subtle pathological changes in the visual field may go undetected until 
significant VAVFL has developed, at which point visual field loss may be symptomatic 
and have a negative impact on the individuals quality of life (97;106).  New methods to 
assess VGB-exposed individuals for the effects of VGB retinotoxicity are needed, 
particularly in individuals in whom perimetry is unreliable or unfeasible.  ppRNFL 
thinning measured using OCT has been suggested to be a sensitive and specific 
indicator of VAVFL (256).  OCT provides an objective quantitative tool that provides 
highly repeatable measures of retinal structure in healthy individuals (346) and in 
individuals with visual impairment (346;347).  If structural changes in the retina, such 
as ppRNFL thinning, are associated with the development of VAVFL as has been 
suggested (229;256), they may be detectable before VAVFL becomes apparent using 
perimetry (348).       
For OCT ppRNFL imaging to be clinically valuable in individuals with VAVFL, any 
detectable structural changes must show an association with functional visual 
impairment.  Additionally the technique must be suitable for use within a population of 
individuals with epilepsy, and show good repeatability of its measurements within that 
population. 
171 
 
3.5 Conclusion 
 
In summary, VAVFL shows progression with continued VGB exposure over a ten-year 
period.  However, this progression may be subtle and difficult to detect using perimetry.  
Assessing VAVFL using perimetry has inherent limitations and new methods are 
undoubtedly needed to monitor VGB-exposed individuals.   
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Chapter 4  The ppRNFL in VGB-exposed individuals; 
exploring the relationship between ppRNFL thickness and 
visual field size  
 
4.1 Introduction  
 
It has been suggested that imaging of the ppRNFL using OCT provides a sensitive and 
specific indicator of VAVFL, and should be considered in all people commencing VGB 
(256).  ppRNFL thinning detected using OCT has been described in a small number of 
patients with VAVFL (229;256), but no studies have explored the relationship between 
ppRNFL thickness and visual field size in VGB-exposed individuals.  Wild et al. 
reported average ppRNFL thickness as a function of Mean Sensitivity (derived using 
standard automated perimetry) for 20 individuals with VAVFL, although no statistical 
analysis of any association was discussed (229).  To optimize the clinical application of 
ppRNFL imaging in VGB-exposed individual, it is important to understand the 
relationship between this structural measure, and functional VAVFL (349).    
The value of any tool in the assessment of VGB-exposed individuals depends partly 
upon the repeatability of its measurements within that population.  Structural measures 
of the retina using OCT show high repeatability and reproducibility in healthy subjects 
(346), and in people with glaucoma (346;347).  A significant source of variability in 
ppRNFL thickness measures, can arise from differences in scan alignment (350), which 
can occur as a result of changes in the subjects fixation during scanning. During 
perimetric testing I have observed that inability to adequately fixate on a visual target 
provides a common source of measurement error in individuals with epilepsy, and 
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therefore may contribute to measurement error during OCT, and reduce its clinical 
utility in this setting. 
4.1.2 Aims  
The aims of this study were to determine the repeatability of OCT ppRNFL thickness 
measurements in a VGB-exposed population and to explore the relationship between 
ppRNFL thickness and visual field size, to establish whether OCT is a suitable tool to 
use in VGB-exposed individuals. 
 
4.2 Methods  
 
4.2.1 Subjects  
VGB-exposed individuals from Group 1A and Group 1B, and healthy controls (Group 
3) were included in the study.  
4.2.2 Perimetry  
Individuals from Group 1A and Group 1B underwent perimetric testing according to the 
methods described.  Individuals in  Group 3 were not assessed using perimetry. 
4.2.3 OCT 
All individuals were assessed using OCT.  Individuals from Group 1A and Group 3 
were assessed using SD-OCT.  Individuals from Group 1B were assessed using TD-
OCT. 
4.2.4 Data analysis 
For the analysis of absolute values of ppRNFL thickness, data obtained from Group 1B 
could not be analysed alongside data from Group 1A and Group 3 as differences in the 
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acquisition methods between the two OCT instruments used do not currently allow 
these data to be pooled for these analyses (336). 
 
4.3 Results  
 
4.3.1 Subjects and performance  
204 VGB-exposed individuals (Group 1A and 1B) and ninety healthy controls (Group 
3) participated in the study.  Demographic details of each Group are shown in Table 2.1 
(Chapter 2).  39 (19.1%) were unable to perform perimetry reliably due to inability to 
cooperate.  13 (6.4%) individuals were also unable to perform OCT (all of whom could 
not perform perimetry).   26/39 (66.7%) of the individuals who were unable to perform 
perimetry could complete OCT.  Visual field data were excluded or missing for a 
further 34 individuals and OCT for 11 individuals, (Table 4.1).  Overall, OCT images 
were acquired for 180 VGB-exposed individuals (129 for Group 1A, 51 for Group 1B); 
visual field data for 131; 126 individuals had both sets of data (84 from Group 1A, 42 
from Group 1B).  OCT data were available for all individuals in Group 3. 
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Table 4.1 Reasons for missing or excluded OCT and visual field data for all VGB-
exposed individuals 
 Visual field  OCT 
Total recruited 204 204 
Unable to perform task 3917 13a 
Unable to perform task due to small pupils (OCT only) 
or physical disability 
5 5
b
 
Visual field data excluded from analysis due to non-
VAVFL visual field defect
c 
18 NA 
Data not available 11d 6e 
Total available for analysis 131 180 
Total with both visual field and OCT data 126 
OCT = optical coherence tomography; VAVFL = vigabatrin associated visual field loss  
a 
All individuals were also unable to perform visual field i.e. all included in the 39 individuals 
with missing visual field data. 
b 
Two individuals refused dilating drops and image acquisition was not possible with Stratus 
OCT. 
c 
Including visual field defects due to intracranial surgery, traumatic injury, infarction or other 
known structural lesion. 
d 
Individuals were unable to be present for the visual field examination. 
e 
OCT data were not available for the right eye.  Data fitting the quality control criteria were 
available for the left eye, however these was not used in the analysis.  
                                                          
17
 OCT data from individuals who were unable to perform perimetry were compared against OCT data 
from individuals from whom visual field data was available, to determine whether there was a 
difference between the two populations.  Results can be seen in Appendix 5. 
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4.3.2 Repeatability  
The intra-session repeatability of ppRNFL imaging was assessed from consecutive 
scans from the same eye that were suitable.  99 individuals from Group 1A, and 30 
individuals from Group 1B, had sequential scans from the same eye taken at the same 
visit which fulfilled the quality control criteria.  The intraclass correlation coefficient 
(ICC) and 95% confidence intervals (CI) for average RNFL thickness and for each of 
the 90
o 
quadrants are shown in Table 4.2.  
 
Table 4.2 ICC and 95% CI for average ppRNFL thickness and for ppRNFL 
thickness in each of the 90
o 
quadrants in Group 1A and 1B   
ppRNFL area Group 1A 
ICC (95% CI) 
Group 1B 
ICC (95% CI) 
Average  0.987 (0.981 – 0.992) 0.985 (0.970 – 0.993) 
Superior 0.968 (0.952 – 0.978) 0.966 (0.931 – 0.984) 
Nasal 0.923 (0.888 – 0.948) 0.909 (0.820 – 0.956) 
Inferior 0.977 (0.966 – 0.985) 0.981 (0.960 – 0.948) 
Temporal  0.956 (0.935 – 0.970) 0.893 (0.790 – 0.948) 
ICC = intraclass correlation coefficient; CI = confidence interval 
Group 1A = VGB-exposed individuals assessed using spectral-domain OCT 
Group 1B = VGB-exposed individuals assessed using time-domain OCT 
Interpreting ICC: an ICC of zero indicates no agreement between the measures, an ICC  of one 
indicates perfect agreement between measures  (319) 
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4.3.3 The prevalence of VAVFL 
67/131 (51.1%) individuals showed VAVFL, according to criteria set out by Wild et al. 
(97).  Of these 30 (44.8%) showed mild, 29 (43.3%) moderate and 8 (11.9%) severe 
VAVFL (Table 4.3). 
 
Table 4.3 The frequency and severity of VAVFL in Group 1A and Group 1B 
 Group 1A 
N=87 
Group 1B 
N=44 
Total 
N=131 
VAVFL 39 (44.8) 28 (63.6) 67 (51.1) 
Mild 20 (51.3) 10 (35.7) 30 (44.8) 
Moderate 17 (43.6) 12 (42.9) 29 (43.3) 
Severe  2 (5.1) 6 (21.4) 8 (11.9) 
VAVFL = vigabatrin associated visual field loss; Group 1A = VGB-exposed individuals 
assessed using SD-OCT; Group 1B = VGB-exposed individuals assessed using TD-OCT 
 
4.3.4 Distribution of ppRNFL thinning across Groups 
The number of individuals showing ppRNFL thinning according to the manufacturers’ 
normative database was determined.  Individuals from Group 1A and Group 1B were 
assessed collectively as each OCT instrument compares quantitative ppRNFL thickness 
data against its own normative database.  Average ppRNFL thickness and ppRNFL 
thickness in each of the 90
o 
quadrants were analysed.  For average ppRNFL thickness, 
58/180 (32.2%) VGB-exposed individuals showed abnormal ppRNFL thinning (i.e. ≤1st 
percentile) and 20.0% of VGB-exposed individuals showed borderline changes (i.e. ≤ 
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5
th–>1st percentile).  Abnormal ppRNFL thinning was most frequently seen in the 
superior and inferior quadrants, (38.9% and 31.1% of individuals respectively), 
followed by the nasal quadrant (9.4% of individuals).  The temporal quadrant showed 
ppRNFL thinning in only 6.1% of individuals (Figure 4.1).  112/180 (62.2%) 
individuals showed ppRNFL thickness changes (either ≤1st percentile or ≤5th–>1st 
percentile) in at least one of the 90
o 
quadrants.   
In agreement with the manufacturer’s normative database, >95% of individuals in 
Group 3 showed normal ppRNFL thickness (i.e. ≤95th–>5th percentile) for average 
ppRNFL thickness and for each of the 90
o 
quadrants (Figure 4.1).  Similarly, ≤1% of 
individuals in Group 3 showed ppRNFL thickness in the abnormal range (i.e. ≤1st 
percentile) for average ppRNFL thickness and for the temporal, nasal and inferior 90
o
 
quadrants.  Only one individual (1.1%) showed abnormal superior quadrant thinning 
(Figure 4.1).   
 
  
179 
 
Figure 4.1: The percentage of VGB-exposed and healthy individuals showing 
thinning for average ppRNFL thickness and for ppRNFL thickness in each of the 
90
o 
quadrants 
 
 
Figure 4.1 legend: The percentage of VGB-exposed individuals (A) and healthy controls 
(B) showing normal, borderline and abnormal ppRNFL thickness in each of the 90
o 
quadrants. 
ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; Normal = ppRNFL 
thickness ≤95th–>5th percentile, according to the manufacturers’ normative database; Borderline 
= ppRNFL thickness ≤5th–>1st percentile, according to the manufacturers normative database; 
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Abnormal = ppRNFL thickness ≤1st percentile according to the manufacturer’s normative 
database 
 
4.3.5 ppRNFL thickness by Group 
The average ppRNFL thickness, and the thickness in each of the 90
o 
quadrants for each 
Group is shown in Table 4.3.  The ppRNFL was significantly thinner in Group 1A than 
in Group 3 for all measures (p<0.01; Table 4.4). 
 
Table 4.4 ppRNFL thickness in Group 1A, 1B and 3 
ppRNFL area Group 1A 
(N =129) 
Group 1B 
(N=51) 
Group 3 
(N=90) 
Average thickness (±SD) (µm)  78.9 (±12.4)*
 
77.5 (±16.3) 94.4 (±8.8) 
Superior thickness (±SD)  (µm) 94.6 (±20.2)* 92.8 (±26.2) 115.9 (±13.9) 
Nasal thickness (±SD) (µm) 62.9 (±10.3)* 58.4 (±19.4) 73.8 (±10.6) 
Inferior thickness (±SD) (µm) 98.8 (±20.8)* 96.6 (±22.0) 122.8 (±14.4) 
Temporal thickness (±SD)  (µm) 58.9 (±10.1)* 62.3 (±11.5) 65.2 (±10.2) 
ppRNFL = peripapillary retinal nerve fibre layer; SD = standard deviation 
Group 1A – VGB-exposed patients assessed using spectral-domain OCT 
*
Statistically significant difference in ppRNFL thickness between Group 1A and Group 3 
(p<0.01; Bonferroni adjusted)  
Group 1B and 3 were not compared as groups were assessed using different OCT models
18
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 See 1.18.3 
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4.3.6 Distribution of ppRNFL thinning according to visual field 
classification 
The number of individuals showing ppRNFL thinning according to the manufacturers’ 
normative database was determined.  All individuals from Group 1A and Group 1B 
were assessed collectively as each OCT instrument compares quantitative ppRNFL 
thickness data against its own normative database.   
In individuals with VAVFL, abnormal ppRNFL thinning was seen most frequently in 
the superior and inferior quadrants (68% and 51.6% of individuals, respectively).  The 
temporal quadrant was the least frequently affected with 85.9% of individuals showing 
normal ppRNFL thickness in this quadrant. 
In VGB-exposed individuals with normal visual fields the superior quadrant most 
frequently showed abnormalities.  21% of VGB-exposed individuals with normal visual 
fields showed either abnormal or borderline ppRNFL thickness in this quadrant. 
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Figure 4.2 The percentage of VGB-exposed individuals showing thinning for 
average ppRNFL thickness and for ppRNFL thickness in each of the 90
o 
quadrants 
according to visual field classification 
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Figure 4.2 legend: The percentage of VGB-exposed individuals with normal visual fields 
(A) mild VAVFL (B), and moderate/severe VAVFL (C), showing normal, borderline and 
abnormal ppRNFL thickness in each of the 90
o 
quadrants. 
ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; Normal = ppRNFL 
thickness ≤95th–>5th percentile, according to the manufacturers’ normative database; Borderline 
= ppRNFL thickness ≤5th–>1st percentile, according to the manufacturers normative database; 
Abnormal = ppRNFL thickness ≤1st percentile according to the manufacturer’s normative 
database. 
 
4.3.7 ppRNFL thickness according to visual field classification 
The ppRNFL thickness in individuals grouped according to their visual field 
classification (i.e. normal, mild VAVFL, moderate VAVFL or severe VAVFL) is 
shown in Table 4.5.  The ppRNFL was significantly thinner (p≤0.01) in individuals with 
VAVFL compared to those with normal VFs in all ppRNFL areas, excluding the 
temporal quadrant.    
 
  
184 
 
Table 4.5 ppRNFL thickness in Group 1A and Group 1B according to visual field 
classification  
ppRNFL area Group 1A Group 1B 
 Normal 
visual fields 
(N=47) 
VAVFL 
(N=37) 
Normal 
visual fields 
(N=15) 
VAVFL  
(N=27) 
Average thickness 
(±SD) (µm) 
86.8 (8.6) 69.7 (9.6)* 94.4 11.7 71.1 10.2* 
Temporal thickness 
(±SD) (µm) 
60.4 (11.0) 58.0 (8.7) 62.9 8.5 62.5 12.8 
Superior thickness 
(±SD) (µm) 
108.2 (13.5) 80.4 (17.1)* 120.7 14.7 81.5 17.1* 
Nasal thickness (±SD) 
(µm) 
66.5 (10.1) 56.5 (10.1)* 75.1 19.4 50.9 13.3* 
Inferior thickness 
(±SD) (µm) 
111.7 (12.3) 83.8 (15.2)* 119.0 16.7 89.3 14.1* 
*Statistically significant difference between individuals with normal visual fields and 
individuals with VAVFL (p≤0.01; Bonfferoni adjusted)  
 
4.3.8 The frequency of ppRNFL thinning according to visual field 
classification  
126 VGB-exposed individuals had both visual field and OCT data.  The number of 
individuals showing ppRNFL thinning (either ≤1st percentile or ≤5th–>1st percentile) in 
at least one of the 90
o 
quadrants, according to visual field classification, was determined 
(Table 4.6).  64/126 (50.8%) individuals had VAVFL.  82/126 (65.1%) showed 
ppRNFL changes in at least one of the 90
o 
quadrants.  100% of individuals with 
moderate or severe VAVFL showed ppRNFL thickness changes in at least one of the 
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90
o 
quadrants.  37.1% of individuals with normal visual fields showed ppRNFL 
thickness changes in at least one of the 90
o 
quadrants.   
 
Table 4.6 The frequency of ppRNFL thinning in VGB-exposed individuals according 
to visual field classification 
 Visual field classification 
Normal  Mild Moderate Severe 
Normal 
ppRNFL 
39 (62.9%) 5 (17.9%) 0 0 
ppRNFL 
thinning 
23 (37.1%) 23 (82.1%) 28 (100%) 8 (100%) 
Normal ppRNFL = all 90
o quadrants fell within ≤95th – >5th percentile 
ppRNFL thinning = ppRNFL thickness fell into either ≤1st percentile or ≤5th–>1st percentile in at 
least one 90
o 
quadrant 
 
4.3.9 ppRNFL and MRD 
126 VGB-exposed individuals had both visual field and OCT data, eighty-four from 
Group 1A and forty-two from Group 1B.  A scatter plot of MRD and average ppRNFL 
thickness is shown for Group 1A and Group 1B in Figures 4.3 and 4.4 respectively.  
Individuals within each group were further classified according the severity of their 
visual field loss (97) (Figure 4.3A and 4.4A), and according to which percentile their 
ppRNFL thickness fell into (Figure 4.3B and 4.4B).  There was a strong correlation 
between MRD and average ppRNFL thickness for Group 1A (r =0.73, p < 0.001; Figure 
4.3), and Group 1B (r = 0.77, p < 0.001; Figure 4.4). 
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The coefficient of determination was calculated to explore how much of the variance in 
MRD was explained by average ppRNFL.  For Group 1A, R
2
 = 0.53, for Group 1B, R
2
 
= 0.59: i.e. just over one half of the variance in MRD can be explained by average 
ppRNFL thickness.  
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Figure 4.3: Correlation between the average ppRNFL thickness and MRD in individuals from Group 1A  
 
 
Figure 4.3 legend: There was a correlation between visual field size (MRD) and average ppRNFL thickness in Group 1A.  (A) Individuals were classified 
according to the degree of VAVFL (97).  Normal (○); mild (◊); moderate (□); severe (∆).  (B) Individuals were classified according to which percentile (≤95th–>5th, 
≤ 5th–>1st, ≤1st) the average ppRNFL thickness falls into, based on the manufacturers’ normative database. Normal (○); borderline (◊); abnormal (∆). 
A B 
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Figure 4.4: Correlation between average ppRNFL thickness and MRD in individuals from Group 1B  
 
Figure 4.4 legend: There was a correlation between visual field size (MRD) and average ppRNFL thickness in Group 1B.  (A) Individuals were classified 
according to the degree of VAVFL (97).  Normal (○); mild (◊); moderate (□); severe (∆).  (B) Individuals were classified according to which percentile (≤95th–>5th, 
≤ 5th–>1st, ≤1st) the average ppRNFL thickness falls into, based on the manufacturers’ normative database (285). Normal (○); borderline (◊); abnormal (∆). 
A B 
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4.4 Discussion 
 
The present study has investigated the prevalence of ppRNFL thinning in a large group 
of VGB-exposed individuals.  In addition, the relationship between structural retinal 
changes and functional visual field defects was explored.  The findings confirm the 
presence of ppRNFL thinning in VGB-exposed individuals and suggest a linear 
relationship between average ppRNFL thickness and visual field size measured by 
MRD.  Additionally, ppRNFL thickness measured using OCT was shown to be highly 
repeatable in a VGB-exposed population of individuals with epilepsy.  The importance 
of the findings from this study are twofold: firstly, they demonstrate the potential for 
using ppRNFL imaging in the assessment of VGB-exposed individuals, particularly its 
potential for use in individuals unable to perform perimetry.  Secondly, the underlying 
retinal pathology leading to visual dysfunction is still debated and the structure-function 
relationship described in this study may provide evidence of the mechanisms leading to 
irreversible VAVFL.   
4.4.1 OCT in individuals unable to perform perimetry  
This study found that 19.1% of VGB-exposed individuals were unable to perform 
reliable perimetry.  This is in agreement with previous observations which have found 
that between 5 and 40% of VGB-exposed individuals could not perform accurate visual 
field testing (229;256).   
Perimetry demands a high degree of attention and co-operation from the subject being 
examined.  Individuals with cognitive impairment may not be able to appreciate the 
demands of the task.  Perimetry requires that the subject maintain fixation for several 
minutes whilst performing a motor response (i.e. pressing a buzzer) to a moving 
stimulus presented in their peripheral vision.  To realise the task accurately and reliably 
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requires adequate attention (351), concentration and psychomotor function as well as an 
understanding of what is required (340).  Impairment in any of these domains can 
impair the subject’s ability to perform the task adequately.  The time taken to obtain a 
reliable visual field result can be up to ten minutes or more to enable a thorough 
assessment of each eye accurately using a range of large and small isopters.  This adds 
further burden to a subject who may fatigue easily, or be unable to maintain sufficient 
concentration and attention for long periods.  These issues are further exaggerated in 
children where perimetry is often unachievable.  It is estimated that up to 80% of VGB-
exposed infants and children are unable to perform formalized perimetric testing 
(122;131;287).  In infants perimetry is not possible, creating a great source of 
contention when considering prescribing VGB for infantile spasms (263), particularly as 
any signs of VAVFL may not be apparent to parents or carers until the visual field loss 
is severe (122).  
ppRNFL scanning using OCT may provide an alternative tool for the assessment of 
VGB-exposed individuals, particularly those who are unable to perform reliable 
perimetry (229).  In the present study, only 6.4% of individuals were unable to undergo 
OCT, and 67% of individuals who were unable to perform perimetry were able to 
complete OCT.  Whilst ppRNFL scanning using OCT does require a degree of co-
operation from the subject under examination, it does not require the subject to respond 
to a stimulus, thus the result is less dependent on the abilities of the individual.  To 
obtain a satisfactory ppRNFL scan, the subject is required to maintain fixation on a 
target for less than two seconds, without blinking whilst the scan is being performed.  
With an SD-OCT instrument the scan circle does not have to be accurately aligned 
around the ONH before the scan is taken as the cube of data obtained during a scan 
allows movement of the scan circle after acquisition into the required position.  In 
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addition, inbuilt centering software automatically centres the scan around the optic 
nerve head after it has been acquired.  The ability to adjust the scan circle after 
acquisition, allows shorter chair time for the subject (as this can all be done after the 
subject has left), which is important particularly in individuals with attention 
difficulties, and allows for less precise fixation during scanning.   
OCT imaging has proved an effective tool in paediatric eye care (352)  and been used 
successfully in the evaluation of children with demyelinating disease (353) and 
glaucoma (354) and in infants with retinopathy of prematurity (355;356) and shaken 
baby syndrome (357).  Studies using standard table-top TD-OCT in healthy children 
and children with eye disease have included children from as young as three years old 
(354;358).  In addition, a newly-developed hand-held SD-OCT instrument has allowed 
the acquisition of retinal images in infants and children whilst in the supine position, 
both under anaesthesia or sedation (355-357) and without any sedation (355;356).  
Studies using handheld devices have included infants from 32 weeks old (355).  
Current guidelines for assessing VAVFL recommend formal perimetry for individuals 
with a developmental age of eight years or more, and ERG and confrontation testing for 
younger subjects, or for those unable to perform perimetry (262;359).  ppRNFL 
imaging using OCT is a useful tool to assess VGB-exposed individuals.  In the present 
study more subjects were able to perform OCT than perimetry, and the technique 
requires a short chair-time.  OCT may be of particular benefit in assessing VGB-
exposed individuals who are unable to complete reliable perimetric testing. 
4.4.2 ppRNFL imaging is repeatable   
In the present study it was shown that measures of ppRNFL thickness using OCT are 
highly repeatable in VGB-exposed individuals with epilepsy.  The ICCs reported in this 
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study are in keeping with those reported in healthy subjects (346), and in individuals 
with glaucoma (346;347).  129/180 (71.7%) patients had two OCT scans which were 
both of adequate quality to include in the analysis
19
.  In the remaining individuals only 
one OCT scan fulfilling the quality control criteria was available for analysis and in 
some individuals multiple attempts to obtain a high quality OCT scan may be needed.   
In the clinical setting, stringent quality control criteria should be applied when both 
performing and evaluating OCT measures of ppRNFL thickness.  Some of the most 
important criteria to consider when obtaining and evaluating ppRNFL thickness scans 
are outlined here. 
4.4.2.1 Signal strength     
A signal strength of at least five out of ten (arbitrary units) (as recommended by the 
manufacturer) should be obtained, as low signal strength can lead to an underestimation 
of the ppRNFL thickness (330) (Figure 4.5).  Consideration of signal strength may be or 
particular importance when evaluating sequential scans for changes in ppRNFL 
thickness over time.  An apparent decrease in ppRNFL thickness may be related to poor 
signal strength rather that actual ppRNFL thinning.  For example, in the present study, a 
healthy individual from Group 3 underwent OCT.  The first scan revealed an average 
ppRNFL thickness of 76µm falling within the ≤ 5th–>1st percentile (borderline thinning).  
The signal strength was noted to be 5/10 (arbitrary units), and the scan was repeated.  
Subsequent scans revealed a normal ppRNFL (average ppRNFL thickness 84µm; ≤95th–
>5
th 
percentile).   
 
  
                                                          
19
 According to the quality control criteria described in 2.6.5 
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Figure 4.5: The effect of signal strength on measures of ppRNFL thickness 
 
Figure 4.5 legend: Two ppRNFL thickness scans taken during the same scanning session 
from the right eye of a healthy individual in Group 3.  The retinal tomograph with optimal 
signal strength (10/10 arbitrary units) (A), shows a bright red/yellow ppRNFL (white arrow).  
The corresponding summary measures indicate a normal ppRNFL thickness (average thickness 
84µm).  In the retinal tomograph with a low signal strength (5/10 arbitrary units) (B), the 
individual retinal layers (including the ppRNFL (white arrow)) are not as clearly discernable.  
The summary measures suggest borderline thinning of the ppRNFL (average thickness 76µm); 
however, this is related to the low signal strength and consequent difficulties with the software 
algorithm in detecting the ppRNFL boundaries, rather than actual retinal pathology.         
  
4.4.2.2 Movement artefacts and missing data  
Where there are significant movement artefacts or missing data, the inbuilt algorithm is 
unable to detect the inner and outer boundaries of the ppRNFL and ppRNFL thickness 
cannot be accurately established (Figure 4.6).  The effect of incomplete data on 
measures of ppRNFL thickness can be seen in Figure 4.6.  ppRNFL scans taken from an 
individual during blinking (Figure 4.6B) and eye movement (Figure 4.6C), show 
markedly different measures of ppRNFL thickness compared to those obtained from a 
high quality scan (Figure 4.6A).  The presence of movement artefacts and missing data 
A
B
Signal strength 10/10
Signal strength 5/10
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(e.g. due to blinking during scan acquisition) can be evaluated easily by reviewing the 
fundus image and tomograph immediately after it is obtained.  Fundus images and 
tomographs that demonstrate these irregularities (Figure 4.6) should be discarded and 
repeated where necessary.     
 
Figure 4.6: The effect of movement artefacts and missing data on measures of 
ppRNFL thickness 
 
Figure 4.6 legend:  Retinal tomographs and ppRNFL thickness data from the right eye of an 
individual taken during the same test session.  (A) shows a high quality scan; (B) shows a scan 
with missing data due to blinking during scan acquisition, and failure of the software algorithm 
to detect ppRNFL boundaries (white arrow); (C) shows a scan with significant movement 
artefact and failure of the software algorithm to detect ppRNFL boundaries (white arrow).  The 
effect of incomplete data on measures of ppRNFL thickness can be seen in the corresponding 
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summary measures of ppRNFL thickness ((b) and (c)) which are markedly different from the 
measures obtained from a high quality scan of the same individual (a). 
 4.4.2.3 Failure to detect ppRNFL boundaries 
Even in apparently good quality scans (i.e. those without movement artefacts or missing 
data), the acquired tomograph should be carefully evaluated to ensure that the inner and 
outer boundaries of the ppRNFL have been accurately established by the software 
algorithm.  Small abnormalities in the ppRNFL thickness may go undetected due to 
image post-processing (360).  In addition, incidental retinal abnormalities such as 
posterior vitreous detachment may lead to a distortion of the ppRNFL boundary 
detection resulting in inaccurate measures of ppRNFL thickness (e.g.; Figure 4.7). 
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Figure 4.7: The effect of distortion of the ppRNFL boundaries 
  
Figure 4.7 legend: Careful inspection of an apparently high quality tomograph (A) reveals 
distortion of the ppRNFL boundary due to posterior vitreous detachment (B).  The effect of this 
on measures of ppRNFL thickness can be seen by comparing the TSNIT plot for each eye (C).  
ppRNFL thickness is largely symmetrical between the eyes; however, where the ppRNFL 
boundary is distorted, the  ppRNFL thickness is significantly thicker than in the fellow  normal 
eye (red circle).    
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4.4.2.4 Scan circle placement 
The location of the scan circle around the ONH can affect the ppRNFL thickness 
measurement (327;361) (Figure 4.8).  The ppRNFL becomes increasingly thicker at 
closer proximity to the ONH (362), thus if the scan circle is not accurately centred on 
the ONH ppRNFL measurements may appear thickener (or thinner) than would be 
expected  if the scan was aligned accurately, and may be interpreted as falsely normal or 
abnormal (361).  This was demonstrated in a VGB-exposed individual from Group 1A.  
Displacement of the scan circle temporally, superiorly, nasally and inferiorly (Figure 
4.8B, C, D and E, respectively) resulted in ppRNFL thickness values that deviated from 
those recorded when the scan circle was centred on the ONH (Figure 4.8A).  Although 
the average ppRNFL thickness did not change substantially with scan displacement, the 
ppRNFL thickness in the 90
o 
quadrants and 30
o 
sectors was significantly affected.  For 
example, the ppRNFL thickness in the superior quadrant measured 63µm when the scan 
circle was centred on the ONH, 73µm when the scan was displaced temporally and 
44µm when the scan was displace superiorly (Figure 4.8).   
The SD-OCT model used in the present study possesses inbuilt software allowing both 
automatic and manual centring of the circular scan around the optic disc after scan 
acquisition.  Other OCT models (including the TD-OCT model used in the present 
study) do not allow this function, and scan alignment is made by the operator before the 
scan is acquired.  In the present study, ppRNFL measurements taken from Group 1A 
(using SD-OCT) had a lower variability than those taken from Group 1B (TD-OCT).  
This is in agreement with previous findings in healthy volunteers and in individuals 
with glaucoma, and probably reflects the shorter scanning time and automatic centring 
of the circular scan around the optic disc with the newer equipment that utilises spectral-
domain technology (363). 
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Figure 4.8: The effect of scan circle placement on measures of ppRNFL thickness  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 legend:  A ppRNFL thickness scan was acquired from the right eye of a VGB-exposed individual in Group 1A.  The scan circle, which was 
automatically centred on the ONH (A), was manually displaced after scan acquisition.  Displacement of the circular scan, relative to the ONH, temporally (B), 
superiorly (C), nasally (D) or inferiorly (E) resulted in ppRNFL thickness values that deviated from those recorded when the scan circle was centred on the ONH. 
Average
90o quadrants
30o sectors
A B C D E
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4.4.3 Prevalence of VAVFL 
51.1% of VGB-exposed individuals included in the present study had VAVFL.  
Previous studies have reported the prevalence of VAVFL to be between 17 and 92% in 
adults (140), and between 6 and 65% in children (Table 1.1).  Recently, a systematic 
review of observational studies investigating the prevalence of VAVFL was published 
(91).  The review identified 32 studies which met the inclusion criteria, and found that 
the random-effects estimate for the proportion of vigabatrin-exposed individuals with 
visual field loss was 52% and 34% for adults and children, respectively (91).   
The large range in the reported prevalence of VAVFL could be due to a number of 
factors (also see Chapter 1).  In the present study, visual fields were classified according 
to the criteria set out by Wild et al. (97).  However, studies have used various perimetric 
techniques to assess the visual field and different methods and criteria to quantify and 
classify VAVFL (Table 2.5 and 2.6) which could result in differences in the reported 
prevalence.  For example, Vanhatalo et al. defined a normal visual field as one in which 
the temporal meridian extended beyond 80
o 
eccentricity.  However, they showed that if 
the criteria for normality were reduced by 10
o 
(i.e. a normal visual field was one in 
which the temporal meridian extended beyond 70
o 
eccentricity) the reported prevalence 
of VAVFL within the population decreased from 55% to 23% (122).  A further 
contribution to the variation in reported prevalence of VAVFL may come from the 
VGB exposure characteristics of populations included in each study.   Studies including 
individuals with a long duration of VGB exposure and high cumulative VGB exposure 
may show higher prevalence of VAVFL compared to studies in which individuals 
received a lesser degree of VGB exposure.    In the present study, the prevalence of 
VAVFL was 44.8% in Group 1A and 63.6% in Group 1B.  All individuals in each 
Group were assessed by the same operator using GKP and the visual field results were 
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quantified and classified by the same examiner using the same methods and criteria.  
However, the mean duration of VGB exposure and the mean cumulative VGB exposure 
were higher for Group 1B than for Group 1A (Table 2.1) which could account for the 
difference in prevalence of VAVFL between the Groups. 
4.4.4 Prevalence of ppRNFL thinning 
In agreement with previous studies (119;229) the present study showed that the 
ppRNFL was significantly thinner in VGB-exposed individuals compared to healthy 
controls.  In addition it was confirmed that the ppRNFL was significantly thinner in 
VGB-exposed individuals with VAVFL compared to VGB-exposed individuals with 
normal visual fields (229).   
The prevalence and distribution of ppRNFL thinning was determined according to the 
manufacturers’ normative database.  Overall, 62.2% of individuals showed ppRNFL 
thickness changes (either ≤1st percentile or ≤5th–>1st percentile) in at least one of the 90o 
quadrants.  Abnormal ppRNFL thinning was most frequently seen in the superior and 
inferior quadrants, (38.9% and 31.1% of individuals respectively), followed by the nasal 
quadrant (9.4% of individuals), with few individuals (6.1%) showing thinning in the 
temporal quadrant. 
A pattern of ppRNFL thinning with relative preservation of the temporal quadrant has 
been described previously in VGB-exposed individuals with VAVFL 
(198;229;256;258) and is in keeping with the reported pattern of RNFL and optic 
atrophy detected using fundus photography in which RGC projecting to the temporal 
aspect of ONH are relatively preserved (147;183;198).  
The distribution of ppRNFL thinning detected in the present study, differs from that 
which has been reported previously.  Lawthom et al. reported that in individuals with 
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VAVFL the nasal quadrant was the most affected quadrant with  11/11 individuals 
showing ppRNFL thinning (either ≤1st percentile or ≤5th–>1st percentile) (256).  In the 
study by Lawthom et al. TD-OCT was used and individuals with VAVFL were 
analysed independently of VGB-exposed individuals with normal visual fields.  For 
comparison, the ppRNFL data from individuals in Group 1B (assessed using TD-OCT), 
who had VAVFL were compared with the data provided by Lawthom et al. (Table 4.7).  
The main difference between the OCT findings in the present study and in the study by 
Lawthom et al. was in relation to the nasal quadrant.  In the present study 40.8% of 
individuals with VAVFL in Group 1B had normal nasal quadrant ppRNFL thickness, 
whereas 100% of individuals in the study by Lawthom et al. showed ppRNFL 
abnormities (either ≤1st percentile or ≤5th–>1st percentile) in the nasal quadrant.  In 
addition, abnormal thinning (≤1st percentile) in the superior quadrant was seen 
considerably more frequently in the present study compared to the study by Lawthom 
(63.0% and 18.2% of individuals, respectively) (Table 4.7).   
The differences in the distribution of ppRNFL thinning between studies are difficult to 
explain as both studies used the same TD-OCT model and compared data against the 
same normative database.  In addition, all individuals included were classified as 
showing VAVFL.  However, different perimetric techniques, and thus visual field 
classification criteria, were used in each study.  Lawthom et al. used automated 
perimetry (Humphrey visual field analyser 30-2 program) which only assesses the 
visual field out to 30
o 
eccentricity.  Conversely, in the present study GKP was used 
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Table 4.7 Comparison of ppRNFL thickness data between individual from Group 1B 
with VAVFL (N=27) and individuals with VAVFL from Lawthom et al. (N=11) (256) 
 Normal ppRNFL 
thickness 
(% of individuals) 
Borderline ppRNFL 
thickness 
(% of individuals) 
Abnormal ppRNFL 
thickness 
(% of individuals) 
ppRNFL 
area 
Lawthom This study Lawthom This study Lawthom This study 
Average  0 11.1 27.3 29.6 72.7 59.3 
Temporal 100 81.5 0 11.1 0 7.4 
Superior 36.4 25.9 45.5 11.1 18.2 63.0 
Nasal 0 40.8 27.3 29.6 72.7 29.6 
Inferior 27.3 25.9 45.5 37.0 27.3 37.0 
11 individuals with VAVFL were included in the study by Lawthom et al.  27 individuals with 
VAVFL were included from the present study.  
 
which assess the visual field out to 90
o
 eccentricity.  It is possible that individuals 
included in the study by Lawthom et al. had more severe VAVFL than individuals 
included in the present study, as those with mild VAVFL, not encroaching on the 
central 30
o 
may not have been included in the VAVFL group in their study.  The 
distribution of ppRNFL thinning may be associated with the severity of VAVFL and 
thus may differ between studies depending on the severity of VAVFL within a study 
population.  In agreement with the findings in the present study, a recent study using 
TD-OCT in nine individuals with VAVFL found that 4/9 (44.4%) individuals had 
normal ppRNFL thickness (≤95th–>5th) in the nasal quadrant (258).  
 Based on their findings Lawthom et al. suggested that ppRNFL thinning in the nasal 
quadrant should be used as a biomarker for VGB toxicity.  The discrepancy in findings 
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between their study and this one shows that further studies are needed to elucidate the 
pattern of VGB-associated ppRNFL thinning before screening recommendations can be 
made.  The pattern of ppRNFL thinning in VGB-exposed individuals will be discussed 
further in Chapter 6. 
4.4.5 ppRNFL thickness and VAVFL 
To compare the ability of OCT ppRNFL imaging to identify retinal structural 
abnormalities, and Goldmann kinetic perimetry to identify abnormalities of visual 
function, the results of individuals who undertook both test procedures were analysed.  
51% of individuals were classified as having VAVFL whereas 65% were identified as 
showing thinning
20
 in at least one of the 90
o 
quadrants.  Interestingly 37% of individuals 
classified as having normal visual fields showed ppRNFL thinning in at least one of the 
90
o 
quadrants, suggesting that thinning of the ppRNFL may be detected before VAVFL 
becomes clinically apparent.  This does not necessarily imply that significant structural 
change (i.e. RGC loss) must take place before VAVFL occurs.  In fact, in this study a 
linear relationship was observed between ppRNFL thickness and visual field size which 
would imply that they occur together (i.e. ppRNFL thinning is linearly related to visual 
field loss) (348).  However, because perimetric results are highly variable, even among 
healthy individuals with normal visual fields (337;341), and the test is subjective and 
difficult to quantify, the ability to detect clinically significant VAVFL in the early/mild 
stages may be difficult (348).   
In five individuals with mild VAVFL, the ppRNFL thickness was normal in all four 90
o 
quadrants.  There are a number of possible explanations for this.  Firstly, these 
individuals could actually have normal visual fields; however, because of psychomotor 
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th
 percentile and <1
st
 percentile  
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slowing, impaired reaction time or other cognitive dysfunction, the visual field may 
have been recorded as smaller than it actually was.  Secondly, the ppRNFL also 
includes a non-axonal component, including glial cells and blood vessels.  When 
ppRNFL thickness is taken to be representative of RGC axon number, it presumes that 
the non-axonal component of the ppRNFL is equal between individuals and does not 
change in response to RGC axon loss (348).  However, this may not be the case.  Some 
individuals may have a larger contribution to ppRNFL thickness from non-neuronal 
cells which may maintain their ppRNFL thickness within normal limits despite 
significant RGC axon loss, thus making ppRNFL imaging less able to detect VAVFL 
that perimetry.  Lastly, dysfunctional RGC (as opposed to dead RGC) may contribute to 
visual impairment despite maintaining structural integrity.  In this case, VAVFL may be 
apparent in some individuals with normal ppRNFL thickness.      
All of the individuals with moderate and severe VAVFL showed ppRNFL thinning in at 
least one 90
o 
quadrant, suggesting that when VAVFL is advanced both instruments are 
likely to have sufficient ability to identify individuals who have visual impairment.  The 
value of ppRNFL imaging in this instance might be in detecting the progression of 
retinal toxicity in individuals who continue VGB therapy, as perimetry may not be 
sensitive enough to detect subtle changes in VAVFL, particularly over short observation 
periods
21
.   
4.4.6 Structure-function relationship  
In this study, a strong linear relationship was observed between visual field size and 
average ppRNFL thickness in VGB-exposed individuals.  A relationship between 
ppRNFL thinning detected using OCT and visual field loss (or reduced visual acuity) 
                                                          
21
 See chapter 3 
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has been described previously for several diseases including glaucoma (348;349;364), 
autosomal dominant optic atrophy (365), non-arteritic anterior ischemic optic 
neuropathy (366) and optic neuritis (367-369).  In all of these diseases the principal 
mechanism of visual impairment is dysfunction or death of RGC in the retinal area 
corresponding to the visual deficit, due to injury of the RGC axon (370).   
Atrophy of the RNFL has also been described in diseases of the outer retina where 
visual dysfunction is related to degeneration of rod and cone photoreceptors (371).  In 
post mortem eyes from individuals with retinitis pigmentosa, a variable degree of RGC 
loss was apparent; yet there was little evidence to suggest that RGC loss contributed 
significantly to the degree visual dysfunction (372).  In some individuals with little or 
no light perception and markedly decreased or absent photoreceptors, the RGC number 
and RNFL remain within normal limits (372;373).  ppRNFL thinning detected using 
OCT has also been described in individuals with retinitis pigmentosa (374-376) (and 
other retinal dystrophies including autosomal recessive cone-rod dystrophies (377)).  
However, no association was found between the degree of ppRNFL thinning and the 
severity of visual field loss (or change in visual acuity) in any of the studies (374-376).  
In the retinal dystrophies it is likely that RGC death, and ppRNFL atrophy, occurs as a 
result of trans-synaptic degeneration after photoreceptor death or dysfunction (371;372); 
however, it is not the major contributor to visual impairment in such diseases (377). 
4.4.7 Mechanisms of VAVFL 
The strong association seen in the present study between ppRNFL thinning and 
decreasing visual field size provides some evidence that irreversible VAVFL may be 
related to RGC injury.  The underlying retinal pathology associated with VAVFL is 
unknown, and previous animal and human pathological, electrophysiological, clinical 
and imaging studies have implicated all retinal cell types from the RPE to the RGC. 
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4.4.7.1 Animal studies – the outer retina 
Pathological studies of animals exposed to VGB have consistently reported structural 
abnormalities in the outer retina, including disorganisation of the ONL with migration 
of photoreceptor nuclei towards the RPE (64;238-242) and morphological abnormalities 
and atrophy of cone photoreceptors (238;240-242).  It is important to note, that almost 
all animal studies of VGB retinotoxicity have been carried out on albino strains of mice 
and rats and probably represent a sensitizing effect of VGB on the retina making the 
photoreceptors more susceptible to light damage (64;65).  The pathological changes 
described in VGB-exposed albino animals did not occur when they were reared in 
darkness or low light conditions (63;239).  Furthermore, these changes were not seen in 
pigmented animals exposed to VGB (63-65;243). 
4.4.7.2 Human electrophysiological studies – the inner retina  
In VGB-exposed individuals electrophysiological data have shown abnormalities in 
measures reflecting both rod and cone photoreceptor pathways involving the RPE, 
amacrine cell, bipolar cell and Müller cell function (see 1.10).  On the basis of human 
ERG data most studies have concluded that the mechanisms of VAVFL lie in the inner 
retina, involving disordered transmission between bipolar, Müller, amacrine and RGCs 
(81;112;121;146;153).  The relationship between ERG abnormities and VAVFL has 
been explored.  In several studies a correlation has been described between reduced 
amplitude of the b-wave (reflecting bipolar and Müller cell finction) and decreased 
visual field size (105;109;135;150;151).  However, others have reported that OP 
amplitude (amacrine cell function) (103;112;135) and the 30Hz flicker amplitude (cone 
pathway function) (106;134) correlate with the severity of VAVFL.      
Although the electrophysiological findings almost certainly implicate an effect of VGB 
on inner retinal electrophysiology, careful inspection of the literature reveals that in 
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most studies electrophysiological abnormalities are not synonymous with VAVFL, i.e. 
for all ERG measures that have been found to be abnormal in individuals with VAVFL, 
they have also been found to be normal in other studies.  Further, the same ERG 
measures are found to be abnormal in some individuals with normal visual fields.  The 
reasons for this are not known.  Differences in findings between studies may relate to 
differences in the VGB-exposed populations included, differences in the 
electrophysiological methods and analysis of recordings, and differences in the 
definitions and classification of ―normal‖ and ―abnormal‖ results between studies.  
However, even within the same studies, where techniques and classifications are 
standardised across subjects, some individuals on VGB with VAVFL can show ERG 
abnormalities where others have normal ERG findings (101;104;120;150).  
Clearly not all ERG abnormalities are associated with the mechanisms that lead to 
VAVFL (145).  Some aspects of the ERG changes may be physiological, and result 
directly from the effect of increased GABA concentrations on normal synaptic 
transmission (145;214).  Furthermore, chronic increases in extracellular GABA 
concentration may lead to down-regulation of GABA receptors (378) and GABA 
transporters, resulting in changes in retinal electrophysiology that may persist after 
VGB withdrawal.  Other changes in the ERG may reflect pathological abnormalities in 
retinal electrophysiology, which result from injury to inner retinal cells leading to 
irreversible changes in cell function and neurotransmission.   
4.4.7.3 Human clinical, imaging and pathological studies – the retinal ganglion cells 
Inspection of the fundus, either directly or with fundus photography, reveals a normal 
retina and optic nerve in most individuals with VAVFL (95;147). However, in some 
individuals, optic disc pallor (78;81;97;101;120;147;183), and atrophy of the peripheral 
RNFL (78;81;105;106;147;183;198) can be seen.  These clinical observations are 
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supported by findings from a post mortem study of a single individual with VAVFL 
which found almost complete loss of RGCs, and severe atrophy of the RNFL, in the 
peripheral retina (162).  Recently, the effect of VGB toxicity on RGC has received new 
attention, as findings from retinal imaging studies further implicate RGC pathology in 
VAVFL.  The ppRNFL is significantly thinner in VGB-exposed individuals compared 
to healthy controls (119;229) or non-exposed individuals with epilepsy (119;229;258).  
In addition, VGB-exposed individuals with VAVFL show significantly thinner ppRNFL 
than VGB-exposed individuals with normal visual fields (229) suggesting that RGC loss 
may be related to the development of VAVFL.     
The strong association seen in the present study between ppRNFL thinning and 
decreasing visual field size provides further evidence that irreversible VAVFL may be 
related to loss of RGC (162).  If irreversible VAVFL were predominantly due to 
dysfunction or death of other retinal cells, then it would be unlikely that such a 
relationship would be seen.  For example, if irreversible visual field loss were related to 
photoreceptor death or dysfunction, and RGC death and ppRNFL atrophy were the 
result of trans-synaptic degenerative processes, one would expect to see visual field loss 
in some cases without RGC loss (and ppRNFL thinning) as is seen in retinitis 
pigmentosa and other retinal degenerations (372;373).  Similarly if death or dysfunction 
of other inner retinal cells including amacrine, bipolar and Müller cell, were directly 
responsible for irreversible VAVFL, then a more consistent relationship would be 
expected to be seen between ERG abnormalities and visual field loss.  Studies using 
mfERG add further weight to this argument.  Several mfERG studies have demonstrated 
that electrophysiological abnormalities in individuals with VAVFL are diffuse and are 
not limited to, or associated with, areas of visual field loss (81;120;134;153). 
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4.4.8 Mechanisms of VGB retinotoxicity - a theory     
Several hypotheses of the mechanisms of VAVFL have been suggested based on the 
available clinical, electrophysiological and pathological human and animal data, yet 
there is a lack of unified understanding that brings together, and explains, all of the 
abnormal findings from various studies of VGB retinotoxicity.  From the findings of the 
present study, alongside a detailed consideration of the existing literature on the effects 
of VGB on the human and animal visual pathway, a theory is proposed as to the 
mechanisms of VGB retinotoxicity and the development of abnormal retinal 
electrophysiology, ppRNFL thinning and VAVFL (Figure 4.9).   
VGB irreversibly inhibits GABA-T leading to an accumulation of GABA in retinal cells 
expressing GABA-T, particularly in Müller cells (234) (Figure 4.9).  In addition, VGB 
increases extracellular GABA by stimulating GABA release (14;23) and reducing 
GABA uptake (16;23;25) (Figure 4.9).  These two mechanisms of VGB-associated 
increases in retinal GABA (intracellular GABA accumulation and increased 
extracellular GABA) might have differential effects on retinal physiology and structure.      
The high levels of extracellular GABA may alter the physiology of retinal cells 
expressing GABA receptors, particularly in the highly GABA-immunoreactive IPL of 
the inner retina, where GABAergic amacrine and interplexiform cells make synaptic 
connections with GABA receptor-expressing bipolar cells and RGCs.  The effect of 
increased extracellular GABA (alongside alterations in intracellular GABA metabolism) 
could have both short-term and long-term effects on inner-retinal physiology.  Short-
term effects may be directly related to increased GABA concentrations in the retina, and 
are likely to be physiological and reversible on cessation of VGB exposure and return of 
normal GABA-T activity.  The long-term effects of elevated extracellular GABA could 
be both physiological and/or pathological.  Persistently elevated retinal GABA could 
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result in up- or down-regulation of GABA receptors, GABA-transporters, enzymes 
involved in normal GABA metabolism and proteins involved in synaptic GABA 
release.  Changes in the expression of these proteins in response to high GABA levels 
may contribute to abnormal retinal physiology during VGB exposure.  Some of the 
abnormalities may reverse after VGB withdrawal, whilst others may persist.  The long- 
and short-term changes in inner-retinal physiology as a result of elevated GABA may 
account for the abnormalities reported in the ERG which suggest a predominant effect 
of VGB on inner retinal function, particularly involving amacrine and bipolar cells.   
As extracellular GABA increases, concurrently the inhibition of GABA-T leads to 
accumulation of GABA within retinal Müller cells (234).  Chronic accumulation of 
GABA within the Müller cell may lead to Müller cell dysfunction and gliosis resulting 
in loss of normal trophic support and regulation of extracellular environment and release 
of neurotoxic factors.  As a consequence RGC loss occurs (see Chapter 6) manifesting 
as ppRNFL thinning, optic atrophy and VAVFL.   
This theory suggests that VGB-induced increases in retinal GABA may have multiple 
influences on retinal physiology and structure through several distinct but interrelated 
mechanisms.  Those mechanisms associated with abnormalities in the ERG and EOG 
may not be directly related to those associated with ppRNFL thinning and the 
development of VAVFL.  Whilst the various mechanisms are inextricably linked, they 
may exist independently of each other to varying degrees.  This model may explain why 
electrophysiological abnormalities have not consistently been shown to be associated 
with the presence of, or severity of, VAVFL, and why no electrodiagnostic measure has 
shown sufficient sensitivity or specificity in identifying individuals with VAVFL (229).  
Furthermore, it demonstrates how the findings from the present study integrate with and 
compliment the wealth of earlier research on VGB retinotoxicity. 
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Figure4.9 A theory as to the mechanisms of VGB retinotoxicity and VAVFL  
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Figure 4.9 legend: GABA = γ-aminobutyric acid; GABA-T = GABA-transaminase; GAT = GABA-transporter; RPE = retinal pigment epithelium; ERG = 
electroretinogram; RGC = retinal ganglion cell; ppRNFL = peripapillary retinal nerve fibre layer; RNFL = retinal nerve fibre layer; VAVFL = vigabatrin associated 
visual field loss 
Orange boxes = retinal cells; red boxes = human clinical/diagnostic findings; Grey boxes = human and animal pathological/experimental findings; white boxes = 
theoretical processes; Dashed arrows = clinical/diagnostic findings that have frequently been shown to be associated with each other; Grey dashed line and boxes 
with grey text = observations only made in VGB-exposed albino rats and mice 
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4.4.8.1 Summary  
VGB appears to have an effect on several retinal cell types, including irreversible, 
pathological structural and functional changes, as well as reversible physiological 
changes probably related to elevated GABA concentrations.  The mechanisms of VGB 
toxicity are unknown, and whilst it is apparent that RGC axon loss does occur, there is 
no clear evidence as to whether the RGC is a primary target of VGB toxicity, or 
whether RGC axon loss occurs secondary to other retinal cell dysfunction or death.  It is 
possible that the mechanisms responsible for the electrophysiolgocal changes seen in 
some VGB-exposed individuals are distinct from those related to the development of 
VAVFL.  
Distinguishing those mechanisms that are responsible for irreversible VAVFL is 
integral to identifying the best screening techniques to use in VGB-exposed individuals.  
Longitudinal studies using perimetry, retinal electrophysiology and OCT imaging are 
needed to further elucidate the relationship between the measurements obtained with 
these techniques to provide a better understanding of the mechanisms and time course 
of VGB retinotoxicity.  Further human pathological data are also needed to better 
characterise the pathological changes that occur in the retina in VGB-exposed 
individuals.  
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 Chapter 5  Factors associated with ppRNFL thinning in 
VGB-exposed individuals  
 
5.1 Introduction  
 
Around 50% of VGB-exposed individuals will develop VAVFL (91) yet currently it is 
unknown which individuals are most at risk.  Whilst some individuals maintain normal 
visual fields after many years of VGB exposure, others develop severe VAVFL after 
relatively low VGB doses.  Identification of factors that predispose to VAVFL may 
allow for safer prescribing of VGB in selected individuals (168). 
Recently, a large, multicentre study of VAVFL in 386 VGB-exposed adults and 
children identified higher duration of VGB exposure, and higher mean daily dose of 
VGB, to be risk factors for VAVFL (92).  Several other studies have reported increased 
risk of VAVFL with increasing cumulative VGB exposure (81;96;113;122;137;163), 
duration of VGB exposure (81;94;96;108;118;126;137;164), maximum daily VGB dose 
(107) and mean daily VGB dose (92;109;137) (Table 5.7).  Conversely, several other 
studies have reported no effect of cumulative VGB exposure (95;97-
100;104;109;124;164), duration of VGB exposure 
(95;97;99;100;109;122;124;128;135), maximum daily VGB dose (99;102;108) or mean 
daily dose (124;126;128;165) on risk of VAVFL (Table 5.7). 
The large, multicentre study also reported male gender as a risk factor for VAVFL (92), 
which is in agreement with previous findings (92;94;95;97;98;103;137;167). Males 
were more than two times as likely to develop VAVFL compared to females (92;140).  
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Conversely, other studies have found no increased risk of VAVFL associated with male 
sex (100;104;122;135).   
Increased risk of VAVFL has also been associated with increasing age (108) and co-
medication with valproate (108;114;164).  However, most demographic, clinical and 
therapeutic factors have shown no association with increased risk of VAVFL, including; 
exposure to other AEDs  (94;97;137), number of other AEDs exposed to (108;112), age 
(97;112;122;135), epilepsy syndrome (104;113), duration of epilepsy (94;112), 
temporal lobe lesions (94), history of status (94) or poor cognitive performance (122).   
ppRNFL thickness, measured using OCT, provides an easily quantifiable and repeatable 
measure of VGB-associated retinal pathology that is highly correlated with the degree 
of VAVFL
22
.  No studies have yet explored factors associated with ppRNFL thinning in 
VGB-exposed individuals.  Identifying factors that are associated with ppRNFL 
thinning may aid in evaluating the benefits and risks of initiating, or discontinuing, 
VGB therapy.    
5.1.1 Aims 
The aims of this study were to identify demographic, clinical and therapeutic factors 
associated with ppRNFL thinning in VGB-exposed individuals.  For comparison of the 
data acquired in this study with other studies of VAVFL, a relationship between the 
amount of VGB exposure and the severity of VAVFL was also explored.   
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5.2 Methods  
5.2.1 Subjects  
VGB-exposed individuals from Group 1A and Group 1B were included in this study.   
Demographic details of each Group are provided in Table 2.1
23
.  
5.2.3 Data analysis  
For the analysis of MRD and VGB exposure, data from Group 1A and Group 1B were 
combined. 
For the analysis of clinical, demographic and therapeutic factors and their association 
with ppRNFL thickness only data from individuals in Group 1A were included.  
ppRNFL thickness data from Group 1A and Group 1B cannot be combined due to 
differences in data acquisition between the two instruments (336) and thus data must be 
analysed separately.  In Group 1B OCT data were only available for 51 individuals of 
whom only 32 had VGB exposure data available, thus the Group was considered to be 
too small for multivariate analysis.   
Data from Group 1B was explored using univariate analysis independently of Group 1A 
data in analysis regarding cumulative VGB exposure and duration of VGB exposure 
and ppRNFL thickness. 
To determine clinical and therapeutic factors associated with average ppRNFL 
thickness, statistical analysis of the data (from Group 1A) were completed in three 
stages in a similar approach to that used by Wild et al. in the analysis of risk factors for 
VAVFL (92).  Firstly, all demographic, clinical and therapeutic variables were explored 
using univariate analysis to determine whether an association existed with average 
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ppRNFL thickness.  Correlation analysis was used for continuous variables (e.g. 
cumulative VGB exposure and age).  Categorical variables (e.g. history of febrile 
seizures) were explored using independent samples T-test.  A p-value of ≤0.05 was 
considered significant.  Parametric and non-parametric tests were applied depending on 
the distribution of the data.  
In the second stage, all categorical and continuous variables that were found to be 
significant in the first analysis were then entered into a standard linear regression model 
with average ppRNFL thickness as the dependent variable.  Finally, variables that were 
retained in the standard linear regression model (p≤0.05) were then entered into a final 
standard linear regression model to determine the combined and unique contribution of 
each of the variables to the average ppRNFL thickness. 
 
5.3 Results  
5.3.1 Subjects and clinical data 
Clinical and therapeutic data were obtained from the medical notes as outlined in 
Chapter 2.  OCT data were available for 129 individuals in Group 1A, but, complete 
clinical and therapeutic data could not be obtained for all individuals
24
.  The number of 
individuals in Group 1A who had OCT data and data regarding each of the clinical and 
therapeutic factors used in the analysis are shown in Table 5.1.  
5.3.2 Relationship between visual field size and VGB exposure 
Individuals from Group 1A and Group 1B were included in the analysis.  A correlation 
was found between MRD and cumulative VGB exposure (r=-0.622; p<0.001; 
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Figure5.1A), duration of VGB exposure (r=-0.525; p<0.001; Figure 5.1B) and 
maximum daily VGB dose (r=-0.44; p<0.001; Figure 5.1C).   
 
Table 5.1 The number of individuals in Group 1A (with OCT data) with data on 
each clinical variable 
Clinical variable  Total number of individuals with 
data 
Age 129 
Gender  129  
Cumulative VGB exposure  92 
Duration of VGB exposure  92 
Max daily VGB dose  92 
Duration of epilepsy  120 
Age at onset  120 
Total number of AEDs exposed to 116 
Learning disability  120  
Epilepsy phenotype 121 
Homonymous visual field defect  84*  
History of febrile seizures  97  
History of head injury  111 
History of status  100  
Smoker   59**  
*determined from visual field examinations undertaken as part of this study 
**data on smoking history was not available from individuals recruited from SEIN 
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Figure 5.1 Correlation between cumulative vigabatrin-exposure (A), duration of VGB exposure (B) and maximum daily VGB dose (C) and 
visual field size 
 
 
A B 
220 
 
 
Figure 5.1 legend: Increasing cumulative vigabatrin exposure (A), duration of VGB 
exposure (B) and maximum daily VGB dose (C) correlated with decreasing visual field size as 
measured using MRD. 
ppRNFL= peripapillary retinal nerve fibre layer; VGB = vigabatrin 
 
  
C 
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Individuals were grouped according to the severity of VAVFL as defined by Wild et al. 
(97).  The median values of the VGB exposure variables for each Group are shown in 
Table 5.2.  
 
Table 5.2 The amount of VGB exposure in individuals grouped according to 
visual field classification 
 Normal 
(N=42) 
Mild 
VAVFL 
(N=19) 
Moderate 
VAVFL 
(N=26) 
Severe 
VAVFL 
(N=5) 
Median cumulative 
VGB exposure 
(grams) [range] 
653.5  
[15-14000] 
2331.0 
[10-14427] 
5825.5* 
[239-20085] 
11883.0* 
[2381-21105] 
Median duration VGB 
exposure (months) 
[range] 
15.0 
[1-219] 
44.5 
[1-228] 
97.5* 
[7-230] 
139.0* 
[25-231] 
Median maximum 
daily VGB dose 
(milligrams) [range] 
2000 
[500-4000] 
2750 
[500-5000] 
3000* 
[1500-4500] 
3500* 
[3000-4000] 
VAVFL – vigabatrin associated visual field loss 
*significantly different compared to VGB-exposed individuals with normal visual fields 
(p<0.008)  
 
Kruskal-Wallis tests showed a significant difference in cumulative VGB exposure, 
duration of VGB exposure and maximum daily VGB dose between Groups (p<0.05).  
Post-hoc comparisons were made using Mann-Whitney U tests between each Group.  A 
Bonferroni adjusted p value of 0.008 was used to allow for multiple testing.   
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In the post-hoc analysis, cumulative VGB exposure, duration of VGB exposure and 
maximum daily VGB dose were significantly higher (p<0.008) in individuals with 
moderate VAVFL compared to individuals with normal visual fields, and in individuals 
with severe VAVFL compared to individuals with normal visual fields.  No statistically 
significant differences were found between other Groups.      
5.3.3 Step 1 – exploring clinical and therapeutic factors associated with 
average ppRNFL thickness  
 
5.3.3.1 Continuous variables 
In Group 1A, a correlation was found between average ppRNFL thickness and 
cumulative VGB exposure, duration of VGB exposure and maximum daily VGB dose 
(Table 5.3; Figure 5.2).  No correlation with average ppRNFL thickness was found for 
age, duration of epilepsy, age of epilepsy onset or number of AEDs exposed to (Table 
5.3).  
 
Table 5.3 Correlations between average ppRNFL thickness and continuous variables  
 Correlation coefficient (r) p-value 
Cumulative VGB exposure -0.53 < 0.001 
Duration of VGB exposure  - 0.41 <0.001 
Maximum daily VGB dose -0.36 < 0.001 
Age -0.05 0.59 
Duration of epilepsy  -0.17 0.17 
Age of epilepsy onset 0.12 0.33 
Number of AEDs exposed to -0.19 0.14 
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5.3.3.2  Relationship between VGB therapy and average ppRNFL thickness 
in Group 1B  
The relationship between VGB exposure and average ppRNFL thickness was also 
explored for Group 1B.  In Group 1B there was no correlation between cumulative 
VGB exposure, duration of VGB exposure or maximum daily VGB dose and average 
ppRNFL thickness (r = -0.21 p=0.26; Figure 5.3A; r= - 0.17; p=0.33; Figure 5.3B; r =-
0.17; p=0.33; Figure 5.3C respectively).  
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Figure 5.2 Correlation between cumulative vigabatrin-exposure (A), duration of VGB exposure (B) and maximum daily VGB dose (C) and 
average ppRNFL thickness for Group 1A 
 
 
A B 
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Figure 5.2 legend: Increasing cumulative vigabatrin-exposure (A), duration of VGB exposure (B) and maximum daily VGB dose (C) correlated with 
decreasing average ppRNFL thickness. 
C 
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Figure 5.3 Correlation between cumulative vigabatrin-exposure, and duration of VGB exposure, and average ppRNFL thickness for 
Group 1B 
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Figure 5.3 legend:  In individuals in group 1B there was no correlation between cumulative vigabatrin-exposure (A), duration of VGB exposure (B) and 
maximum daily VGB dose (C) and average ppRNFL thickness.  Individuals may develop significant ppRNFL thinning after receiving a relatively small cumulative 
VGB exposure (red circle), whilst others maintain normal ppRNFL thickness despite receiving a large cumulative VGB exposure (red arrow). 
C 
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5.3.3.3 Categorical variables  
The effect of particular clinical features on average ppRNFL thickness was explored 
using independent samples T-tests.  The ppRNFL was significantly thinner in males 
compared to females (75.3µm and 82.2µm, respectively; p<0.001) and in individuals 
with homonymous visual field defects compared to those without (72.1µm and 79.7µm, 
respectively; p=0.01).  There was no effect of any other clinical factor, or exposure to 
any other AED on ppRNFL thickness (p>0.05; Table 5.4). 
 
Table 5.4 Mean average ppRNFL thickness according to clinical and therapeutic factors  
 Mean average ppRNFL 
thickness (µm) 
(number of individuals) 
P value 
Variable Yes No  
Smoker  82.2 
(15) 
77.7 
(44) 
0.28 
History of status 79.5 
(14) 
77.4 
(86) 
0.63 
History of head injury 78.6 
(15) 
79.1 
(96) 
0.93 
History of febrile 
seizure 
79.5 
(19) 
79.1 
(78) 
0.92 
Sex Male 
 75.3 
(63) 
Female 
82.2 
(66) 
<0.001* 
LD 78.3 76.8 0.67 
Homonymous visual 
field defect 
72.1 
(21) 
79.7 
(63) 
0.01* 
Acetazolamide 78.7 
(28) 
76.9 
(88) 
0.61 
Clobazam 77.4 78.6 0.79 
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(93) (23) 
Clonazepam 78.5 
(38) 
76.9 
(78) 
0.64 
Ethosuximide 78.7 
(11) 
79.6 
(105) 
0.87 
Felbamate 71.3 
(7) 
79.4 
(109) 
0.06 
Gabapentin 76.2 
(50) 
81.1 
(66) 
0.09 
Lacosamide 78.4 
(10) 
78.9 
(106) 
0.89 
Lamotrigine  79.1 
(92) 
75.8 
(24) 
0.45 
Levetiracetam 76.7 
(83) 
81.2 
(33) 
0.29 
Oxcarbazepine  76.9 
(43) 
79.0 
(73) 
0.76 
Phenobarbital 75.9 
(49) 
80.5 
(67) 
0.10 
Pregabalin  75.4 
(82) 
79.7 
(34) 
0.34 
Primidone 75.5 
(22) 
79.0 
(94) 
0.14 
Phenytoin 76.9 
(85) 
80.3 
(31) 
0.40 
Valproate 77.4 
(90) 
78.1 
(26) 
0.88 
Topiramate 78.6 
(69) 
78.5 
(47) 
0.99 
Tiagabine 76.2 
(25) 
78.0 
(91) 
0.64 
Zonisamide 80.2 
(19) 
76.5 
(97) 
0.32 
*significant difference  
Only one individual had never been exposed to carbamazepine therefore it was not included in 
the analysis  
230 
 
At the time of testing less than 5 individuals had been exposed to each of ACTH and 
chlordiazepoxide therefore these antiepileptic drugs were not included in the analysis.   
 
Epilepsy type 
Individuals with hippocampal sclerosis (N=34); malformations of cortical development 
(N=18) and individuals with partial epilepsy of unknown cause (N=40) were compared 
using one-way ANOVA.  There was no significant difference in average ppRNFL 
thickness between these groups (p>0.05). 
Individuals with other epilepsy types included those with angioma or vascular 
malformation, stroke, infection, neurocutaneous syndromes, tumour and trauma.  These 
individuals were not included in the analysis due to the small numbers of individuals 
within each group.    
 
5.3.4 Step 2 – Multiple regression  
In step one of the analysis, cumulative VGB exposure, duration of VGB exposure, 
maximum daily VGB dose, sex and homonymous visual field defect were found to be 
significantly associated with average ppRNFL thickness.  These variables were entered 
into a standard linear regression model to determine the combined and unique 
contribution of each VGB exposure variable to average ppRNFL thickness.   
The total model explained 30.8% of the variance in average ppRNFL thickness (R 
Square = 0.308; p<0.001).  The contribution of each individual variable in the model 
was compared (Table 5.5).  Cumulative VGB exposure and duration of VGB exposure 
did not contribute uniquely to this model (cumulative VGB exposure (beta=0.019; 
p=0.935), duration of VGB exposure (beta=-0.283, p=0.201). 
231 
 
 
Table 5.5 Standardised Beta coefficients and p-values for all variables in the Step 2 model  
Variable Beta p-value  
Cumulative VGB exposure 0.019 0.94 
Duration of VGB exposure 0.283 0.20 
Maximum daily VGB dose 0.296 0.01* 
Gender 0.228 0.02* 
Homonymous visual field defect 0.246 0.01* 
*Significant (p<0.05) 
 
The regression analysis showed that cumulative VGB exposure and duration of VGB 
exposure were highly correlated (r=0.88; p<0.001), indicating multicollinearity.  When 
multicollinearity is present within a regression model, results regarding the contribution 
of individual variables to the model may be misleading (e.g. a p-value may not indicate 
significance, even though the variable is contributing).  In this case, one of the 
contributing variables should be omitted from the model (379)
25
.  As cumulative VGB 
exposure was calculated from duration of VGB exposure and daily VGB dose (which 
includes maximum daily VGB dose), cumulative VGB exposure was excluded from the 
model.    
5.3.5 Step 3 – The final model   
A final model was created after excluding cumulative VGB exposure.   The total model 
explained 30.8% of the variance in average ppRNFL thickness (R Square = 0.308; 
                                                          
25
 In some cases collinear variables can also be combined to form one new independent variable which 
can then be included in the model.  
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p<0.001).  The contribution of each individual VGB exposure variable in the final 
model was compared (Table 5.6), and showed that all of the variables included in the 
model contributed significantly (p<0.05) to average ppRNFL thickness.  Maximum 
daily VGB dose made the strongest unique contribution to average ppRNFL thickness 
(beta -0.291), uniquely contributing to 8.1% of the total variance in average ppRNFL 
thickness, (derived from squaring the Part correlation coefficient (-0.285
2 
x 100)) (379). 
 
Table 5.6 Standardised Beta coefficients and p-values for all variables in the final model  
Variable Beta p-value  Part correlation 
coefficient 
Duration of VGB exposure -0.267 0.007* -0.261 
Maximum daily VGB dose -0.291 0.003* -0.285 
Sex  -0.228 0.02* -0.227 
Homonymous visual field defect -0.246 0.01* -0.245 
*Significant (p<0.05) 
 
5.4 Discussion  
 
5.4.1 Clinical and therapeutic factors associated with average ppRNFL 
thickness   
This is the first study to explore clinical and therapeutic factors associated with 
ppRNFL thinning in VGB-exposed individuals.  Cumulative VGB exposure, duration of 
VGB exposure, maximum daily VGB dose, male gender and the presence of a 
homonymous visual field defect were found to be independently associated with 
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average ppRNFL thickness in individuals in Group 1A.  After entering these variables 
into a standard linear regression model, cumulative VGB exposure was excluded due to 
multicollinearity with duration of VGB therapy.  A final model showed that duration of 
VGB exposure, maximum daily VGB dose, male gender and the presence of a 
homonymous visual field defect were both independently and collectively associated 
with average ppRNFL thickness and explained 30.8% of the variance in average 
ppRNFL thickness. 
5.4.2 The relationship between VGB exposure and VGB retinotoxicity 
Although a correlation was found between average ppRNFL thickness and cumulative 
VGB exposure, duration of VGB exposure and maximum daily VGB dose for Group 
1A (Figure 5.2), no association was found for Group 1B (Figure 5.3).  Only one other 
study has discussed the relationship between ppRNFL thickness measured using OCT, 
and degree of VGB exposure.  Lawthom et al. demonstrated a weak correlation between 
increasing cumulative VGB exposure and decreasing ppRNFL thickness in the nasal 
quadrant in 27 individuals (256).  Conversely, using scanning laser polarimetry, 
cumulative VGB exposure and duration of VGB exposure were not found to correlate 
with any measures of ppRNFL thickness, (including average, superior, inferior and 
nerve fibre indicator), in eight VGB-exposed individuals (257).   
The inconsistency in findings between studies, and within this study, regarding the 
relationship between the degree of VGB exposure and the degree of ppRNFL thinning 
reflects the contradicting evidence in the literature concerning the relationship between 
increasing VGB exposure and increased risk of VAVFL.  In the present study, 
increasing cumulative VGB exposure, duration of VGB exposure and maximum daily 
VGB dose were associated with decreasing visual field size (as measured using MRD) 
(Figure 5.1).  In agreement, increasing cumulative VGB exposure 
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(81;96;113;122;137;163), duration of VGB exposure (81;94;96;108;118;126;137;164), 
maximum daily VGB dose (107) and mean daily VGB dose (92;109;137) have been 
associated with increased risk of VAVFL in some studies (Table 5.7).  However, 
several other studies have reported no effect of cumulative VGB dose (95;97-
100;104;109;124;164), duration of therapy (95;97;99;100;109;122;124;128;135), 
maximum daily VGB dose (99;102;108) or mean daily dose (124;126;128;165) on risk 
of VAVFL (Table 5.7). 
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Table 5.7 Summary of studies exploring an association between the amount of VGB exposure and the risk of VAVFL 
Reference Number of 
individuals 
Method to determine association between VGB exposure and VAVFL Association between VGB exposure 
and VAVFL 
   Cumulative 
VGB 
exposure 
Mean daily 
VGB dose 
Duration 
of VGB 
exposure 
Wild 2009 (92) 386 Individuals were grouped by visual field classification.  Groups included 
―VAVFL‖ and ―no VAVFL‖ 
Univariate analysis was used to identify variables associated with VAVFL.  
Significant variables from this analysis were then put into a step-wise 
multivariate logistic regression model.  Variables retaining significance in the 
model were transformed into categorical variables and odds ratios were 
determined    
N
d 
Y Y 
Hardus 2000 (94) 109 Individuals were grouped by duration of VGB exposure.  Groups included ―0-
2years‖, ―2-4years‖ and ―>4years VGB exposures‖ 
Differences in the amount of visual field loss (using the Esterman grid) between 
groups was assessed using one way ANOVA 
NA NA Y
c 
Newman 2002 (95) 100 Individuals were grouped by visual field classification.  Groups included visual N NA N 
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field size of ―>30MRD‖ and ―<30MRD‖ 
Differences in VGB exposure between groups were assessed using ANOVA○ 
Malmgren 2001 (96) 99 Individuals were grouped by visual field classification.  Groups included 
―normal‖ and ―visual field loss‖ 
Differences in VGB exposure between groups was assessed using a Mann 
Whitney U test 
Y NA Y 
Nicolson 2002 (98) 98 Individuals were grouped by cumulative VGB exposure.  Groups included 
―<2KG‖, ―2-4KG‖, ―4-6KG‖, ―6-10KG‖, ―>10KG cumulative VGB exposure‖ 
Differences in the frequency of visual field loss between the groups were 
assessed using a chi squared test●  
N NA NA 
Kinirons 2006 (99) 93 Correlation between visual field size (MRD) and VGB exposure variables N N
a 
N 
This paper 92 Spearman correlation between visual field size (MRD) and VGB exposure 
variables  
Individuals were grouped by visual field status.  Groups included “normal”, 
“mild VAVFL”, “moderate VAVFL” and “severe VAVFL” 
Differences in VGB exposure were assessed using A Kruskall Wallis test 
Y
β
 Y
aβ 
Y
β
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with post-hoc analysis using Mann-Whitney U Test 
Hardus 2001 (137) 92 Correlation between percentage visual field loss and VGB exposure 
Linear regression to identify factors associated with visual field size 
Y Y Y 
Vanhatalo 2002 
(122) 
91 Individuals were grouped by visual field classification.  Groups included 
―normal‖ and ―abnormal‖ visual fields  
Differences in VGB exposure between the groups were assessed using T-tests  
Linear regression of temporal visual field extent and VGB exposure variables*  
Y* NA Y* # 
Nousiainen 2001 
(100) 
60 Linear regression using the extent of the visual field in the Temporal, Superior, 
Nasal or Inferior meridians and VGB exposure 
N NA N 
Arndt 2002 (164) 52 Correlation between visual field size and VGB exposure N NA Y 
Wild 1999 (97) 42 Individuals were grouped by visual field classification.  Groups included 
―VAVFL‖ and ―non-VAVFL‖** 
Individuals were grouped by duration of VGB exposure.  Groups included ―<4 
years‖ and ―>4 years of VGB exposure‖ 
No statistical tests applied  
N NA N 
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Tseng 2006 (102) 34 Individuals were grouped by visual field classification.  Groups included ―no 
visual field defect‖, ―visual field defect‖ 
Differences in VGB exposure between the groups were assessed using Mann 
Whitney U test and Fisher’s Exact Test.  Logistic regression was also performed. 
N N
a 
N 
Kalviainen (1999) 
(104) 
32 Correlation between the extent of the visual field in the Temporal, Superior, 
Nasal or Inferior meridians and VGB exposure  
N NA N 
Conway 2008 (107) 31 Multiple regression between severity of visual field loss and VGB exposure N Y
a 
N 
Werth 2006 (124) 30 Pearson correlation between visual field size and VGB exposure ◊  NA N N 
van der Torren  (109) 29 Correlation between extent of nasal visual field and VGB exposure  N Y NA 
Harding 2000 (165) 26 Individuals were grouped by visual field classification. Groups included ―no 
VAVFL‖, ―mild/moderate VAVFL‖ and ―severe VAVFL‖ 
No statistical tests applied. 
Y N N 
Schmitz 2002 (108) 23 Individuals were grouped by visual field classification.  Groups included ―visual 
field loss‖ and ―no visual field loss‖. 
Differences in VGB exposure between groups were assessed using Mann 
Whitney U test  
NA N
a 
Y 
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Manuchehri 2000 
(113) 
20 Spearman correlation between percentage total visual field loss and VGB 
exposure  
Y NA NA 
Gross-Tsur 2000 
(126) 
17 Biserial correlation between ―ocular dysfunction‖♦ and VGB exposure  NA N Y 
Lawden 1999 (81) 16 Individuals were grouped by visual field classification.  Groups included 
―VAVFL‖ and ―no VAVFL‖  
No statistical tests applied. 
Y NA
 a, b 
NA
b 
Ascaso 2003 (128) 15 Individuals were grouped by visual field classification.  Groups included 
―normal‖ or ―visual field defect‖  
Differences in VGB exposure between the groups were assessed using T-tests□ 
NA N N 
Toggweiler 2001 
(118) 
15 Repeated measures ANOVA with VGB exposure variables as covariates NA NA Y
∞
 
Comaish 2002 (135) 14 Correlation between visual field size and VGB exposure  NA NA N 
Frisen 2004 (163) 10 Linear regression between ―hit rate‖ in the temporal and nasal visual field and 
VGB exposure 
Y NA NA 
Where ―no statistical tests were applied‖ conclusions regarding differences in VGB exposure between groups were made on observations of the data.  
a
Maximum daily VGB dose analysed  
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b
Summary measures of these available in paper but not statistically assessed or discussed by authors  
c
However, there was a plateau effect (i.e. there was no difference in % visual field loss in the 2-4 year exposure and 4-6 year exposure groups)   
d
Lost from multiple regression after duration of therapy and mean daily dose added (due to multicollinearity)  
#There was a significant difference in cumulative VGB exposure between the ―normal‖ and ―abnormal‖ visual field groups, but no significant difference was found 
for the duration of VGB exposure between groups (independent samples T-test).  
*Using linear regression a correlation was found between the temporal extent of the visual field and the cumulative VGB exposure and duration of VGB exposure.  
However, there was no relationship when the extent of the nasal visual field was used.    
**The ―no VAVFL‖ group was comprised of 12 individuals, 2 of whom had ―unreliable‖ visual field test results and 6 had ―uninterruptable‖ test results.  Some of 
these individuals may have had VAVFL 
♦Measures of ―ocular dysfunction‖ included abnormalities in perimetric studies, VEP and ERG 
□Only 3 individuals in the ―visual field defect‖ group 
●No post-hoc analysis (there appeared to be a difference between the <2 (30%) and > 10 kg (53%) group)  
○The ―>30MRD‖ group would include individuals with normal visual fields and individuals with mild/moderate visual field loss 
◊Non-commercial arc-perimeter used which may not be accurate enough to detect small changes in the peripheral visual field 
β
Post-hoc analysis revealed statistical differences ONLY between individuals with normal visual fields and those with either moderate or severe VAVFL 
∞There was no association for the inner-most isopter tested (I1e) 
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The conflicting findings between studies regarding the relationship between the degree 
of VGB exposure and the development of retinotoxic sequela (i.e. ppRNFL thinning 
and VAVFL) may be due to several factors.   
5.4.2.1 Small sample sizes  
A number of the studies exploring associations between VGB exposure variables and 
risk of VAVFL have been based on small populations.  Eleven of the 25 studies 
identified in this review of the literature included 30 or fewer participants (Table 5.7).  
Small studies may have insufficient power to detect a significant association between 
VGB exposure and risk of VAVFL.  For example Ascaso et al. (128) reported no 
difference in the duration of VGB exposure, and mean daily VGB dose between 
individuals with and without VAVFL.  However, the study included only 15 individuals 
with just three individuals comprising the VAVFL group.  In some studies statistical 
analysis was not performed (possibly due to small sample sizes), and conclusions 
regarding VGB exposure variables and risk of VAVFL were based upon observations of 
the data (81;165).   
Within a VGB-exposed population there appear to be ―extreme responders‖, i.e. those 
individuals who develop significant VAVFL or ppRNFL thinning after receiving a 
relatively small exposure to VGB (Figure 5.3), and others who maintain normal vision 
and ppRNFL thickness despite receiving a large exposure (Figure 5.3).  These ―outliers‖ 
within a dataset may affect the ability to identify correlations and association between 
variables, particularly if the number of observations is small (380).  In Group 1B, 
extreme responders were particularly apparent (Figure 5.3).  In this Group only 32 
individuals had both OCT and VGB dose data, the small sample size and the presence 
of extreme responders could account for the lack of association seen in the present study 
in Group 1B between the degree of VGB exposure and ppRNFL thickness.   
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5.4.2.2 The visual field variable 
In this study the visual field was analysed as both a continuous (quantitative) variable 
(i.e. visual field size as measured by MRD) and a categorical variable (i.e. ―normal‖, 
―mild VAVFL‖, ―moderate VAVFL‖ and ―severe VAVFL‖).  Other studies have also 
used both approaches (Table 5.7).  For analysis of the visual field and its association 
with the degree of VGB exposure, the visual field recorded from the chosen perimetric 
technique has to be quantified and/or classified according to certain criteria.  The lack of 
a standardised method to quantify and classify visual field size (or the size of a visual 
field defect) has resulted in the use of different techniques in different studies (see Table 
2.5 and 2.6).  For example, in a study of 91 VGB-exposed children, a correlation was 
found between the degree of VGB exposure (cumulative exposure and duration of 
exposure) and the extent of the temporal visual field (in degrees).  However, no 
correlation was found between the degree of VGB exposure (cumulative exposure and 
duration of exposure) when the extent of the nasal visual field (in degrees) was analysed 
(122).  In a different study, a relationship was found between decreasing size of the 
outer isopters (V4e, I4e, I3e and I2e) of the visual field and increasing duration of VGB 
exposure; however, the size of the inner-most isopter was not associated with duration 
of VGB exposure (118).   
Similarly, when classifying VAVFL, differences in the criteria used to determine 
whether a visual field shows normal, mild or severe VAVFL may contribute to the 
variation in results seen between studies.  In some studies, determination of the 
relationship between VAVFL and the degree of VGB exposure was carried out by 
comparing individuals grouped according to visual field status (i.e. VAVFL or normal 
visual fields) (81;92;95-97;102;108;122;128;134).  The majority of these studies 
however, have used different criteria to classify the visual field (Table 2.6).  For 
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example, Vanhatalo et al. classified a normal visual field as one in which the largest 
isopter tested using Goldmann kinetic perimetry (usually the V4e) extended by more 
than 70
o 
in the temporal meridian, whilst Malmgren et al. used a cut off of 80
o
 in the 
temporal meridian.     
5.4.2.3 Accurate VGB exposure data  
Most studies of VAVFL are retrospective and determination of VGB exposure is made 
from the clinical notes.  VGB-exposed individuals can often have complex medical 
histories with multiple hospital referrals making accurate determination of the amount 
of, or duration of, VGB exposure difficult (94).  In the present study, data on cumulative 
VGB exposure, duration of VGB therapy and maximum daily VGB dose was only 
included for an individual if a complete history of the VGB exposure were available in 
the clinical notes (see Chapter 2).  If records describing VGB exposure were missing, 
prohibiting calculation of VGB exposure (e.g. clinic letters describing initiation or 
withdrawal of VGB, or letter describing VGB dose changes), the VGB exposure data 
were considered missing for that individual.  Although every effort was made to 
calculate the VGB exposure variables as accurately as possible it may not represent the 
individual’s actual VGB exposure.  Around a quarter of individuals are estimated to be 
non-compliant with their recommended AED regime (381).  Even if the individual is 
fully compliant, and follows the exact recommendations made in a clinic letter (e.g. 
increase VGB dose by 1000mg), the actual dates that the individual put into place these 
recommendations cannot usually be determined.  The date of the clinic was used in the 
calculation of duration of VGB exposure and cumulative VGB exposure; but the 
individual may not have implemented the changes until sometime after the clinic date.  
These difficulties with accurately determining VGB exposure may also contribute to the 
variations in findings between studies. 
244 
 
 
5.4.3 Male sex and ppRNFL thinning 
In the present study, male sex was found to be associated with ppRNFL thinning in 
VGB-exposed individuals after controlling for VGB exposure.  This is in agreement 
with several other studies that have found male sex to be a risk factor for VAVFL 
(92;94;95;97;98;103;137;167) (Table 1.4).  Sex differences in whole retinal thickness at 
the level of the macula, measured using OCT, have been reported, with males having 
significantly thicker retinas compared to females (382-384).  However, OCT measures 
of ppRNFL thickness generally show no gender difference in healthy volunteers (Table 
5.8).  Only two studies have reported thinner ppRNFL in males compared to females, in 
the temporal (385) and inferior quadrant (386).  This suggests that the susceptibility of 
males to VAVFL and ppRNFL thinning may not be due to sex differences in RGC 
number and ppRNFL thickness, but due to other factors that have no influence of RGC 
integrity in the healthy retina.       
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Table 5.8 Summary of studies comparing ppRNFL thickness measured using OCT 
between healthy males and females 
Reference Number of 
individuals 
OCT model  Findings 
(387) 146  TD-OCT No difference  
(285) 328  TD-OCT No difference  
(385) 199  TD-OCT Temporal quadrant thinner in males  
(386) 312  TD-OCT Inferior quadrant thinner in males  
(388) 99  TD-OCT No difference  
(389) 460  TD-OCT  No difference  
(390) 201  TD-OCT No difference  
(391) 109  TD-OCT No difference  
(392) 170 SD-OCT No difference 
(393) 100 TD-OCT No difference 
TD-OCT = time-domain optical coherence tomography; SD-OCT = spectral-domain optical 
coherence tomography 
 
In mice and rats there is evidence for sexual dimorphism in CNS GABAergic systems 
in certain brain regions, including sex differences in GABA concentrations (394;395); 
GABA receptor subunit expression (394); GABA synthesis (396) and 
electrophysiological properties of some GABAergic neurones (397).   
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Susceptibility of males to VGB retinotoxicity may be related to sex differences in 
retinal GABAergic systems (135), such as differences in GABAergic cell numbers, 
expression of GABA receptors, GABA synthesis and release and GABA metabolism.  
In male rats, GABA accumulation in the substantia nigra was significantly higher than 
in female rats up to 10 minutes after sacrifice (396).   Since GABA degradation via 
GABA-T is oxygen-dependent, and presumed to stop immediately after death (396), the 
accumulation of GABA post mortem probably reflects continued GABA-synthesis 
(396), suggesting that in the substantia nigra GABA synthesis is greater in males than in 
females (396).  Similar sexual dimorphism may also exist in the retinal GABAergic 
system.  Greater GABA synthesis in the retina in males compared to females could 
explain the increased susceptibility to VGB retinotoxicity in males.  Higher levels of 
synthesised GABA may lead to increased synaptic GABA release resulting in 
augmented accumulation of GABA in the retina in males after exposure to VGB.   
 
5.4.4 Age and ppRNFL thickness   
Histological studies of human retina have shown that the number of RGC axons 
decreases with age (398-400).  This age-related thinning can be detected using OCT 
ppRNFL imaging, which shows a decreases in ppRNFL thickness with age at a rate of 
between 0.16 and 0.44 µm per year (285;390;401;402).  No effect of age on ppRNFL 
thickness was found in this study.  It is likely that any small effect of age on the 
ppRNFL thickness is masked by the greater effects of VGB on the ppRNFL thickness.     
5.4.5 Other antiepileptic drugs and ppRNFL thickness   
It has been suggested that combination therapy with VGB and valproate may be 
associated with increased risk of VAVFL (108;114;164).  However, in two studies that 
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have reported this (108;114), the association between combination therapy with VGB 
and valproate and the development of VAVFL was based on a small sample of 
individuals (403).  In the study by Ardnt et al. (114) only one individual was treated 
with VGB and valproate combination therapy.  Although this individual developed 
severe VAVFL; in the same study, severe VAVFL was also reported in individuals 
receiving VGB monotherapy and VGB and carbamazepine combination therapy.  
Furthermore in a large study of 386 VGB-exposed individuals, concomitant exposure to 
any other AED was not associated with risk of VAVFL (92).  In addition, valproate 
monotherapy is not associated with visual field abnormalities (404;405) or retinal 
electrophysiological abnormalities (405).  However, in a study of individuals receiving 
VGB combination therapy with either carbamazepine (N=31) or valproate (N=21), 
those receiving valproate had significantly smaller visual fields compared to those 
receiving carbamazepine, despite similar cumulative VGB exposure and duration of 
VGB exposure between the two groups (164).   
No effect of exposure to valproate was found in the present study.  However, only 
―exposure‖ to each AED was assessed, AEDs taken in combination with VGB were not 
evaluated, and thus a combination effect of VGB and valproate cannot be ruled out.  
Valproate  increases whole brain levels of GABA (406) probably through inhibition of 
succinate semialdehyde dehydrogenase, resulting in elevated levels of succinate  which 
inhibits GABA-T activity (407).  Inhibition of GABA-T by both VGB and valproate 
when used concomitantly could lead to increased risk of VGB retinotoxicity.  Further 
studies are needed to assess the risk of VAVFL with concomitant AED use during 
VGB-exposure.     
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5.4.6 Homonymous visual field defects and ppRNFL thickness   
The ppRNFL was significantly thinner in individuals with homonymous quadrantinopic 
or hemianopic defects than in individuals without homonymous defects.  Twenty one 
individuals had a homonymous visual field defect that was detected on visual field 
testing.  One individual had ―left sided cavitatory brain damage‖ and homonymous 
hemianopia, one individual had ischaemic brain damage following a ruptured aterio-
venous malformation and a homonymous hemianopia, and one individual had Sturge-
Weber syndrome and a homonymous hemianopia.  18/21 individuals had had a 
homonymous quadrantinopia from resection of epileptogenic foci (16/18 from the 
temporal lobe, 2/18 from the parietal lobe). 
Homonymous visual field defects are a common complication of epilepsy surgery, 
particularly after anterior temporal lobe resection, and occur due to damage to the 
anterior aspect of the optic radiation, (Meyer’s loop) (Figure 5.4).  The incidence of 
visual field defects after temporal lobe resection is estimated to be between 15 and 
100% (408;409).   
In individuals with lesions to the optic radiation, ppRNFL thinning may result from 
retrograde trans-synaptic degeneration.  In humans, retrograde trans-synaptic 
degeneration of RGC as a result of post-geniculate visual pathway lesions is 
controversial (410), and was not thought to occur (411).  Miller and Newman reported 
normal, healthy optic discs, with no indication of atrophy, in an individual with a 
homonymous hemianopia following a cerebro-vascular accident 57 years previously 
(412).  Conversely, several other case reports suggest that optic atrophy (413-415), 
RNFL thinning (416) and degeneration of the anterior visual pathway (414) can be seen 
between 6 and 35 years following an occipital lobe lesion (413-415).  In non-human 
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Figure 5.4 Projections of the optic radiation and Meyer’s loop in the anterior 
temporal lobe 
 
Figure 5.4 legend:  The optic radiations are shown in red.  The anterior aspect of the optic 
radiation (Meyer’s loop) takes a ventral course into the anterior temporal lobe.  Surgical 
resection of the anterior temporal lobe can result in damage to nerve fibres in Meyer’s loop 
leading to a homonymous superior quadrantinopia.     
 
primates RGC atrophy is observed after occipital lobectomy (417), excision of the 
striate cortex (418), and after small lesions to the striate cortex (419).   
Recently, thinning of the ppRNFL has been detected using OCT in individuals with 
homonymous hemianopia secondary to congenital (295;420) and acquired lesions (295) 
of the occipital cortex.  Additionally, in two individuals with homonymous hemianopia 
resulting from acquired lesions to the striate cortex, degeneration of the ipsilateral optic 
tract was detected using MRI (410).  These studies suggest that retrograde trans-
synaptic degeneration occurs in the human visual pathway and that in some individuals 
this can be detected using OCT imaging of ppRNFL thickness (295).  The presence of 
Lateral geniculate 
neucleus
Temporal horn of 
lateral ventricle 
Meyer’s loop
Hippocampus 
Anterior 
temporal lobe
Optic radiation
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retrograde trans-synaptic degeneration of RGC resulting from lesions to the optic 
radiation has not been systematically explored.  However, the data from this study 
suggest that this may occur after lesions from surgical procedures (e.g. anterior temporal 
lobectomy).   
A limitation of studying the effects of lesions to the optic radiations on the ppRNFL 
thickness in this population is that VGB has a significant effect on the ppRNFL 
thickness (229;256).  The true effect of optic radiation lesions on the ppRNFL may be 
hidden or exaggerated by the effect of VGB.  Additionally as this was a cross-sectional 
study, the thinner ppRNFL in the individuals with homonymous visual field defects 
cannot definitely be attributed to the lesion, but may be related to another factor. 
Prospective, longitudinal studies are needed to determine whether retrograde trans-
synaptic degeneration occurs after acquired lesions to the optic radiation (e.g. as a result 
of anterior temporal lobectomy).  There is particular scope for this in individuals with 
epilepsy undergoing anterior temporal lobe resections, who will usually undergo pre 
and post surgical perimetry and in whom OCT ppRNFL imaging could be included in 
the assessment.  However, the duration of time between optic radiation lesion and RGC 
atrophy is uncertain, and may not be clinically detectable opthalmoscopically for up to 
35 years after the insult (414), if ever (256;412).  OCT ppRNFL imaging provides a 
technique that may detect subtle loss of RGC axons before it is clinically detectable 
using opthamoscopy (295).  Recently Jindahra et al. presented an abstract describing 
longitudinal changes in ppRNFL thickness, using OCT, in seven individuals with post-
geniculate visual pathway lesions.  In three individuals with hemianopia, ppRNFL 
thinning was evident at three months post injury and showed a trend from further 
decline over a one year follow-up period (421).   
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In disagreement with the present study, the work presented by Jindahara found no 
ppRNFL thing in individuals with homonymous quadrantinopia (421).  Homonymous 
superior quadrantinopia is a common complication of temporal lobectomy, and 16/18 of 
the individuals with homonymous visual field defects included in the present study had 
this visual field defect.  The risk of VAVFL in individuals with post-geniculate visual 
pathway lesions has not been systematically explored.  Often visual field test results 
showing a homonymous visual field defect are excluded from analyses because of the 
confounding effect on quantification of visual field size
26
.  However, interestingly, one 
of the few studies that has reported that VAVFL progresses with continued VGB 
exposure was in individuals who had undergone temporal lobe surgery  (152).  In the 
study reported by Hardus et al. (152) only surgical candidates were included, so a 
comparison could not be made about the progressiveness of VAVFL in individuals who 
had not undergone surgery.   It is possible that loss of neurons post-synaptic to RGC 
after post-geniculate visual pathway injury (i.e. as a result of temporal lobe surgery) 
may make the RGC more susceptible to VGB toxicity.  Thus in individuals not exposed 
to VGB, post-geniculate lesions resulting in quadrantinopias do not result in a 
significant degree of RGC loss that can be detected using OCT.  However, in VGB-
exposed individuals with already ―injured‖ RGC as a result of VGB toxicity, further 
injury to the visual pathway may be exaggerated.     
5.4.7 Genetic variation and ppRNFL thickness   
Genetic variation may play a role in the development of VAVFL (168) and ppRNFL 
thinning.  Heredity studies have demonstrated that genetic factors are strong 
determinants of ppRNFL thickness (393;422).    Individual variation in RGC number 
prior to VGB exposure could contribute to susceptibility to VGB-induced ppRNFL 
                                                          
26
 See 2.4.4 
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thinning, and explain the degree of variability seen in ppRNFL thickness between 
individuals.  Curcio and Allen found that in healthy human retina the total number of 
RGC ranged from 710,000 to 1.54 million (423).  These findings are in keeping with 
RGC axon number in human optic nerve, which has been shown to range from 730,000 
to 1.7 million (399;424;425).  Individuals with lower numbers of RGC (and thinner 
ppRNFL) may be more susceptible to the effects of diseases, or processes, which target 
the RGC apparatus (398;423;426) and may be at greater risk of developing VAVFL at 
lower VGB doses. 
Males sex was found to be associated with ppRNFL thinning after VGB exposure.  
OCT studies show that ppRNFL thickness does not differ between healthy males and 
females (Table 5.8) suggesting that baseline RGC number may not be the only 
contribution to susceptibility to VGB retinotoxicity.  Genetically-determined differences 
in retinal GABAergic pathways including differences in GABAergic cell number and 
GABA-transporter and GABA receptor expression; and GABA metabolism, including 
differences in GABA-T activity, may also increase or decrease risk of VGB 
retinotoxicity in an individual.  In a previous study, three candidate genes were found to 
be associated with increased risk of VAVFL including a gene encoding GABAB 
receptor (GABRR1/2) and two genes encoding GABA-transporters (GAT1/3 and 
GAT2).  However, no significant association was found on replication of the study by 
the same authors in a second independent cohort (168).  The initial genetic association 
found in the study by Kinirons et al. (168) probably represents a false positive result.  A 
real association between the gene variants detected in their study, or indeed other 
variants, cannot be ruled out.  The study may have been underpowered to detect variants 
of small effect; in addition findings may have been confounded by variability in the 
visual field measurement (168).  A chosen phenotype must be reliably and consistently 
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determined (427) as phenotype variation may influence the ability to identify
 
causal 
variants (428).  Perimetry is subject to multiple confounding influences on the recorded 
visual field, which may be further exaggerated in individuals with epilepsy (see Chapter 
3) and thus may not provide the most suitable phenotype for the assessment of genetic 
determinants of VGB toxicity.  OCT ppRNFL imaging may provide a more robust 
phenotype to use in pharmacogenetic studies of VAVFL.  As part of the work carried 
out for this study it was shown that in a VGB-exposed population OCT ppRNFL 
thickness measures are highly repeatable (Chapter 4).  In addition, measures of ppRNFL 
thickness are objective and easily quantifiable and are not subject to the same degree of 
subject-related and examiner-related variability as perimetry.  Additionally, as more 
patients are able to complete OCT than can complete perimetry (Chapter 4), this will 
allow collection of larger numbers of VGB-exposed individuals and increased study 
power.  Future studies should explore whether particular genetic variants are associated 
with ppRNFL thickness in VGB-exposed individuals. 
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Chapter 6  Patterns of ppRNFL thinning in VGB-
exposed individuals  
 
6.1 Introduction  
 
Although the precise mechanisms of VAVFL are not known, it is becoming 
increasingly evident that RGC loss is implicated.  In a single post mortem study from an 
individual with VAVFL pathological analysis of the retina and optic nerve revealed 
severe loss of RGC and their axons in the peripheral retina, with relative preservation of 
RGC in the central retina (162).  A similar pattern of RGC atrophy has also been 
reported in studies using fundus photography to assess the integrity of the RNFL and 
ONH.  Frisen et al. describe a series of 21 VGB-exposed children all of whom showed a 
distinct pattern of RNFL atrophy (147).  In some individuals, atrophy of the RNFL was 
confined to the nasal peripapillary area.  In others the areas of atrophic RNFL extended 
to involve the superior and inferior poles of the ONH.  Conversely, the temporal 
ppRNFL was spared in all cases (147).  In addition, a unique pattern of ―inverse‖ (183) 
or ―C-shaped‖ (147) optic atrophy has been described in VGB-exposed individuals, 
resulting from loss of RGC axons from the nasal aspect of the ONH with preservation 
of those in the temporal portion.   
This pattern of RGC atrophy has been described as ―inverse‖ optic atrophy, to 
distinguish it from the more common pattern of temporal optic atrophy, and macula 
RNFL attenuation, seen with toxic-nutritional optic neuropathies (183).  In the toxic-
nutritional optic neuropathies visual impairment typically involves central visual 
pathways, a caecocentral visual field defect, decreased visual acuity and abnormal 
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colour vision with atrophy of RGC subserving the fovea, parafoveal area and 
caecocentral area and atrophy of the temporal aspect of the ONH (248). 
Conversely, VGB toxicity is associated with a bilateral, symmetrical, concentric visual 
field defect, affecting the peripheral visual field and sparing central vision (97).  Even in 
individuals with severe VAVFL the central visual field is spared and colour vision and 
visual acuity are typically normal (101;139;146).  The pattern of RNFL attenuation and 
optic atrophy seen in VGB-exposed individuals is consistent with a pathological process 
involving RGC in the peripheral retina, resulting in peripheral visual field loss.  RGC 
axons in the temporal peripheral retina, take an increasingly arcuate course to enter the 
ONH at the superior and inferior poles (247-249).  Axons from RGC in the nasal retina 
(including the nasal periphery), take a radial trajectory and enter the ONH on the nasal 
side (247-249).   
More recently a pattern of ppRNFL thinning, detected using OCT, has been explored in 
individuals with VAVFL.  In agreement with the appearance of the RNFL and ONH in 
studies using fundus photography, studies using OCT have reported a relative 
preservation of the ppRNFL thickness in the temporal quadrant (119;229;256;258).  In 
addition, varying degrees of ppRNFL thinning in the nasal, superior and inferior 
quadrants have been reported (119;229;256;258).  Lawthom et al. found that 100% of 
individuals with VAVFL showed ppRNFL thinning in the nasal quadrant (256).  
Conversely, in a study by Moseng et al. the distribution of ppRNFL thinning was equal 
across the superior, inferior and nasal quadrants, with 55.6% of individuals showing 
thinning in each of these areas (258).  However, both of these studies were small with 
11 individuals include in the study by Lawthom et al. and 9 individuals in the study by 
Moseng et al.  In a larger study of 64 individuals with VAVFL carried out as part of this 
work, the number of individuals showing ppRNFL thinning in each of the 90
o
 quadrants 
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was assessed (see 4.3.6).  The superior and inferior quadrants most frequently showed 
ppRNFL thinning (68.8% and 51.6% of individuals, respectively), with only 18.8% of 
individuals with VAVFL showing thinning in the nasal quadrant.   
The differences in findings between the studies may be related to the criteria used to 
define ppRNFL thinning.  In the studies by Lawthom et al.  (256) and Moseng et al. 
(258) ppRNFL thinning was defined as a measure falling below the 5
th
 percentile of the 
manufacturers’ normative database.  Conversely in the study carried out as part of this 
work, ppRNFL thinning was defined as measures falling within the ≤1st percentile of the 
manufactures’ normative database.  In addition, in the studies by Lawthom et  al.  (256) 
and Moseng et al. (258) TD-OCT was used to determine ppRNFL thickness, whereas in 
this study both TD-OCT and SD-OCT were used.   
To make a reliable comparison of the results between the three studies, data from 
individuals with VAVFL included in this study who were examined using TD-OCT 
were extracted.  The definition for ppRNFL thinning as applied to the Lawthom et al. 
and Moseng et al. studies was applied to these data (Table 6.1).   
The main difference between the studies was that whilst Lawthom et al. reported nasal 
quadrant thinning in 100% of individuals,  only 55-60% of individuals were found to 
show abnormal nasal quadrant thickness in this study, and in the study carried out by 
Moseng et al. (Table 6.1). 
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Table 6.1 Comparison of the reported pattern of ppRNFL thinning in individuals 
with VAVFL across three studies using the same TD-OCT model 
 Abnormal ppRNFL thinning 
(≤5th percentile of the manufacturers’ normative database) 
 Lawthom (256) 
(N=11) 
Moseng (258) 
(N=9) 
This 
(N=27) 
Temporal 0 22.2 18.5 
Superior 63.6 55.6 74.1 
Nasal 100 55.6 59.2 
Inferior 72.7 55.6 74.1 
TD-OCT = time-domain optical coherence tomography 
 
The differences in the distribution of ppRNFL thinning are difficult to explain as all 
studies used the same TD-OCT model, and ppRNFL thickness scan protocol, and 
compared data against the same normative database.  In addition, all individuals were 
classified as showing VAVFL.  Different perimetric techniques, and thus visual field 
classification criteria, were used in each study.  Lawthom et al. used automated 
perimetry (Humphrey visual field analyser 30-2 program) which only assesses the 
visual field out to 30
o 
eccentricity.  Conversely in this study Goldmann kinetic 
perimetry was used which assess the visual field out to 90
o
, and in the study by Moseng 
et al., the full-field 120-point screening test was used which examines out to 60
o 
eccentricity.  It is possible that individuals with mild VAVFL, not encroaching on the 
central 30
o 
could have been missed in the study by Lawthom et al. and those wild mild 
VAVFL may be contributing to the differences in findings between the studies.  
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Different patterns of ppRNFL thinning may be associated with various stages of 
VAVFL, or degree of VGB exposure.  Frisen et al. suggested that RNFL attenuation 
associated with VAVFL may be progressive with continued VGB exposure.  A ―staging 
system‖  based on the photographic appearance of the RNFL was developed, with 
atrophy  initially only detectable in the nasal peripapillary area and later progressing to 
involve the superior and inferior poles of the ONH (147) (Table 6.2).  Later stages 
involving the temporal aspect of the ONH may also occur (147).  
 
Table 6.2 Staging of ppRNFL atrophy in VGB-exposed individuals using fundus 
photography  
Stage Appearance of the RNFL 
1 Partial atrophy of the nasal quadrant  
 
2 Severe atrophy of the nasal quadrant with partial atrophy of the 
nasal sectors of the superior and inferior quadrants   
 
3 Severe atrophy of the nasal quadrant and severe atrophy of the nasal 
sectors of the superior and inferior quadrants with partial atrophy of 
the temporal sectors of the superior and inferior quadrants   
 
4 Severe atrophy of the nasal quadrant and severe atrophy of the 
superior and inferior quadrants  
Table adapted from Frisen et al. (147) 
 
Based on their findings Lawthom et al. suggested that ppRNFL thinning in the nasal 
quadrant should be used as a biomarker for VGB toxicity, however, the discrepancy in 
findings between OCT studies shows that further investigation is needed to elucidate the 
pattern of VGB-associated ppRNFL thinning before screening recommendations can be 
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made.  If ppRNFL imaging is to be used in the assessment of VGB-exposed individuals 
as has been suggested (256;259), then the precise characteristics of VGB-associated 
ppRNFL attenuation need to be determined.  Understanding patterns of ppRNFL 
thinning after VGB exposure could aid clinicians in monitoring patients for retinal 
changes and may improve the ability to detect subtle change in the ppRNFL.  
Furthermore, if loss of RGC apparatus is progressive (147), discrete ppRNFL areas may 
show thinning early on (i.e. after a low dose of VGB).  Knowledge of a particular 
pattern of ppRNFL thinning may facilitate early detection of subtle defects and improve 
screening strategies to prevent clinical visual field loss.  In addition, if low cumulative 
doses of VGB do lead to subtle defects, this may have implications for trials of VGB as 
an anti-addiction therapy and in short-duration treatment strategies (142;429).  A more 
complete understanding of patterns of RNFL atrophy may help reveal mechanisms of 
VGB toxicity. 
6.1.1 Aims 
To determine whether a pattern of ppRNFL loss can be identified in VGB-exposed 
individuals using OCT.  Further this study will explore the relationship between 
cumulative dose of VGB and patterns of ppRNFL loss to determine whether subtle, 
discrete defects occur early after exposure.   
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6.2 Methods  
 
6.2.1 Subjects  
VGB-exposed individuals from Group 1A and non-exposed individuals with epilepsy 
(Group 2) were included in this study.  The demographic details of individuals in Group 
1A and Group 2 can be seen in Table 2.1
27
 
6.2.2 VGB exposure groups 
For 91 VGB-exposed participants from Group 1A, sufficient data were available to 
determine cumulative dose of VGB.  These participants were further grouped according 
to cumulative VGB exposure.  Group I included 41 participants with exposure to ≤1000 
grams of VGB; Group II comprised 23 individuals with exposure to >1000≤2500 
grams; Group III comprised 16 people with exposure to >2500≤5000 grams; Group IV 
included 11 individuals with exposure to > 5000 grams.  Demographic details of each 
VGB exposure Group are presented in Table 6.3.   
6.2.3 OCT 
All individuals were assessed using SD-OCT 
6.2.4 Data analysis  
Where t-tests were used to explore differences in ppRNFL thickness across the twelve 
30
o 
sectors, a Bonferroni adjusted p-value of 0.004 was used.  Similarly in the analysis 
of 64 four-scan segments, a Bonferroni adjusted p-value of 0.0008 was used to allow for 
multiple testing (379). 
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 Chapter 2 
261 
 
Table 6.3 Characteristics of VGB-exposed individuals according to Group.   
 Group I 
(n=41) 
Group II 
(n=23) 
Group III  
(n=16) 
Group IV  
(n=11) 
Cumulative VGB 
exposure 
≤1000  >1000≤2500  >2500≤5000  >5000  
Mean cumulative 
VGB exposure 
(grams) (SD) 
341.3 (± 
276.7) 
1494.5 (± 
469.5) 
3834.4 (± 
846.0) 
9718.6 (± 
3982.1) 
Mean duration of 
VGB exposure 
(months) (SD) 
9.8 (± 12.7) 36.1 (± 18.9) 78.3 (± 36.7) 131.4 (± 53.4)  
Mean age (years) (SD) 49.6 (± 11.4) 46.9 (± 11.6) 47.6 (± 12.8) 43.8 (± 7.1) 
Sex (male %) 63.0 56.0 
 
43.8 72.0 
VGB = vigabatrin; SD = standard deviation; Group I ≤1000 grams of VGB exposure; Group II 
>1000 ≤2500 grams of VGB exposure; Group III >2500 ≤5000 grams of VGB exposure; Group 
IV >5000 grams of VGB exposure  
 
6.3 Results  
 
Data from all individuals in Group 1A who were able to complete OCT were included 
in the analysis (n=129)
28
.  3/90 (3.3%) non-exposed individuals (Group 2) were unable 
to complete OCT and data from 87 individuals were used in the analysis.        
                                                          
28
 See Chapter 4 
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6.3.1 The ppRNFL in VGB-exposed versus non-exposed individuals 
The ppRNFL thickness, and normal distribution percentiles, in each 30
o 
sector were 
compared between VGB-exposed individuals and non-exposed individuals. 
6.3.1.1 ppRNFL thickness 
The average ppRNFL thickness was significantly thinner in VGB-exposed individuals 
compared to non-exposed participants (78.9 and 88.8µm, respectively; p≤0.004).  The 
ST, Sup, SN, NS, NI, IN, Inf and IT ppRNFL sectors were significantly thinner in 
VGB-exposed compared to non-exposed individuals (p<0.004; Table 6.4).  The 
percentage difference in ppRNFL thickness in VGB-exposed compared to non-exposed 
participants was determined for each sector.  The largest differences were found for the 
NS, IN and SN sectors (18.1%, 17.9% and 17.8% respectively; Table 6.4).  
6.3.1.2 Frequency and distribution of ppRNFL thinning 
The number of individuals showing ppRNFL thinning, according to the manufacturers’ 
normal database, was determined for each of the 30
o 
sectors (Table 6.4).  28.8% of 
VGB-exposed individuals showed abnormal, (i.e. ≤1st percentile), average ppRNFL 
thickness compared to 8.0% of non-exposed individuals.  19.2% showed borderline, 
(i.e. ≤5th–>1st percentile), average ppRNFL thickness compared to 13.8% of non-
exposed individuals.  In VGB-exposed individuals, thinning was most frequently seen 
in the SN, IN, Inf and Sup sectors (32.0%, 25.6%, 24.8% and 21.6% respectively).  
Significantly more VGB-exposed participants were classified as showing abnormal 
ppRNFL thickness in the ST, Sup, SN, NS, IN and Inf sectors (p<0.004). 
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Table 6.4 ppRNFL thickness in each 30
o 
sector. in VGB-exposed and non-exposed 
individuals  
ppRNFL 
area 
VGB-exposed 
(n=129) 
Thickness 
(µm) 
Non-exposed 
(n=87) 
Thickness 
(µm) 
Difference in 
ppRNFL 
thickness (non-
exposed - 
exposed) (µm 
(%)) 
VGB-exposed  
Percentage 
showing 
ppRNFL 
thinning
a
  
Non-exposed  
Percentage 
showing 
ppRNFL 
thinning
a 
≤1st ≤ 5th–
>1
st
  
≤1st ≤ 5th–
>1
st
 
Average  78.9* 88.8 10.2 (11.6) 28.8
# 
19.2 8.0 13.8 
Temp  46.8 48.6 1.8 (3.7) 1.6 8.8 1.1 9.2 
TS  70.2* 74.6 4.4 (5.9) 9.6 8.0 3.4 6.9 
ST  113.3* 127.8 14.5 (11.3) 5.6
# 
16.8 1.1 6.9 
Sup  92.8* 105.8 13.0 (12.3) 21.6
#
 9.6 9.2 8.0 
SN  76.4* 92.9 16.5 (17.8) 32.0
#
 19.2 9.2 13.8 
NS  71.7* 87.5 15.8 (18.1) 4.0
#
 15.2 1.1 4.6 
Nas  57.6 58.3 0.7 (1.2) 3.2 2.4 1.1 5.7 
NI  58.8* 65.6 6.8 (10.4) 3.2 8.0 2.3 4.6 
IN  75.9* 92.4 16.5 (17.9) 25.6
#
 16.8 9.2 8.0 
Inf  107.4* 124.1 16.7 (13.5) 24.8
#
 7.2 9.2 8.0 
IT  111.4* 125.1 13.7 (11.0) 8.0 12.8 2.3 6.9 
TI  59.6 63.0 3.4 (5.4) 1.6 8.0 1.1 4.6 
ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; T = temporal; TS = 
temporal-superior; ST = superior-temporal; S = superior; SN = superior-nasal; NS = nasal-
superior; N = nasal; NI = nasal-inferior; IN = inferior-nasal; I = inferior; IT = inferior-temporal; 
TI = temporal-inferior
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a
As defined by the manufacturers’ normative database.  The percentage of individuals falling 
within the abnormal (i.e. ≤1st percentile) and borderline (i.e. ≤ 5th–>1st percentile) are shown.  
*Significant difference in ppRNFL thickness between exposed and non-exposed participants in 
these sectors (p≤0.004; independent samples T-test) 
# 
Significant difference between number of VGB-exposed and non-exposed individuals classed 
as having abnormal ppRNFL thickness (p<0.004; Chi squared test for independence) 
 
6.3.2 ppRNFL thickness according to VGB exposure Group  
The ppRNFL thickness in each 30
o 
sector was calculated for each VGB exposure Group 
(Table 6.5), and plotted as a graph (Figure 6.1).  Significant differences in ppRNFL 
thickness were assessed using a one-way ANOVA with post hoc testing was carried out 
using Tukey HSD. 
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Table 6.5 ppRNFL thickness in each 30
o 
sector in VGB-exposed individuals 
according to VGB exposure Group 
ppRNFL area Group I  
(n=40) 
Group II 
(n=22) 
Group III 
(n=16) 
Group VI  
(n=11) 
R 
squared 
Average  84.3 74.0
x 
* 73.2
x 
* 66.0
x
 * 0.33 
Temp sector thickness 
(µm) 
47.8 44.6 48.4 46.9 0.03 
TS sector thickness (µm) 71.9 66.5 71.7 67.1 0.04 
ST sector thickness (µm) 119.3 109.5
x 
107.6
x 
92.6
x 
* 0.18 
Sup sector thickness (µm) 104.8 85.7
x 
77.1
x 
* 64.9
x 
* 0.20 
SN sector thickness (µm) 89.1 68.5
x 
* 68.0
x 
* 54.1
x 
* 0.31 
NS sector thickness (µm) 75.3
x 
67.6
x 
67.0
x 
58.9
x 
* 0.27 
Nas sector thickness (µm) 58.2 54.3 56.9 57.7 0.02 
NI sector thickness (µm) 62.2 54.1
x 
54.3
x 
54.2
x 
0.13 
IN sector thickness (µm) 86.1 71.6
x 
65.4
x 
* 59.8
x 
* 0.21 
Inf sector thickness (µm) 120.0 100.5
x 
95.9
x 
*
 
81.8
x 
* 0.18 
IT sector thickness (µm) 116.2 108.8
x 
106.9
x 
95.3
x 
0.12 
TI sector thickness (µm) 60.4 56.6 58.9 57.9 0.03 
ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; Temp = temporal; TS = 
temporal-superior; ST = superior-temporal; Sup = superior; SN = superior-nasal; NS = nasal-
superior; Nas = nasal; NI = nasal-inferior; IN = inferior-nasal; Inf = inferior; IT = inferior-
temporal; TI = temporal-inferior 
Group I ≤1000 grams of VGB exposure; Group II >1000 ≤2500 grams of VGB exposure; Group 
III >2500 ≤5000 grams of VGB exposure; Group IV >5000 grams of VGB exposure  
x
ppRNFL thickness significantly thinner compared to non-exposed individuals (p<0.05) 
*ppRNFL thickness significantly thinner compared to Group I (p<0.05) 
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Figure 6.1 Graph showing ppRNFL thickness across the 30
o 
sectors according 
to VGB exposure Group 
 
 
Figure 6.1 legend: The pattern of ppRNFL thinning according to cumulative VGB 
exposure.  The ppRNFL is thinner in most areas with increasing cumulative VGB exposure.  
The temporal areas show no change in ppRNFL thickness with increasing VGB exposure. 
* Significant difference in ppRNFL thickness between non-exposed individuals and Group I 
(p<0.05) 
× Significant difference in ppRNFL thickness between non-exposed individuals and Groups II, 
III and IV (P<0.05)  
♦ Significant difference in ppRNFL thickness between Group I and Group II, III and IV 
(p<0.05) 
# Significant difference in ppRNFL thickness between Group I and Group III and IV (p<0.05) 
● Significant difference in ppRNFL thickness between Group I and Group IV (p<0.05) 
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ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; Temp = temporal; TS = 
temporal-superior; ST = superior-temporal; Sup = superior; SN = superior-nasal; NS = nasal-
superior; Nas = nasal; NI = nasal-inferior; IN = inferior-nasal; Inf = inferior; IT = inferior-
temporal; TI = temporal-inferior; Group I ≤1000 grams cumulative VGB exposure; Group II 
>1000 ≤2500 grams cumulative VGB exposure; Group III >2500 ≤5000 grams cumulative 
VGB exposure; Group IV >5000 grams cumulative VGB exposure 
 
 
6.3.2.1 VGB exposure Groups compared to non-exposed  
The ppRNFL was significantly thinner in Groups II, III and IV compared to non-
exposed individuals in the ST, Sup, SN, NS, NI, IN, Inf and IT sectors (Table 6.5; 
Figure 6.1).   
In Group I the ppRNFL was found to be significantly thinner in the NS sector compared 
to non-exposed individuals.  No differences were found for any other ppRNFL sectors 
in Group I compared to non-exposed individuals.  A scatter plot of ppRNFL thickness 
in the NS sector and cumulative dose of VGB is shown for individuals in Group I 
(Figure 6.2).  Four individuals were classified as shwing borderline ppRNFL thinning 
(≤5th >1st percentile)29.  Data on the visual field status of 25/40 of the Group I patients 
were available 
30
.  According to criteria set out by Wild et al. (97) 19 individuals from 
Group I had normal visual fields, 5 had mild visual field loss and 1 showed moderate 
visual field loss.   
There were no significant differences between any of the VGB exposure Groups and the 
non-exposed individuals in the Temp, TS, TI and Nas sectors.   
 
                                                          
29
 To determine whether the significant effect was driven by the four individuals showing borderline 
ppRNFL thickness they were excluded from the analysis.  The repeated analysis still showed a significant 
difference in ppRNFL thickness in the NS sector in Group I compared to non-exposed individuals.    
30
 From visual field testing carried out as part of study described in Chapter 4 
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 Figure 6.2 ppRNFL thickness in the NS sector and cumulative dose of VGB for 
individuals in Group 1 
 
Figure 6.2 legend: ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; 
NS = nasal-superior; Group I ≤1000 grams of VGB exposure 
○ Normal ppRNFL thickness (≤95th–>5th percentile according to the manufacturers’ normative 
database) 
♦ Borderline ppRNFL attenuation (≤ 5th–>1st percentile according to the manufacturers’ 
normative database) 
 
6.3.2.2 Inter-group comparison between VGB exposure Groups 
Group II, III and IV all showed significantly thinner ppRNFL compared to Group I for 
the SN sector.  Group III and IV also showed significantly thinner ppRNFL for the Sup, 
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IN and Inf sectors.  In addition, the ppRNFL thickness was significantly thinner in 
Group IV than Group I in the NS and ST sectors.  There were no significant differences 
in ppRNFL thickness between Groups II, III and IV for any sector.      
The coefficient of determination was calculated to explore how much of the variance in 
ppRNFL thickness in each sector was explained by cumulative VGB exposure.  R 
squared values ranged from 0.02 for the Nas sector to 0.31 for the SN sector (Table 
6.5).  The largest R squared values were found for the SN and NS sectors (0.31 and 
0.27).  Around a third of the variance in ppRNFL thickness in these sectors can be 
explained by cumulative dose of VGB (Table 6.5).   
 
6.3.3 ppRNFL thickness according to VAVFL Group  
The ppRNFL thickness in each 30
o 
sector was calculated according to each VAVFL 
classification (Table 6.6), and plotted as a graph (Figure 6.6).  Individuals with 
moderate and severe VAVFL were combined owing to the small numbers in each 
group.  Significant differences in ppRNFL thickness were assessed using a one-way 
ANOVA with post hoc testing was carried out using Tukey HSD. 
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Table 6.6 ppRNFL thickness in each 30
o 
sector in VGB-exposed individuals 
according to VAVFL classification 
ppRNFL area Normal visual 
fields 
(n=47) 
Mild VAVFL 
(n=18) 
Moderate/severe 
VAVFL 
(n=19) 
Temp sector thickness (µm) 47.3 47.3 46.3 
TS sector thickness (µm) 72.5 69.5 67.1 
ST sector thickness (µm) 125.5 110.3
x
 95.0
x
* 
Sup sector thickness (µm) 109.7 83.3
x
* 72.4
x
* 
SN sector thickness (µm) 89.4 69.2
x
* 53.2
x
*# 
NS sector thickness (µm) 79.6x 67.1x* 56.3
x
* 
Nas sector thickness (µm) 59.0 53.7 54.3 
NI sector thickness (µm) 60.8 57.6 50.4
x
* 
IN sector thickness (µm) 88.2 67.8
x
* 54.4
x
* 
Inf sector thickness (µm) 127.3 95.6
x
* 77.3
x
* 
IT sector thickness (µm) 119.6 111.7 97.2
x
* 
TI sector thickness (µm) 61.6 59.4 58.3 
ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; Temp = temporal; TS = 
temporal-superior; ST = superior-temporal; Sup = superior; SN = superior-nasal; NS = nasal-
superior; Nas = nasal; NI = nasal-inferior; IN = inferior-nasal; Inf = inferior; IT = inferior-
temporal; TI = temporal-inferior 
x
ppRNFL thickness significantly thinner compared to non-exposed individuals (p<0.05) 
*ppRNFL thickness significantly thinner compared to VGB-exposed with normal visual fields 
(p<0.05) 
#ppRNFL thickness significantly thinner compared to mild VAVFL (p<0.05) 
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Figure 6.3 Graph showing ppRNFL thickness across the 30
o 
sectors according 
to VAVFL Group 
 
 
Figure 6.3 legend: The pattern of ppRNFL thinning according to severity of VAVFL.  The 
ppRNFL is thinner in most areas with increasing severity of VAVFL.  The temporal areas show 
no change in ppRNFL thickness with severity of VAVFL. 
* Significant difference in ppRNFL thickness between non-exposed individuals and VGB-
exposed individuals with normal visual fields (p<0.05) 
x Significant difference in ppRNFL thickness between non-exposed individuals and VGB-
exposed individuals with mild VAVFL and moderate/severe VAVFL (P<0.05)  
# Significant difference in ppRNFL thickness between non-exposed individuals and VGB-
exposed individuals with moderate/severe VAVFL (P<0.05) 
● Significant difference in ppRNFL thickness between VGB-exposed individuals with mild 
VAVFL and VGB-exposed individuals with moderate/severe VAVFL (p<0.05) 
*
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ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; VAVFL = vigabatrin 
associated visual field loss; Temp = temporal; TS = temporal-superior; ST = superior-temporal; 
Sup = superior; SN = superior-nasal; NS = nasal-superior; Nas = nasal; NI = nasal-inferior; IN = 
inferior-nasal; Inf = inferior; IT = inferior-temporal; TI = temporal-inferior
 
 
6.3.3.1 VAVFL Groups compared to non-exposed  
The ppRNFL was significantly thinner in individuals with mild VAVFL and in 
individuals with moderate/severe VAVFL compared to non-exposed individuals in the 
ST, Sup, SN, NS, IN and Inf sectors (Table 6.6; Figure 6.3) and in individuals with 
moderate/severe VAVFL only in the NI and IT sectors.     
In VGB-exposed individuals with normal visual fields the ppRNFL was found to be 
significantly thinner in the NS sector compared to non-exposed individuals.  No 
differences were found for any other ppRNFL sectors in VGB-exposed individuals with 
normal visual fields compared to non-exposed individuals.   
There were no significant differences between any of the VAVFL Groups and the non-
exposed individuals in the Temp, TS, TI and Nas sectors.   
6.3.3.2 Inter-group comparison between VAVFL Groups 
Individuals with mild VAVFL and individuals with moderate/severe VAVFL, showed 
significantly thinner ppRNFL compared to VGB-exposed individuals with normal 
visual fields for the Sup, SN, NS, IN and Inf sectors.  Individuals with moderate/severe 
VAVFL also showed significantly thinner ppRNFL compared to VGB-exposed 
individuals with normal visual fields for the ST, IT and NI sectors.  The only difference 
seen between individuals with mild VAVFL and individuals with moderate/severe 
VAVFL was in the SN sector where the ppRNFL was significantly thinner in 
individuals with moderate/severe VAVFL (Table 6.6; Figure 6.3). 
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6.3.4 ppRNFL thickness across 256 scans in VGB-exposed and non-exposed 
For 71 VGB-exposed and 87 non-exposed participants, data were available to export the 
TSNIT profiles to a personal computer using Research Browser Software Version 5.0.  
A TSNIT profile for each group (VGB-exposed and non-exposed), was plotted from the 
256 individual ppRNFL thickness scans (Figure 6.4).   
A one-way between-groups multivariate analysis of variance was performed to 
investigate the effect of VGB exposure on ppRNFL thickness across 64 ppRNFL 
regions.  There was a statistically significant difference between VGB-exposed and non-
exposed individuals when all 64 ppRNFL were combined (F (64, 88) = 1.75, p = 0.008; 
Wilks’ Lambda = 0.44; partial eta squared = 0.56).  When each of the 64 ppRNFL areas 
were considered separately there was significant difference in 29 of the areas (Figure 
6.4 and Figure 6.5) using a Bonferroni adjusted alpha level of 0.0008 (379).  This 
included segments 10-14, 21-28 and 38-53 (Figure 6.4 and 6.5).  For comparison, the 
location of the 64 four-scan segments and the twelve 30
o 
sectors were mapped onto the 
same figure (Figure 6.5). 
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Figure 6.4 ppRNFL thickness across 256 scans for VGB-exposed and non-
exposed individuals   
  
Figure 6.4 legend: ppRNFL = peripapillary retinal nerve fibre layer; VGB = vigabatrin; T 
= temporal; S = superior; N = nasal; I = inferior 
Grey areas indicate significant ppRNFL thinning in VGB-exposed compared to non-exposed 
individuals (p<0.0008) 
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Figure 6.5 Distribution of ppRNFL thinning in the 64 four-scan segments 
 
Figure 6.5 legend: Distribution of 64 four-scan segments on a ppRNFL scan compared 
with the distribution of the 30
o
 sectors (bold outline). Red areas indicate segments showing 
significantly thinner ppRNFL in VGB-exposed composed to non-exposed individuals within the 
64 four-scan segments (p<0.0008). 
ppRNFL = peripapillary retinal nerve fibre layer; Temp = temporal; TS = temporal-superior; ST 
= superior-temporal; Sup = superior; SN = superior-nasal; NS = nasal-superior; Nas = nasal; NI 
= nasal-inferior; IN = inferior-nasal; Inf = inferior; IT = inferior-temporal; TI = temporal-
inferior 
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6.4 Discussion  
 
This is the first study using OCT to explore in detail patterns of ppRNFL thinning in 
VGB-exposed individuals.  Previous OCT studies have described patterns of ppRNFL 
thinning in a small number of individuals with VAVFL according to the 90
o
 quadrants 
provided in the manufacturers’ summary report (256). In the present study patterns of 
ppRNFL thinning were explored across the twelve 30
o
 sectors provided in the 
manufacturers’ summary report.  In addition, a novel ppRNFL thickness summary 
measure was created comprising 64 four-scan segments, across which patterns of 
ppRNFL thinning could be determined in smaller ONH areas.  Furthermore, patterns of 
ppRNFL thinning were determined according to cumulative VGB exposure and severity 
of VAVFL 
6.4.1 Patterns of ppRNFL thinning in VGB-exposed compared to non-
exposed individuals  
The ppRNFL was significantly thinner in VGB-exposed individuals compared to non-
exposed individuals in most of the 30
o 
sectors (Figure 6.6).  Only the Temporal, TI and 
Nasal 30
o
 sectors showed no difference in absolute ppRNFL thickness between the 
Groups (Figure 6.6).  In addition, in the TS sector there was no difference in the number 
of individuals showing ppRNFL thinning (i.e. ≤1st percentile of the manufacturers’ 
normative database) between the Groups (Figure 6.6).  The relative preservation of the 
temporal ppRNFL in VGB-exposed individuals is in agreement with previous studies 
(198;229;256;257). 
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Figure 6.6 Difference in ppRNFL thickness between VGB-exposed and non-
exposed individuals 
 
 
Figure 6.6 legend: (A) Red areas indicate 30
o 
sectors showing significant difference in 
absolute ppRNFL thickness between VGB-exposed and non-exposed (p<0.004).  (B) Red areas 
indicate 30
o 
sectors showing a significant difference in the percentage of individuals showing 
abnormal ppRNFL thickness (i.e. ≤1st percentile) according to the manufacturers’ normative 
database between VGB-exposed and non-exposed individuals (p<0.004).   
 
The ppRNFL was up to 18% thinner in VGB-exposed individuals compared to non-
exposed individuals in some 30
o
 sectors (SN, NS and IN), whilst in other 30
o
 sectors 
there was little difference in ppRNFL thickness between Groups.  In particular, the 
Nasal and Temporal 30
o
 sectors were only 1.2% and 3.7% thinner, respectively in the 
VGB-exposed Group compared to the non-exposed Group.  This suggests that there 
may be differential susceptibility of RGC to the retinotoxic effects of VGB, as some 
ppRNFL areas showed significant loss whilst others were relatively spared.  Of 
importance is the variation in ppRNFL thinning between adjacent 30
o 
sectors.  For 
example, the NS, Nasal and NI 30
o
 sectors all comprise the Nasal 90
o 
quadrant, yet the 
percentage difference in ppRNFL thickness between VGB-exposed and non-exposed 
individuals was dissimilar across these 30
o
 sectors.  The NS 30
o
 sector was the most 
affected sector with VGB-exposed individuals having a ppRNFL 18.1% thinner than 
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non-exposed individuals, whilst the adjacent Nasal sector was the least affected sector, 
with only a 1.2% difference between VGB-exposed and non-exposed individuals.  The 
NI sector showed a modest 10.4% difference in ppRNFL thickness between the two 
Groups (Table 6.4).  The variation in ppRNFL loss across adjacent sectors has a two-
fold importance.  Firstly, it suggests that ppRNFL thinning may occur in discrete areas, 
representing loss of distinct populations of RGC.  Secondly it suggests that analysis of 
summary measures (e.g. the 90
o quadrants) provided in the manufacturers’ summary 
reports, may be insufficient to detect subtle patterns of ppRNFL thinning, as adjacent 
areas of preserved ppRNFL thickness may mask any ppRNFL loss.          
6.4.2 ppRNFL thinning in non-exposed individuals    
An unexpected finding from this study was the high number of non-exposed individuals 
who showed ppRNFL thinning according to the manufacturers’ normative database.  
8% of individuals in Group 2 had an average ppRNFL thickness that fell within the ≤1st 
percentile, and 13.8% of individuals fell into the ≤ 5th–>1st percentile.  The significance 
of these findings is explored further in Chapter 7.  However, these results also have 
implications for the interpretation of the results in this study.  As ―epilepsy‖ may have 
an effect on ppRNFL thickness, all further discussion of the effect of VGB on ppRNFL 
thickness in VGB-exposed individuals is made in comparison to non-exposed 
individuals, rather than compared to healthy controls.   
6.4.3 Effect of cumulative VGB exposure on the pattern of ppRNFL 
thinning  
 
6.4.3.1 An early pattern of ppRNFL thinning 
A major concern for VGB treatment strategies is whether irreversible retinal damage 
can occur after a short period of VGB exposure (429).  This is a particular concern for 
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use of VGB as an anti-addiction medication (142), and for treatment of infantile spasms, 
where VGB may be used as first-line therapy.  In this study significant ppRNFL 
thinning was found in the NS sector in individuals with a cumulative VGB exposure of 
less than 1000 grams (average cumulative VGB exposure 351 grams), compared to non-
exposed individuals.  This was the only 30
o 
sector to show a significant difference in 
ppRNFL thickness between these Groups, and suggests that thinning in the NS ppRNFL 
area may provide an early indication of VGB retinotoxicity.   
It is uncertain why the ppRNFL in the NS 30
o 
sector may show thinning early in the 
course of VGB retinotoxicity.  The peripheral, concentric characteristics of VAVFL, 
and the circumferentially-diffuse RNFL atrophy detected by fundus photography, 
suggest that VGB-associated RGC loss occurs relatively uniformly in the retinal 
periphery.  There is no functional or structural evidence to suggest that RNFL loss 
associated with VGB toxicity is limited to, or defined by, RNFL bundles.  In fact, it is 
probably this characteristic of uniform, peripheral RNFL loss (198) that makes 
detection of RNFL atrophy difficult by direct observation, or photography (147), and 
why ophthalmoscopic features of VGB retinotoxicity are generally absent, even in some 
individuals with severe VAVFL (i.e. visual field less than 20
o
 eccentricity) (139;146).  
In primate models of traumatic optic nerve damage, it was demonstrated that RNFL 
defects were not detectable using fundoscopy if lesions led to less than 50% reduction 
in RNFL thickness (430).  If the lost RGC axons were grouped together, i.e. within a 
bundle, detection of RNFL atrophy was relatively easy.  However, if loss of RGC axons 
occurred in a circumferential pattern, not limited to RNFL bundles, detection was more 
difficult as a greater number of RGC would need to be lost to reach the threshold for 
detection (430).  In addition, diffuse RGC axon loss is more difficult to detect directly 
as areas of atrophic RNFL lack adjacent normal RNFL for comparison (431;432). 
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The mechanisms that may lead to preferential involvement of RGC projecting to the NS 
area of the ONH are unknown.  Variations in local retinal anatomy, physiology or 
pharmacology may make these cells and/or axons particularly susceptible to VGB 
toxicity.  Alternatively, RGC damage may be uniform throughout the retinal periphery, 
as is suggested from the characteristics of VAVFL, however, the NS ppRNFL area may 
receive a high proportion of peripheral RGC projections relative to central RGC 
projections, and thus proportionally more ppRNFL thinning occurs in this area early on. 
Of interest, no individuals with less than 1000grams cumulative VGB exposure showed 
a ppRNFL thickness in the NS sector that fell into what is considered to be the 
abnormal range (i.e. ≤1st percentile of the manufacturers’ normative database), and only 
four individuals showed borderline changes (i.e. ≤ 5th–>1st percentile) (Figure 6.2).  The 
range in normal ppRNFL thickness (i.e. ≤95th–>5th percentile of the manufacturers’ 
normative database) in the NS 30
o 
sector was wide in both VGB-exposed and non-
exposed individuals, with VGB-exposed individuals showing thickness ranging from 62 
– 100µm (Figure 6.2).  It is possible that small amounts of ppRNFL loss may occur 
early after VGB exposure but it may be difficult to detect this loss if relying on the 
manufacturers’ summary report percentiles to assess the data.  For example, in 
individuals with ppRNFL thickness in the NS on the upper-end of normal (e.g. > 100µm 
thick) significant ppRNFL loss in the NS sector (as much as 40% (or around 40µm) of 
the ppRNFL thickness), could occur before they would be considered to be showing 
borderline or abnormal changes in this sector.  Significant ppRNFL loss could have 
occurred in some of the individuals included in the <1000grams cumulative VGB 
exposure Group, however, the degree of ppRNFL atrophy was not considerable enough 
to be detectable using the normal percentiles.  In future studies using OCT in VGB-
exposed individuals, baseline assessments of ppRNFL thickness should be undertaken 
281 
 
and absolute changes in ppRNFL thickness should be monitored.  Using this technique 
it may be possible to detect early indications of VGB retinotoxicity, allowing well-
informed decisions to be made about the risk and benefits of continued VGB exposure.    
6.4.3.2 A progressive pattern of ppRNFL thinning 
In the present study a clear trend was seen for decreasing ppRNFL thickness with 
increasing VGB exposure (Figure 6.1).  However, after receiving a cumulative dose of 
more than 1000 grams (Groups II, III and IV) there was no significant difference in 
ppRNFL thickness at any of the 30
o 
sectors between Groups II, III and IV.  This was 
most noticeable between Group II and Group III where although the mean cumulative 
VGB exposure was more than 2000grams higher in Group III, the pattern and degree of 
ppRNFL thinning was similar to that in Group II (Figure 6.1).   
When each of the VGB exposure Groups comprised of individuals receiving >1000 
grams cumulative VGB exposure (Groups II, III and IV) were compared against Group 
I (<1000g cumulative VGB exposure), the pattern of ppRNFL thinning in each Group 
appeared to suggested a progressive pattern of ppRNFL thinning across the 30
o 
sectors,  
i.e. with increasing VGB exposure each Group showed ppRNFL thinning in the same 
30
o 
sectors as the previous Group, plus thinning in an additional combination of 30
o 
sectors (Figure 6.7).  Interestingly, the NS sector which was the only sector found to 
show ppRNFL thinning in Group I compared to non-exposed individuals did not show 
further significant ppRNFL thinning until >5000g cumulative VGB exposure (Group 
IV).  This could suggest that the RGC projecting to this ppRNFL area are susceptible to 
small amounts of VGB toxicity, yet the RGC that remain after the initial toxic insult are 
relatively insensitive to additional VGB exposure until later in the course of the toxicity.  
The reasons for this are unknown but may relate to differences in RGC size or subtype, 
or differences in the local retinal environment.  
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Figure 6.7 Difference in ppRNFL thickness in each 30
o 
sector between VGB 
exposure Groups 
 
 
Figure 6.7 legend: Red areas indicate 30
o 
sectors showing significant difference in 
absolute ppRNFL thickness between Groups (p<0.05).  (A) Group II compared to Group I.  (B) 
Group III compared to Group I.  (C) Group IV compared to Group I.  
 
Whilst this is by necessity a cross-sectional study, the implication is that ppRNFL 
thinning progresses with increasing cumulative VGB exposure (147;152).  This is in 
keeping with the earlier findings in this body of research that showed a progressive 
decrease in visual field size with continued VGB exposure over a ten-year follow-up 
period
31
.  ppRNFL thinning occurs early on in the NS sector, progressing to involve 
adjacent superior areas (Figure 6.7A), later involving the inferior nasal ppRNFL (Figure 
6.7B) and subsequently extending to involve more superior temporal areas (Figure 
6.7C).  It is important to note however, that the lack of significant difference in 
ppRNFL thickness seen between Groups II, II and IV (i.e. after >1000 grams 
cumulative VGB exposure) in any 30
o 
sector, suggests that progression may be slow 
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with further increases in cumulative VGB exposure, and may be difficult to detect 
particularly if baseline ppRNFL thickness data are not available.      
 
6.4.4 Effect of VAVFL severity on the pattern of ppRNFL thinning 
In VGB-exposed individuals with normal visual fields the ppRNFL was significantly 
thinner in the NS sector compared to non-exposed individuals (Figure 6.8A).  This is 
the same sector that was found to be significantly thinner in individuals who had less 
than 1000g cumulative VGB exposure, and adds further evidence that thinning in this 
ppRNFL sector may provide an early indication of VGB retinotoxicity, when VAVFL is 
clinically undetectable.  
 
Figure 6.8 Difference in ppRNFL thickness in each 30
o 
sector according to 
VAVFL classification 
 
Figure 6.8 legend: Red areas indicate 30
o 
sectors showing significant difference in 
absolute ppRNFL thickness compared to non-exposed individuals (Group 2) (p<0.05) 
(A) VGB-exposed individuals with normal visual fields compared to Group 2. (B) Individuals 
with mild VAVFL compared to Group 2.  (C) Individuals with moderate/severe VAVFL 
compared to Group 2  
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In this body of research it has already been demonstrated that average ppRNFL 
thickness correlates with visual field size (measured using MRD)
32
 in VGB-exposed 
individuals.  In the present study a pattern of ppRNFL thinning associated with the 
severity of VAVFL is suggested.  In individuals with mild VAVFL the pattern of 
ppRNFL thinning involves the superior and inferior poles of the ONH, extending into 
the nasal area and sparing the temporal aspect of the ONH, and involving the superior 
pole more extensively than the inferior pole (Figure 6.8B).  In individuals with 
moderate/severe VAVFL there was further involvement of the ppRNFL in the inferior 
pole, however the temporal aspect of the ONH is still relatively spared (Figure 6.8C).  
These findings suggest that in VGB-exposed individuals who are unable to undergo 
perimetry a combination of the average ppRNFL thickness and the pattern of ppRNFL 
thinning may be useful surrogate markers of the presence of and severity of VAVFL.  It 
is important to note that in a previous study of ppRNFL thickness in individuals with 
VAVFL thinning in the nasal 90
o
 quadrant was proposed as a bio-marker for VGB 
toxicity (256).  However, in this body of  work, nasal quadrant ppRNFL thinning was 
not present in more than 40% of individuals with VAVFL
33
.  In the present study, the 
extreme nasal area (Nasal 30
o 
sector) does not appear to be preferentially susceptible to 
VGB toxicity, but thinning occurs predominantly in the nasal aspect of the superior and 
inferior poles, indicating that nasal quadrant attenuation may not be a suitable marker 
for VGB toxicity.  
Exploration of the significance of subtle ppRNFL thinning after low VGB exposure and 
in VGB-exposed individuals with normal visual fields was limited by the cross-
                                                          
32
 Chapter 4 
33
 Individuals were assess n the same OCT model as those included in the study reporting that 100% of 
individuals with VAVAL had ppRNFL thinning in the nasal 90
o 
quadrant (See Chapter 4) 
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sectional nature of this study.  Prospective longitudinal studies are needed to explore the 
evolution of ppRNFL loss and to establish whether subtle patterns of ppRNFL thinning, 
(particularly in the NS sector), after low doses of VGB, provide early predictors of 
which individuals will go on to develop VAVFL with continued VGB exposure.   There 
is particular scope for such prospective studies currently within the United States where 
the Food and Drug Administration have recently approved VGB for use as a first-line 
therapy for infantile spasms, and as add-on therapy for adults with drug-resistant 
complex partial seizures (263;433).   
6.4.5 Analysis of 64 four-scan segments  
In this study it was noted that the ppRNFL in adjacent 30
o 
sectors showed variable 
susceptibility to VGB toxicity.  For example, the NS sector showed significant thinning 
in VGB-exposed individuals with normal visual fields, and in individuals with small 
cumulative VGB exposure.  In addition, the NS sector showed the largest difference in 
ppRNFL thickness in VGB-exposed compared to non-exposed individuals, with a mean 
ppRNFL thickness 18% thinner in VGB-exposed individuals.  Conversely the adjacent 
Nasal 30
o 
sector did not show significant ppRNFL thinning in any analysis performed, 
even in individuals with more than 5000g cumulative VGB exposure and 
moderate/severe VAVFL.  In addition, the mean Nasal ppRNFL thickness was only 
1.2% thinner in VGB-exposed compared to non-exposed individuals.     
It is possible that analysis of summary parameters, such as 90
o 
quadrants or 30
o 
sectors, 
may obscure or underestimate true areas of ppRNFL thinning (360) due to contributions 
from adjacent normal ppRNFL thickness.  Therefore, the 256 ppRNFL scans that 
comprise the circle of ppRNFL thickness data were analysed independently of the 
manufacturers arbitrarily-divided output. Although the 64 sectors are also arbitrarily 
defined, they represent much smaller areas of the ONH than the twelve 30
o 
sectors so it 
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is more feasible that relevant areas of ppRNFL thinning may be found.  Ideally the 
analysis would explore ppRNFL thickness in each of the 256 scan locations.  However, 
this would require a much larger dataset to provide adequate power to detect significant 
differences.  Significant ppRNFL thinning was found in VGB-exposed compared to 
non-exposed individuals in 29/64 of the four-scan segments (Figure 6.4).  When aligned 
with the 30
o
 sectors, most of the abnormal 29 four-scan segments did not occupy the 
entire extent of the 30
o
 sectors (Figure 6.4).  This suggests that if discrete areas of 
ppRNFL thinning occur within a 30
o 
sector, it may go undetected if neighbouring areas 
within the same 30
o 
sector are relatively preserved.  This may contribute to the finding 
in the present study that although the absolute ppRNFL was significantly thinner in the 
NS 30
o 
sector in individuals with less than 1000grams cumulative VGB exposure, the 
ppRNFL thickness was still classified as being within the normal limits (i.e. within the 
≤95th–>5th percentile of the manufacturers’ normative database) (Figure 6.2).       
In the 64-segment analysis, preservation of the temporal area was found (Figure 6.4).  In 
the inferior pole the pattern of thinning was comparable to that which was seen in VGB-
exposed individuals after analysis of the 30
o 
sectors.  Thinning in the superior pole was 
also found.  However, the extreme superior aspect was spared with thinning 
demonstrated in the temporal-superior and nasal-superior areas.  In agreement with the 
findings from the 30
o
sector analysis, the most nasal aspect, and part of the nasal-inferior 
area, were unaffected (Figure 6.4).  This dataset was too small to undertake the 64 four-
scan segment analyses according to VGB exposure or severity of VAVFL.  Further 
large studies are needed using this detailed analysis to determine if subtle changes in 
ppRNFL do occur after low VGB exposure.    
Use of a smaller scan segments, such as the 64 four-scan segments described in this 
study, in the analysis of ppRNFL thinning, may prove useful in other diseases.  For 
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example, in glaucoma, small wedge-shaped defects in the RNFL are common (434) and 
may not be detected by analysis of the manufacturers’ arbitrarily-defined 30o sectors or 
90
o 
quadrants (360).  Recently Leung et al. used the RNFL thickness deviation map 
provided in the Cirrus HD-OCT to characterise the pattern of RNFL defects in 
glaucoma, outside of the constraints of the manufacturers’ summary reports (360).  
They found that the most common area of RNFL loss was in the inferio-temporal ONH 
area, between 270
o 
and 288
o 
(where 0
o 
is the temporal horizontal meridian).  This area 
between 270
o 
and 280
o straddles two of the manufacturers’ 30o sectors, the inferior and 
IT sectors, which occupy 255-285
o 
and 285-315
o
, respectively.  Thus, analysis of the 
30
o 
sectors to assess the integrity of the ppRNFL thickness may not reveal ppRNFL 
thinning until much later in the course of the disease, as areas of intact ppRNFL may 
mask areas of ppRNFL atrophy within a 30
o 
sector.          
6.4.6 Pattern of ppRNFL thinning is in keeping with peripheral retinal 
pathology 
It is suggested that the peripheral retina is particularly susceptible to VGB toxicity 
(84;101;216).  The characteristics of VAVFL are of a peripheral and concentric visual 
field loss, with sparing of the central visual field, visual acuity and colour vision.  
Studies of animals exposed to VGB have described retinal changes that are commonly 
confined to the peripheral retina (64;238;243).  In addition the only human pathological 
study of the retina and optic nerve from a VGB-exposed individual described severe 
loss of RGC in the peripheral retina, with relative sparing of cells in the central retina 
(162).  Studies using wide field multifocal ERG, have suggested that retinal 
electrophysiological abnormalities are not diffuse, but are localised to areas of VAVFL 
in the peripheral retina (103).   
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The pattern of ppRNFL thinning described in the present study is in keeping with the 
proposed peripheral retinal pathology associated with VGB retinotoxicity and the 
characteristics of VAVFL.  RGC axons entering the temporal aspect of the ONH, which 
were found to be spared in analysis of all VGB-exposed Groups are those from RGC in 
the fovea, extrafoveal area and caecocentral area which are responsible for central 
visual function.  Conversely, RGC in the peripheral temporal retina, representing the 
peripheral nasal visual field, take an increasingly arcuate course to enter the ONH at the 
superior and inferior poles (247-249), those which were found to show ppRNFL 
thinning in VGB-exposed individuals.  Axons from RGC in the nasal retina (including 
the nasal periphery) which represent the temporal visual field take a radial trajectory 
and enter the ONH on the nasal side (247-249). 
6.4.7 Discussion of possible mechanisms of VGB-associated ppRNFL 
thinning with reference to the pattern of ppRNFL thinning 
 
6.4.7.1 RGC size  
Susceptibility of RGCs to VGB toxicity has been suggested to be dependent on the 
length of the non-myelinated segment of the RGC axon (147).  Frisen et al. proposed 
that long RGC axons are preferentially susceptible to VGB toxicity, and in severe 
RNFL atrophy only RGC with short axons projecting to the central retina remain (147).  
Whilst this theory in part fits the pattern of atrophy seen in VAVFL, it is not entirely 
compatible with our understanding of RGC projections.  Short axons are found around 
the entirety of the ONH projecting from RGC in the peripapillary area (247;435).  If 
toxicity were dependent on length of unmyelinated axon, the ensuing visual field defect 
would be centred on the ONH (physiological blind spot), as short RGC axons were 
preserved. The pattern of visual field loss in severe VAVFL does not suggest that this is 
the case.  As part of the work carried out for this study severe cases of VAVFL were 
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observed with only 10
o
 of central vision remaining, and in which the scotoma 
encompasses peripapillary visual function.   
The pattern of ppRNFL thinning described in this study may indicate that susceptibility 
to VGB toxicity is related to the size of the RGC apparatus, and may be explained by 
regional variations in RGC characteristics and subtypes.  In the non-human primate, 
RGC can be divided into two main classes based on size.  The most numerous are the 
smaller P-cells (projecting to the parvocellular layers of the lateral geniculate nucleus 
(LGN)).  Larger M-cells (projecting to the magnocellular layers of the LGN) comprise 
around 10% of the RGC population (230).  RGC are not uniform throughout the retina.  
In the central retina proportionally more RGC are P-cells (230).  RGC bodies are small 
(436-438), and densely-packed (423;436), with compact dendritic fields (439) and small 
axon diameters (440).  With increasing eccentricity all of these attributes increase in 
size, so that in the peripheral retina RGC have larger cell bodies with expansive 
dendritic fields and larger axons (436-440).  The majority of M-cells are found in the 
retinal periphery (230).  Susceptibility of RGC with large cell bodies, dendritic fields or 
axon diameters to VGB toxicity would result in loss of peripheral RGC, with sparing of 
small cells in the central retina.  This pattern of loss of RGC would lead to the 
characteristic peripheral visual field defect seen in VAVFL and would result in a pattern 
of ppRNFL thinning as described in this study.   
Other regional differences in RGC characteristics have also been described. In the 
periphery, RGC soma sizes are smaller, and more densely-packed, in the nasal than in 
the temporal hemiretina at corresponding eccentricities (423;436;439).  Greater 
susceptibility to VGB toxicity of larger RGC in the temporal periphery compared to the 
smaller RGC in nasal periphery, would be in agreement with the reported nasal 
predominance of VAVFL which has been reported by some groups (81;97;126).  In the 
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nasal hemiretina, RGC along the nasal horizontal meridian compose the visual streak 
(423;436).  Here RGC bodies are smaller (436) and more densely-packed (423;436) 
than RGC in the non-visual streak nasal retina.  We found that axons projecting to the 
most nasal aspect of the ONH, (i.e. the Nas sector), were not affected by VGB exposure.  
The extreme nasal aspect of the ONH may be predominantly occupied by axons of RGC 
in the visual streak, which may be less susceptible to VGB toxicity due to their small 
size. 
Susceptibility of RGC to injury based on size has been shown in several disease models 
(441).  In animal models of glaucoma, RGC with large cell bodies showed an increased 
susceptibility to high intraocular pressure compared to RGC with small cell bodies 
(442-445).  Furthermore, large RGC have been found to be selectively damaged in 
humans with glaucoma (398).  In addition, large RGC have been shown to be more 
susceptible to neurotoxic injury (446;447).  The mechanisms of selective RGC death is 
unknown, but may be related to differences in expression of receptors that may be 
stimulated by neurotoxic factors (445). For example, in an animal model of ocular 
hypertension, large RGCs expressing the NMDA receptor NR1 subunit were 
preferentially lost compared to RGCs expressing AMPA receptor GluR 2/3 subunits, 
suggesting that glutamate excitotoxicity may differentially affect cells expressing 
specific receptor subtypes (445).  Susceptibility of large RGC in the peripheral retina 
may be related to differences in the expression of neurotransmitter receptors and 
transporters compared to small RGC in the central retina, resulting in differential 
susceptibility to VGB toxicity.  Alternatively differences in axonal transport and repair 
mechanisms in some RGC may make them more susceptible injury (448).    Particular 
RGC subtypes may account for this.  Frisen et al. suggested that that RGC with large 
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axons may be more susceptible to VGB toxicity due to their larger surface area and thus 
greater potential exposure to VGB (147). 
6.4.7.2 Müller cell density 
An alternative pathological-mechanism that could account for the peripheral pattern of 
RGC loss after VGB exposure could be related to Müller cell dysfunction (101;216).  
Several groups have suggested that Müller cell dysfunction may play a significant role 
in the mechanisms leading to VAVFL (101;150;216;449). Müller cells are the principal 
glial cells of the human retina.  After endogenous release, GABA is transported into 
Müller cells via the high affinity GABA transporters, GAT-3 and GAT-1 (233).  Once 
inside the Müller cell, GABA is rapidly metabolised by the mitochondrial enzyme 
GABA-T (237).  Due to the efficiency of this reaction, in healthy conditions Müller 
cells contain very low levels of intracellular GABA (26), and in retinal sections from 
healthy animals GABA is undetectable in Müller cells using immunhistochemical 
techniques (26;234;237;450).  However, after exposure to VGB, which irreversibly 
inhibits GABA-T, retinal sections from rats showed significant GABA-
immunoreactivity in Müller cells, demonstrated as vertical streaks of staining extending 
through the depth of the retina to the ELM (234).  The prominent Müller cell GABA-
immunoreactivity seen in VGB-exposed animals suggests that the inhibition of GABA-
T leads to abnormal accumulation of GABA in these cells (234).  In further support of 
this, VGB was found to accumulate in Müller cells in the peripheral retina in VGB-
exposed non-human primates (451).  
Differences in Müller cell density in the peripheral and central retina may account for 
the increased susceptibility of peripheral RGCs to VGB toxicity (101).  In mammals, 
Müller cell density in the central retina is around 9000-17000 cells per mm
2
 (452), with 
densities of up to
 
30,000 Müller cells per mm
2 
in the parafoveal area in some species 
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(453).  In the peripheral retina, Müller cell densities are much lower and are between 
5000-8000 cells per mm
2 
(452;453).   
Presuming that VGB is equally distributed across the retina and is taken uniformly into 
Müller cells regardless of eccentricity, the inhibitory effects of VGB on GABA-T 
should lead to less accumulation of GABA in Müller cells in the central retina where 
cell numbers are higher, compared to in the periphery where cell numbers are 
comparatively low (101).  In the peripheral retina where Müller cell density is low, 
VGB may inhibit a high proportion of the available GABA-T.  Any remaining GABA-T 
that has not been inhibited by VGB may be unable to sufficiently metabolise GABA, 
resulting in accumulation within the Müller cell.  In the central retina where Müller cell 
density is high, proportionally less GABA-T may be inhibited by VGB, leaving higher 
levels of active GABA-T able to metabolise the available GABA, and preventing 
accumulation within the Müller cell.     
Chronic accumulation of GABA in the Müller cell may result in it becoming 
dysfunctional (216;449).  In agreement with this, increased Müller cell GFAP 
expression has been reported in animals exposed to VGB (240-242).  In some animals 
this was most notable in the peripheral retina (236;238) where other pathological retinal 
abnormalities were localised.  Up-regulation of Müller cell GFAP is a sensitive marker 
of retinal injury (454), and further suggests that Müller cells may be implicated in 
mechanisms of VAVFL.   
Müller cell dysfunction after VGB exposure is supported by human electrophysiological 
data.  In VGB-exposed individuals, a reduction in the amplitude of the b-wave of the 
electroretinogram, which reflects combined Müller cell and bipolar cell function, has 
been demonstrated (101;104;120;138;150;154;196). Furthermore, the b-wave amplitude 
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reduction persists even after VGB withdrawal (150;151;153).  In addition, of all retinal 
electrophysiological measures, the reduction in the b-wave amplitude has most 
consistently been shown to be correlated with the severity of VAVFL 
(105;109;135;150;151).   
Although Müller cell dysfunction would not result in visual field loss itself (216), it may 
lead to loss of RGC by increasing their susceptibility to toxic stimuli (454).  Müller 
cells are important regulators of the extracellular environment and supply metabolites 
and neurotrophic factors to retinal cells (26;450) including RGC (455).  In addition, in 
experimental studies Müller cells have been found to protect RGC from glutamate 
excitotoxicity (456-459), hypoxia (459) and optic nerve injury (460), probably through 
uptake and metabolism of toxins and releases of neurotrophic factors (460).  Müller cell 
dysfunction, as a consequence of GABA accumulation, may lead to RGC death (101).  
This could result from the lack of normal regulation of the RGC extracellular 
environment by the Müller cell.  For example, Müller cells are also involved in 
glutamate uptake after synaptic release from bipolar cells and clearance of glutamate 
from the synaptic cleft by Müller cells is essential for the prevention of glutamate 
excitotoxicity (461). Impairment of normal glutamate uptake by Müller cells may result 
RGC death (462).  RGC death as a consequence of glutamate excitotoxicity has 
implicated in glaucoma (463) and retinal hypoxia/ischemic (464) although this is 
controversial (465;466).  In addition, under continued exposure to toxic or injurious 
conditions Müller cells may undergo gliotic changes, which may be associated with 
enhancing vulnerability of RGC to injury and induce RGC death, by release of 
cytokines (e.g. tumour necrosis factor-alpha (454;467;468)). 
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6.4.8 Summary  
The ppRNFL is significantly thinner in VGB-exposed individuals compared to non-
exposed individuals in a pattern consistent with the reported peripheral retinal pathology 
and the peripheral, concentric characteristics of VAVFL.  After VGB exposure, 
ppRNFL thinning involves the superior and inferior poles of the ONH with relative 
sparing of the temporal and extreme nasal aspect of the ppRNFL.  The pattern of 
ppRNFL thinning described in this study may reveal more about the mechanisms of 
VGB retinotoxicity.  Differences in RGC size and/or Müller cell density may lead to 
differences in suggestibility between the peripheral and central retina to VGB toxicity.    
ppRNFL thinning  in the NS 30
o
 sector may occur early after VGB exposure in 
individuals with normal visual fields.  With increasing VGB exposure ppRNFL thinning 
may progress to involve RGC projections in the superior and inferior poles of the ONH.     
Caution should be exercised when exploring patterns of ppRNFL thinning according to 
the manufacturers’ arbitrarily-defined 30o sectors and 90o quadrants which may obscure 
or underestimate true areas of thinning.  Use of smaller scan segments, such as the 64 
four-scan segments described in this study, in the analysis of ppRNFL thinning, may 
prove a useful tool for understanding patterns of ppRNFL thinning in VGB 
retinotoxicity and other disease involving RGC loss.  Prospective longitudinal studies 
are needed to explore the evolution of ppRNFL thinning with continued VGB exposure 
and its relationship to the development of VAVFL.  In addition, larger (possibly cross-
centre) studies would enable analysis of ppRNFL thickness based on individual A-scan 
data, as opposed to using arbitrarily-defined ONH regions. 
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Chapter 7  ppRNFL thickness in individuals with 
epilepsy not exposed to vigabatrin   
 
7.1 Introduction  
 
In recent years there has been a resurgence of interest in studying the retina as a window 
to the brain and neurological disease processes (469-471).  The retina has been 
described as an ―outgrowth of the brain‖, and during development is formed by an optic 
outgrowth of the diencephalon.  Thus pathological changes in the brain parenchyma 
may also be present in the retina.  For example, one of the pathological hallmarks of 
Alzheimer’s disease includes the accumulation of β-amyloid protein in the brain.  
Recently, in a mouse model of Alzheimer’s disease, β-amyloid immunereactive plaques 
were detected in the retina, most prominently in the RGC layer (472).  In addition RGC 
degeneration has been described in retinas from individuals with Alzheimer’s disease 
(473).  Thus the retina provides a unique window into the CNS, as unmyelinated axons 
(RGC axons in the RNFL) can be viewed easily and non-invasively using a variety of 
imaging techniques.  In particular, imaging of the ppRNFL using OCT has been 
explored in several neurological diseases (474;475).  Thinning of the ppRNFL has been 
reported in individuals with Alzheimer’s disease (476;477), Parkinson’s disease (478), 
Friedreich’s ataxia (479), migraine (480), cerebral autosomal dominant arteriopathy 
with subcortical leukoencephalopathy (CADASIL) (481) and multiple sclerosis (with 
and without optic neuritis) (369;482).  In individuals with multiple sclerosis, ppRNFL 
thickness correlated with disability scores, which included non-visual functions (e.g. 
motor function) (483), suggesting that in MS, damage to CNS white matter may be 
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detected by imaging of the ppRNFL (484).  It is suggested that OCT imaging of the 
retina may provided insights into neurological disease pathogenesis, and ultimately may 
provide biomarkers for disease progression, and possibly for neuroprotection in clinical 
trials.  In fact, OCT imaging has been incorporated into a number of large neurological 
clinical trials that will take place over the next decade (475).   
Whilst several studies have explored ppRNFL thickness in individuals with epilepsy 
exposed to VGB (119;229;256;257), only one study has looked at individuals with 
epilepsy not exposed to VGB (260).  In a study by Lobefalo et al. no difference was 
found in the ppRNFL between individuals with epilepsy (n=45) and age-matched 
healthy controls.  The individuals included in the study were adolescents (age 11-18 
years) with newly-diagnosed epilepsy and monotherapy with either carbamazepine or 
valproic acid for one year duration.  In disagreement with the findings by Lobefalo et al. 
abnormal ppRNFL thinning has been described in non-exposed control populations in 
OCT studies of VAVFL (229;256).  In the individuals with epilepsy not exposed to 
VGB (Group 2) included in the present study, 9% showed abnormal average ppRNFL 
thinning and 13.8% showed borderline changes
34
.  
In individuals with epilepsy, ppRNFL thinning may be associated with certain clinical 
features or prognostic factors.  Understanding factors associated with ppRNFL thinning 
in non-exposed individuals may also help to identify risk factors for VAVFL.    
7.1.1 Aims 
The aim of this study was to determine if individuals with epilepsy not exposed to 
vigabatrin show ppRNFL thinning compared to healthy individuals.  Furthermore, the 
study will explore factors that may contribute to ppRNFL thinning. 
                                                          
34
 See Chapter 6 
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7.2 Methods 
 
7.2.1 Patients 
Non-exposed individuals with epilepsy (Group 2) and healthy controls (Group 3) were 
included in the analysis. 
7.2.2 OCT 
All OCT ppRNFL imaging was carried out using SD-OCT. 
 
7.3 Results 
 
OCT ppRNFL data were available for 87 individuals with epilepsy not exposed to VGB 
(Group 2) and 90 healthy controls (Group 3). 
7.3.1 ppRNFL thickness in non-exposed individuals with epilepsy 
compared to healthy individuals 
Average ppRNFL thickness was significantly thinner in Group 2 compared to Group 3 
(88.8µm and 94.4µm respectively; p < 0.001; Table 7.1).  The superior, inferior and 
temporal quadrants were significantly thinner in Group 2 compared to Group 3 (p<0.05; 
Table 7.1) 
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Table 7.1 Average ppRNFL thickness and ppRNFL thickness in each of the 90
o 
quadrants in Group 2 and Group 3 
ppRNFL area  Group 2 
N = 87 
Group 3 
N = 90 
Group 2 
Percentage 
showing 
ppRNFL 
thinning
a
  
Group 3 
Percentage 
showing 
ppRNFL 
thinning
a 
≤1st ≤ 5th–
>1
st
 
≤1st ≤ 5th–
>1
st
 
Average thickness 
(±SD) (µm)  
88.8 (±10.9)* 94.4 (±8.8) 8.0 13.8 0 4.5 
Superior thickness 
(±SD)  (µm) 
108.8 (±16.4)* 115.9 (±13.9) 10.3 8.0 1.1 1.1 
Nasal thickness 
(±SD) (µm) 
70.4 (±12.2) 73.8 (±10.6) 2.3 3.4 0 0 
Inferior thickness 
(±SD) (µm) 
113.9 (±18.5)* 122.8 (±14.4) 10.3 13.8 0 1.1 
Temporal thickness 
(±SD)  (µm) 
62.1 (±9.2)* 65.2 (±10.2) 2.3 2.3 0 3.4 
Group 2 = non-exposed individuals; Group 3 = healthy individuals 
ppRNFL = peripapillary retinal nerve fibre layer;  
*ppRNFL significantly thinner in Group 2 compared to Group 3 (P<0.05) 
 
7.3.2 Clinical features associated with ppRNFL thinning in non-exposed 
individuals with epilepsy 
For individuals in Group 2, independent samples T-tests were used to explore 
differences in ppRNFL thickness according to clinical and demographic features.  There 
was no effect of gender, smoking, history of febrile seizures or drug resistance on 
ppRNFL thickness (p>0.05; Table 7.2).  The ppRNFL was significantly thinner in 
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individuals with learning disability compared to individuals without learning disability 
(p=0.015; Table 7.2) 
 
Table 7.2 Mean average ppRNFL thickness in Group 2 according to clinical features 
 Average ppRNFL thickness (µm) (±SD) 
Sex Male Female 
 87.1 (± 12.0) 90.0 (± 10.2) 
 Yes No 
Smoker  89.2 (± 9.9)  87.4(± 12.4) 
 
Drug-resistance 86.6 (± 11.5)  91.1 (± 10.5)  
Learning disability 81.7 (± 9.9)* 89.1 (± 11.1)  
History of febrile seizures  85.6 (± 8.1)  88.3 (± 11.3)  
*ppRNFL significantly thinner in individuals with learning disability P = 0.015 
 
7.3.3 History of neurosurgery and ppRNFL thickness  
8/87 Individuals had undergone neurosurgery.  Seven of theses were temporal lobe 
resections and one was an excision of a parietal haemagioma.  ppRNFL thickness was 
compared between individuals who had undergone and those who had no history of 
neurosurgery.  No significant difference in average ppRNFL thickness, or ppRNFL 
thickness in any the 90
o
 quadrants was found between the two groups, although there 
was a trend for decreased ppRNFL thickness in the inferior quadrant of individuals who 
had undergone neurosurgery (p>0.05) (Table 7.3).   
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Table 7.3 ppRNFL thickness in Group 2 individuals with a history of neurosurgery 
compared to individuals with no history of neurosurgery 
ppRNFL area History of neurosurgery 
Yes  
(N=8) 
No 
(N=79) 
Average thickness (±SD) (µm) 87.1 (±9.3) 89.0 (±11.1) 
Temporal thickness (±SD)  (µm) 61.3 (±8.4) 62.2(±9.3) 
Superior thickness (±SD)  (µm) 110.3 (±19.1) 108.7 (±16.2) 
Nasal thickness (±SD) (µm) 69.0 (±9.8) 70.6 (±12.4) 
Inferior thickness (±SD) (µm) 107.6 (±19.2) 114.5 (±18.5) 
 
7.3.4 Epilepsy type and ppRNFL thickness  
Individuals with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with 
HS) (N=20) were compared with individuals with partial epilepsy of unknown cause 
(N=31) (Table 7.4).  There was no significant difference in average ppRNFL thickness.  
The ppRNFL was significantly thinner in the inferior quadrant in individuals with 
MTLE with HS compared to individuals with partial epilepsy of unknown cause 
(p=0.025; Table 7.4).  Individuals with other epilepsy types included those with 
malformation of cortical development (N=11) and ―other‖ types (including angioma or 
vascular malformation, stroke, infection, neurocutaneous syndromes, tumour and 
trauma) (N=25).  These individuals were not included in the analysis due to the small 
numbers of individuals within each group.    
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Table 7.4 ppRNFL thickness in Group 2 individuals with MTLE with HS compared 
to individuals with partial epilepsy of unknown cause 
ppRNFL area MTLE with HS 
(N = 20) 
Partial epilepsy of 
unknown cause 
(N = 31) 
Average thickness (±SD) (µm)  84.4 (±9.2) 89.4 (±9.6) 
Superior thickness (±SD)  (µm) 104.5 (±17.1) 109.6 (±12.4) 
Nasal thickness (±SD) (µm) 66.4 (±8.5)  70.2 (±11.7) 
Inferior thickness (±SD) (µm) 104.9 (±17.6)* 117.2 (±17.9) 
Temporal thickness (±SD)  (µm) 63.3 (±10.3) 58.3 (±12.4) 
ppRNFL = peripapillary retinal nerve fibre layer; MTLE + HS = Mesial temporal lobe epilepsy 
with hippocampal sclerosis 
*ppRNFL significantly thinner in HS compared to cryptogenic P = 0.025 
 
7.3.5 Age and duration of epilepsy and ppRNFL thickness  
There was no correlation between age and average ppRNFL thickness (p=0.071) or age 
of epilepsy onset and average ppRNFL thickness (p=0.281).  There was a weak 
correlation between duration of epilepsy and average ppRNFL thickness (r=-0.24; 
p=0.025; Figure 7.1).  However, this was not found to be significant after controlling for 
age (p=0.15).  
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Figure 7.1 Scatter plot of average ppRNFL thickness and duration of epilepsy 
 
Figure 7.1 legend: There was a weak correlation between ppRNFL thickness and duration 
of epilepsy (r=-0.24; p=0.025; N=87) which was not found to be significant after controlling for 
age (p=0.15). 
 
7.3.6 Antiepileptic drug exposure  and ppRNFL thickness  
There was no effect of exposure to any antiepileptic drug, (excluding vigabatrin), on 
ppRNFL thickness (p>0.05). No correlation was found between number of drugs used 
and mean ppRNFL thickness (r=-0.153, p=0.15). 
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7.4 Discussion  
 
To my knowledge, this is the largest study to explore ppRNFL thickness in individuals 
with epilepsy not exposed to vigabatrin, and the first to explore clinical factors 
associated with ppRNFL thinning.  We found that the ppRNFL is significantly thinner 
in individuals with epilepsy not exposed to VGB compared to age-matched healthy 
controls. 8.0% of individuals had average ppRNFL thickness that fell into the abnormal 
range, and 13.8% showed borderline changes, according to the manufacturers’ 
normative database.   
The findings from this study are in disagreement with the only other study of ppRNFL 
thickness in non-exposed individuals with epilepsy.  In a study by Lobefalo et al. there 
was no difference in ppRNFL thickness in any of the four 90
o
 quadrants compared to 
age-matched healthy controls (260).  The population included in the study by Lobefalo 
was dissimilar to the one included in this study (Table 7.5).  In the study by Lobefalo, 
individuals had newly diagnosed epilepsy and exposure to only one AED (either 
carbamazepine or valproate monotherapy) for one year.  In comparison, the population 
included in this study had exposure to between 1 and 15 AEDs and had a mean duration 
of epilepsy of 24 years Table 7.5).  No further clinical details of the subjects epilepsy 
were provided in the study by Lobefalo et al. so we are unable to compare the 
populations on other clinical characteristics.   
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Table 7.5 Comparison of characteristics of individuals included in the study by Lobefalo et 
al. and the present study 
 Lobefalo et al. (260) 
(N=45) 
This study 
(N=89) 
Age (years) [range] 15.7 [11-18] 37.3 [18-70] 
Mean duration of 
epilepsy (years) [range] 
1 [1] 24 [3-58] 
Mean number of AEDs 
exposed to [range] 
1 [1] 6 [1-15] 
AEDs exposed to  CBZ, VPA ACE, ACTH, CBZ, CDP, 
CLB, CLN, ETS, FBM, GBP, 
LAC, LEV, LTG, OXC, PB, 
PHT, PGB, PMD, TGB, TPM, 
VPA, ZNS 
AED = antiepileptic drug; ACE = acetazolamide; ACTH = adrenocorticotrophic hormone; CBZ 
= carbamazepine; = CDP = chlordiazepoxide; CLB = clobazam; CLN = clonazepam; ETS = 
ethosuximide; FBM = felbamate; GBP = gabapentin; LAC = lacosamide; LEV = levetiracetam; 
LTG = lamotrigine; OXC = oxcarbazepine; PB = phenobarbital; PHT = phenytoin; PGB = 
pregabalin; PMD = primidone; TGB = tiagabine; TPM = topiramate; VPA = valproate; ZNS = 
zonisamide;  
 
In agreement with this study, Lawthom et al. reported that 3/12 non-exposed individuals 
with epilepsy had a ppRNFL thickness that fell into the abnormal range (i.e. ≤5th 
percentile of the manufacturers’ normative database) in at least one 90o quadrant, 
although all individuals showed normal average ppRNFL thickness.  The authors 
postulated that the ppRNFL thinning in these individuals may be due to transynaptic 
retrograde degeneration because of long-standing cerebral lesions.  However, they say 
that in an unpublished study of nine individuals with visual field defects from cortical 
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lesions, ppRNFL thickness was normal suggesting that trans-synaptic degeneration is 
not present, or is not identifiable using OCT.  The authors concluded that the 
abnormalities probably arose due to misalignment of the subject or scan circle during 
the ppRNFL scanning procedure (256). 
The reasons for ppRNFL thinning in individuals with epilepsy not exposed to VGB are 
uncertain.  Atrophy of the optic nerve was found to be common in children presenting 
with their first unprovoked seizure, however in most cases this was thought to be related 
to neonatal birth injury (485).  To my knowledge, the occurrence of optic atrophy in 
adults with epilepsy has not been explored.   
7.4.1 Mechanisms of ppRNFL thinning in individuals with epilepsy  
The cell  body and proximal unmyelinated portion of the RGC axon lie within the 
retina, YET, MOST of the RGC axon is located outside the globe forming the 
intraorbital, intracanalicular and intracranial portions of the optic nerve, the optic 
chiasm and optic tract (230).  More than 80% of RGC axons terminate in the lateral 
geniculate neucleus (LGN) of the thalamus, where they make synaptic connections with 
LGN relay neurones that project to the striate cortex.  The projections to the striate 
cortex comprise the optic radiation (genicuolstriate fasciculus).  Damage to any part of 
the visual pathway from the RGC body to the striate cortex could result in RNFL 
thinning detectable using OCT imaging.  For example, in VGB-exposed individuals, 
primary or secondary toxic effects of elevated retinal VGB and/or GABA my lead to 
RNFL thinning due to RGC damage at the level of the retina (101)
35
.  Conversely, 
RNFL thinning can also occur as a result of retrograde-transynaptic degeneration of 
RGC after lesions involving the occipital lobe (295;419;420).  Some of the possible 
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causes of ppRNFL thinning seen in non-exposed individuals with epilepsy in the 
present study are discussed here. 
7.4.2  ppRNFL thinning as a result of retinotoxicity 
In this study, no association was found between ppRNFL thinning and exposure to any 
particular AED.  However, AEDs are commonly associated with retinal 
electrophysiological and visual functional abnormalities (176).  After the initial reports 
of VAVFL, concerns were raised as to whether retinotoxicity was a class effect of 
GABAergic drugs.  Early reports of visual field loss associated with exposure to 
tiagabine (486;487), a GAT-1 blocker, led to further concerns.  However, subsequent 
studies showed that tiagabine was not associated with the development of visual field 
loss (105;192).  In addition, rats exposed to a dose of tiagabine did not show increased 
retinal GABA concentrations, whereas rats exposed to VGB had retinal GABA 
concentrations of more than 260% of control animals (15).  The proposed mechanisms 
of action of tiagabine are through blocking the high affinity GABA transporter GAT-1.  
This allows temporarily sustained synaptic GABA concentrations after endogenous 
release (488), but does not result in widespread increases in GABA concentrations (16).   
In individuals receiving VGB, co-medication with valproate has received attention as a 
possible promoter of the retinotoxic effects of VGB (108;114;164).  Valproate  inhibits 
the enzyme succinate semialdehyde dehydrogenase, resulting in elevated levels of 
succuinate which is a potent inhibitor of GABA-T activity (407).  Inhibition of GABA-
T by both VGB and valproate when used concomitantly could lead to increased risk of 
VGB-retinotocicity.  However, Wild et al., Lobefalo et al. and others (405)  have found 
normal ppRNFL thickness in individuals receiving valproate monotherapy (229;260).  
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A retinotoxic class effect of the GABAergic AEDs is therefore unlikely (105;489).  
However, around 40% of retinal cells are GABA-immunoreactive (490) and thus 
pharmacological manipulation of GABAergic pathways by AEDs can be associated 
with retinal electrophysiological changes and visual impairment (176).  In addition 
many AEDs with non-GABAergic mechanisms of action are also associated with visual 
side effects (176).  Visual disturbances including diplopia, blurred vision, abnormal 
colour perception and nystagmus are relatively common side effects of many AEDs.  
These visual side effects are predominantly related to neurotoxic drug levels, over-dose 
or long-term use, and subside after the drug is reduced or withdrawn (for a review see 
(175;176)) and are not known to be related to long-term structural retinal changes 
7.4.3 ppRNFL thinning as a result of brain pathology 
It is becoming apparent that retrograde trans-synaptic degeneration can occur in the 
human visual pathway (295;420)
36
.  High resolution in vivo imaging techniques such as 
OCT may be more sensitive at detecting subtle patterns of ppRNFL atrophy than has 
been previously achievable by direct clinical observation (295).  Recently, thinning of 
the ppRNFL has been detected using OCT in individuals with homonymous hemianopia 
secondary to congenital (295;420) and acquired lesions (295) of the occipital cortex.  
Similarly, as part of this body of research it was found that the ppRNFL was 
significantly thinner in VGB-exposed individuals with homonymous quadrantinopic or 
hemianopic defects than in individuals without homonymous defects, after controlling 
for the amount of VGB exposure.  This was suggested to be due to retrograde trans-
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synaptic degeneration secondary to lesions in the optic radiation as a result of surgical 
resection of the temporal lobe
37
.  
7.4.4 Neurosurgery and ppRNFL thinning   
In the present study, no difference in ppRNFL thickness was found in non-exposed 
individuals who had undergone neurosurgery.  Although a trend for decreased ppRNFL 
thickness in the inferior quadrant was seen in individuals who had undergone surgery, 
where the average ppRNFL thickness was 107.6 µm, compared to individuals with no 
history of surgery where the thickness was 114.5µm.  Only 8/87 individuals had a 
history of surgery and so the lack of significance may be due to the small numbers 
included in the study.   
A weakness in this study was that visual fields were not routinely assessed in 
individuals with epilepsy not exposed to VGB, thus it was unknown whether any of the 
individuals who had undergone surgery showed homonymous visual field defects.  
Seven of the individuals who had a history of neurosurgery had undergone temporal 
lobe resections which are associated with post-operative visual field defects in between 
15 and 100% of individuals (408).  Visual field defects associated with temporal lobe 
resections (or other temporal lobe lesions) result from disruption of the optic radiations 
in the temporal lobe.  The visual pathways are retinotopically organised, such that 
lesions in any part of the pathway will result in a defect in a known area of the visual 
field.  After leaving the LGN, fibres in the optic radiation project in a retinotopicaly 
organised pattern, where fibres in the most anterior aspect of the optic radiation 
(Meyer’s loop) are those which have received afferent input in the LGN from RGC in 
the inferior retina (including uncrossed RGC axons from the ipsilateral inferior temporal 
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retina, and crossed RGC axons from the contralateral inferior nasal retina).  Lesions 
involving the anterior optic radiation result in a defect of the superior quadrant of the 
visual field, immediately adjacent to the vertical meridian, ipsilateral to the lesion (409).  
Lesions involving the anterior portion of the optic radiation (Myers loop) resulting in 
homonymous superior quadrantinopias, may be associated with retrograde trans-
synaptic degeneration of the RGC in the corresponding inferior retina.  RGC projections 
in the RNFL respect the horizontal meridian, thus atrophy of RGC axons in the inferior 
retina may be detected as ppRNFL thinning in the inferior aspect of the ONH.  In the 
manufacturers’ summary report for a ppRNFL thickness scan using OCT, RGC in the 
inferior retina would be most represented in the inferior 90
o
 quadrant.  The nasal and 
temporal 90
o
 quadrants straddle the horizontal meridian and thus will receive 
projections from both the superior and inferior retina, and the superior quadrant lies 
superiorly to the horizontal meridian.  The trend towards ppRNFL thinning in the 
inferior 90
o
 quadrant in individuals who had undergone neurosurgery (7/8 of whom had 
temporal lobe resections), may be related to trans-synaptic retrograde degeneration 
involving these projections.   
7.4.5 Epilepsy type and ppRNFL thinning  
ppRNFL thickness changes were also seen in the inferior quadrant in individuals with 
MTLE wit HS where the ppRNFL was significantly thinner compared to individuals 
with partial epilepsy of unknown cause.  This finding could also be related to 
pathological changes in the anterior optic radiation and resulting trans-synaptic 
degeneration of RGGs in the corresponding inferior retina.  MTLE is commonly 
associated with abnormalities of the hippocampus and mesial temporal lobe structures 
that can be detected using routine MRI.  Until recently brain pathology associated with 
MTLE was thought largely to be confined to these mesial temporal lobe structures.  
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However, advances in neuroimaging and computerised analysis techniques have 
demonstrated that in individuals with MTLE, brain atrophy and abnormality extends to 
involve brain areas outside of the mesial temporal lobe, involving cortical and 
subcortical grey matter (491;492) and widespread white matter networks (493-495).  In 
addition, a recent pathological study of post mortem brains from individuals with drug-
resistant epilepsy and hippocampal sclerosis found widespread neocortical and white 
matter pathology (496).    
Using advanced neuroimaging techniques, including diffusion tensor imaging, voxel-
based morphometry and proton magnetic resonance spectroscopy,  abnormalities of the 
temporal (497-499) and extra-temporal white matter (497), have been reported in 
individuals with MTLE.  The abnormalities reported include decreased whole brain 
white matter volume (500), and decreased white matter volume in the temporal lobe, 
ipsilateral (499;501;502) and contralateral (502) to the seizure focus.  Additionally, 
features suggestive of abnormal or reduced myelination (297;493-495), and axonoal 
loss (297;493;498), have been detected in white matter tracts, including the corpus 
callosum (297;494;495;501-504); cingulum (297;503); external capsule (297;494;495); 
the fronto-temporal and temporo-occipital projections (493), and the uncinate (505), 
fronto-occipital and superior longitudinal fasciculus (504).  
The pathophysiology and aetiology of white matter abnormalities in individuals with 
epilepsy are unknown.  A number of possible causes have been suggested including 
direct damage from chronic, recurrent epileptic activity (296;502), disruptions of normal 
white matter development in individuals with childhood seizures (296;497;502;506) and 
exposure to AEDs (502).  White matter volume reduction was associated with earlier 
age at seizure onset and longer duration of epilepsy (296) 
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White matter abnormalities might also be present in the optic radiation, and may be 
associated with trans-synaptic retrograde degeneration of retinal ganglion cells in the 
inferior retina.  Generalised atrophy involving the optic radiations could result in loss of 
RGC through trans-synaptic degeneration and account for the decrease in average 
ppRNFL thickness seen in individuals with epilepsy.  More focal atrophy could be 
related to local pathology, including HS and surgical resection, leading to focal 
ppRNFL thickness changes that are detectable on analysis of the 90
o
 quadrants or 30
o
 
sectors.    
7.4.6 White matter abnormalities and cognitive function  
Diffuse white matter pathology may also explain differences in ppRNFL thickness seen 
in individuals with and without learning disability.  In this study individuals with 
learning difficulty were found to have significantly thinner average ppRNFL thickness 
compared to individuals without learning difficulty (p=0.015).   An association between 
cognitive function and ppRNFL thickness has been found in studies of individuals with 
multiple sclerosis where ppRNFL thinning is associated with cognitive disability (as 
measured using the Brief Repeatable Battery – Neuropsychology) (293).  Similarly in 
healthy, young individuals ppRNFL thickness was found to be associated with level of 
cognitive functioning (294).  In addition, ppRNFL thinning is found in individuals with 
Alzheimer’s disease (476;477) and mild cognitive impairment (477). 
Cognitive impairment is a recognised co-morbidity of chronic epilepsy, adding further 
to the burden of the disorder (507-510).  Much research has focused on factors that may 
contribute to cognitive dysfunction such as seizure frequency and severity, chronic AED 
use, age of epilepsy onset and duration of epilepsy (511;512). Recent research has 
aimed to identify the neural mechanisms of cognitive impairment in epilepsy (511).  
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Individuals with epilepsy can have impairments in multiple cognitive domains including 
memory impairment, frontal lobe dysfunction, language deficits and psychomotor 
slowing (507;510).  A ―disconnection model‖ has been suggested to explain this profile 
of widespread cognitive impairment (493;513).  Normal cognitive function depends on 
the coordinated activity of several brain regions, and disruption of cerebral networks 
may lead to pervasive cognitive decline (493;511;513).   
It is becoming evident that diffuse white matter pathology in individuals with epilepsy 
may contribute to cognitive impairment (514).  Global reduction in white matter volume 
has been associated with cognitive dysfunction in individuals with epilepsy (515).  
Similarly, in individuals with TLE widespread white matter abnormalities identified 
using diffusion tensor imaging, were associated with poor cognitive performance in 
tasks involving memory (493;505;514), language (514) and executive function (493).  
The characteristics of the diffusion changes seen using diffusion tensor imaging in 
individuals with TLE were suggesting of chronic Wallerian degeneration, possibly due 
to seizure-induced cell damage in the temporal lobe (505).  Furthermore it is suggested 
that abnormalities detected using diffusion tensor imaging can be used to predict 
cognitive impairment in individuals with TLE (514).  
The ppRNFL thinning identified in this study in individuals with learning disability may 
be associated with the global white matter abnormalities identified in neuroimaging 
studies of individuals with cognitive impairment.  Widespread abnormalities and 
atrophy of cerebral white matter may result in trans-synaptic changes in RGC, resulting 
in RGC axon loss and associated RNFL thinning that can be detected by measuring 
ppRNFL thickness.   
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7.4.7 Grey matter abnormalities  
Neuroimaging studies have demonstrated that individuals with TLE show brain atrophy 
and abnormality involving cortical and subcortical grey matter (491;492).  A review of 
studies using voxel-based morphometry identified twenty-six grey matter regions that 
were found to be significantly reduced in volume in individuals with TLE compared to 
healthy controls (492).  The most frequently reported abnormality was in the 
hippocampus, with abnormalities of the thalamus as the second most reported brain 
changes in individuals with TLE (492).  In individuals with TLE, atrophy of the 
thalamus has been reported in several recent studies (300;491;516;517).  The pattern of 
abnormal signal detected in the thalamus using diffusion tensor imaging in individuals 
with MTLE (with and without HS), were consistent with neuronal loss and gliosis 
(516;518).  
The lateral geniculate nucleus is one of the nuclei of the thalamus.  More than 80% of 
RGC axons terminate in the LGN in a highly organised retinotopic pattern, where they 
make synapses with geniculocalcarine neurones that project to the primary visual 
cortex.  Thalamic atrophy involving the LGN could lead to loss or RGC axons which 
could be detected using OCT imaging.  
7.4.8 Duration of epilepsy  
In the present study, longer duration of epilepsy showed a weak association with 
decreasing average ppRNFL thickness.  In individuals with TLE, both grey- (299;300) 
and white matter (296-298) abnormalities and atrophy have been associated with longer 
duration of epilepsy, indicating that in some individuals progressive brain atrophy may 
occur with continuing seizure activity (299).  Longer duration of epilepsy is also 
associated with the development and progression of cognitive impairment which may be 
associated with progressive neuronal loss (299;507;508).  The decreasing ppRNFL 
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thickness associated with increasing duration of epilepsy seen in this study may be 
reflecting the progressive cerebral grey- and white matter abnormalities identified using 
neuroimaging techniques in individuals with TLE.  However, both the present study, 
and those reporting grey and white matter changes associated with duration of epilepsy, 
have been cross-sectional studies.  After controlling for age, duration of epilepsy was 
not associated with ppRNFL thinning, and thus the correlation seen may reflect age-
related loss in ppRNFL thickness, which has been described in healthy individuals 
(285;390;401;402).  However, age was not found to correlate with ppRNFL thickness in 
this population.  Further studies are needed in a larger population to determine the effect 
of duration of epilepsy and age on ppRNFL thickness.    
7.4.9 The utility of OCT in epilepsy 
The findings from the present study suggest that OCT ppRNFL imaging may have the 
potential to become a valuable tool in the evaluation of clinical and prognostic factors in 
epilepsy.  OCT imaging is non-invasive and entails little, if any, discomfort or distress 
for the subject being examined.  It is easily quantifiable and highly repeatable, in 
addition it is of low cost and has a relatively short examination time (less than 10 
minutes) compared to neuroimaging techniques (519).    
Of particular interest in the present study is the association between ppRNFL thinning 
and cognitive impairment and duration of epilepsy.  Larger, longitudinal studies are 
needed to determine whether ppRNFL thinning reflects progressive cognitive decline in 
association with global or local changes in brain white matter volume in individuals 
with chronic drug-resistant epilepsy.  In the present study the presence of cognitive 
impairment (or ―learning disability‖) was determined from the clinical notes of each 
subject.  No distinction was made as to the severity or nature of the learning disability, 
or in some cases whether the individual had undergone formal neuropsychological 
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assessment.  It is possible that in some cases an individual with learning disability may 
not have been included in the ―learning disability‖ group as there was no record of 
impairment in the medical notes.  Future studies should use more detailed and 
unambiguous measures of cognitive function, including formal neuropsychological 
assessments, aiming to determine the relationship between impairment of specific or 
global cognitive domains and ppRNFL thickness.  As cognitive function is reassessed 
overtime, OCT ppRNFL imaging should also be repeated to determine whether any 
change in cognitive function is associated with changes in the ppRNFL thickness.  If a 
relationship is present this may suggest a potential for the use of OCT ppRNFL imaging 
a as a biomarker for disease modifying therapies and for neuroprotective strategies in 
epilepsy.   
Finally, a possible cause of continued seizures following temporal lobectomy for 
hippocampal sclerosis could be due to more widespread neocortical and white matter 
pathological changes (496;520;521).  If ppRNFL thinning is a marker for widespread 
neuronal abnormality and loss, it may provide a useful biological marker of surgical 
outcome in individuals with drug-resistant epilepsy.  Further studies should investigate 
the relationship between ppRNFL thickness measured pre-surgically and post-surgical 
seizure outcome.       
 
7.5 Conclusion  
ppRNFL thinning may be present in up to 22% of individuals with epilepsy not exposed 
to VGB.  ppRNFL thinning may be associated with cognitive impairment, longer 
duration of epilepsy and specific epilepsy types, in particular MTLE with HS.  ppRNFL 
thinning may occur due to transynaptic degeneration of RGC as a result of white matter 
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pathology involving the postgeniculate visual pathway.  This could entail diffuse axonal 
loss occurring throughout the CNS or focal lesions involving the visual pathway (484).  
Alternatively, loss of RGC may result from atrophy of the thalamic nuclei including the 
lateral geniculate nucleus.  Larger longitudinal studies of individuals undergoing 
detailed neuropsychological assessment, white matter imaging (e.g. using diffusion 
tensor imaging) and ppRNFL imaging using OCT are needed to fully determine the 
clinical utility of OCT ppRNFL imaging in epilepsy. 
  
317 
 
Chapter 8  Conclusions, limitations and future work 
 
8.1 Study limitations  
The limitations and weaknesses of the present study must be considered in the 
interpretation of results and conclusions presented in this thesis, and should be 
addressed in the development of future work. 
 
8.1.1 General limitations  
 
Study design 
A major limitation to the present study is the cross sectional design. The results from 
this study suggest that ppRNFL thinning and VAVFL progress with continued VGB 
exposure (Chapter 3, 5 and 6).  In addition, it is suggested that in non-exposed 
individuals, ppRNFL thinning may be associated with longer duration of epilepsy 
(Chapter 7).  These conclusions were inferred from cross sectional data after grouping 
individuals according to VGB exposure, or by using correlation analysis.  Evidently, 
further prospective studies using OCT in individuals with epilepsy are needed to 
confirm these finding. 
 
In Chapter 3, the progression of VAVFL with continued VGB exposure was assessed 
retrospectively by quantifying visual field examinations performed by several 
examiners over a ten-year period.  The limitations of perimetry are discussed in depth in 
Chapter 3.  With regard to the retrospective design of the study, several important issues 
must be considered.  These include inter-examiner sources of variability in the visual 
field assessment; non-blinded assessments and examiner bias (all examinations were 
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performed because the individuals were receiving VGB) and missing reports and data 
(e.g. notes from the examiner on the reliability of the subjects performance).   
 
Small numbers  
 
Although, to my knowledge, this is the largest study to date on ppRNFL thinning in 
individuals with epilepsy, some of the subgroups included in the analyses were small.  
For example, in non-exposed individuals there was a non-significant trend for ppRNFL 
thinning in the inferior quadrant in those who had undergone neurosurgery.  However, 
only eight individuals were included in this group, and the study may have been 
underpowered to detect a significant effect.     
 
 
Non-blinded 
 
For the majority of individuals with epilepsy, the VGB exposure status was known by 
the examiner (L.M.C) prior to assessment and during the quantification and 
classification of results (i.e. visual fields and ppRNFL thickness).  This may have led to 
bias, particularly in the acquisition of visual field data and the quantification and 
classification of visual fields, where there is some subjectivity in the measurement 
(309).  In an effort to validate the visual field quantification and classification methods, 
a second examiner was asked to assess a subset of visual field results.  The second 
examiner was blinded to the VGB exposure status of each individual.  The inter-rater 
reliability was high for both the quantification and classification of the visual fields 
(Chapter 2), demonstrating that bias from the non-blinded first examiner (L.M.C) 
probably had little effect on these measures of visual field size.  For future studies the 
examiner should be blinded as to the VGB exposure status of participants.  Where this 
is not possible (e.g. the individuals are known to the examiner), visual field tests should 
be repeated, preferably by a different examiner.  Knowledge of the VGB exposure 
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status of individuals may also have lead to bias in the selection of OCT scans to use for 
analysis.  Most individuals underwent at least two OCT scans of the right eye.  Strict 
scan selection criteria were utilised to avoid selection bias.  For example, if one 
individual had two right eye scans, both fulfilling the quality control criteria and both 
with equal signal strength, the most recently acquired scan was selected in all instances.  
However, because quality control criteria were largely subjective, future studies should 
be blinded to avoid any selection bias.        
 
Co-existing ophthalmological disease   
 
All participants underwent a screening questionnaire, and examination of colour vision 
and visual acuity to ensure that individuals who may have had visual field loss and/or 
retinal pathology related to underlying eye disease were excluded.  However, 
individuals did not undergo formal ophthalmological assessment (i.e. fundus 
examination and measurement of intra-ocular pressure), and it is possible that some 
individuals may have had an undiagnosed ophthalmological disease which may have 
accounted for, or contributed to, visual field loss and/or ppRNFL thinning.  Of 
particular concern may be undiagnosed glaucoma, which manifests with visual field 
loss (which may be asymptomatic in the early stages) and ppRNFL thinning that can be 
detected using OCT (252), and has a prevalence of around 1% in the UK in individuals 
aged 40-89 years (522).       
 
 
 
8.1.2 Phenotyping issues   
The challenges of phenotyping individuals with epilepsy are well known (427;523).  In 
the present study all clinical, demographic and therapeutic data were obtained 
retrospectively from the individuals medical records.  This method of data collection 
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assumes that the information provide in the medical notes is correct and complete.  
However, in many cases, clinical data relies on detailed histories from the patient, 
family or carers which may not always be accurate.  
AED exposure 
For all AEDs (excluding VGB), details of the dose and duration of therapy were not 
considered, similarly the combinations in which the AEDs were used was not recorded.  
Any individual or combined effect of particular AEDs on ppRNFL thickness may not 
have been detected.  This could be owing to the diverse AED histories of individuals 
included in the study, and the use of only binary AED exposure data.  For example, a 
group of individuals with a positive history of exposure to a particular AED may 
include individuals who were exposed for several days and those exposed for several 
years.  To further explore the effects of AEDs (alone, or in combination) on ppRNFL 
thickness, larger studies are needed with more comprehensive exposure data.   
Of particular concern for the present study, data regarding exposure to AEDs may be 
missing or incomplete, particularly if an individual’s AED history is deduced from the 
patient, family or carers memory.  It is possible that some individuals included in the 
―non-exposed‖ Group may have been exposed to VGB.          
Accurate VGB exposure data 
In the present study details of VGB exposure were obtained retrospectively from the 
medical notes.  The issues with accurately quantifying the amount and duration of VGB 
exposure are outlined in Chapter 2 (see 2.2.2).  Although every effort was made to 
establish an accurate estimation of the amount of VGB exposure, ascertaining detailed 
AED exposure data retrospectively from clinical notes is challenging and imprecise.  
Frequently, adequate details of initiation of VGB, dose changes and VGB withdrawal 
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were not available, resulting in a large number of individuals with missing VGB dose 
data, decreasing the numbers of individuals available for certain analyses.  Future 
studies should carefully record VGB exposure prospectively, possibly alongside 
frequent testing of VGB serum levels.       
 
Duration of epilepsy  
The duration of epilepsy was determined from the date of epilepsy diagnosis, as 
outlined in the medical notes; however, it is possible that individuals experienced 
seizures long before their diagnosis.  In these cases, the duration of epilepsy recorded 
from the medical notes would be shorter than the actual duration of seizures.   
Learning disability  
Discussed in Chapter 7.      
Clinical history  
Clinical data obtained from the medical notes often relies on historical accounts from 
the patient, family or carers which may not always be accurate.  To overcome this, strict 
criteria can be applied for the inclusion of certain historical data.  For example, a 
positive history of febrile seizures may only be included if there is a hospital record of 
the event, or if a parent or carer can account for the event, thereby minimising the risk 
of inaccurate data.  In the present study, no such criteria were applied, and any record in 
the medical notes of a particular clinical feature was used to determine a positive history 
of that variable.    
The heterogeneous nature of the group of individuals with epilepsy makes it difficult to 
determine any individual or combined clinical factors that may be associated with 
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ppRNFL thinning.    Even within a particular clinical variable there may diversity as to 
the type, severity and frequency of that clinical feature.  For example, a history of 
―status epilepticus‖ was determined from the medical notes, although details of the type 
of status epilepticus or the duration of the event were not determined.  Similarly, a 
history of head injury was recorded, but the severity, type and temporal relationship of 
the head injury to seizure onset was not documented.  Whilst ―splitting‖ individuals 
according to more specific clinical criteria may reduce the heterogeneity of the group, it 
may result in small, underpowered samples (523).  Conversely, ―lumping‖ individual 
into a broader group may increase the heterogeneity whilst gaining a larger sample size 
(523).    
The heterogeneity of the individuals included in the present study, alongside the broad 
criteria used to define the presence or absence of a clinical feature, may dilute any effect 
of discrete clinical, demographic or therapeutic features on ppRNFL thinning.  Larger 
studies with strict, comprehensive phenotype definitions are needed to explore this 
further.   
 
8.1.3 Limitations of perimetry  
The limitations of perimetry have been discussed in Chapter 3.  With regards to the 
methods employed in this study, there are several weaknesses to consider.  Each 
individual underwent only one visual field assessment, although it has been suggested 
that several repeated assessments should be performed in order to account for a learning 
effect or other sources of normal variability (107).  Furthermore, an assessment of the 
intra- and inter-examiner reliability in the examination of the visual field using GKP 
was not performed.  Future studies should consider repeating visual field assessments to 
ensure that the recorded field is a reliable.  Although the visual field quantification and 
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classification methods used in the present study were found to show good intra- and 
inter-rater reliability (see 2.5.3), errors in the quantification and classification of visual 
fields may also have occurred.   
 
8.1.4 Limitations of OCT 
 
Manufacturers’ normative database  
 
In the present study, measurements of ppRNFL thickness were compared against the 
manufacturers’ normative database, and classified according to the manufacturers’ 
normal distribution percentiles.  Details of this normative database are available for the 
TD-OCT instrument used, including the age ranges, gender and ethnicity of the 
included subjects (285).  Increasing age is known to be associate with ppRNFL thinning 
(285;390;401;402) and is controlled for in the comparison of each subject to the 
manufacturers’ normative database.  However, gender and ethnicity are not considered.  
Recent studies suggest that there may be ethnic differences in normal ppRNFL 
thickness (285;358;524-528).  Similarly, some studies suggest that there may be gender 
differences in ppRNFL thickness (385;386).  Ethnicity was not considered in the present 
study, and may have had an effect on the ppRNFL thickness that was not accounted for 
in the analyses.    
 
Scan circle placement  
The location of the scan circle relative to the ONH has an effect on the ppRNFL 
thickness measurements (see 4.4.2.4) (327).  For ppRNFL scans acquired using SD-
OCT, inbuilt software automatically centres the scan around the ONH after it has been 
acquired.  In addition, the scan circle can be manually adjusted to optimise its location.  
The disadvantage of this is that the placement of the scan circle can be subjectively 
324 
 
determined, and the chosen ―optimal‖ position may differ between operators, leading to 
differences in the measures of ppRNFL thickness.  Studies are needed to determine the 
effect of intra- and inter-examiner reproducibility of scan circle placement and the effect 
this may have on measures of ppRNFL thickness.     
 
The TD-OCT model used in the present study does not allow manual adjustment of the 
scan circle after scan acquisition.  ―Optimal‖ scan circle placement is subjectively 
determined by the examiner before the scan is acquired.  The fundus image, provided 
with the tomograph in the manufacturers’ summary report, is used to assess the scan 
circle placement.  However, the fundus image showing the scan circle, and the 
tomograph from which ppRNFL measurements are taken, are not acquired at the same 
time, and thus the two images do not correspond exactly (529).  Because of this, the 
examiner cannot be certain that that the tomograph was acquired in the optimal location 
(i.e. centred on the ONH), which may lead to errors in the measurement of ppRNFL 
thickness due to the misaligned scan (529).      
 
Floor effect  
ppRNFL thickness measured using OCT may show a ―floor effect‖ whereby further 
structural damage cannot be detected whilst functional deterioration (e.g. VAVFL) 
continues (229;530).  In some individuals with no visual perception, due to ischaemic 
optic neuropathy (530) or advanced glaucoma (531), a residual ppRNFL thickness is 
maintained, suggesting that even when there are no remaining RGCs ppRNFL thickness 
measured using OCT will not be reduced to zero (530). Contributions to the residual 
ppRNFL thickness may be from normal, non-axonal components of the RNFL, 
including glial cells and blood vessels which are not affected by RGC disease an loss 
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(530;531).  In addition, RGC loss may lead to migration of astrocytes into the RNFL, 
phagocytosing cellular debris and synthesising new extracellular matrix components 
(532), and contributing to residual ppRNFL thickness.  Lastly, the inbuilt OCT 
algorithm used to define and measure the ppRNFL may contribute to residual ppRNFL 
thickness(530),  as it attempts to detect RNFL borders from the reflectivity profile, even 
when there is extremely low reflectivity (284) (i.e. due to a RNFL depleted of RGC 
axons).   
The utility of OCT in individuals with severe VAVFL and ppRNFL thinning needs to 
be evaluated further.   It is possible that in these cases, functional assessment of the 
visual field may provide a more suitable tool for continued monitoring of VAVFL 
progression.   
64 four-scan segments  
In this study a novel summary parameter was created to analyse ppRNFL thickness 
data; the 64 four-scan segments.  Small eye movements during scanning may lead to 
displacement or distortion of individual A-scans.  These may be ―smoothed out‖ during 
image post-processing, and in the validated summary measures have little effect on the 
average ppRNFL thickness.  However, in the smaller four-scan segments, any distortion 
of individual A-scans may have a large effect on the average ppRNFL thickness in each 
segment, giving an inaccurate representation of the true ppRNFL thickness in that ONH 
area.  Analysing ppRNFL thickness data using this method needs validation before it 
can be more widely applied.   
8.2 Conclusions 
 
The aims of this study were to explore the effects of VGB on ppRNFL thickness 
measured using OCT in a large population of individuals with epilepsy.  The findings of 
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this study have important implications for four areas of concern regarding the use of 
VGB in individuals with epilepsy.   
Firstly, and perhaps most importantly are the issues with assessing the retinotoxic 
effects of VGB and the associated VAVFL in individuals who are unable to appreciate 
the demands of perimetry (see 8.2.1).   
Secondly, the mechanisms of VGB retinotoxicity have not been identified and the 
pathological retinal changes leading to VAVFL are unknown.  Understanding the 
mechanisms leading to irreversible VAVFL may lead to more targeted diagnostic and 
monitoring strategies, and improved ability to identify individuals at risk of VAVFL 
(see 8.2.2).     
Thirdly, the prevalence of VAVFL in VGB-exposed individuals is around 50%, yet 
currently it is unknown which individuals are most at risk.  The identification of risk 
factors for VAVFL may allow safer prescribing of VGB in some individuals (see 8.2.3). 
Lastly, the evolution of VAVFL with continued VGB exposure is uncertain.  This adds 
further apprehension to the use of VGB particularly over long periods of time which 
may be needed in individuals with drug-resistant complex partial seizures (see 8.2.4). 
8.2.1 Using ppRNFL imaging in assessment VGB-exposed individuals 
The present study has provided new evidence for the clinical utility of ppRNFL imaging 
in VGB-exposed individuals.  More individuals are able to comply with OCT than 
perimetry, In addition, ppRNFL imaging is highly repeatable in a VGB-exposed 
population, particularly when using the latest SD-OCT technology, which has a faster 
scanning time and allows post image-acquisition scan alignment.  In individuals who 
are unable to perform perimetry average ppRNFL thickness and the pattern of any 
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ppRNFL thinning can provide a surrogate marker for the integrity of the visual field and 
enable a judgement to be made about the presence of and severity of VAVFL. 
ppRNFL thinning measured using OCT may be detectable before VAVFL is clinically 
apparent. In the analysis of patterns of ppRNFL thinning the NS sector appears a likely 
candidate for showing ppRNFL changes associated with early VGB toxicity.  Although 
thinning in the NS sector may occur early after VGB exposure, the ppRNFL thickness 
measurements may remain within the manufacturers’ ―normal‖ boundaries (i.e. ≤95th–
>5
th 
percentile), thus baseline measurements before the initiation of VGB are essential, 
and subsequent examinations should be compared against baseline thickness 
measurements.   
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8.2.2 Mechanisms of VGB retinotoxicity 
The findings from this study suggest that RGC loss is the pathological mechanism 
leading to irreversible VAVFL.  However, other distinct but interrelated mechanisms 
may account for reversible and irreversible abnormalities in retinal electrophysiology 
and defects in colour vision, visual acuity and contrast sensitivity. 
8.2.3 Risk factors for VGB retinotoxicity 
Risk factors for ppRNFL thinning in VGB-exposed individuals include higher 
maximum daily VGB dose, higher duration of VGB exposure, male gender and the 
presence of a homonymous visual field defect related to co-existing visual pathway 
pathology.  These factors explained 31% of the variance in ppRNFL thickness between 
VGB-exposed individuals indicating that there are yet unknown factors that 
significantly contribute to the risk of ppRNFL thinning (and VAVFL) after VGB 
exposure.  It is possible that genetic variation could play a role in the development of 
VAVFL.  Genetic variability leading to differences in RGC number, and differences in 
the expression of proteins involved in GABAergic pathways and GABA metabolism in 
the retina may be implicated.     
 8.2.4 The evolution of VGB retinotoxicity  
The present study has provided evidence that ppRNFL thinning and VAVFL progress 
with continued VGB exposure.  The progression of the retinotoxic effects of VGB may 
be subtle and difficult to detect using perimetry.  ppRNFL imaging may provide a more 
sensitive indicator of progression.  Prospective longitudinal studies are needed to 
confirm this.  
8.2.5 ppRNFL thinning in individuals with epilepsy  
An unexpected finding in this study was the presence of ppRNFL thinning in 
individuals with epilepsy who had no history of VGB exposure.  ppRNFL thinning may 
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be associated with cognitive impairment, longer duration of epilepsy and specific 
epilepsy types, in particular MTLE with HS.  ppRNFL thinning may occur due to 
transynaptic degeneration of RGC as a result of white matter pathology involving the 
postgeniculate visual pathway.  This could entail diffuse axonal loss occurring 
throughout the CNS or focal lesions involving the visual pathway (484).  Alternatively, 
loss of RGC may result from atrophy of the thalamic nuclei including the lateral 
geniculate nucleus.   
 
 
8.3 Future work 
 
8.3.1 Prospective longitudinal studies  
The findings from this study have provided valuable evidence that ppRNFL imaging 
using OCT is a useful tool to use in the assessment of VGB-exposed individuals.  In 
addition the findings have made contributions to understanding of the mechanisms of, 
and possible risk factors for, VAVFL.  However, there are limitations to this study, the 
most apparent being the cross-sectional design of the research.  Further prospective 
longitudinal studies are needed to fully appreciate the utility of ppRNFL imaging in the 
management of VGB-exposed individuals.  Where possible, studies should combine 
ppRNFL imaging, perimetry and retinal electrodiagnostics alongside careful recording 
of VGB exposure.  Baseline examinations are essential, and careful comparison of 
repeated assessments should be made.  Few adult individuals are newly started on VGB 
now, creating difficulties in performing this type of study, and cross-centre 
collaborations will probably be required.  There may be particular scope for such 
prospective studies currently within the United States where the FDA have recently 
approved VGB. 
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8.3.2 Genetic association studies  
Genetic variation may play a role in the development of ppRNFL thinning and VAVFL.  
Individual variation in RGC, amacrine and Müller cell number could contribute to 
differential susceptibility to VGB retinotoxicity.  Furthermore, genetic differences in 
proteins involved in retinal GABAergic pathways and metabolism including GABA-
transaminase, GABA-transporters and GABA-receptors may also be associated with 
differences in response to persistently elevated retinal GABA after VGB exposure.   
Genetic association studies are needed to determine the presence of genetic risk factors 
for VGB retinotoxicity.  OCT ppRNFL imaging provides a robust phenotype to use in 
pharmacogenetic studies as it is highly repeatable, objective and easily quantifiable.  
Identification of genetic risk factors that predispose to VAVFL may allow for safer 
prescribing of VGB in selected individuals. 
8.3.3 Analysis of other retinal layers  
The findings in this study implicate RGC axonal loss in the pathogenesis of VAVFL.  
However, it is not possible to determine whether RGC axons are a primary target of 
VGB toxicity, or whether RGC axon loss occurs secondary to other retinal cell 
dysfunction or death.  Measurement of other retinal layers may reveal further insights 
into the mechanisms of VGB retinotoxicity.  For example, measurement of ONL 
thickness may provide evidence as to whether photoreceptor loss is present in VGB-
exposed individuals as has been described in VGB-exposed albino rats.   
8.3.4 Pathological studies  
Only one pathological study of the retina and anterior visual pathway from a VGB-
exposed individual has been undertaken.  Further pathological studies in humans are 
needed to confirm the effects of VGB on retinal structure particularly on the RGC and 
RNFL.  Difficulties in obtaining and performing histological analysis of human retina 
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(250) require alternative methods to be explored.  The visual pathways are 
reitnotopically organised, thus analyses of sections from post mortem samples of optic 
nerve, optic tract and lateral geniculate nucleus of VGB-exposed individuals may 
provide pathological evidence of RGC axon loss in addition to providing further 
evidence as to a retinotopic pattern of RGC atrophy.  In the LGN, specific RGC 
subtypes terminate in defined laminae (533), loss of RGC in specific LGN laminae may 
indicate susceptibility of classes of RGC to VGB toxicity.  For example, if M-cells are 
particularly susceptible to vigabatrin toxicity, atrophy will be seen preferentially in 
lamina one and two which contain projections from this RGC subtype.     
8.3.4 Large studies of individuals with epilepsy  
The finding that individuals with epilepsy not exposed to VGB have thinner ppRNFL 
than healthy individuals merits further investigation.  Larger studies are needed with 
carefully phenotyped individuals     
Larger longitudinal studies of individuals undergoing detailed neuropsychological 
assessment, white matter imaging (e.g. using diffusion tensor imaging) and ppRNFL 
imaging using OCT are needed to fully determine the clinical utility of OCT ppRNFL 
imaging in epilepsy.  However, these preliminary findings suggest that potential for 
OCT ppRNFL imaging a as a biomarker for disease modifying therapies and for 
neuroprotective strategies in epilepsy.  
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Appendix 1 
Information sheets 1 and 2 and participant consent form. 
  
333 
 
 
 
The National Hospital for Neurology and Neurosurgery 
  
Department of Clinical & Experimental Epilepsy  
Box 29 
Queen Square 
London 
WC1N 3BG 
 
Version 2, 04
th
 February 2008 
 
PARTICIPANT INFORMATION SHEET (1) FOR STUDY : “ASSESSMENT OF CANDIDATE 
POLYMORPHISMS FOR VIGABATRIN-INDUCED ADVERSE REACTIONS” 
QUESTIONS AND SAMPLE 
 
We would like to invite you to take part in a study at The National Hospital for Neurology & 
Neurosurgery and Institute of Neurology.  Before you decide whether to participate it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if there is anything that is 
not clear or if you would like more information.  Take time to decide whether or not you wish to take 
part. 
 
What is the purpose of the study? 
Vigabatrin is an important anti epileptic drug.  About 40% of patients who have taken the drug develop an 
irreversible loss of peripheral vision, such that vigabatrin is now rarely started as treatment in people who 
have epilepsy.  There are some people whose epilepsy was more controlled on vigabatrin, and who 
remain on vigabatrin, and continue to have eye tests to monitor their visual fields.  Vigabatrin is still used 
for the treatment of some sorts of severe epilepsy in children.  If it were possible to identify which 
patients were more likely to develop visual field loss when given vigabatrin, and which patients might not 
develop these side effects, then it might be possible to use vigabatrin again.  This would be an important 
achievement, as vigabatrin can be an effective anti epileptic drug for some people with epilepsy. 
There is reason to believe that some people are more likely to develop visual field loss when given 
vigabatrin than other people, and that this vulnerability is at least partly due to people’s individual genetic 
make up.  Our research has established that there do appear to be some common genetic variants which 
increase the risk of developing visual field loss on exposure to vigabatrin.  These results were obtained 
from genetic studies.  We now wish to establish whether these gene variants are indeed likely to have an 
effect that might make some people more vulnerable to the adverse affects of vigabatrin.  If our genetic 
findings are real, we would expect to be able to detect the effects of the genetic variants using specific 
tests that are described below. 
Our findings might lead not only to the chance of using vigabatrin again for some people with epilepsy, 
but also to the development of new tests that could identify early signs of impending visual field loss in 
people with epilepsy given vigabatrin.   
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Why have I been chosen? 
You have kindly volunteered to take part in this study.  The first part of this study involves taking a 
sample of blood, to work out whether you have the gene variants in which we are interested.  If you do, or 
if you are taking an antiepileptic drug, you may also be invited to take part in the second part of the study.  
This is detailed in Participant Information Sheet (2) 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign the consent form.  Once you have joined the study you will 
still be free to withdraw at any time and without giving a reason.  Your decision whether to take part, or 
to withdraw at a later point, will not affect any medical care you are receiving. 
 
What is involved in the study? 
We will first ask you a series of questions to make sure that you could take part in the second part of the 
study if you have the appropriate genetic variants, or if you are taking certain antiepileptic drugs.  To 
work out whether you have the appropriate genetic variants, we will take a sample of blood (20ml, about 
two tablespoons).  This will be taking by routine venepuncture.  A tourniquet will be tightened around 
your upper arm.  The area over a vein will be cleaned and the blood drawn from this site.  Usually this is 
at the front of the elbow but sometimes another site in the arm may be used.  Afterwards the area may be 
compressed to stop any bleeding and a dressing applied. 
 
Are there any risk involved in taking part? 
There are no serious risks involved.  Some people may experience discomfort when the blood sample is 
taken.  On some occasions more than one attempt may have to be made to obtain samples.  There is a low 
risk of persistent bleeding from the site, requiring additional compression and dressing.  An area of 
bruising may also be caused at the site.  Some people feel light headed during and after the procedure.  
The amount of blood being taken however is very small and should not cause this. 
 
Will I be asked to do anything else as part of this study? 
If you have the appropriate genetic variants, of if you are taking an antiepileptic drug, you may be invited 
to take part in the second part of the study.  The details are given in Participant Information Sheet (2).   
 
What will happen to my blood samples? 
The blood samples will be stored at the Institute of Neurology, University College London.  The samples 
will be labelled with a code rather than your real name, for confidentiality purposes.  We will then 
arrange for the blood sample to be tested for the genetic variants of interest.  This may take place at the 
Institute of Neurology, or in a collaborators laboratory in the United States of America.  If the sample is 
transferred to the United States of America, the collaborators there will only receive coded samples, and 
will not know your identity at any stage. 
 
What will happen to the information from the study? 
The information will be processed and stored in the Department of Clinical and Experimental Epilepsy, 
Institute of Neurology, University College London.  The information will be labelled with a code rather 
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than your real name, for confidentiality purposes.  This means that you cannot be identified from the 
information.  The information will be used to address the questions described above. 
Professor Sisodiya is the acting custodian of your information.  The information will be kept for at least 
ten years and destroyed if no longer needed in the future.  The information remains your property; this 
means that we will destroy it at an earlier stage if you wish.  Information may be used in other research 
studies, but if this happens it will first be made totally anonymous in order to destroy any links back to 
you.  Any further research using anonymous samples will first be reviewed by a research ethics 
committee to see if this is appropriate. 
 
What are the possible benefits of taking part? 
This study is being done to help establish whether the genetic variants we have identified are likely to 
have a real role in increasing susceptibility to vigabatrin associated visual field loss.  If we do find that the 
genetic variants are associated with changes in the eye or in the brain that may well increase vulnerability 
to field loss on exposure to vigabatrin, then it may be that if you have the variants that increase 
vulnerability it would be best for you not to receive vigabatrin in the future, or to consider coming off 
vigabatrin if you are taking it currently.  This might mean a change to your treatment if you are currently 
taking vigabatrin.  These decisions, however, are complicated and depend on several factors.  If the 
information we obtain is significant, we will pass it back to your treating doctors, to discuss further with 
you.   
 
What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation in this study and 
every care will be taken to ensure your safety.  However, UCL has (insurance) arrangements in place for 
no-fault compensation in the unlikely event that something unforeseen does go wrong, and on the balance 
of probabilities, harm is attributed as a result of taking part in the research study 
Regardless of this, if you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, you can contact the Research Governance 
Sponsor of this study, University College London. Please write to the Joint UCLH/UCL Biomedical 
Research Unit, R&D Directorate, Rosenheim Wing, Ground Floor, 25 Grafton Way, London WC1E 5DB 
quoting reference BRD/07/154.  All communication will be dealt in strict confidence. 
You can also contact the relevant local Patient Advisory Liaison Service (PALS) if you have any 
concerns regarding the care you have received, or as an initial point of contact if you have a complaint.  
For the PALS at UCLH call 020 7380 9975 or email pals@uclh.nhs.uk.  You can also visit PALS by 
asking at any hospital reception.   
 
What information will be held about me? 
Some personal details will be held about you including your name, age, clinical history and the type of 
treatment you are on if you are taking antiepileptic drugs.  If the results from the study are published there 
will be no personal details included.  All the information which is collected about you during the course 
of the research will be kept strictly confidential.  If you consent to take part in the research the people 
conducting the study will abide by the Data Protection Act 1998, and the rights you have under this act. 
 
What will happen to the results of the research study? 
This study is being undertaken in part fulfilment of a research student’s PhD. The results of the study will 
be published in a clinical research journal, however, you will not be identified in any reports or 
publications arising from the study.  A copy of the published results will be available through your 
neurologist.   
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Who is organising and funding the research? 
The study is funded by a grant received from the Tuberous Sclerosis Association.  The doctor conducting 
this research is not being paid for including you, or looking after you, in this study. 
 
Who is reviewing this study? 
The National Hospital for Neurology and Neurosurgery and the Institute of Neurology Joint Research 
Ethics Committee.  
 
Contact for further information 
If you wish to take part in this study or if you require any further information, please contact Lisa Clayton 
by phone on 0203 108 0097 or by email at l.clayton@ion.ucl.ac.uk.  You can also contact Professor 
Sanjay Sisodiya at the Institute of Neurology and The National Hospital for Neurology & Neurosurgery 
on 0203 108 0125.  Please leave a message and you will be contact at the earliest convenience. 
Thank you for taking the time to read this information sheet. 
 
 
 
 
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, the 
Elizabeth Garrett Anderson & Obstetric Hospital, the Heart Hospital, the Hospital for 
Tropical Diseases, the Middlesex Hospital, the National Hospital for Neurology & 
Neurosurgery, The Royal London Homeopathic Hospital and University College 
Hospital. 
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The National Hospital for Neurology and Neurosurgery 
  
Department of Clinical & Experimental Epilepsy  
Box 29 
Queen Square 
London 
WC1N 3BG 
 
Version 3, 15
th
 June 2009 
 
PARTICIPANT INFORMATION SHEET (2) FOR STUDY : “ASSESSMENT OF CANDIDATE 
POLYMORPHISMS FOR VIGABATRIN-INDUCED ADVERSE REACTIONS” 
 
TMS, OCT AND VISUAL FIELDS 
 
We would like to invite you to take part in a study at The National Hospital for Neurology & 
Neurosurgery and Institute of Neurology.  Before you decide whether to participate it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if there is anything that is 
not clear or if you would like more information.  Take time to decide whether or not you wish to take 
part. 
 
What is the purpose of the study? 
Vigabatrin is an important anti epileptic drug.  About 40% of patients who have taken the drug develop an 
irreversible loss of peripheral vision, such that vigabatrin is now rarely started as treatment in people who 
have epilepsy.  There are some people whose epilepsy was more controlled on vigabatrin, and who 
remain on vigabatrin, and continue to have eye tests to monitor their visual fields.  Vigabatrin is still used 
for the treatment of some sorts of severe epilepsy in children.  If it were possible to identify which 
patients were more likely to develop visual field loss when given vigabatrin, and which patients might not 
develop these side effects, then it might be possible to use vigabatrin again.  This would be an important 
achievement, as vigabatrin can be an effective anti epileptic drug for some people with epilepsy. 
There is reason to believe that some people are more likely to develop visual field loss when given 
vigabatrin than other people, and that this vulnerability is at least partly due to people’s individual genetic 
make up.  Our research has established that there do appear to be some common genetic variants which 
increase the risk of developing visual field loss on exposure to vigabatrin.  These results were obtained 
from genetic studies.  We now wish to establish whether these gene variants are indeed likely to have an 
effect that might make some people more vulnerable to the adverse affects of vigabatrin.  If our genetic 
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findings are real, we would expect to be able to detect the effects of the genetic variants using specific 
tests that are described below. 
Recent research has suggested that deficiency in the amino acid taurine may be related to the 
development of visual field loss when taking vigabatrin.  Normal levels of taurine are usually easily 
obtained from our diet; however, some patients taking vigabatrin have been shown to have lower taurine 
levels than normal.  It is possible that low levels of taurine contribute to the development of visual field 
loss in some people taking vigabatrin, though we still need to establish whether there is a relationship 
between vigabatrin use, taurine levels and visual field loss. 
Our findings might lead not only to the chance of using vigabatrin again for some people with epilepsy, 
but also to the development of new tests that could identify early signs of impending visual field loss in 
people with epilepsy given vigabatrin.   
 
Why have I been chosen? 
You have been chosen either because the genetic tests you have had show that you have the gene variants 
we are interested in or you are taking an antiepileptic drug that we are interested in studying.  We know 
this information about you either as a result of the genetic study you have previously helped us with, or as 
a result of the first part of this study for which you volunteered.   
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign the consent form.  Once you have joined the study you will 
still be free to withdraw at any time and without giving a reason.  Your decision whether to take part, or 
to withdraw at a later point, will not affect any medical care you are receiving. 
 
What is involved in the study? 
There are two sets of tests in this study.  In the first set, we will examine your eyes.  We will first check 
your visual acuity, using a test you may have had before at your optician.  We will then measure your 
visual fields, using a test we routinely employ.  This involves sitting comfortably, and placing your head 
on a headrest attached to the device, after which you will be asked to say when you see a light.  Lastly, we 
will look at the thickness of a particular part of your eye, called the retina.  You will be given 1% 
tropicamide eye drops to dilate your pupils so that we can scan your eyes easily.  These drops are used 
routinely in clinical practice and very rarely cause serious side effects.  A consultant ophthalmologist will 
be present in case advice is needed.  The drops may sting for a few seconds afterwards and cause some 
blurring of vision.  You are advised not to drive or operate machinery until your vision is clear which 
could take a few hours.  Again you will be seated comfortably at the machine, and asked to place your 
head on a headrest.  You will then be asked to look at a target, and you may have one eye covered briefly 
with a patch.  We will then quickly scan the back of your eye using our special machine.  You will see a 
brief flash of light when we do this.  You may temporarily continue to see the light, particularly when you 
close your eyes, as sometimes happens with flash photography.   
The second set of tests will be done in a different building.  These tests are called electrophysiological 
tests, which are tests looking at how brain and nerve cells in your body connect up and communicate with 
each other.  We plan to use the technique called transcranial magnetic stimulation (TMS) to examine the 
excitability of your brain.  This technique has been used for many years to examine the function of the 
339 
 
brain.  You will be seated comfortably in an armchair.  Three small electrodes will be taped to your hand; 
these will record activity in your muscle.  A small magnetic pulse will be delivered through a coil held 
close to your head.  This is painless but you may feel one or two small taps on your head.  You may also 
feel the muscles in your hand twitch.  This will be done around 120 times; each pulse separated by five 
seconds.  There will be chance for breaks throughout and overall it should take about one hour.  TMS has 
been used safely in thousands of individuals around the world.  It can be harmful in people who have a 
pacemaker, an implanted medication pump, a metal plate in the skull, or metal objects inside the eye or 
skull (for example after brain surgery or a shrapnel wound) or you have a vagal nerve stimulator.  Please 
inform the investigators if you might have any of these.  Please do not consume and caffeinated drinks 
including tea and coffee, or any alcohol on the day of the study as these can affect the results. Since the 
effects of magnetic stimulation on the foetus are unknown, please also let us know if you think you might 
be pregnant.  During the transcranial magnetic stimulation, you might feel a light tingling on the skin, 
which fades away very fast.   
If you are taking the antiepileptic drugs that we are interested you will be asked to provide some saliva 
into a special pot so that we can estimate the levels of the drugs in your body.  We may also look at your 
hospital notes to find further information about the drugs you are taking and the diagnostic tests that you 
have had in the past.  
For your participation in this part of the study we will reimburse you with £20 as compensation for your 
time. 
 
Are there any risk involved in taking part? 
There are no serious risks involved.  TMS can theoretically cause seizures, which have been rare in 
practice and difficult to produce on purpose, even in people who have epilepsy.  Please note that since the 
introduction of agreed safety guidelines (which we will implement), there have been no reports of 
seizures.  In the unlikely event of a seizure, you will be given appropriate medical treatment.  Besides 
seizures, the only known risk of TMS is a headache, which has always gone away promptly with non-
prescription medication.  In the very unlikely event of seizures, the Driving Licence Authority (DVLA) 
has told us that subjects who suffer seizures during TMS experiments will not be banned from driving if 
they already have a licence.  Please let us know if you are applying for or hold an HGV licence, as we do 
not intend to perform TMS studies on such people.   
 
What will happen to the information from the study? 
The information will be processed and stored in the Department of Clinical and Experimental Epilepsy, 
Institute of Neurology, University College London.  The information will be labelled with a code rather 
than your real name, for confidentiality purposes.  This means that you cannot be identified from the 
information.  The information will be used to address the questions described above. 
Professor Sisodiya is the acting custodian of your information.  The information will be kept for at least 
ten years and destroyed if no longer needed in the future.  The information remains your property; this 
means that we will destroy it at an earlier stage if you wish.  Information may be used in other research 
studies, but if this happens it will first be made totally anonymous in order to destroy any links back to 
you.  Any further research using anonymous samples will first be reviewed by a research ethics 
committee to see if this is appropriate. 
 
What are the possible benefits of taking part? 
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This study is being done to help establish whether the genetic variants we have identified are likely to 
have a real role in increasing susceptibility to vigabatrin associated visual field loss.  If we do find that the 
genetic variants are associated with changes in the eye or in the brain that may well increase vulnerability 
to field loss on exposure to vigabatrin, then it may be that if you have the variants that increase 
vulnerability it would be best for you not to receive vigabatrin in the future, or to consider coming off 
vigabatrin if you are taking it currently.  This might mean a change to your treatment if you are taking 
vigabatrin.  These decisions, however, are complicated and depend on several factors.  If the information 
we obtain is significant, we will pass it back to your treating doctors, to discuss further with you.   
 
What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation in this study and 
every care will be taken to ensure your safety.  However, UCL has (insurance) arrangements in place for 
no-fault compensation in the unlikely event that something unforeseen does go wrong, and on the balance 
of probabilities, harm is attributed as a result of taking part in the research study 
Regardless of this, if you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, you can contact the Research Governance 
Sponsor of this study, University College London. Please write to the Joint UCLH/UCL Biomedical 
Research Unit, R&D Directorate, Rosenheim Wing, Ground Floor, 25 Grafton Way, London WC1E 5DB 
quoting reference BRD/07/154.  All communication will be dealt in strict confidence. 
You can also contact the relevant local Patient Advisory Liaison Service (PALS) if you have any 
concerns regarding the care you have received, or as an initial point of contact if you have a complaint.  
For the PALS at UCLH call 020 7380 9975 or email pals@uclh.nhs.uk.  You can also visit PALS by 
asking at any hospital reception.   
 
What information will be held about me? 
Some personal details will be held about you including your name, age, clinical history and the type of 
treatment you are on.  If the results from the study are published there will be no personal details 
included.  All the information which is collected about you during the course of the research will be kept 
strictly confidential.  If you consent to take part in the research the people conducting the study will abide 
by the Data Protection Act 1998, and the rights you have under this act. 
 
What will happen to the results of the research study? 
This study is being undertaken in part fulfilment of a research student’s PhD. The results of the study will 
be published in a clinical research journal; however, you will not be identified in any reports or 
publications arising from the study.  A copy of the published results will be available through your 
neurologist.   
 
Who is organising and funding the research? 
The study is funded by a grant received from the Tuberous Sclerosis Association.  The doctor conducting 
this research is not being paid for including you, or looking after you, in this study. 
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Who is reviewing this study? 
The National Hospital for Neurology and Neurosurgery and the Institute of Neurology Joint Research 
Ethics Committee.  
 
Contact for further information 
If you wish to take part in this study or if you require any further information, please contact Lisa Clayton 
by phone on 0203 108 0097 or by email at l.clayton@ion.ucl.ac.uk.  You can also contact Professor 
Sanjay Sisodiya at the Institute of Neurology and The National Hospital for Neurology & Neurosurgery 
on 0203 108 0125.  Please leave a message and you will be contact at the earliest convenience. 
Thank you for taking the time to read this information sheet. 
 
 
 
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, the 
Elizabeth Garrett Anderson & Obstetric Hospital, the Heart Hospital, the Hospital for 
Tropical Diseases, the Middlesex Hospital, the National Hospital for Neurology & 
Neurosurgery, The Royal London Homeopathic Hospital and University College 
Hospital. 
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The National Hospital for Neurology and Neurosurgery 
  
Department of Clinical & Experimental Epilepsy  
Box 29 
Queen Square 
London 
WC1N 3BG 
 
Version 2, 04
th
 February 2008 
 
Centre Number:  
Study Number: 08/0115  
Identification Number for this trial: 
 
CONSENT FORM 
Title of project: Assessment of candidate polymorphisms for vigabatrin-induced adverse reactions 
Name of Researcher: Prof SM Sisodiya 
 
Please tick to confirm 
1. I confirm that I have read and understand the information sheet dated 04.02.2008 (version 2) 
for the above study  
 
   
2.  I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
   
3. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
   
4. I understand that sections of any of my medical notes and data collected during the study 
may be looked at by responsible individuals from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in research. I give permission for these 
individuals to have access to my records. 
 
   
5. I understand that any blood taken is given as a gift and may be used in future research.  
343 
 
   
6. I agree to my GP being informed of my participation in the study.  
   
7. I agree to take part in the above research study. 
 
 
 
_____________________   _________  ____________________ 
Name of patient                Date   Signature 
 
_______________    ________  ______________________ 
Name of Person taking consent  Date   Signature 
(if different from researcher) 
 
_________________   _________  _______________________ 
Researcher    Date   Signature 
 
1 copy for patient, 1 copy for Researcher, 1 copy to be kept with hospital notes 
If you have any comments or concerns you may discuss these with the Investigator. If you wish to go 
further and complain about any aspect of the way you have been approached or treated during the course 
of the study, you should write or get in touch with the Complaints Manager, UCLH. Please quote the 
UCLH project number at the top of this consent form. 
 
 
 
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, the 
Elizabeth Garrett Anderson & Obstetric Hospital, the Heart Hospital, the Hospital for 
Tropical Diseases, the Middlesex Hospital, the National Hospital for Neurology & 
Neurosurgery, The Royal London Homeopathic Hospital and University College 
Hospital. 
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Appendix 2 
Screening Questionnaire  
  Yes or No 
Do you currently have any problems with your eyes 
or vision?  
  
Are you currently taking any medication for 
problems with your eyes or vision?  
  
Have you had any problems with your eyes or 
vision in the past that you were treated for? 
  
Have you ever had any surgery to your eyes?   
Do you have diabetes?    
Do you have glaucoma?    
Does anyone in your family have glaucoma?   
Do you wear glasses and/or contact lenses?   
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Appendix 3 
Translation of instructions for OCT and perimetry into Dutch  
Perimetry instructions  
 Een oog wordt afgedekt met een lapje.  Het is belangrijk dat u niets door het 
afgedekte oog kunt zien. 
 Aan uw rechter kant is ere en belletje, waar u op kunt drukken als u een bewegend 
lichtjee ziet. 
 Leg uw kin op de houder en druk uw voorhoofd tegen de hoofdsteun aan de 
bovenkant. 
 Kijk recht vooruit in het cirkeltje voor u.  Lisa zal u dit wijzen. 
 Het is erg belangrijk dat u de hele tijd naar dit cirkeltje blijft kijken. 
 Een wit lichtje zal bewegen vanuit de buitenkant van uw gezichtsveld, waar u het 
kunt zien.  Op het moment dat u het lichtje ziet drukt u op het belletje. 
 Beweeg de ogen niet om het lichtje te zoeken, blijf de hele tijd recht vooruit kijken. 
OCT instructions 
 De houder voor de kin wordt in de juiste stand gezet  
 Leg de kin op de houder aan de kant die Lisa aangeeft 
 Leg uw hoord tegen de hoofdsteun 
 Kijk recht in de camera lens 
 De houder voor de kin wordt voorwaarts bewogen naar de lens.  Houdt de kin in de 
houder en laat het hoofd rusten tegen de hoofdsteun terwijl dit gebeurt.  Probeer 
meet e bewegen met de houder voor de kin. 
 Wanneer je dichter bij de lens bent zul je een groene ster zien.  Blijf de hele tijd naar 
de ster kijken. 
 Als u wilt kunt u even knipperen met de ogen als dit nodig is, daarna zal Lisa u 
vragen niet te knipperen (zij zedt: don’t blink) tijdens het maken van de scan. 
 Het is erg belangrijk dat wanneer de scan genomen wordt u blijft kijken naar de 
groene ster, beweeg niet met het hoofd en niet knipperen met de ogen.   
 Wanneer één oog gedaan is, zal Lisa vragen de kin op de andere kant van de houder 
te leggen om het andere oog te kunnen scannen 
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Appendix 4 
Average ppRNFL thickness in the right eye was found to be significantly thickener than 
average ppRNFL thickness in the left eye in VGB-exposed individuals (from Group 
1A) and healthy individuals (Group 3) (Table A1).  There was a significant correlation 
between average ppRNFL thickness in the right eye and average ppRNFL thickness in 
the left eye (r = 0.95, p<0.001 and r = 0.88, p<0.001 for VGB-exposed and healthy 
individuals, respectively).  
 
Table A1: Average ppRNFL thickness in the right and left eyes in VGB-
exposed and healthy individuals  
 Right eye average ppRNFL 
thickness (µm) [SD] 
Left eye average ppRNFL 
thickness (µm) [SD] 
P value 
VGB-exposed 
(N= 60) 
77.1 (13.1) 74.9 (13.5) <0.001 
Healthy controls 
(N= 89) 
94.0 (9.0) 92.7 (9.6) 0.005 
 
  
347 
 
Appendix 5 
OCT data from individuals who were unable to perform perimetry were compared 
against OCT data from individuals from whom visual field data was available to 
determine whether there was a difference between the two populations.   
There was no significant difference in ppRNFL thickness between the two groups 
(p>0.05) (Table A2).   
Table A2: Comparison of average ppRNFL thickness between individuals able 
to perform perimetry and those unable to perform perimetry. 
 
 Able to perform perimetry  Unable to perform 
perimetry  
Average ppRNFL thickness 
(µm) [range]  
79.0 ±12.5  [48-105] 80.6 ±12.0 [49-99] 
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